cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
UVM	cis	rs2739330	0.929	rs5751775	ENSG00000273295.1	AP000350.5	11.48	7.16e-16	1.85e-09	1.01	0.85	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.892	rs5751776	ENSG00000273295.1	AP000350.5	11.48	7.16e-16	1.85e-09	1.01	0.85	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.929	rs5751777	ENSG00000273295.1	AP000350.5	11.48	7.16e-16	1.85e-09	1.01	0.85	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23901432~23907068:-
UVM	cis	rs1799949	0.965	rs8067269	ENSG00000198496.9	NBR2	-10.87	5.36e-15	1.85e-09	-1.05	-0.83	Menopause (age at onset);	chr17:43083782	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs8176202	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43078211	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs8176198	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43078520	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.93	rs8176194	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43079204	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs8176193	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43079499	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs4793197	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43079885	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs1060915	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43082453	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs3950989	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43085936	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs8176161	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43089373	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.894	rs8176160	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43089486	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs2070834	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43090268	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs16942	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43091983	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs16941	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43092418	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs799917	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43092919	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs16940	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43093220	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.93	rs66499067	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43096467	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs8176145	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43097077	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs8176140	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43099629	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs67060599	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43103085	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.896	rs35908185	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43103094	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs799912	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43105117	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs8176133	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43105441	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs8176130	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43106026	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs8176120	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43109216	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs12936816	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43149692	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs4793212	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43150733	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs34534709	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43150923	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs34059614	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43151054	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs33926631	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43152446	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs1960605	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43153380	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs2037075	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43153809	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs2037076	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43153866	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs12950779	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43154506	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.929	rs12937015	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43155456	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs4340367	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43155755	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs4792981	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43156257	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs1973646	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43158478	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs6503727	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43160842	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs35521261	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43161595	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.896	rs33933393	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43165415	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs4793215	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43166915	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs33946455	ENSG00000198496.9	NBR2	-10.84	5.98e-15	1.85e-09	-1.06	-0.83	Menopause (age at onset);	chr17:43169829	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs8176126	ENSG00000198496.9	NBR2	10.84	5.98e-15	1.85e-09	1.06	0.83	Menopause (age at onset);	chr17:43107032	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs35070007	ENSG00000198496.9	NBR2	10.84	5.98e-15	1.85e-09	1.06	0.83	Menopause (age at onset);	chr17:43164730	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.773	rs2137990	ENSG00000198496.9	NBR2	10.84	5.98e-15	1.85e-09	1.06	0.83	Menopause (age at onset);	chr17:43165879	chr17:43125610~43153671:+
UVM	cis	rs507080	0.733	rs7108144	ENSG00000255239.1	AP002954.6	10.75	7.97e-15	1.92e-09	0.91	0.83	Serum metabolite levels;	chr11:118698985	chr11:118688039~118690600:-
UVM	cis	rs507080	0.663	rs523793	ENSG00000255239.1	AP002954.6	10.75	7.97e-15	1.92e-09	0.91	0.83	Serum metabolite levels;	chr11:118699988	chr11:118688039~118690600:-
UVM	cis	rs507080	0.736	rs659564	ENSG00000255239.1	AP002954.6	10.75	7.97e-15	1.92e-09	0.91	0.83	Serum metabolite levels;	chr11:118700205	chr11:118688039~118690600:-
UVM	cis	rs507080	0.736	rs642224	ENSG00000255239.1	AP002954.6	10.75	7.97e-15	1.92e-09	0.91	0.83	Serum metabolite levels;	chr11:118700210	chr11:118688039~118690600:-
UVM	cis	rs507080	0.733	rs541631	ENSG00000255239.1	AP002954.6	10.75	7.97e-15	1.92e-09	0.91	0.83	Serum metabolite levels;	chr11:118700314	chr11:118688039~118690600:-
UVM	cis	rs507080	0.736	rs658676	ENSG00000255239.1	AP002954.6	10.75	7.97e-15	1.92e-09	0.91	0.83	Serum metabolite levels;	chr11:118700414	chr11:118688039~118690600:-
UVM	cis	rs507080	0.733	rs488141	ENSG00000255239.1	AP002954.6	10.75	7.97e-15	1.92e-09	0.91	0.83	Serum metabolite levels;	chr11:118700459	chr11:118688039~118690600:-
UVM	cis	rs507080	0.733	rs657769	ENSG00000255239.1	AP002954.6	10.75	7.97e-15	1.92e-09	0.91	0.83	Serum metabolite levels;	chr11:118700607	chr11:118688039~118690600:-
UVM	cis	rs507080	0.733	rs544452	ENSG00000255239.1	AP002954.6	10.75	7.97e-15	1.92e-09	0.91	0.83	Serum metabolite levels;	chr11:118700648	chr11:118688039~118690600:-
UVM	cis	rs507080	0.697	rs656287	ENSG00000255239.1	AP002954.6	10.75	7.97e-15	1.92e-09	0.91	0.83	Serum metabolite levels;	chr11:118701081	chr11:118688039~118690600:-
UVM	cis	rs507080	0.733	rs570949	ENSG00000255239.1	AP002954.6	10.75	7.97e-15	1.92e-09	0.91	0.83	Serum metabolite levels;	chr11:118701202	chr11:118688039~118690600:-
UVM	cis	rs507080	0.733	rs4486664	ENSG00000255239.1	AP002954.6	10.72	9.02e-15	1.98e-09	0.9	0.83	Serum metabolite levels;	chr11:118698358	chr11:118688039~118690600:-
UVM	cis	rs507080	0.733	rs4393358	ENSG00000255239.1	AP002954.6	10.72	9.02e-15	1.98e-09	0.9	0.83	Serum metabolite levels;	chr11:118698388	chr11:118688039~118690600:-
UVM	cis	rs1799949	0.931	rs9912203	ENSG00000198496.9	NBR2	10.61	1.28e-14	2.76e-09	1.03	0.83	Menopause (age at onset);	chr17:43367777	chr17:43125610~43153671:+
UVM	cis	rs2739330	0.929	rs5751775	ENSG00000218537.1	MIF-AS1	10.57	1.47e-14	2.96e-09	1.23	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.892	rs5751776	ENSG00000218537.1	MIF-AS1	10.57	1.47e-14	2.96e-09	1.23	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.929	rs5751777	ENSG00000218537.1	MIF-AS1	10.57	1.47e-14	2.96e-09	1.23	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23894426~23898930:-
UVM	cis	rs1799949	0.859	rs11657004	ENSG00000198496.9	NBR2	-10.5	1.9e-14	2.96e-09	-1.04	-0.82	Menopause (age at onset);	chr17:43365383	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs11080034	ENSG00000198496.9	NBR2	-10.5	1.9e-14	2.96e-09	-1.04	-0.82	Menopause (age at onset);	chr17:43365646	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.931	rs34474989	ENSG00000198496.9	NBR2	-10.5	1.9e-14	2.96e-09	-1.04	-0.82	Menopause (age at onset);	chr17:43368042	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.794	rs116409325	ENSG00000198496.9	NBR2	-10.5	1.9e-14	2.96e-09	-1.04	-0.82	Menopause (age at onset);	chr17:43368092	chr17:43125610~43153671:+
UVM	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-10.36	2.99e-14	2.96e-09	-0.96	-0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-10.36	2.99e-14	2.96e-09	-0.96	-0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	10.36	2.99e-14	2.96e-09	0.96	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	10.36	2.99e-14	2.96e-09	0.96	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	10.36	2.99e-14	2.96e-09	0.96	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	10.36	2.99e-14	2.96e-09	0.96	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	10.36	2.99e-14	2.96e-09	0.96	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	10.36	2.99e-14	2.96e-09	0.96	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	10.36	2.99e-14	2.96e-09	0.96	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	10.36	2.99e-14	2.96e-09	0.96	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
UVM	cis	rs1799949	0.965	rs11650132	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43174070	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs11654731	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43174923	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs2271574	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43175631	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs33994002	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43176801	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs33920795	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43176993	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs33918839	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43177155	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs11651623	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43177830	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs11657883	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43178007	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs11656945	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43178248	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs12944430	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43178803	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs11653460	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43179289	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs11653231	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43179443	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs11650913	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43179580	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs12936831	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43179799	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs1399323	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43180313	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs35954893	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43181769	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.93	rs35292991	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43181999	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs11658499	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43182732	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.93	rs4445938	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43185883	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs8074136	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43190296	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.93	rs34210004	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43218318	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.894	rs71367985	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43222443	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.501	rs2343819	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43332285	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.55	rs2343818	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43332406	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.501	rs35399157	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43334234	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.536	rs4793227	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43334882	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.602	rs4600503	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43336956	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.526	rs4352088	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43337311	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.501	rs9675035	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43337648	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs34633610	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43342017	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs11654051	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43342288	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs11649954	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43342667	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs1824889	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43344508	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.93	rs56729776	ENSG00000198496.9	NBR2	-10.32	3.47e-14	2.96e-09	-1.02	-0.82	Menopause (age at onset);	chr17:43344763	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs4239149	ENSG00000198496.9	NBR2	10.32	3.47e-14	2.96e-09	1.02	0.82	Menopause (age at onset);	chr17:43176078	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.894	rs36062488	ENSG00000198496.9	NBR2	10.32	3.47e-14	2.96e-09	1.02	0.82	Menopause (age at onset);	chr17:43185455	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs4793229	ENSG00000198496.9	NBR2	10.32	3.47e-14	2.96e-09	1.02	0.82	Menopause (age at onset);	chr17:43340966	chr17:43125610~43153671:+
UVM	cis	rs507080	0.733	rs489126	ENSG00000255239.1	AP002954.6	10.3	3.7e-14	2.96e-09	0.9	0.82	Serum metabolite levels;	chr11:118702038	chr11:118688039~118690600:-
UVM	cis	rs507080	0.733	rs611733	ENSG00000255239.1	AP002954.6	10.3	3.7e-14	2.96e-09	0.9	0.82	Serum metabolite levels;	chr11:118702051	chr11:118688039~118690600:-
UVM	cis	rs7188445	0.736	rs11642757	ENSG00000261390.4	RP11-345M22.2	-10.16	6.07e-14	4.32e-09	-0.87	-0.82	Urate levels;	chr16:79719570	chr16:79715232~79770563:-
UVM	cis	rs507080	0.807	rs7926944	ENSG00000255239.1	AP002954.6	10.11	6.99e-14	4.85e-09	0.87	0.81	Serum metabolite levels;	chr11:118689119	chr11:118688039~118690600:-
UVM	cis	rs2739330	0.796	rs5760097	ENSG00000273295.1	AP000350.5	10.11	7.16e-14	4.87e-09	0.95	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.828	rs4822451	ENSG00000273295.1	AP000350.5	10.11	7.16e-14	4.87e-09	0.95	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.828	rs5760098	ENSG00000273295.1	AP000350.5	10.11	7.16e-14	4.87e-09	0.95	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.828	rs5760099	ENSG00000273295.1	AP000350.5	10.11	7.16e-14	4.87e-09	0.95	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.828	rs5760102	ENSG00000273295.1	AP000350.5	10.11	7.16e-14	4.87e-09	0.95	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	10.11	7.16e-14	4.87e-09	0.95	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
UVM	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	10.03	9.22e-14	5.56e-09	1.08	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	10.03	9.22e-14	5.56e-09	1.08	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	10.03	9.22e-14	5.56e-09	1.08	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	10.03	9.22e-14	5.56e-09	1.08	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	10.03	9.22e-14	5.56e-09	1.08	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	10.03	9.22e-14	5.56e-09	1.08	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	10.03	9.22e-14	5.56e-09	1.08	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	10.03	9.22e-14	5.56e-09	1.08	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
UVM	cis	rs507080	0.883	rs692750	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118667599	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs4589335	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118668431	chr11:118688039~118690600:-
UVM	cis	rs507080	0.961	rs34413584	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118675072	chr11:118688039~118690600:-
UVM	cis	rs507080	0.961	rs600969	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118675087	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs12577485	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118676793	chr11:118688039~118690600:-
UVM	cis	rs507080	0.961	rs673770	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118679892	chr11:118688039~118690600:-
UVM	cis	rs507080	0.961	rs642530	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118680047	chr11:118688039~118690600:-
UVM	cis	rs507080	0.961	rs642497	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118680075	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs4938524	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118681365	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs519848	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118682006	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs592280	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118682509	chr11:118688039~118690600:-
UVM	cis	rs507080	0.885	rs693037	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118682617	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs12788848	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118683079	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs4474473	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118683180	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs12796373	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118684230	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs625513	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118685010	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs525485	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118685045	chr11:118688039~118690600:-
UVM	cis	rs507080	0.845	rs613377	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118685375	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs546890	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118686489	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs555356	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118687369	chr11:118688039~118690600:-
UVM	cis	rs507080	0.883	rs693306	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118687624	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs514143	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118687740	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs558907	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118687746	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs561845	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118688118	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs638805	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118688180	chr11:118688039~118690600:-
UVM	cis	rs507080	0.845	rs510408	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118688192	chr11:118688039~118690600:-
UVM	cis	rs507080	0.845	rs509641	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118688243	chr11:118688039~118690600:-
UVM	cis	rs507080	0.883	rs563549	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118688244	chr11:118688039~118690600:-
UVM	cis	rs507080	0.885	rs533144	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118688538	chr11:118688039~118690600:-
UVM	cis	rs507080	0.885	rs7926959	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118689157	chr11:118688039~118690600:-
UVM	cis	rs507080	0.663	rs7926970	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118689172	chr11:118688039~118690600:-
UVM	cis	rs507080	0.885	rs4938530	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118689861	chr11:118688039~118690600:-
UVM	cis	rs507080	0.883	rs12798453	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118690701	chr11:118688039~118690600:-
UVM	cis	rs507080	0.883	rs558593	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118691811	chr11:118688039~118690600:-
UVM	cis	rs507080	0.845	rs667982	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118692058	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs582630	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118692090	chr11:118688039~118690600:-
UVM	cis	rs507080	0.883	rs527475	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118692530	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs585039	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118692672	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs558781	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118693688	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs508640	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118693704	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs471227	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118693892	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs516153	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118694053	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs518028	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118694273	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs519982	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118694522	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs478371	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118694627	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs502601	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118694970	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs7114458	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118695466	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs7114216	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118695525	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs533646	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118696037	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs642662	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118696311	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs478296	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118696666	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs493834	ENSG00000255239.1	AP002954.6	10.01	1.01e-13	5.56e-09	0.87	0.81	Serum metabolite levels;	chr11:118696735	chr11:118688039~118690600:-
UVM	cis	rs916888	0.773	rs199457	ENSG00000262539.1	RP11-259G18.3	9.96	1.21e-13	6.35e-09	1.25	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46259551~46260606:-
UVM	cis	rs916888	0.687	rs199456	ENSG00000262539.1	RP11-259G18.3	9.96	1.21e-13	6.35e-09	1.25	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46259551~46260606:-
UVM	cis	rs916888	0.773	rs199451	ENSG00000262539.1	RP11-259G18.3	9.96	1.21e-13	6.35e-09	1.25	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46259551~46260606:-
UVM	cis	rs916888	0.773	rs199448	ENSG00000262539.1	RP11-259G18.3	9.96	1.21e-13	6.35e-09	1.25	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46259551~46260606:-
UVM	cis	rs916888	0.773	rs199447	ENSG00000262539.1	RP11-259G18.3	9.96	1.21e-13	6.35e-09	1.25	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46259551~46260606:-
UVM	cis	rs916888	0.773	rs199445	ENSG00000262539.1	RP11-259G18.3	9.96	1.21e-13	6.35e-09	1.25	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46259551~46260606:-
UVM	cis	rs916888	0.773	rs199443	ENSG00000262539.1	RP11-259G18.3	9.96	1.21e-13	6.35e-09	1.25	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46259551~46260606:-
UVM	cis	rs916888	0.773	rs199535	ENSG00000262539.1	RP11-259G18.3	9.96	1.21e-13	6.35e-09	1.25	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46259551~46260606:-
UVM	cis	rs916888	0.773	rs199534	ENSG00000262539.1	RP11-259G18.3	9.96	1.21e-13	6.35e-09	1.25	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46259551~46260606:-
UVM	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	9.96	1.21e-13	6.35e-09	1.25	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
UVM	cis	rs916888	0.773	rs199533	ENSG00000262539.1	RP11-259G18.3	9.96	1.21e-13	6.35e-09	1.25	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46259551~46260606:-
UVM	cis	rs916888	0.773	rs1378358	ENSG00000262539.1	RP11-259G18.3	9.93	1.33e-13	6.83e-09	1.26	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46259551~46260606:-
UVM	cis	rs916888	0.773	rs538628	ENSG00000262539.1	RP11-259G18.3	9.93	1.33e-13	6.83e-09	1.26	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46259551~46260606:-
UVM	cis	rs916888	0.773	rs169201	ENSG00000262539.1	RP11-259G18.3	9.93	1.33e-13	6.83e-09	1.26	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46259551~46260606:-
UVM	cis	rs916888	0.773	rs199439	ENSG00000262539.1	RP11-259G18.3	9.93	1.33e-13	6.83e-09	1.26	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46259551~46260606:-
UVM	cis	rs507080	0.733	rs517445	ENSG00000255239.1	AP002954.6	9.89	1.54e-13	7.65e-09	0.88	0.81	Serum metabolite levels;	chr11:118702826	chr11:118688039~118690600:-
UVM	cis	rs507080	0.771	rs687664	ENSG00000255239.1	AP002954.6	9.89	1.54e-13	7.65e-09	0.88	0.81	Serum metabolite levels;	chr11:118703476	chr11:118688039~118690600:-
UVM	cis	rs507080	0.771	rs523715	ENSG00000255239.1	AP002954.6	9.89	1.54e-13	7.65e-09	0.88	0.81	Serum metabolite levels;	chr11:118703479	chr11:118688039~118690600:-
UVM	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	9.86	1.7e-13	8.41e-09	1.04	0.81	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
UVM	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-9.86	1.72e-13	8.5e-09	-0.93	-0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
UVM	cis	rs10935480	0.904	rs13065271	ENSG00000239445.4	ST3GAL6-AS1	-9.77	2.34e-13	1.14e-08	-0.71	-0.8	Blood protein levels;	chr3:98715649	chr3:98714330~98732651:-
UVM	cis	rs507080	0.922	rs644498	ENSG00000255239.1	AP002954.6	9.72	2.7e-13	1.24e-08	0.86	0.8	Serum metabolite levels;	chr11:118696777	chr11:118688039~118690600:-
UVM	cis	rs507080	0.922	rs644867	ENSG00000255239.1	AP002954.6	9.72	2.7e-13	1.24e-08	0.86	0.8	Serum metabolite levels;	chr11:118696836	chr11:118688039~118690600:-
UVM	cis	rs507080	0.845	rs481903	ENSG00000255239.1	AP002954.6	9.71	2.8e-13	1.25e-08	0.86	0.8	Serum metabolite levels;	chr11:118697024	chr11:118688039~118690600:-
UVM	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	9.68	3.15e-13	1.31e-08	0.95	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
UVM	cis	rs1799949	1	rs9646412	ENSG00000198496.9	NBR2	-9.66	3.36e-13	1.35e-08	-1.02	-0.8	Menopause (age at onset);	chr17:43348525	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs9646418	ENSG00000198496.9	NBR2	-9.66	3.36e-13	1.35e-08	-1.02	-0.8	Menopause (age at onset);	chr17:43348533	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs4793230	ENSG00000198496.9	NBR2	-9.66	3.36e-13	1.35e-08	-1.02	-0.8	Menopause (age at onset);	chr17:43350035	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs4793231	ENSG00000198496.9	NBR2	-9.66	3.36e-13	1.35e-08	-1.02	-0.8	Menopause (age at onset);	chr17:43350101	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs11651341	ENSG00000198496.9	NBR2	-9.66	3.36e-13	1.35e-08	-1.02	-0.8	Menopause (age at onset);	chr17:43350693	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs34572725	ENSG00000198496.9	NBR2	-9.66	3.36e-13	1.35e-08	-1.02	-0.8	Menopause (age at onset);	chr17:43351298	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs9897425	ENSG00000198496.9	NBR2	-9.66	3.36e-13	1.35e-08	-1.02	-0.8	Menopause (age at onset);	chr17:43352811	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs4534897	ENSG00000198496.9	NBR2	-9.66	3.36e-13	1.35e-08	-1.02	-0.8	Menopause (age at onset);	chr17:43354440	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs1842147	ENSG00000198496.9	NBR2	-9.65	3.46e-13	1.37e-08	-1.03	-0.8	Menopause (age at onset);	chr17:43357824	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs4793233	ENSG00000198496.9	NBR2	-9.65	3.46e-13	1.37e-08	-1.03	-0.8	Menopause (age at onset);	chr17:43358069	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.864	rs60309406	ENSG00000198496.9	NBR2	-9.65	3.46e-13	1.37e-08	-1.03	-0.8	Menopause (age at onset);	chr17:43358297	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs4793234	ENSG00000198496.9	NBR2	-9.65	3.46e-13	1.37e-08	-1.03	-0.8	Menopause (age at onset);	chr17:43358815	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs4793236	ENSG00000198496.9	NBR2	-9.65	3.46e-13	1.37e-08	-1.03	-0.8	Menopause (age at onset);	chr17:43359072	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs4793237	ENSG00000198496.9	NBR2	-9.65	3.46e-13	1.37e-08	-1.03	-0.8	Menopause (age at onset);	chr17:43359227	chr17:43125610~43153671:+
UVM	cis	rs916888	0.61	rs199529	ENSG00000262539.1	RP11-259G18.3	9.58	4.43e-13	1.74e-08	1.24	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46259551~46260606:-
UVM	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-9.57	4.57e-13	1.79e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	9.51	5.67e-13	1.85e-08	1.04	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	9.51	5.67e-13	1.85e-08	1.04	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	9.51	5.67e-13	1.85e-08	1.04	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	9.51	5.67e-13	1.85e-08	1.04	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	9.51	5.67e-13	1.85e-08	1.04	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	9.51	5.67e-13	1.85e-08	1.04	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	9.51	5.67e-13	1.85e-08	1.04	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs7714455	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818281	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	9.51	5.67e-13	1.85e-08	1.04	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	9.51	5.67e-13	1.85e-08	1.04	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	9.51	5.67e-13	1.85e-08	1.04	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-9.51	5.67e-13	1.85e-08	-1.04	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	9.51	5.67e-13	1.85e-08	1.04	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	9.51	5.67e-13	1.85e-08	1.04	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	9.51	5.67e-13	1.85e-08	1.04	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	9.51	5.67e-13	1.85e-08	1.04	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	9.51	5.67e-13	1.85e-08	1.04	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
UVM	cis	rs6597981	0.57	rs4963163	ENSG00000279672.1	CMB9-55F22.1	9.45	7.06e-13	2.29e-08	0.72	0.79	Breast cancer;	chr11:762441	chr11:779617~780755:+
UVM	cis	rs1799949	0.965	rs9646413	ENSG00000198496.9	NBR2	-9.43	7.71e-13	2.44e-08	-1	-0.79	Menopause (age at onset);	chr17:43348789	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs35956818	ENSG00000198496.9	NBR2	-9.42	7.95e-13	2.49e-08	-1.01	-0.79	Menopause (age at onset);	chr17:43345617	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs9646417	ENSG00000198496.9	NBR2	-9.42	7.95e-13	2.49e-08	-1.01	-0.79	Menopause (age at onset);	chr17:43346885	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs1545764	ENSG00000198496.9	NBR2	-9.42	7.95e-13	2.49e-08	-1.01	-0.79	Menopause (age at onset);	chr17:43347197	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.93	rs4584865	ENSG00000198496.9	NBR2	-9.42	7.95e-13	2.49e-08	-1.01	-0.79	Menopause (age at onset);	chr17:43347551	chr17:43125610~43153671:+
UVM	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-9.4	8.53e-13	2.55e-08	-1.03	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	9.4	8.55e-13	2.55e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-9.4	8.55e-13	2.55e-08	-1.02	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
UVM	cis	rs507080	0.883	rs656575	ENSG00000255239.1	AP002954.6	9.38	8.97e-13	2.66e-08	0.85	0.79	Serum metabolite levels;	chr11:118679199	chr11:118688039~118690600:-
UVM	cis	rs507080	0.961	rs656505	ENSG00000255239.1	AP002954.6	9.38	8.97e-13	2.66e-08	0.85	0.79	Serum metabolite levels;	chr11:118679245	chr11:118688039~118690600:-
UVM	cis	rs507080	0.961	rs660489	ENSG00000255239.1	AP002954.6	9.38	8.97e-13	2.66e-08	0.85	0.79	Serum metabolite levels;	chr11:118679255	chr11:118688039~118690600:-
UVM	cis	rs507080	0.961	rs543327	ENSG00000255239.1	AP002954.6	9.38	8.97e-13	2.66e-08	0.85	0.79	Serum metabolite levels;	chr11:118679276	chr11:118688039~118690600:-
UVM	cis	rs507080	0.961	rs543413	ENSG00000255239.1	AP002954.6	9.38	8.97e-13	2.66e-08	0.85	0.79	Serum metabolite levels;	chr11:118679308	chr11:118688039~118690600:-
UVM	cis	rs6597981	0.604	rs7945912	ENSG00000279672.1	CMB9-55F22.1	9.38	9.08e-13	2.69e-08	0.7	0.79	Breast cancer;	chr11:750849	chr11:779617~780755:+
UVM	cis	rs2739330	1	rs2739330	ENSG00000273295.1	AP000350.5	9.32	1.11e-12	3.22e-08	0.95	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23953099	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.729	rs9612523	ENSG00000273295.1	AP000350.5	9.32	1.11e-12	3.22e-08	0.95	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23954339	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.964	rs2739338	ENSG00000273295.1	AP000350.5	9.32	1.11e-12	3.22e-08	0.95	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23954943	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.615	rs2858911	ENSG00000273295.1	AP000350.5	9.32	1.11e-12	3.22e-08	0.95	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23955008	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.576	rs2858912	ENSG00000273295.1	AP000350.5	9.32	1.11e-12	3.22e-08	0.95	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23955010	chr22:23901432~23907068:-
UVM	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	9.32	1.13e-12	3.27e-08	1.02	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
UVM	cis	rs507080	0.961	rs520543	ENSG00000255239.1	AP002954.6	9.27	1.35e-12	3.84e-08	0.84	0.79	Serum metabolite levels;	chr11:118667448	chr11:118688039~118690600:-
UVM	cis	rs507080	0.961	rs4457789	ENSG00000255239.1	AP002954.6	9.27	1.35e-12	3.84e-08	0.84	0.79	Serum metabolite levels;	chr11:118668461	chr11:118688039~118690600:-
UVM	cis	rs507080	0.961	rs1784298	ENSG00000255239.1	AP002954.6	9.27	1.35e-12	3.84e-08	0.84	0.79	Serum metabolite levels;	chr11:118677956	chr11:118688039~118690600:-
UVM	cis	rs507080	0.961	rs4938522	ENSG00000255239.1	AP002954.6	9.27	1.35e-12	3.84e-08	0.84	0.79	Serum metabolite levels;	chr11:118677962	chr11:118688039~118690600:-
UVM	cis	rs507080	0.961	rs4938523	ENSG00000255239.1	AP002954.6	9.27	1.35e-12	3.84e-08	0.84	0.79	Serum metabolite levels;	chr11:118678129	chr11:118688039~118690600:-
UVM	cis	rs507080	1	rs507080	ENSG00000255239.1	AP002954.6	9.27	1.35e-12	3.84e-08	0.84	0.79	Serum metabolite levels;	chr11:118678873	chr11:118688039~118690600:-
UVM	cis	rs507080	1	rs659969	ENSG00000255239.1	AP002954.6	9.27	1.35e-12	3.84e-08	0.84	0.79	Serum metabolite levels;	chr11:118679094	chr11:118688039~118690600:-
UVM	cis	rs507080	0.961	rs607527	ENSG00000255239.1	AP002954.6	-9.27	1.35e-12	3.84e-08	-0.84	-0.79	Serum metabolite levels;	chr11:118667478	chr11:118688039~118690600:-
UVM	cis	rs1799949	1	rs8176109	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43113759	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs8176103	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43115033	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.896	rs8176098	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43116189	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs8176087	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43118649	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs35668327	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43121078	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs34942571	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43121362	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.896	rs8176086	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43122761	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs8176083	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43123134	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.93	rs3765640	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43124230	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs8176077	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43124331	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.929	rs799905	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43125170	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.929	rs799906	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43126099	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs11655505	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43126360	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs799908	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43126899	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs4793204	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43127281	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs799910	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43127544	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs12947782	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43127865	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs33945274	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43128056	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs33925201	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43128665	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs11653069	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43131360	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs6503726	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43132725	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs2175957	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43134805	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.93	rs1554063	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43135128	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs33988650	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43135863	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs33961729	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43135907	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs11656097	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43138596	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs2292595	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43138657	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs11657835	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43139936	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs1135214	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43140306	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs11658754	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43140722	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs11652332	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43143472	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.93	rs33968979	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43145975	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs12952790	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43147590	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs12950607	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43147911	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs11079056	ENSG00000198496.9	NBR2	-9.24	1.47e-12	3.9e-08	-1.05	-0.79	Menopause (age at onset);	chr17:43148782	chr17:43125610~43153671:+
UVM	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-9.24	1.48e-12	3.92e-08	-1.04	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-9.24	1.48e-12	3.92e-08	-1.04	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-9.24	1.48e-12	3.92e-08	-1.04	-0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
UVM	cis	rs2739330	0.627	rs9608219	ENSG00000273295.1	AP000350.5	9.17	1.93e-12	5.04e-08	0.91	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23901432~23907068:-
UVM	cis	rs801193	1	rs13239306	ENSG00000226824.5	RP4-756H11.3	9.14	2.11e-12	5.5e-08	1.08	0.79	Aortic root size;	chr7:66671030	chr7:66654538~66669855:+
UVM	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	9.14	2.12e-12	5.5e-08	1.01	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	9.14	2.12e-12	5.5e-08	1.01	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	9.12	2.24e-12	5.76e-08	1.02	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	9.12	2.24e-12	5.76e-08	1.02	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.628	rs311606	ENSG00000253404.1	AC034243.1	9.1	2.41e-12	6.12e-08	1.02	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709551	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	9.1	2.41e-12	6.12e-08	1.02	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	9.1	2.41e-12	6.12e-08	1.02	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	9.1	2.41e-12	6.12e-08	1.02	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	9.1	2.41e-12	6.12e-08	1.02	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
UVM	cis	rs1799949	0.965	rs2236762	ENSG00000198496.9	NBR2	-9.1	2.45e-12	6.21e-08	-1.03	-0.78	Menopause (age at onset);	chr17:43074658	chr17:43125610~43153671:+
UVM	cis	rs7188445	0.615	rs4340340	ENSG00000261390.4	RP11-345M22.2	-9.07	2.66e-12	6.65e-08	-0.82	-0.78	Urate levels;	chr16:79716720	chr16:79715232~79770563:-
UVM	cis	rs2739330	1	rs2739330	ENSG00000218537.1	MIF-AS1	9.06	2.82e-12	6.92e-08	1.16	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23953099	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.729	rs9612523	ENSG00000218537.1	MIF-AS1	9.06	2.82e-12	6.92e-08	1.16	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23954339	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.964	rs2739338	ENSG00000218537.1	MIF-AS1	9.06	2.82e-12	6.92e-08	1.16	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23954943	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.615	rs2858911	ENSG00000218537.1	MIF-AS1	9.06	2.82e-12	6.92e-08	1.16	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23955008	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.576	rs2858912	ENSG00000218537.1	MIF-AS1	9.06	2.82e-12	6.92e-08	1.16	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23955010	chr22:23894426~23898930:-
UVM	cis	rs7188445	0.592	rs4404082	ENSG00000261390.4	RP11-345M22.2	8.98	3.79e-12	9.08e-08	0.82	0.78	Urate levels;	chr16:79716615	chr16:79715232~79770563:-
UVM	cis	rs7188445	0.932	rs3813582	ENSG00000261390.4	RP11-345M22.2	-8.96	4.04e-12	9.34e-08	-0.84	-0.78	Urate levels;	chr16:79715456	chr16:79715232~79770563:-
UVM	cis	rs7569084	0.663	rs6546150	ENSG00000204929.10	AC074391.1	-8.96	4.05e-12	9.34e-08	-1.23	-0.78	Sum eosinophil basophil counts;	chr2:65415066	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.687	rs963539	ENSG00000204929.10	AC074391.1	-8.96	4.05e-12	9.34e-08	-1.23	-0.78	Sum eosinophil basophil counts;	chr2:65421413	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.687	rs6755006	ENSG00000204929.10	AC074391.1	-8.96	4.05e-12	9.34e-08	-1.23	-0.78	Sum eosinophil basophil counts;	chr2:65426008	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.687	rs6755128	ENSG00000204929.10	AC074391.1	-8.96	4.05e-12	9.34e-08	-1.23	-0.78	Sum eosinophil basophil counts;	chr2:65426065	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.687	rs12993075	ENSG00000204929.10	AC074391.1	8.96	4.05e-12	9.34e-08	1.23	0.78	Sum eosinophil basophil counts;	chr2:65431010	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.687	rs4671663	ENSG00000204929.10	AC074391.1	8.96	4.05e-12	9.34e-08	1.23	0.78	Sum eosinophil basophil counts;	chr2:65434400	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.687	rs11692813	ENSG00000204929.10	AC074391.1	8.96	4.05e-12	9.34e-08	1.23	0.78	Sum eosinophil basophil counts;	chr2:65435172	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.663	rs11126037	ENSG00000204929.10	AC074391.1	8.96	4.05e-12	9.34e-08	1.23	0.78	Sum eosinophil basophil counts;	chr2:65436024	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.687	rs11126038	ENSG00000204929.10	AC074391.1	8.96	4.05e-12	9.34e-08	1.23	0.78	Sum eosinophil basophil counts;	chr2:65436100	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.663	rs11694714	ENSG00000204929.10	AC074391.1	8.96	4.05e-12	9.34e-08	1.23	0.78	Sum eosinophil basophil counts;	chr2:65436802	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.663	rs4671128	ENSG00000204929.10	AC074391.1	8.96	4.05e-12	9.34e-08	1.23	0.78	Sum eosinophil basophil counts;	chr2:65438130	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.687	rs35839762	ENSG00000204929.10	AC074391.1	8.96	4.05e-12	9.34e-08	1.23	0.78	Sum eosinophil basophil counts;	chr2:65441318	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.687	rs1437462	ENSG00000204929.10	AC074391.1	8.96	4.05e-12	9.34e-08	1.23	0.78	Sum eosinophil basophil counts;	chr2:65449559	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.663	rs1437461	ENSG00000204929.10	AC074391.1	8.96	4.05e-12	9.34e-08	1.23	0.78	Sum eosinophil basophil counts;	chr2:65452578	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.687	rs7562559	ENSG00000204929.10	AC074391.1	8.96	4.05e-12	9.34e-08	1.23	0.78	Sum eosinophil basophil counts;	chr2:65452719	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.687	rs1370394	ENSG00000204929.10	AC074391.1	8.96	4.05e-12	9.34e-08	1.23	0.78	Sum eosinophil basophil counts;	chr2:65453176	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.687	rs934731	ENSG00000204929.10	AC074391.1	8.96	4.05e-12	9.34e-08	1.23	0.78	Sum eosinophil basophil counts;	chr2:65456353	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.687	rs7577452	ENSG00000204929.10	AC074391.1	8.96	4.05e-12	9.34e-08	1.23	0.78	Sum eosinophil basophil counts;	chr2:65456694	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.64	rs11126039	ENSG00000204929.10	AC074391.1	8.96	4.05e-12	9.34e-08	1.23	0.78	Sum eosinophil basophil counts;	chr2:65457953	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.687	rs12614851	ENSG00000204929.10	AC074391.1	8.96	4.05e-12	9.34e-08	1.23	0.78	Sum eosinophil basophil counts;	chr2:65458050	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.687	rs1344891	ENSG00000204929.10	AC074391.1	8.96	4.05e-12	9.34e-08	1.23	0.78	Sum eosinophil basophil counts;	chr2:65458890	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.687	rs11675538	ENSG00000204929.10	AC074391.1	8.96	4.05e-12	9.34e-08	1.23	0.78	Sum eosinophil basophil counts;	chr2:65459327	chr2:65436711~66084639:+
UVM	cis	rs1799949	0.931	rs34410138	ENSG00000198496.9	NBR2	-8.92	4.59e-12	1.05e-07	-1.07	-0.78	Menopause (age at onset);	chr17:43127753	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs799916	ENSG00000198496.9	NBR2	8.9	4.91e-12	1.12e-07	1.04	0.78	Menopause (age at onset);	chr17:43091173	chr17:43125610~43153671:+
UVM	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	8.9	4.94e-12	1.12e-07	1.13	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	8.9	4.94e-12	1.12e-07	1.13	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	8.9	4.94e-12	1.12e-07	1.13	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	8.9	4.94e-12	1.12e-07	1.13	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	8.9	4.94e-12	1.12e-07	1.13	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	8.9	4.94e-12	1.12e-07	1.13	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	8.9	4.94e-12	1.12e-07	1.13	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	8.9	4.94e-12	1.12e-07	1.13	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-8.9	4.94e-12	1.12e-07	-1.13	-0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-8.9	4.94e-12	1.12e-07	-1.13	-0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
UVM	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	8.87	5.45e-12	1.21e-07	0.99	0.78	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
UVM	cis	rs7188445	0.592	rs7196490	ENSG00000261390.4	RP11-345M22.2	-8.85	5.94e-12	1.32e-07	-0.82	-0.78	Urate levels;	chr16:79718572	chr16:79715232~79770563:-
UVM	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-8.8	7.1e-12	1.57e-07	-1.1	-0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
UVM	cis	rs12541595	0.928	rs72716972	ENSG00000249816.5	LINC00964	-8.71	9.62e-12	2.11e-07	-0.76	-0.77	Left ventricle diastolic internal dimension;	chr8:124846279	chr8:124848737~124954328:+
UVM	cis	rs1799949	0.683	rs55737636	ENSG00000198496.9	NBR2	-8.71	9.94e-12	2.17e-07	-1.02	-0.77	Menopause (age at onset);	chr17:43112722	chr17:43125610~43153671:+
UVM	cis	rs2739330	0.627	rs9608219	ENSG00000218537.1	MIF-AS1	8.7	1.01e-11	2.2e-07	1.1	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23894426~23898930:-
UVM	cis	rs7188445	0.932	rs17767904	ENSG00000261390.4	RP11-345M22.2	-8.66	1.16e-11	2.51e-07	-0.81	-0.77	Urate levels;	chr16:79716078	chr16:79715232~79770563:-
UVM	cis	rs10935480	0.771	rs7634817	ENSG00000239445.4	ST3GAL6-AS1	8.65	1.21e-11	2.62e-07	0.63	0.77	Blood protein levels;	chr3:98743681	chr3:98714330~98732651:-
UVM	cis	rs2882667	0.554	rs1368425	ENSG00000253404.1	AC034243.1	8.64	1.25e-11	2.71e-07	0.99	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944528	chr5:138744434~138753309:-
UVM	cis	rs507080	0.922	rs654792	ENSG00000255239.1	AP002954.6	-8.62	1.36e-11	2.92e-07	-0.82	-0.77	Serum metabolite levels;	chr11:118682287	chr11:118688039~118690600:-
UVM	cis	rs7188445	0.899	rs58722186	ENSG00000261390.4	RP11-345M22.2	-8.57	1.6e-11	3.42e-07	-0.81	-0.77	Urate levels;	chr16:79717694	chr16:79715232~79770563:-
UVM	cis	rs7188445	0.899	rs57652769	ENSG00000261390.4	RP11-345M22.2	-8.57	1.6e-11	3.42e-07	-0.81	-0.77	Urate levels;	chr16:79720079	chr16:79715232~79770563:-
UVM	cis	rs7188445	0.932	rs4575545	ENSG00000261390.4	RP11-345M22.2	-8.57	1.6e-11	3.42e-07	-0.81	-0.77	Urate levels;	chr16:79721549	chr16:79715232~79770563:-
UVM	cis	rs1799949	1	rs2298862	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43024671	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.93	rs2298861	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43024814	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs915945	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43027847	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs12944458	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43028755	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs36036395	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43029280	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs72829113	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43029818	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs11653253	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43030645	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs12951869	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43035550	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs12944597	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43035667	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs12942277	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43035957	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs9911630	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43036325	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs34616041	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43036769	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs11654452	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43037366	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs4793189	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43038698	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs11657053	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43039112	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs8071278	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43041893	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs7223952	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43042868	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs11659028	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43043008	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs8176323	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43043694	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs8176322	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43043756	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs12516	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43044391	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs8176318	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43045257	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs8176310	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43047896	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs4793190	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43048092	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs3092988	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43049685	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs8070179	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43050671	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs8176297	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43051308	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs8176296	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43051574	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs4793191	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43052360	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs4793192	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43052373	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.965	rs7212284	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43053924	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs8176289	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43054039	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.86	rs8176279	ENSG00000198496.9	NBR2	-8.56	1.65e-11	3.42e-07	-1.04	-0.76	Menopause (age at onset);	chr17:43058379	chr17:43125610~43153671:+
UVM	cis	rs9322193	0.962	rs6914319	ENSG00000231760.4	RP11-350J20.5	8.56	1.68e-11	3.47e-07	0.95	0.76	Lung cancer;	chr6:149806304	chr6:149796151~149826294:-
UVM	cis	rs7188445	0.556	rs7194711	ENSG00000261390.4	RP11-345M22.2	-8.55	1.73e-11	3.58e-07	-0.84	-0.76	Urate levels;	chr16:79715134	chr16:79715232~79770563:-
UVM	cis	rs12541595	1	rs12541595	ENSG00000249816.5	LINC00964	8.55	1.76e-11	3.63e-07	0.75	0.76	Left ventricle diastolic internal dimension;	chr8:124845117	chr8:124848737~124954328:+
UVM	cis	rs7188445	0.556	rs7203910	ENSG00000261390.4	RP11-345M22.2	-8.54	1.82e-11	3.75e-07	-0.86	-0.76	Urate levels;	chr16:79711722	chr16:79715232~79770563:-
UVM	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	8.53	1.87e-11	3.85e-07	1.12	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
UVM	cis	rs12541595	0.93	rs55679363	ENSG00000249816.5	LINC00964	-8.5	2.09e-11	4.3e-07	-0.74	-0.76	Left ventricle diastolic internal dimension;	chr8:124855592	chr8:124848737~124954328:+
UVM	cis	rs7188445	0.836	rs3813580	ENSG00000261390.4	RP11-345M22.2	-8.47	2.34e-11	4.78e-07	-0.83	-0.76	Urate levels;	chr16:79715383	chr16:79715232~79770563:-
UVM	cis	rs2882667	0.69	rs11750163	ENSG00000253404.1	AC034243.1	8.45	2.46e-11	4.82e-07	1.05	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138705920	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	8.45	2.46e-11	4.82e-07	1.05	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	8.45	2.46e-11	4.82e-07	1.05	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	8.45	2.46e-11	4.82e-07	1.05	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	8.45	2.46e-11	4.82e-07	1.05	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	8.45	2.46e-11	4.82e-07	1.05	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	8.45	2.46e-11	4.82e-07	1.05	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	8.45	2.46e-11	4.82e-07	1.05	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	8.45	2.46e-11	4.82e-07	1.05	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	8.45	2.46e-11	4.82e-07	1.05	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-8.45	2.46e-11	4.82e-07	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-8.45	2.46e-11	4.82e-07	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-8.45	2.46e-11	4.82e-07	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-8.45	2.46e-11	4.82e-07	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-8.45	2.46e-11	4.82e-07	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-8.45	2.46e-11	4.82e-07	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-8.45	2.46e-11	4.82e-07	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-8.45	2.46e-11	4.82e-07	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-8.45	2.46e-11	4.82e-07	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-8.45	2.46e-11	4.82e-07	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-8.45	2.46e-11	4.82e-07	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-8.45	2.46e-11	4.82e-07	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-8.45	2.46e-11	4.82e-07	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-8.45	2.46e-11	4.82e-07	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-8.45	2.46e-11	4.82e-07	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-8.45	2.46e-11	4.82e-07	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-8.45	2.46e-11	4.82e-07	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-8.45	2.46e-11	4.82e-07	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-8.45	2.46e-11	4.82e-07	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-8.45	2.46e-11	4.82e-07	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-8.45	2.46e-11	4.82e-07	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-8.45	2.46e-11	4.82e-07	-1.05	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
UVM	cis	rs7188445	0.932	rs73575095	ENSG00000261390.4	RP11-345M22.2	-8.45	2.48e-11	4.86e-07	-0.81	-0.76	Urate levels;	chr16:79716435	chr16:79715232~79770563:-
UVM	cis	rs12541595	0.93	rs35006907	ENSG00000249816.5	LINC00964	-8.44	2.6e-11	5.07e-07	-0.72	-0.76	Left ventricle diastolic internal dimension;	chr8:124847575	chr8:124848737~124954328:+
UVM	cis	rs12541595	0.93	rs34866937	ENSG00000249816.5	LINC00964	-8.44	2.6e-11	5.07e-07	-0.72	-0.76	Left ventricle diastolic internal dimension;	chr8:124847608	chr8:124848737~124954328:+
UVM	cis	rs12541595	0.93	rs7461129	ENSG00000249816.5	LINC00964	-8.44	2.6e-11	5.07e-07	-0.72	-0.76	Left ventricle diastolic internal dimension;	chr8:124849132	chr8:124848737~124954328:+
UVM	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	8.39	3.08e-11	5.89e-07	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	8.39	3.08e-11	5.89e-07	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	8.39	3.08e-11	5.89e-07	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	8.39	3.08e-11	5.89e-07	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	8.39	3.08e-11	5.89e-07	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	8.39	3.08e-11	5.89e-07	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	8.39	3.08e-11	5.89e-07	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	8.39	3.08e-11	5.89e-07	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	8.39	3.08e-11	5.89e-07	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	8.39	3.08e-11	5.89e-07	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	8.39	3.08e-11	5.89e-07	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	8.39	3.08e-11	5.89e-07	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	8.39	3.08e-11	5.89e-07	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	8.39	3.08e-11	5.89e-07	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	8.39	3.08e-11	5.89e-07	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	8.39	3.08e-11	5.89e-07	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	8.39	3.08e-11	5.89e-07	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	8.39	3.08e-11	5.89e-07	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	8.39	3.08e-11	5.89e-07	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-8.39	3.08e-11	5.89e-07	-1.03	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
UVM	cis	rs507080	0.922	rs4936433	ENSG00000255239.1	AP002954.6	-8.38	3.19e-11	6.1e-07	-0.79	-0.76	Serum metabolite levels;	chr11:118681711	chr11:118688039~118690600:-
UVM	cis	rs7569084	0.663	rs10190233	ENSG00000204929.10	AC074391.1	-8.38	3.24e-11	6.19e-07	-1.17	-0.76	Sum eosinophil basophil counts;	chr2:65413095	chr2:65436711~66084639:+
UVM	cis	rs8013143	1	rs8013143	ENSG00000279656.1	RP11-298I3.6	-8.37	3.35e-11	6.37e-07	-1.08	-0.76	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025068	chr14:23023083~23024217:-
UVM	cis	rs8013143	1	rs941718	ENSG00000279656.1	RP11-298I3.6	-8.37	3.35e-11	6.37e-07	-1.08	-0.76	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025839	chr14:23023083~23024217:-
UVM	cis	rs8013143	0.961	rs7147308	ENSG00000279656.1	RP11-298I3.6	-8.37	3.35e-11	6.37e-07	-1.08	-0.76	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23028420	chr14:23023083~23024217:-
UVM	cis	rs113525195	1	rs113525195	ENSG00000279656.1	RP11-298I3.6	-8.37	3.35e-11	6.37e-07	-1.08	-0.76	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Mean corpuscular hemoglobin;	chr14:23030112	chr14:23023083~23024217:-
UVM	cis	rs2882667	0.69	rs311608	ENSG00000253404.1	AC034243.1	8.36	3.42e-11	6.49e-07	1.03	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138708000	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	8.36	3.48e-11	6.58e-07	1.08	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	8.36	3.48e-11	6.58e-07	1.08	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	8.36	3.48e-11	6.58e-07	1.08	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	8.36	3.48e-11	6.58e-07	1.08	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	8.36	3.48e-11	6.58e-07	1.08	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
UVM	cis	rs7188445	0.787	rs7189954	ENSG00000261390.4	RP11-345M22.2	8.35	3.57e-11	6.75e-07	0.82	0.76	Urate levels;	chr16:79701150	chr16:79715232~79770563:-
UVM	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	8.34	3.73e-11	6.77e-07	0.99	0.76	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	8.34	3.73e-11	6.77e-07	0.99	0.76	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	8.34	3.73e-11	6.77e-07	0.99	0.76	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	8.34	3.73e-11	6.77e-07	0.99	0.76	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
UVM	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	8.34	3.73e-11	6.77e-07	0.99	0.76	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	8.34	3.73e-11	6.77e-07	0.99	0.76	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	8.34	3.73e-11	6.77e-07	0.99	0.76	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	8.34	3.73e-11	6.77e-07	0.99	0.76	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	8.34	3.73e-11	6.77e-07	0.99	0.76	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
UVM	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	8.34	3.73e-11	6.77e-07	0.99	0.76	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	8.34	3.73e-11	6.77e-07	0.99	0.76	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	8.34	3.73e-11	6.77e-07	0.99	0.76	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
UVM	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
UVM	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
UVM	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
UVM	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
UVM	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
UVM	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
UVM	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
UVM	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
UVM	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
UVM	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-8.34	3.73e-11	6.77e-07	-0.99	-0.76	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
UVM	cis	rs12541595	0.787	rs12542527	ENSG00000249816.5	LINC00964	-8.33	3.8e-11	6.87e-07	-0.73	-0.76	Left ventricle diastolic internal dimension;	chr8:124864202	chr8:124848737~124954328:+
UVM	cis	rs9322193	0.884	rs9688699	ENSG00000231760.4	RP11-350J20.5	8.33	3.81e-11	6.89e-07	0.9	0.76	Lung cancer;	chr6:149733680	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9767652	ENSG00000231760.4	RP11-350J20.5	8.33	3.81e-11	6.89e-07	0.9	0.76	Lung cancer;	chr6:149734502	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs10782314	ENSG00000231760.4	RP11-350J20.5	8.33	3.81e-11	6.89e-07	0.9	0.76	Lung cancer;	chr6:149735527	chr6:149796151~149826294:-
UVM	cis	rs916888	0.779	rs199528	ENSG00000262539.1	RP11-259G18.3	8.32	3.93e-11	6.97e-07	1.19	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46259551~46260606:-
UVM	cis	rs916888	0.821	rs199525	ENSG00000262539.1	RP11-259G18.3	8.32	3.93e-11	6.97e-07	1.19	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46259551~46260606:-
UVM	cis	rs916888	0.821	rs70600	ENSG00000262539.1	RP11-259G18.3	8.32	3.93e-11	6.97e-07	1.19	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46259551~46260606:-
UVM	cis	rs916888	0.697	rs199516	ENSG00000262539.1	RP11-259G18.3	-8.32	3.93e-11	6.97e-07	-1.19	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46259551~46260606:-
UVM	cis	rs916888	0.738	rs199515	ENSG00000262539.1	RP11-259G18.3	-8.32	3.93e-11	6.97e-07	-1.19	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46259551~46260606:-
UVM	cis	rs916888	0.821	rs199514	ENSG00000262539.1	RP11-259G18.3	-8.32	3.93e-11	6.97e-07	-1.19	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46259551~46260606:-
UVM	cis	rs916888	0.821	rs199513	ENSG00000262539.1	RP11-259G18.3	-8.32	3.93e-11	6.97e-07	-1.19	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46259551~46260606:-
UVM	cis	rs916888	0.821	rs199512	ENSG00000262539.1	RP11-259G18.3	-8.32	3.93e-11	6.97e-07	-1.19	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46259551~46260606:-
UVM	cis	rs916888	0.821	rs199509	ENSG00000262539.1	RP11-259G18.3	-8.32	3.93e-11	6.97e-07	-1.19	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46259551~46260606:-
UVM	cis	rs916888	0.821	rs199507	ENSG00000262539.1	RP11-259G18.3	-8.32	3.93e-11	6.97e-07	-1.19	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46259551~46260606:-
UVM	cis	rs916888	0.821	rs199506	ENSG00000262539.1	RP11-259G18.3	-8.32	3.93e-11	6.97e-07	-1.19	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46259551~46260606:-
UVM	cis	rs916888	0.821	rs415430	ENSG00000262539.1	RP11-259G18.3	-8.32	3.93e-11	6.97e-07	-1.19	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46259551~46260606:-
UVM	cis	rs916888	0.779	rs430685	ENSG00000262539.1	RP11-259G18.3	-8.32	3.93e-11	6.97e-07	-1.19	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46259551~46260606:-
UVM	cis	rs916888	0.821	rs199505	ENSG00000262539.1	RP11-259G18.3	-8.32	3.93e-11	6.97e-07	-1.19	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46259551~46260606:-
UVM	cis	rs916888	0.821	rs70602	ENSG00000262539.1	RP11-259G18.3	-8.32	3.93e-11	6.97e-07	-1.19	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46259551~46260606:-
UVM	cis	rs9322193	0.962	rs2065664	ENSG00000231760.4	RP11-350J20.5	8.32	3.94e-11	6.97e-07	0.91	0.76	Lung cancer;	chr6:149762485	chr6:149796151~149826294:-
UVM	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	8.32	4.03e-11	6.97e-07	0.94	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
UVM	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
UVM	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
UVM	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
UVM	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
UVM	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
UVM	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
UVM	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
UVM	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
UVM	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
UVM	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
UVM	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
UVM	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
UVM	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
UVM	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
UVM	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
UVM	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
UVM	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
UVM	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
UVM	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
UVM	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
UVM	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
UVM	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
UVM	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
UVM	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
UVM	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
UVM	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
UVM	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	8.32	4.03e-11	6.97e-07	0.99	0.76	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
UVM	cis	rs9322193	0.923	rs14314	ENSG00000231760.4	RP11-350J20.5	8.3	4.27e-11	7.34e-07	0.92	0.75	Lung cancer;	chr6:149820395	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs1413655	ENSG00000231760.4	RP11-350J20.5	8.3	4.27e-11	7.34e-07	0.92	0.75	Lung cancer;	chr6:149821815	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.926	rs9383546	ENSG00000231760.4	RP11-350J20.5	8.3	4.27e-11	7.34e-07	0.92	0.75	Lung cancer;	chr6:149822743	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs1889473	ENSG00000231760.4	RP11-350J20.5	8.3	4.27e-11	7.34e-07	0.92	0.75	Lung cancer;	chr6:149825485	chr6:149796151~149826294:-
UVM	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	8.3	4.28e-11	7.35e-07	1.03	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
UVM	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	8.28	4.63e-11	7.94e-07	1.05	0.75	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
UVM	cis	rs9322193	0.847	rs56103941	ENSG00000231760.4	RP11-350J20.5	8.27	4.85e-11	8.3e-07	0.94	0.75	Lung cancer;	chr6:149816095	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.847	rs12210605	ENSG00000231760.4	RP11-350J20.5	8.27	4.85e-11	8.3e-07	0.94	0.75	Lung cancer;	chr6:149817267	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9371199	ENSG00000231760.4	RP11-350J20.5	8.27	4.85e-11	8.3e-07	0.94	0.75	Lung cancer;	chr6:149817526	chr6:149796151~149826294:-
UVM	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-8.26	4.89e-11	8.36e-07	-0.99	-0.75	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-8.26	4.89e-11	8.36e-07	-0.99	-0.75	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
UVM	cis	rs2739330	0.796	rs5760097	ENSG00000218537.1	MIF-AS1	8.26	4.97e-11	8.44e-07	1.09	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.828	rs4822451	ENSG00000218537.1	MIF-AS1	8.26	4.97e-11	8.44e-07	1.09	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.828	rs5760098	ENSG00000218537.1	MIF-AS1	8.26	4.97e-11	8.44e-07	1.09	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.828	rs5760099	ENSG00000218537.1	MIF-AS1	8.26	4.97e-11	8.44e-07	1.09	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.828	rs5760102	ENSG00000218537.1	MIF-AS1	8.26	4.97e-11	8.44e-07	1.09	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	8.26	4.97e-11	8.44e-07	1.09	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
UVM	cis	rs9322193	0.923	rs10872651	ENSG00000231760.4	RP11-350J20.5	8.24	5.26e-11	8.91e-07	0.94	0.75	Lung cancer;	chr6:149768273	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs3805749	ENSG00000231760.4	RP11-350J20.5	8.24	5.26e-11	8.91e-07	0.94	0.75	Lung cancer;	chr6:149772546	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.847	rs9505972	ENSG00000231760.4	RP11-350J20.5	8.24	5.26e-11	8.91e-07	0.94	0.75	Lung cancer;	chr6:149775255	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs3805752	ENSG00000231760.4	RP11-350J20.5	8.24	5.26e-11	8.91e-07	0.94	0.75	Lung cancer;	chr6:149795490	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs10872649	ENSG00000231760.4	RP11-350J20.5	8.23	5.5e-11	9.3e-07	0.91	0.75	Lung cancer;	chr6:149759454	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs10872650	ENSG00000231760.4	RP11-350J20.5	8.23	5.5e-11	9.3e-07	0.91	0.75	Lung cancer;	chr6:149760959	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs12660304	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149739647	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs12175575	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149763351	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs4869966	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149763714	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs1112730	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149766383	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs1112729	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149766491	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs10452626	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149767481	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs62441303	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149767547	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs9765929	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149769680	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs3805748	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149772542	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.736	rs10457851	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149775216	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.886	rs10872652	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149775303	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.886	rs12525871	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149775882	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.886	rs17672976	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149776207	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs2184369	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149776681	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs2342861	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149777561	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.926	rs2342860	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149777641	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs10872653	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149778907	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs9505974	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149779294	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs11155683	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149779341	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.926	rs9689036	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149780563	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9372044	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149780867	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs11155685	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149781649	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs9322218	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149782183	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs9322219	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149782263	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs9322220	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149782897	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs10214845	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149783124	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs9767122	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149783553	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs1413654	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149783956	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs9688809	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149787920	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs9689242	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149787970	chr6:149796151~149826294:-
UVM	cis	rs9322193	1	rs9767077	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149788479	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.926	rs9766562	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149788709	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9688938	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149788941	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs9688940	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149788977	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs9689447	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149789350	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.632	rs3828700	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149791033	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.736	rs3828701	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149791063	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.736	rs3805750	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149791065	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.926	rs3805751	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149791193	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs9689269	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149791861	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs62441335	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149792658	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs13215691	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149792666	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs4816	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149793609	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs3805753	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149795662	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.926	rs952166	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149798774	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs952165	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149798900	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs10872656	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149799444	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.926	rs9285525	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149801253	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs9322223	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149801509	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.884	rs2342858	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149805967	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.884	rs2095375	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149807037	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs4869730	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149808187	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.884	rs11155689	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149808470	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs2151913	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149809506	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs2342857	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149809537	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.884	rs933055	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149809701	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs4869731	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149810072	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs4552	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149811183	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs9397022	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149812052	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs9397357	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149812465	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs17673294	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149813857	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs6899661	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149818093	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs3763163	ENSG00000231760.4	RP11-350J20.5	8.21	5.94e-11	9.47e-07	0.91	0.75	Lung cancer;	chr6:149819770	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs6903998	ENSG00000231760.4	RP11-350J20.5	8.18	6.58e-11	1.04e-06	0.9	0.75	Lung cancer;	chr6:149831357	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs1984111	ENSG00000231760.4	RP11-350J20.5	8.18	6.58e-11	1.04e-06	0.9	0.75	Lung cancer;	chr6:149831720	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs2151912	ENSG00000231760.4	RP11-350J20.5	8.18	6.58e-11	1.04e-06	0.9	0.75	Lung cancer;	chr6:149831772	chr6:149796151~149826294:-
UVM	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-8.17	6.79e-11	1.07e-06	-0.98	-0.75	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
UVM	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-8.17	6.79e-11	1.07e-06	-0.98	-0.75	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
UVM	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-8.17	6.79e-11	1.07e-06	-0.98	-0.75	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
UVM	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-8.17	6.79e-11	1.07e-06	-0.98	-0.75	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
UVM	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-8.17	6.79e-11	1.07e-06	-0.98	-0.75	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
UVM	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	8.17	6.79e-11	1.07e-06	0.98	0.75	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
UVM	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	8.17	6.79e-11	1.07e-06	0.98	0.75	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
UVM	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	8.17	6.79e-11	1.07e-06	0.98	0.75	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
UVM	cis	rs9322193	0.962	rs2342764	ENSG00000231760.4	RP11-350J20.5	8.17	6.88e-11	1.08e-06	0.9	0.75	Lung cancer;	chr6:149835068	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.886	rs2065663	ENSG00000231760.4	RP11-350J20.5	8.17	6.88e-11	1.08e-06	0.94	0.75	Lung cancer;	chr6:149760331	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs12205092	ENSG00000231760.4	RP11-350J20.5	8.17	6.88e-11	1.08e-06	0.94	0.75	Lung cancer;	chr6:149761375	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs10782318	ENSG00000231760.4	RP11-350J20.5	8.15	7.38e-11	1.16e-06	0.91	0.75	Lung cancer;	chr6:149754137	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs7745915	ENSG00000231760.4	RP11-350J20.5	8.14	7.73e-11	1.21e-06	0.9	0.75	Lung cancer;	chr6:149834111	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs2275046	ENSG00000231760.4	RP11-350J20.5	8.14	7.73e-11	1.21e-06	0.9	0.75	Lung cancer;	chr6:149835865	chr6:149796151~149826294:-
UVM	cis	rs2882667	0.628	rs311607	ENSG00000253404.1	AC034243.1	8.13	7.99e-11	1.25e-06	1.03	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709231	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	8.13	7.99e-11	1.25e-06	1.03	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	8.13	7.99e-11	1.25e-06	1.03	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	8.13	7.99e-11	1.25e-06	1.03	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
UVM	cis	rs9322193	0.962	rs7740784	ENSG00000231760.4	RP11-350J20.5	8.12	8.22e-11	1.28e-06	0.92	0.75	Lung cancer;	chr6:149833364	chr6:149796151~149826294:-
UVM	cis	rs2739330	0.752	rs2330634	ENSG00000273295.1	AP000350.5	8.1	8.7e-11	1.35e-06	0.82	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23901432~23907068:-
UVM	cis	rs1799949	1	rs8176273	ENSG00000198496.9	NBR2	-8.1	8.81e-11	1.36e-06	-1.02	-0.75	Menopause (age at onset);	chr17:43059636	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs35330014	ENSG00000198496.9	NBR2	-8.1	8.81e-11	1.36e-06	-1.02	-0.75	Menopause (age at onset);	chr17:43060530	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs8077486	ENSG00000198496.9	NBR2	-8.1	8.81e-11	1.36e-06	-1.02	-0.75	Menopause (age at onset);	chr17:43060788	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs8176269	ENSG00000198496.9	NBR2	-8.1	8.81e-11	1.36e-06	-1.02	-0.75	Menopause (age at onset);	chr17:43061609	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs8176265	ENSG00000198496.9	NBR2	-8.1	8.81e-11	1.36e-06	-1.02	-0.75	Menopause (age at onset);	chr17:43061979	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs3092994	ENSG00000198496.9	NBR2	-8.1	8.81e-11	1.36e-06	-1.02	-0.75	Menopause (age at onset);	chr17:43063808	chr17:43125610~43153671:+
UVM	cis	rs9322193	0.923	rs9766037	ENSG00000231760.4	RP11-350J20.5	8.09	9.04e-11	1.39e-06	0.91	0.75	Lung cancer;	chr6:149616921	chr6:149796151~149826294:-
UVM	cis	rs916888	0.821	rs199504	ENSG00000262539.1	RP11-259G18.3	-8.07	9.7e-11	1.49e-06	-1.18	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46259551~46260606:-
UVM	cis	rs7188445	0.932	rs17767419	ENSG00000261390.4	RP11-345M22.2	-8.04	1.09e-10	1.67e-06	-0.83	-0.74	Urate levels;	chr16:79710651	chr16:79715232~79770563:-
UVM	cis	rs7188445	0.932	rs17689455	ENSG00000261390.4	RP11-345M22.2	-8.04	1.11e-10	1.69e-06	-0.84	-0.74	Urate levels;	chr16:79712438	chr16:79715232~79770563:-
UVM	cis	rs7188445	0.932	rs73575083	ENSG00000261390.4	RP11-345M22.2	-8.04	1.11e-10	1.69e-06	-0.84	-0.74	Urate levels;	chr16:79713958	chr16:79715232~79770563:-
UVM	cis	rs7188445	0.932	rs73575085	ENSG00000261390.4	RP11-345M22.2	-8.04	1.11e-10	1.69e-06	-0.84	-0.74	Urate levels;	chr16:79714179	chr16:79715232~79770563:-
UVM	cis	rs7188445	0.932	rs73575086	ENSG00000261390.4	RP11-345M22.2	-8.04	1.11e-10	1.69e-06	-0.84	-0.74	Urate levels;	chr16:79714588	chr16:79715232~79770563:-
UVM	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-8.03	1.13e-10	1.72e-06	-0.97	-0.74	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
UVM	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	8.03	1.14e-10	1.74e-06	1.14	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
UVM	cis	rs7188445	0.592	rs17767281	ENSG00000261390.4	RP11-345M22.2	-8.02	1.16e-10	1.77e-06	-0.84	-0.74	Urate levels;	chr16:79708544	chr16:79715232~79770563:-
UVM	cis	rs7188445	0.932	rs7203756	ENSG00000261390.4	RP11-345M22.2	8	1.25e-10	1.9e-06	0.83	0.74	Urate levels;	chr16:79711709	chr16:79715232~79770563:-
UVM	cis	rs7188445	0.592	rs7199794	ENSG00000261390.4	RP11-345M22.2	8	1.26e-10	1.91e-06	0.86	0.74	Urate levels;	chr16:79708296	chr16:79715232~79770563:-
UVM	cis	rs9322193	0.923	rs12176034	ENSG00000231760.4	RP11-350J20.5	8	1.28e-10	1.94e-06	0.95	0.74	Lung cancer;	chr6:149800557	chr6:149796151~149826294:-
UVM	cis	rs8013143	1	rs11846575	ENSG00000279656.1	RP11-298I3.6	-7.99	1.33e-10	2.02e-06	-1.05	-0.74	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23022075	chr14:23023083~23024217:-
UVM	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-7.98	1.36e-10	2.06e-06	-0.92	-0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
UVM	cis	rs9322193	0.886	rs4870049	ENSG00000231760.4	RP11-350J20.5	7.97	1.4e-10	2.11e-06	0.89	0.74	Lung cancer;	chr6:149837058	chr6:149796151~149826294:-
UVM	cis	rs7188445	0.932	rs17689625	ENSG00000261390.4	RP11-345M22.2	-7.95	1.5e-10	2.22e-06	-0.84	-0.74	Urate levels;	chr16:79715065	chr16:79715232~79770563:-
UVM	cis	rs7188445	0.932	rs17767742	ENSG00000261390.4	RP11-345M22.2	-7.95	1.5e-10	2.22e-06	-0.84	-0.74	Urate levels;	chr16:79715108	chr16:79715232~79770563:-
UVM	cis	rs2739330	0.892	rs4822455	ENSG00000273295.1	AP000350.5	7.94	1.58e-10	2.28e-06	0.81	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23901432~23907068:-
UVM	cis	rs57368286	1	rs57368286	ENSG00000204929.10	AC074391.1	-7.94	1.61e-10	2.31e-06	-1.23	-0.74	Granulocyte percentage of myeloid white cells;	chr2:65415453	chr2:65436711~66084639:+
UVM	cis	rs9322193	1	rs9399693	ENSG00000231760.4	RP11-350J20.5	7.91	1.79e-10	2.53e-06	0.88	0.74	Lung cancer;	chr6:149612718	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs55993747	ENSG00000231760.4	RP11-350J20.5	7.91	1.79e-10	2.53e-06	0.88	0.74	Lung cancer;	chr6:149622016	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.847	rs12191643	ENSG00000231760.4	RP11-350J20.5	7.91	1.79e-10	2.53e-06	0.88	0.74	Lung cancer;	chr6:149628912	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.884	rs9688794	ENSG00000231760.4	RP11-350J20.5	7.91	1.79e-10	2.53e-06	0.88	0.74	Lung cancer;	chr6:149632121	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9689084	ENSG00000231760.4	RP11-350J20.5	7.91	1.79e-10	2.53e-06	0.88	0.74	Lung cancer;	chr6:149639648	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs11155670	ENSG00000231760.4	RP11-350J20.5	7.91	1.79e-10	2.53e-06	0.88	0.74	Lung cancer;	chr6:149644992	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs12529698	ENSG00000231760.4	RP11-350J20.5	7.91	1.79e-10	2.53e-06	0.88	0.74	Lung cancer;	chr6:149650951	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9322208	ENSG00000231760.4	RP11-350J20.5	7.91	1.79e-10	2.53e-06	0.88	0.74	Lung cancer;	chr6:149658547	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9800736	ENSG00000231760.4	RP11-350J20.5	7.91	1.79e-10	2.53e-06	0.88	0.74	Lung cancer;	chr6:149661281	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs35961297	ENSG00000231760.4	RP11-350J20.5	7.91	1.79e-10	2.53e-06	0.88	0.74	Lung cancer;	chr6:149667929	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs66516768	ENSG00000231760.4	RP11-350J20.5	7.91	1.79e-10	2.53e-06	0.88	0.74	Lung cancer;	chr6:149671999	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs62439842	ENSG00000231760.4	RP11-350J20.5	7.91	1.79e-10	2.53e-06	0.88	0.74	Lung cancer;	chr6:149675847	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9800686	ENSG00000231760.4	RP11-350J20.5	7.89	1.88e-10	2.65e-06	0.91	0.74	Lung cancer;	chr6:149634464	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs55849538	ENSG00000231760.4	RP11-350J20.5	7.89	1.88e-10	2.65e-06	0.91	0.74	Lung cancer;	chr6:149635330	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.81	rs62439811	ENSG00000231760.4	RP11-350J20.5	7.89	1.88e-10	2.65e-06	0.91	0.74	Lung cancer;	chr6:149640416	chr6:149796151~149826294:-
UVM	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-7.89	1.93e-10	2.71e-06	-1.03	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-7.89	1.93e-10	2.71e-06	-1.03	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-7.89	1.93e-10	2.71e-06	-1.03	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-7.89	1.93e-10	2.71e-06	-1.03	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-7.89	1.93e-10	2.71e-06	-1.03	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-7.89	1.93e-10	2.71e-06	-1.03	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	7.89	1.93e-10	2.71e-06	1.03	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	7.89	1.93e-10	2.71e-06	1.03	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
UVM	cis	rs2739330	0.752	rs2330634	ENSG00000218537.1	MIF-AS1	7.88	1.94e-10	2.72e-06	1	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.652	rs2000469	ENSG00000273295.1	AP000350.5	7.88	1.98e-10	2.77e-06	0.93	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23901432~23907068:-
UVM	cis	rs9322193	0.683	rs113281309	ENSG00000231760.4	RP11-350J20.5	7.87	2.05e-10	2.85e-06	0.88	0.74	Lung cancer;	chr6:149787289	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.884	rs11155675	ENSG00000231760.4	RP11-350J20.5	7.87	2.08e-10	2.89e-06	0.96	0.74	Lung cancer;	chr6:149742883	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.651	rs9322188	ENSG00000231760.4	RP11-350J20.5	-7.85	2.18e-10	3.02e-06	-0.88	-0.74	Lung cancer;	chr6:149588355	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.961	rs9767713	ENSG00000231760.4	RP11-350J20.5	7.85	2.21e-10	3.07e-06	0.92	0.74	Lung cancer;	chr6:149588241	chr6:149796151~149826294:-
UVM	cis	rs7188445	0.932	rs17767491	ENSG00000261390.4	RP11-345M22.2	-7.85	2.22e-10	3.07e-06	-0.78	-0.74	Urate levels;	chr16:79711590	chr16:79715232~79770563:-
UVM	cis	rs9322193	0.884	rs9371201	ENSG00000231760.4	RP11-350J20.5	7.84	2.27e-10	3.13e-06	0.97	0.74	Lung cancer;	chr6:149823865	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.847	rs62439808	ENSG00000231760.4	RP11-350J20.5	7.84	2.29e-10	3.15e-06	0.89	0.74	Lung cancer;	chr6:149629690	chr6:149796151~149826294:-
UVM	cis	rs875971	0.66	rs2191268	ENSG00000226824.5	RP4-756H11.3	-7.84	2.3e-10	3.16e-06	-0.97	-0.74	Aortic root size;	chr7:66645237	chr7:66654538~66669855:+
UVM	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	7.83	2.38e-10	3.27e-06	1.01	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	7.83	2.38e-10	3.27e-06	1.01	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	7.83	2.38e-10	3.27e-06	1.01	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-7.83	2.39e-10	3.27e-06	-1.03	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
UVM	cis	rs9322193	0.962	rs3763162	ENSG00000231760.4	RP11-350J20.5	-7.83	2.39e-10	3.28e-06	-0.91	-0.74	Lung cancer;	chr6:149819674	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.884	rs10872647	ENSG00000231760.4	RP11-350J20.5	7.82	2.44e-10	3.34e-06	0.97	0.74	Lung cancer;	chr6:149758687	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.884	rs9480009	ENSG00000231760.4	RP11-350J20.5	7.82	2.49e-10	3.4e-06	0.89	0.73	Lung cancer;	chr6:149758502	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs10747276	ENSG00000231760.4	RP11-350J20.5	7.82	2.49e-10	3.4e-06	0.89	0.73	Lung cancer;	chr6:149758739	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9480031	ENSG00000231760.4	RP11-350J20.5	7.82	2.49e-10	3.4e-06	0.89	0.73	Lung cancer;	chr6:149758875	chr6:149796151~149826294:-
UVM	cis	rs7188445	0.932	rs73575079	ENSG00000261390.4	RP11-345M22.2	-7.81	2.53e-10	3.46e-06	-0.83	-0.73	Urate levels;	chr16:79711344	chr16:79715232~79770563:-
UVM	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	7.81	2.57e-10	3.51e-06	0.88	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
UVM	cis	rs9322193	0.923	rs9371486	ENSG00000231760.4	RP11-350J20.5	7.8	2.65e-10	3.61e-06	0.96	0.73	Lung cancer;	chr6:149832090	chr6:149796151~149826294:-
UVM	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-7.77	2.9e-10	3.93e-06	-0.93	-0.73	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
UVM	cis	rs1799949	1	rs8176242	ENSG00000198496.9	NBR2	-7.75	3.17e-10	4.1e-06	-1	-0.73	Menopause (age at onset);	chr17:43065857	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs4793194	ENSG00000198496.9	NBR2	-7.75	3.17e-10	4.1e-06	-1	-0.73	Menopause (age at onset);	chr17:43066316	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs8176234	ENSG00000198496.9	NBR2	-7.75	3.17e-10	4.1e-06	-1	-0.73	Menopause (age at onset);	chr17:43067763	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs8176233	ENSG00000198496.9	NBR2	-7.75	3.17e-10	4.1e-06	-1	-0.73	Menopause (age at onset);	chr17:43067787	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs8176220	ENSG00000198496.9	NBR2	-7.75	3.17e-10	4.1e-06	-1	-0.73	Menopause (age at onset);	chr17:43070445	chr17:43125610~43153671:+
UVM	cis	rs1799949	0.93	rs3092987	ENSG00000198496.9	NBR2	-7.75	3.17e-10	4.1e-06	-1	-0.73	Menopause (age at onset);	chr17:43070706	chr17:43125610~43153671:+
UVM	cis	rs1799949	1	rs1799966	ENSG00000198496.9	NBR2	-7.75	3.17e-10	4.1e-06	-1	-0.73	Menopause (age at onset);	chr17:43071077	chr17:43125610~43153671:+
UVM	cis	rs9322193	1	rs9377228	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149600862	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.961	rs2064520	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149603650	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.924	rs9498382	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149610982	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9377230	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149613607	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9404048	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149616188	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9767554	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149616860	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9505982	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149618465	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.886	rs9485408	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149618888	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9322196	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149619645	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs1080670	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149620161	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs10782310	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149622458	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs10782311	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149622592	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.884	rs10782312	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149622669	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs10747275	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149622782	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.886	rs9322198	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149623772	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.847	rs12234128	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149627553	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs57012784	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149627691	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9505823	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149628899	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9322200	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149630078	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9689599	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149631973	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9800580	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149632845	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.884	rs11155669	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149633501	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.887	rs9505824	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149633663	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9505826	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149633912	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9322204	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149636047	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9766886	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149637048	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9688861	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149637924	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs7740278	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149640116	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs12174716	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149644487	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9800871	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149644540	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9800614	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149644604	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs11155671	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149650996	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9689716	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149655662	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9689723	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149655935	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9322207	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149657185	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9968911	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149657419	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9767123	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149660323	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs3924871	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149662080	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs35830138	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149668635	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.884	rs62439836	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149669173	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs4869812	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149669447	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs4870267	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149671572	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs35967444	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149675588	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs4380763	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149678086	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs7767622	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149681766	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs4421206	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149682891	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs3798761	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149683643	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9322209	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149691226	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.884	rs9322210	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149695440	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs4354168	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149696642	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.884	rs7450246	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149702517	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs11155674	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149711111	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9383812	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149712355	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs2185352	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149714640	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.847	rs9383844	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149716268	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs4870529	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149716436	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9767309	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149716807	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs12174349	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149718012	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs2297932	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149718225	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs2297930	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149718360	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs2297928	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149718584	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs17745062	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149721079	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs62441279	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149721194	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9479094	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149725083	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9478291	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149729434	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9688350	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149730977	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9479494	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149739108	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs56397000	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149739347	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9800806	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149740350	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9688517	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149740655	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.884	rs9689702	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149740720	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs10782315	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149743093	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs1572229	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149743841	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.884	rs10872646	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149746539	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.884	rs12528279	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149750892	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.809	rs9479808	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149751328	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs62441284	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149751542	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs10782316	ENSG00000231760.4	RP11-350J20.5	7.75	3.22e-10	4.1e-06	0.85	0.73	Lung cancer;	chr6:149752755	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs57938011	ENSG00000231760.4	RP11-350J20.5	7.74	3.32e-10	4.2e-06	0.88	0.73	Lung cancer;	chr6:149642969	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.884	rs62439837	ENSG00000231760.4	RP11-350J20.5	7.74	3.32e-10	4.2e-06	0.88	0.73	Lung cancer;	chr6:149670380	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs62439840	ENSG00000231760.4	RP11-350J20.5	7.74	3.32e-10	4.2e-06	0.88	0.73	Lung cancer;	chr6:149674639	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs9393175	ENSG00000231760.4	RP11-350J20.5	7.74	3.32e-10	4.2e-06	0.88	0.73	Lung cancer;	chr6:149677587	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs4870509	ENSG00000231760.4	RP11-350J20.5	7.74	3.32e-10	4.2e-06	0.88	0.73	Lung cancer;	chr6:149702212	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9322214	ENSG00000231760.4	RP11-350J20.5	7.74	3.32e-10	4.2e-06	0.88	0.73	Lung cancer;	chr6:149703986	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.887	rs9767113	ENSG00000231760.4	RP11-350J20.5	7.74	3.32e-10	4.2e-06	0.88	0.73	Lung cancer;	chr6:149718157	chr6:149796151~149826294:-
UVM	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	7.74	3.33e-10	4.21e-06	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
UVM	cis	rs7188445	0.932	rs17689159	ENSG00000261390.4	RP11-345M22.2	-7.73	3.36e-10	4.25e-06	-0.86	-0.73	Urate levels;	chr16:79708493	chr16:79715232~79770563:-
UVM	cis	rs9322193	0.962	rs9478848	ENSG00000231760.4	RP11-350J20.5	7.71	3.71e-10	4.69e-06	0.86	0.73	Lung cancer;	chr6:149825080	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.961	rs9285521	ENSG00000231760.4	RP11-350J20.5	7.71	3.71e-10	4.69e-06	0.87	0.73	Lung cancer;	chr6:149585576	chr6:149796151~149826294:-
UVM	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-7.7	3.74e-10	4.72e-06	-0.95	-0.73	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
UVM	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	7.7	3.74e-10	4.72e-06	0.95	0.73	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
UVM	cis	rs9322193	0.923	rs4455682	ENSG00000231760.4	RP11-350J20.5	7.7	3.87e-10	4.88e-06	0.85	0.73	Lung cancer;	chr6:149700161	chr6:149796151~149826294:-
UVM	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-7.69	3.92e-10	4.88e-06	-0.98	-0.73	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
UVM	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-7.69	3.92e-10	4.88e-06	-0.98	-0.73	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
UVM	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	7.69	3.94e-10	4.88e-06	1.07	0.73	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
UVM	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	7.69	3.94e-10	4.88e-06	1.07	0.73	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
UVM	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	7.69	3.94e-10	4.88e-06	1.07	0.73	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
UVM	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	7.69	3.94e-10	4.88e-06	1.07	0.73	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
UVM	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	7.69	3.94e-10	4.88e-06	1.07	0.73	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
UVM	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	7.69	3.94e-10	4.88e-06	1.07	0.73	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
UVM	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	7.69	3.94e-10	4.88e-06	1.07	0.73	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
UVM	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	7.69	3.94e-10	4.88e-06	1.07	0.73	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
UVM	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	7.69	3.94e-10	4.88e-06	1.07	0.73	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
UVM	cis	rs12439619	0.846	rs62012059	ENSG00000278603.1	RP13-608F4.5	7.69	3.94e-10	4.88e-06	1.07	0.73	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472203~82472426:+
UVM	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	7.69	3.94e-10	4.88e-06	1.07	0.73	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
UVM	cis	rs12439619	0.846	rs28697264	ENSG00000278603.1	RP13-608F4.5	7.69	3.94e-10	4.88e-06	1.07	0.73	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472203~82472426:+
UVM	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-7.68	4.16e-10	4.97e-06	-0.98	-0.73	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-7.68	4.16e-10	4.97e-06	-0.98	-0.73	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-7.68	4.16e-10	4.97e-06	-0.98	-0.73	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
UVM	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-7.68	4.16e-10	4.97e-06	-0.98	-0.73	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
UVM	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	7.68	4.16e-10	4.97e-06	0.98	0.73	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-7.68	4.16e-10	4.97e-06	-0.98	-0.73	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
UVM	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-7.68	4.16e-10	4.97e-06	-0.98	-0.73	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
UVM	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-7.68	4.16e-10	4.97e-06	-0.98	-0.73	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-7.68	4.16e-10	4.97e-06	-0.98	-0.73	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
UVM	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-7.68	4.16e-10	4.97e-06	-0.98	-0.73	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
UVM	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-7.68	4.16e-10	4.97e-06	-0.98	-0.73	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
UVM	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-7.68	4.16e-10	4.97e-06	-0.98	-0.73	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
UVM	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-7.68	4.16e-10	4.97e-06	-0.98	-0.73	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
UVM	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	7.68	4.16e-10	4.97e-06	0.98	0.73	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
UVM	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-7.68	4.16e-10	4.97e-06	-0.98	-0.73	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
UVM	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-7.68	4.16e-10	4.97e-06	-0.98	-0.73	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
UVM	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-7.68	4.16e-10	4.97e-06	-0.98	-0.73	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-7.68	4.16e-10	4.97e-06	-0.98	-0.73	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
UVM	cis	rs12439619	0.846	rs7496227	ENSG00000278603.1	RP13-608F4.5	7.66	4.37e-10	5.22e-06	1.07	0.73	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472203~82472426:+
UVM	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	7.66	4.37e-10	5.22e-06	1.07	0.73	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
UVM	cis	rs7188445	0.899	rs17689024	ENSG00000261390.4	RP11-345M22.2	-7.65	4.58e-10	5.43e-06	-0.85	-0.73	Urate levels;	chr16:79706081	chr16:79715232~79770563:-
UVM	cis	rs7188445	0.932	rs56738967	ENSG00000261390.4	RP11-345M22.2	-7.65	4.58e-10	5.43e-06	-0.85	-0.73	Urate levels;	chr16:79706644	chr16:79715232~79770563:-
UVM	cis	rs9322193	0.847	rs11155672	ENSG00000231760.4	RP11-350J20.5	7.63	4.9e-10	5.8e-06	0.86	0.73	Lung cancer;	chr6:149662982	chr6:149796151~149826294:-
UVM	cis	rs2739330	0.892	rs4822455	ENSG00000218537.1	MIF-AS1	7.62	5.1e-10	6.01e-06	0.98	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23894426~23898930:-
UVM	cis	rs9322193	0.924	rs9322189	ENSG00000231760.4	RP11-350J20.5	7.61	5.27e-10	6.2e-06	0.85	0.73	Lung cancer;	chr6:149588797	chr6:149796151~149826294:-
UVM	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	7.61	5.28e-10	6.21e-06	1.07	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
UVM	cis	rs9322193	0.962	rs9688412	ENSG00000231760.4	RP11-350J20.5	-7.58	5.9e-10	6.93e-06	-0.88	-0.72	Lung cancer;	chr6:149803147	chr6:149796151~149826294:-
UVM	cis	rs2739330	0.685	rs4822453	ENSG00000273295.1	AP000350.5	7.57	6.1e-10	7.14e-06	0.85	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23901432~23907068:-
UVM	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	7.56	6.29e-10	7.36e-06	0.84	0.72	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	7.56	6.29e-10	7.36e-06	0.84	0.72	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	7.56	6.29e-10	7.36e-06	0.84	0.72	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
UVM	cis	rs9322193	0.884	rs2064521	ENSG00000231760.4	RP11-350J20.5	-7.55	6.61e-10	7.7e-06	-0.86	-0.72	Lung cancer;	chr6:149625336	chr6:149796151~149826294:-
UVM	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-7.54	6.72e-10	7.78e-06	-0.94	-0.72	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
UVM	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-7.54	6.72e-10	7.78e-06	-0.94	-0.72	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
UVM	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-7.54	6.76e-10	7.83e-06	-1.06	-0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
UVM	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-7.54	6.84e-10	7.88e-06	-0.97	-0.72	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
UVM	cis	rs4853012	0.887	rs7570950	ENSG00000217702.2	RP11-287D1.4	7.54	6.87e-10	7.88e-06	1.14	0.72	Gestational age at birth (maternal effect);	chr2:74111815	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	7.54	6.87e-10	7.88e-06	1.14	0.72	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.887	rs6737314	ENSG00000217702.2	RP11-287D1.4	7.54	6.87e-10	7.88e-06	1.14	0.72	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	7.54	6.87e-10	7.88e-06	1.14	0.72	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	7.54	6.87e-10	7.88e-06	1.14	0.72	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	7.54	6.87e-10	7.88e-06	1.14	0.72	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	7.54	6.87e-10	7.88e-06	1.14	0.72	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	7.54	6.87e-10	7.88e-06	1.14	0.72	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	7.54	6.87e-10	7.88e-06	1.14	0.72	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	7.54	6.87e-10	7.88e-06	1.14	0.72	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	7.54	6.87e-10	7.88e-06	1.14	0.72	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	7.54	6.87e-10	7.88e-06	1.14	0.72	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	7.54	6.87e-10	7.88e-06	1.14	0.72	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	7.54	6.87e-10	7.88e-06	1.14	0.72	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	7.54	6.87e-10	7.88e-06	1.14	0.72	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	7.54	6.87e-10	7.88e-06	1.14	0.72	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	7.54	6.87e-10	7.88e-06	1.14	0.72	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	7.54	6.91e-10	7.92e-06	1.12	0.72	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
UVM	cis	rs1799949	0.832	rs2070835	ENSG00000198496.9	NBR2	-7.52	7.34e-10	8.4e-06	-0.97	-0.72	Menopause (age at onset);	chr17:43022008	chr17:43125610~43153671:+
UVM	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-7.51	7.56e-10	8.64e-06	-0.96	-0.72	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
UVM	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	7.5	7.79e-10	8.9e-06	0.96	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-7.5	7.79e-10	8.9e-06	-0.96	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
UVM	cis	rs9322193	0.923	rs1934534	ENSG00000231760.4	RP11-350J20.5	7.5	7.98e-10	9.09e-06	0.88	0.72	Lung cancer;	chr6:149711896	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9767105	ENSG00000231760.4	RP11-350J20.5	7.49	8.15e-10	9.28e-06	0.86	0.72	Lung cancer;	chr6:149659591	chr6:149796151~149826294:-
UVM	cis	rs7188445	0.932	rs73575076	ENSG00000261390.4	RP11-345M22.2	-7.47	8.94e-10	1.01e-05	-0.84	-0.72	Urate levels;	chr16:79710251	chr16:79715232~79770563:-
UVM	cis	rs7188445	0.932	rs17767383	ENSG00000261390.4	RP11-345M22.2	-7.47	8.94e-10	1.01e-05	-0.84	-0.72	Urate levels;	chr16:79710504	chr16:79715232~79770563:-
UVM	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	7.46	9.07e-10	1.03e-05	0.81	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
UVM	cis	rs9322193	0.923	rs10872644	ENSG00000231760.4	RP11-350J20.5	7.45	9.39e-10	1.05e-05	0.84	0.72	Lung cancer;	chr6:149741819	chr6:149796151~149826294:-
UVM	cis	rs2739330	0.791	rs9612520	ENSG00000273295.1	AP000350.5	7.45	9.57e-10	1.07e-05	0.81	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23901432~23907068:-
UVM	cis	rs2486288	0.656	rs2461705	ENSG00000259520.4	CTD-2651B20.3	7.45	9.62e-10	1.08e-05	0.91	0.72	Glomerular filtration rate;	chr15:45278043	chr15:45251580~45279251:-
UVM	cis	rs9322193	0.923	rs10872645	ENSG00000231760.4	RP11-350J20.5	7.4	1.14e-09	1.26e-05	0.85	0.72	Lung cancer;	chr6:149742840	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs12211511	ENSG00000231760.4	RP11-350J20.5	7.4	1.14e-09	1.26e-05	0.85	0.72	Lung cancer;	chr6:149745206	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9479810	ENSG00000231760.4	RP11-350J20.5	7.4	1.14e-09	1.26e-05	0.85	0.72	Lung cancer;	chr6:149751359	chr6:149796151~149826294:-
UVM	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	7.39	1.17e-09	1.29e-05	0.94	0.72	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
UVM	cis	rs9322193	0.884	rs1125	ENSG00000231760.4	RP11-350J20.5	7.38	1.22e-09	1.35e-05	0.91	0.72	Lung cancer;	chr6:149658280	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs11155677	ENSG00000231760.4	RP11-350J20.5	7.37	1.26e-09	1.4e-05	0.83	0.71	Lung cancer;	chr6:149756953	chr6:149796151~149826294:-
UVM	cis	rs7188445	0.614	rs62043313	ENSG00000261390.4	RP11-345M22.2	-7.37	1.27e-09	1.4e-05	-0.87	-0.71	Urate levels;	chr16:79710237	chr16:79715232~79770563:-
UVM	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-7.36	1.31e-09	1.44e-05	-0.73	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-7.36	1.33e-09	1.46e-05	-0.81	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
UVM	cis	rs11214589	0.747	rs11214577	ENSG00000270179.1	RP11-159N11.4	7.34	1.4e-09	1.53e-05	0.89	0.71	Neuroticism;	chr11:113333544	chr11:113368478~113369117:+
UVM	cis	rs2882667	0.861	rs7703288	ENSG00000253404.1	AC034243.1	7.34	1.42e-09	1.56e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139030850	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.898	rs10079634	ENSG00000253404.1	AC034243.1	7.34	1.42e-09	1.56e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077364	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	7.34	1.42e-09	1.56e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.893	rs10044672	ENSG00000253404.1	AC034243.1	7.31	1.58e-09	1.71e-05	0.86	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954790	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.893	rs13180851	ENSG00000253404.1	AC034243.1	7.31	1.58e-09	1.71e-05	0.86	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954918	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.893	rs7717375	ENSG00000253404.1	AC034243.1	7.31	1.58e-09	1.71e-05	0.86	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138955716	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.893	rs10054796	ENSG00000253404.1	AC034243.1	7.31	1.58e-09	1.71e-05	0.86	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958655	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.893	rs10069961	ENSG00000253404.1	AC034243.1	7.31	1.58e-09	1.71e-05	0.86	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958879	chr5:138744434~138753309:-
UVM	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	7.3	1.62e-09	1.75e-05	1.01	0.71	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
UVM	cis	rs9322193	1	rs58189451	ENSG00000231760.4	RP11-350J20.5	7.3	1.66e-09	1.79e-05	0.89	0.71	Lung cancer;	chr6:149600252	chr6:149796151~149826294:-
UVM	cis	rs4853012	0.752	rs13413795	ENSG00000217702.2	RP11-287D1.4	7.28	1.77e-09	1.86e-05	1.13	0.71	Gestational age at birth (maternal effect);	chr2:74122712	chr2:74130583~74135395:+
UVM	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.898	rs11749944	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077090	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.867	rs6868085	ENSG00000253404.1	AC034243.1	7.28	1.77e-09	1.86e-05	0.83	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:139096757	chr5:138744434~138753309:-
UVM	cis	rs2486288	0.656	rs12440356	ENSG00000259520.4	CTD-2651B20.3	-7.28	1.78e-09	1.86e-05	-0.89	-0.71	Glomerular filtration rate;	chr15:45275331	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs12911861	ENSG00000259520.4	CTD-2651B20.3	7.28	1.78e-09	1.86e-05	0.89	0.71	Glomerular filtration rate;	chr15:45274520	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs11639349	ENSG00000259520.4	CTD-2651B20.3	7.28	1.78e-09	1.86e-05	0.89	0.71	Glomerular filtration rate;	chr15:45276062	chr15:45251580~45279251:-
UVM	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	7.28	1.79e-09	1.86e-05	0.94	0.71	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
UVM	cis	rs875971	0.577	rs34888281	ENSG00000226824.5	RP4-756H11.3	7.28	1.79e-09	1.86e-05	0.94	0.71	Aortic root size;	chr7:66120784	chr7:66654538~66669855:+
UVM	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	7.28	1.79e-09	1.86e-05	0.94	0.71	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
UVM	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	7.28	1.79e-09	1.86e-05	0.94	0.71	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
UVM	cis	rs2486288	0.656	rs1706768	ENSG00000259520.4	CTD-2651B20.3	7.28	1.79e-09	1.86e-05	0.89	0.71	Glomerular filtration rate;	chr15:45277245	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs62026703	ENSG00000259520.4	CTD-2651B20.3	7.28	1.79e-09	1.86e-05	0.89	0.71	Glomerular filtration rate;	chr15:45277731	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs7171312	ENSG00000259520.4	CTD-2651B20.3	7.28	1.79e-09	1.86e-05	0.89	0.71	Glomerular filtration rate;	chr15:45278027	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs7165039	ENSG00000259520.4	CTD-2651B20.3	7.28	1.79e-09	1.86e-05	0.89	0.71	Glomerular filtration rate;	chr15:45278215	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs6493143	ENSG00000259520.4	CTD-2651B20.3	7.28	1.79e-09	1.86e-05	0.89	0.71	Glomerular filtration rate;	chr15:45278583	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs7166580	ENSG00000259520.4	CTD-2651B20.3	7.28	1.79e-09	1.86e-05	0.89	0.71	Glomerular filtration rate;	chr15:45279011	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs12908818	ENSG00000259520.4	CTD-2651B20.3	7.28	1.79e-09	1.86e-05	0.89	0.71	Glomerular filtration rate;	chr15:45279470	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.586	rs12909625	ENSG00000259520.4	CTD-2651B20.3	7.28	1.79e-09	1.86e-05	0.89	0.71	Glomerular filtration rate;	chr15:45279855	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.586	rs12909883	ENSG00000259520.4	CTD-2651B20.3	7.28	1.79e-09	1.86e-05	0.89	0.71	Glomerular filtration rate;	chr15:45279856	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs1719232	ENSG00000259520.4	CTD-2651B20.3	7.28	1.79e-09	1.86e-05	0.89	0.71	Glomerular filtration rate;	chr15:45279874	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs12910009	ENSG00000259520.4	CTD-2651B20.3	7.28	1.79e-09	1.86e-05	0.89	0.71	Glomerular filtration rate;	chr15:45280210	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs6493145	ENSG00000259520.4	CTD-2651B20.3	7.28	1.79e-09	1.86e-05	0.89	0.71	Glomerular filtration rate;	chr15:45281664	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs8024620	ENSG00000259520.4	CTD-2651B20.3	7.28	1.79e-09	1.86e-05	0.89	0.71	Glomerular filtration rate;	chr15:45282131	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs1706770	ENSG00000259520.4	CTD-2651B20.3	7.28	1.79e-09	1.86e-05	0.89	0.71	Glomerular filtration rate;	chr15:45282864	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.554	rs1719235	ENSG00000259520.4	CTD-2651B20.3	7.28	1.79e-09	1.86e-05	0.89	0.71	Glomerular filtration rate;	chr15:45283910	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs1719236	ENSG00000259520.4	CTD-2651B20.3	7.28	1.79e-09	1.86e-05	0.89	0.71	Glomerular filtration rate;	chr15:45285585	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs11637364	ENSG00000259520.4	CTD-2651B20.3	7.28	1.79e-09	1.86e-05	0.89	0.71	Glomerular filtration rate;	chr15:45287040	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs8039153	ENSG00000259520.4	CTD-2651B20.3	7.28	1.79e-09	1.86e-05	0.89	0.71	Glomerular filtration rate;	chr15:45287615	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs2413773	ENSG00000259520.4	CTD-2651B20.3	7.27	1.81e-09	1.88e-05	0.9	0.71	Glomerular filtration rate;	chr15:45257244	chr15:45251580~45279251:-
UVM	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-7.27	1.84e-09	1.91e-05	-0.93	-0.71	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
UVM	cis	rs9549328	0.67	rs2873372	ENSG00000267868.1	RP11-120K24.3	7.26	1.89e-09	1.96e-05	0.88	0.71	Systolic blood pressure;	chr13:112959069	chr13:112964835~112966131:-
UVM	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	7.24	2.03e-09	2.1e-05	1.13	0.71	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	7.24	2.03e-09	2.1e-05	1.13	0.71	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	7.24	2.03e-09	2.1e-05	1.13	0.71	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	7.24	2.03e-09	2.1e-05	1.13	0.71	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
UVM	cis	rs916888	0.779	rs199498	ENSG00000262539.1	RP11-259G18.3	7.24	2.05e-09	2.11e-05	1.19	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46259551~46260606:-
UVM	cis	rs2486288	0.656	rs1706767	ENSG00000259520.4	CTD-2651B20.3	7.24	2.08e-09	2.14e-05	0.91	0.71	Glomerular filtration rate;	chr15:45276901	chr15:45251580~45279251:-
UVM	cis	rs9322193	0.962	rs7818	ENSG00000231760.4	RP11-350J20.5	7.23	2.14e-09	2.2e-05	0.82	0.71	Lung cancer;	chr6:149810956	chr6:149796151~149826294:-
UVM	cis	rs12541595	0.79	rs28455756	ENSG00000249816.5	LINC00964	-7.23	2.16e-09	2.22e-05	-0.76	-0.71	Left ventricle diastolic internal dimension;	chr8:124881909	chr8:124848737~124954328:+
UVM	cis	rs9322193	0.923	rs7753812	ENSG00000231760.4	RP11-350J20.5	7.22	2.17e-09	2.23e-05	0.82	0.71	Lung cancer;	chr6:149690150	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs12195866	ENSG00000231760.4	RP11-350J20.5	7.22	2.17e-09	2.23e-05	0.82	0.71	Lung cancer;	chr6:149693334	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9285524	ENSG00000231760.4	RP11-350J20.5	7.22	2.17e-09	2.23e-05	0.82	0.71	Lung cancer;	chr6:149694122	chr6:149796151~149826294:-
UVM	cis	rs2486288	0.656	rs11631021	ENSG00000259520.4	CTD-2651B20.3	7.22	2.21e-09	2.26e-05	0.89	0.71	Glomerular filtration rate;	chr15:45264631	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs6493144	ENSG00000259520.4	CTD-2651B20.3	-7.22	2.21e-09	2.26e-05	-0.89	-0.71	Glomerular filtration rate;	chr15:45281291	chr15:45251580~45279251:-
UVM	cis	rs1153858	0.621	rs1719237	ENSG00000259520.4	CTD-2651B20.3	-7.22	2.22e-09	2.27e-05	-0.99	-0.71	Homoarginine levels;	chr15:45287624	chr15:45251580~45279251:-
UVM	cis	rs1153858	0.621	rs1706824	ENSG00000259520.4	CTD-2651B20.3	-7.22	2.22e-09	2.27e-05	-0.99	-0.71	Homoarginine levels;	chr15:45287750	chr15:45251580~45279251:-
UVM	cis	rs916888	0.779	rs199526	ENSG00000262539.1	RP11-259G18.3	-7.19	2.45e-09	2.48e-05	-1.07	-0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46259551~46260606:-
UVM	cis	rs9322193	0.923	rs12526675	ENSG00000231760.4	RP11-350J20.5	-7.16	2.7e-09	2.67e-05	-0.83	-0.7	Lung cancer;	chr6:149729540	chr6:149796151~149826294:-
UVM	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
UVM	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	7.16	2.72e-09	2.67e-05	0.81	0.7	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-7.16	2.72e-09	2.67e-05	-0.81	-0.7	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
UVM	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-7.16	2.72e-09	2.67e-05	-0.81	-0.7	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
UVM	cis	rs9322193	0.923	rs10782317	ENSG00000231760.4	RP11-350J20.5	-7.16	2.77e-09	2.72e-05	-0.83	-0.7	Lung cancer;	chr6:149753911	chr6:149796151~149826294:-
UVM	cis	rs11214589	0.747	rs10502172	ENSG00000270179.1	RP11-159N11.4	-7.15	2.85e-09	2.79e-05	-0.9	-0.7	Neuroticism;	chr11:113328424	chr11:113368478~113369117:+
UVM	cis	rs11214589	0.719	rs10891535	ENSG00000270179.1	RP11-159N11.4	-7.15	2.85e-09	2.79e-05	-0.9	-0.7	Neuroticism;	chr11:113330558	chr11:113368478~113369117:+
UVM	cis	rs11214589	0.747	rs1893695	ENSG00000270179.1	RP11-159N11.4	-7.15	2.85e-09	2.79e-05	-0.9	-0.7	Neuroticism;	chr11:113335363	chr11:113368478~113369117:+
UVM	cis	rs11214589	0.747	rs2155462	ENSG00000270179.1	RP11-159N11.4	-7.15	2.85e-09	2.79e-05	-0.9	-0.7	Neuroticism;	chr11:113336077	chr11:113368478~113369117:+
UVM	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	7.14	2.91e-09	2.85e-05	0.81	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
UVM	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	7.14	2.93e-09	2.86e-05	0.78	0.7	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	7.14	2.93e-09	2.86e-05	0.78	0.7	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	7.14	2.93e-09	2.86e-05	0.78	0.7	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
UVM	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	7.14	2.93e-09	2.86e-05	0.78	0.7	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	7.14	2.93e-09	2.86e-05	0.78	0.7	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	7.14	2.93e-09	2.86e-05	0.78	0.7	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
UVM	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	7.14	2.93e-09	2.86e-05	0.78	0.7	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	7.14	2.93e-09	2.86e-05	0.78	0.7	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
UVM	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	7.14	2.93e-09	2.86e-05	0.78	0.7	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	7.14	2.93e-09	2.86e-05	0.78	0.7	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
UVM	cis	rs916888	0.531	rs183211	ENSG00000262539.1	RP11-259G18.3	7.14	2.95e-09	2.87e-05	0.98	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46259551~46260606:-
UVM	cis	rs916888	0.61	rs199438	ENSG00000262539.1	RP11-259G18.3	7.14	2.95e-09	2.87e-05	0.98	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46259551~46260606:-
UVM	cis	rs916888	0.61	rs199453	ENSG00000262539.1	RP11-259G18.3	7.14	2.99e-09	2.89e-05	0.97	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46259551~46260606:-
UVM	cis	rs916888	0.647	rs199449	ENSG00000262539.1	RP11-259G18.3	7.14	2.99e-09	2.89e-05	0.97	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46259551~46260606:-
UVM	cis	rs916888	0.61	rs199444	ENSG00000262539.1	RP11-259G18.3	7.14	2.99e-09	2.89e-05	0.97	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46259551~46260606:-
UVM	cis	rs916888	0.61	rs199442	ENSG00000262539.1	RP11-259G18.3	7.14	2.99e-09	2.89e-05	0.97	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46259551~46260606:-
UVM	cis	rs916888	0.61	rs199436	ENSG00000262539.1	RP11-259G18.3	-7.14	2.99e-09	2.89e-05	-0.97	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46259551~46260606:-
UVM	cis	rs916888	0.61	rs199454	ENSG00000262539.1	RP11-259G18.3	-7.14	2.99e-09	2.89e-05	-0.97	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46259551~46260606:-
UVM	cis	rs916888	0.61	rs199446	ENSG00000262539.1	RP11-259G18.3	-7.14	2.99e-09	2.89e-05	-0.97	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46259551~46260606:-
UVM	cis	rs916888	0.61	rs199536	ENSG00000262539.1	RP11-259G18.3	-7.14	2.99e-09	2.89e-05	-0.97	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46259551~46260606:-
UVM	cis	rs916888	0.61	rs199530	ENSG00000262539.1	RP11-259G18.3	-7.14	2.99e-09	2.89e-05	-0.97	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46259551~46260606:-
UVM	cis	rs1155848	0.571	rs7983556	ENSG00000227354.5	RBM26-AS1	7.13	3.04e-09	2.93e-05	0.99	0.7	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79608777	chr13:79406309~79424328:+
UVM	cis	rs1155848	0.571	rs6563127	ENSG00000227354.5	RBM26-AS1	7.13	3.04e-09	2.93e-05	0.99	0.7	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79642012	chr13:79406309~79424328:+
UVM	cis	rs9322193	0.961	rs9027	ENSG00000231760.4	RP11-350J20.5	7.13	3.07e-09	2.94e-05	0.83	0.7	Lung cancer;	chr6:149594921	chr6:149796151~149826294:-
UVM	cis	rs9322193	1	rs9322193	ENSG00000231760.4	RP11-350J20.5	7.13	3.07e-09	2.94e-05	0.83	0.7	Lung cancer;	chr6:149598007	chr6:149796151~149826294:-
UVM	cis	rs9322193	1	rs9377229	ENSG00000231760.4	RP11-350J20.5	7.13	3.07e-09	2.94e-05	0.83	0.7	Lung cancer;	chr6:149607655	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs9322197	ENSG00000231760.4	RP11-350J20.5	7.13	3.07e-09	2.94e-05	0.83	0.7	Lung cancer;	chr6:149622577	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.884	rs9688858	ENSG00000231760.4	RP11-350J20.5	7.13	3.07e-09	2.94e-05	0.83	0.7	Lung cancer;	chr6:149637911	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs9322206	ENSG00000231760.4	RP11-350J20.5	7.13	3.07e-09	2.94e-05	0.83	0.7	Lung cancer;	chr6:149641481	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs9688750	ENSG00000231760.4	RP11-350J20.5	7.13	3.07e-09	2.94e-05	0.83	0.7	Lung cancer;	chr6:149657633	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.923	rs12175504	ENSG00000231760.4	RP11-350J20.5	7.13	3.07e-09	2.94e-05	0.83	0.7	Lung cancer;	chr6:149664079	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs35443312	ENSG00000231760.4	RP11-350J20.5	7.13	3.07e-09	2.94e-05	0.83	0.7	Lung cancer;	chr6:149670625	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs62439843	ENSG00000231760.4	RP11-350J20.5	7.13	3.07e-09	2.94e-05	0.83	0.7	Lung cancer;	chr6:149676521	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.962	rs35031906	ENSG00000231760.4	RP11-350J20.5	7.13	3.07e-09	2.94e-05	0.83	0.7	Lung cancer;	chr6:149677438	chr6:149796151~149826294:-
UVM	cis	rs3091242	0.804	rs631133	ENSG00000261349.1	RP3-465N24.5	-7.13	3.12e-09	2.98e-05	-0.66	-0.7	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25266102~25267136:-
UVM	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-7.12	3.18e-09	3.03e-05	-0.93	-0.7	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
UVM	cis	rs801193	0.901	rs4273746	ENSG00000226824.5	RP4-756H11.3	7.12	3.18e-09	3.03e-05	0.93	0.7	Aortic root size;	chr7:66836124	chr7:66654538~66669855:+
UVM	cis	rs3091242	0.934	rs666686	ENSG00000261349.1	RP3-465N24.5	-7.11	3.31e-09	3.15e-05	-0.7	-0.7	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25266102~25267136:-
UVM	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-7.11	3.34e-09	3.17e-05	-0.9	-0.7	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
UVM	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	7.11	3.34e-09	3.17e-05	0.9	0.7	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	7.11	3.34e-09	3.17e-05	0.9	0.7	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	7.11	3.34e-09	3.17e-05	0.9	0.7	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
UVM	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	7.11	3.36e-09	3.18e-05	0.98	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
UVM	cis	rs1153858	0.621	rs2413769	ENSG00000259520.4	CTD-2651B20.3	-7.1	3.41e-09	3.23e-05	-0.98	-0.7	Homoarginine levels;	chr15:45269670	chr15:45251580~45279251:-
UVM	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-7.1	3.45e-09	3.26e-05	-0.9	-0.7	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
UVM	cis	rs9549328	0.589	rs36164841	ENSG00000267868.1	RP11-120K24.3	-7.1	3.46e-09	3.28e-05	-0.85	-0.7	Systolic blood pressure;	chr13:112962265	chr13:112964835~112966131:-
UVM	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	7.08	3.69e-09	3.47e-05	0.92	0.7	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
UVM	cis	rs9549328	0.731	rs2873371	ENSG00000267868.1	RP11-120K24.3	7.08	3.74e-09	3.52e-05	0.88	0.7	Systolic blood pressure;	chr13:112961928	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.7	rs2185001	ENSG00000267868.1	RP11-120K24.3	7.08	3.74e-09	3.52e-05	0.88	0.7	Systolic blood pressure;	chr13:112962055	chr13:112964835~112966131:-
UVM	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	7.07	3.82e-09	3.59e-05	0.9	0.7	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
UVM	cis	rs2486288	0.656	rs7162022	ENSG00000259520.4	CTD-2651B20.3	7.07	3.9e-09	3.59e-05	0.89	0.7	Glomerular filtration rate;	chr15:45273055	chr15:45251580~45279251:-
UVM	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
UVM	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
UVM	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
UVM	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
UVM	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
UVM	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
UVM	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	7.06	4e-09	3.59e-05	0.89	0.7	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
UVM	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
UVM	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
UVM	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
UVM	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
UVM	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
UVM	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
UVM	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
UVM	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
UVM	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
UVM	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
UVM	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
UVM	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
UVM	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
UVM	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
UVM	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
UVM	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
UVM	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
UVM	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
UVM	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
UVM	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
UVM	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
UVM	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
UVM	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
UVM	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
UVM	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
UVM	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
UVM	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
UVM	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
UVM	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
UVM	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
UVM	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
UVM	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
UVM	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
UVM	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
UVM	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-7.06	4e-09	3.59e-05	-0.89	-0.7	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
UVM	cis	rs9322193	0.923	rs12174035	ENSG00000231760.4	RP11-350J20.5	7.05	4.08e-09	3.65e-05	0.89	0.7	Lung cancer;	chr6:149763311	chr6:149796151~149826294:-
UVM	cis	rs2739330	0.791	rs9612520	ENSG00000218537.1	MIF-AS1	7.04	4.22e-09	3.74e-05	0.98	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23894426~23898930:-
UVM	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-7.04	4.22e-09	3.74e-05	-0.89	-0.7	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-7.04	4.22e-09	3.74e-05	-0.89	-0.7	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-7.04	4.22e-09	3.74e-05	-0.89	-0.7	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	7.04	4.22e-09	3.74e-05	0.89	0.7	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
UVM	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	7.04	4.22e-09	3.74e-05	0.89	0.7	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
UVM	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	7.04	4.22e-09	3.74e-05	0.89	0.7	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	7.04	4.22e-09	3.74e-05	0.89	0.7	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
UVM	cis	rs12439619	0.705	rs4778665	ENSG00000278603.1	RP13-608F4.5	7.04	4.27e-09	3.78e-05	1.11	0.7	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472203~82472426:+
UVM	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-7.04	4.32e-09	3.82e-05	-0.89	-0.7	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
UVM	cis	rs2283792	0.812	rs240066	ENSG00000224086.5	LL22NC03-86G7.1	7.04	4.32e-09	3.82e-05	0.76	0.7	Multiple sclerosis;	chr22:21938623	chr22:21938293~21977632:+
UVM	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	7.04	4.35e-09	3.83e-05	0.82	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
UVM	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	7.03	4.49e-09	3.96e-05	1.03	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
UVM	cis	rs9549328	0.566	rs62635340	ENSG00000267868.1	RP11-120K24.3	-7.03	4.51e-09	3.97e-05	-0.86	-0.7	Systolic blood pressure;	chr13:112962120	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.501	rs62635341	ENSG00000267868.1	RP11-120K24.3	-7.03	4.51e-09	3.97e-05	-0.86	-0.7	Systolic blood pressure;	chr13:112962121	chr13:112964835~112966131:-
UVM	cis	rs12541595	0.897	rs6985130	ENSG00000249816.5	LINC00964	7.02	4.62e-09	4.06e-05	0.66	0.7	Left ventricle diastolic internal dimension;	chr8:124838774	chr8:124848737~124954328:+
UVM	cis	rs2486288	0.656	rs1060896	ENSG00000259520.4	CTD-2651B20.3	7.01	4.81e-09	4.21e-05	0.88	0.7	Glomerular filtration rate;	chr15:45262069	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs11632419	ENSG00000259520.4	CTD-2651B20.3	7.01	4.81e-09	4.21e-05	0.88	0.7	Glomerular filtration rate;	chr15:45265258	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs2271438	ENSG00000259520.4	CTD-2651B20.3	7.01	4.81e-09	4.21e-05	0.88	0.7	Glomerular filtration rate;	chr15:45265270	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs11854365	ENSG00000259520.4	CTD-2651B20.3	7.01	4.81e-09	4.21e-05	0.88	0.7	Glomerular filtration rate;	chr15:45265885	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs2413768	ENSG00000259520.4	CTD-2651B20.3	7.01	4.81e-09	4.21e-05	0.88	0.7	Glomerular filtration rate;	chr15:45269786	chr15:45251580~45279251:-
UVM	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-7.01	4.83e-09	4.21e-05	-0.65	-0.7	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-7.01	4.83e-09	4.21e-05	-0.65	-0.7	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
UVM	cis	rs12541595	0.866	rs10107090	ENSG00000249816.5	LINC00964	6.99	5.19e-09	4.37e-05	0.63	0.7	Left ventricle diastolic internal dimension;	chr8:124837372	chr8:124848737~124954328:+
UVM	cis	rs1167827	1	rs1167827	ENSG00000127957.15	PMS2P3	-6.98	5.34e-09	4.4e-05	-0.62	-0.7	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75502930~75528148:-
UVM	cis	rs7188445	1	rs7188445	ENSG00000261390.4	RP11-345M22.2	-6.98	5.36e-09	4.4e-05	-0.79	-0.7	Urate levels;	chr16:79701090	chr16:79715232~79770563:-
UVM	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-6.98	5.42e-09	4.4e-05	-1.02	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
UVM	cis	rs2882667	0.931	rs3749665	ENSG00000253404.1	AC034243.1	6.97	5.43e-09	4.4e-05	0.8	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:138744434~138753309:-
UVM	cis	rs3091242	0.809	rs660129	ENSG00000261349.1	RP3-465N24.5	-6.97	5.51e-09	4.42e-05	-0.65	-0.7	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.728	rs706845	ENSG00000261349.1	RP3-465N24.5	-6.97	5.51e-09	4.42e-05	-0.65	-0.7	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.9	rs1883427	ENSG00000261349.1	RP3-465N24.5	-6.97	5.51e-09	4.42e-05	-0.65	-0.7	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25266102~25267136:-
UVM	cis	rs55794721	0.509	rs2982358	ENSG00000261349.1	RP3-465N24.5	-6.97	5.51e-09	4.42e-05	-0.65	-0.7	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25266102~25267136:-
UVM	cis	rs55794721	0.509	rs2375313	ENSG00000261349.1	RP3-465N24.5	-6.97	5.51e-09	4.42e-05	-0.65	-0.7	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25266102~25267136:-
UVM	cis	rs12541595	0.866	rs7003871	ENSG00000249816.5	LINC00964	6.97	5.55e-09	4.44e-05	0.66	0.69	Left ventricle diastolic internal dimension;	chr8:124839268	chr8:124848737~124954328:+
UVM	cis	rs12541595	0.836	rs6980636	ENSG00000249816.5	LINC00964	6.97	5.55e-09	4.44e-05	0.66	0.69	Left ventricle diastolic internal dimension;	chr8:124840274	chr8:124848737~124954328:+
UVM	cis	rs12541595	0.897	rs7001128	ENSG00000249816.5	LINC00964	6.97	5.55e-09	4.44e-05	0.66	0.69	Left ventricle diastolic internal dimension;	chr8:124840288	chr8:124848737~124954328:+
UVM	cis	rs9549328	0.731	rs7983602	ENSG00000267868.1	RP11-120K24.3	6.96	5.75e-09	4.6e-05	0.83	0.69	Systolic blood pressure;	chr13:112966168	chr13:112964835~112966131:-
UVM	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	6.96	5.78e-09	4.61e-05	0.75	0.69	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
UVM	cis	rs1153858	0.621	rs12913645	ENSG00000259520.4	CTD-2651B20.3	6.96	5.8e-09	4.63e-05	0.98	0.69	Homoarginine levels;	chr15:45262868	chr15:45251580~45279251:-
UVM	cis	rs7188445	1	rs11150189	ENSG00000261390.4	RP11-345M22.2	-6.95	6.04e-09	4.79e-05	-0.81	-0.69	Urate levels;	chr16:79700330	chr16:79715232~79770563:-
UVM	cis	rs7188445	0.932	rs11150191	ENSG00000261390.4	RP11-345M22.2	-6.95	6.04e-09	4.79e-05	-0.81	-0.69	Urate levels;	chr16:79700390	chr16:79715232~79770563:-
UVM	cis	rs7188445	0.899	rs7195321	ENSG00000261390.4	RP11-345M22.2	-6.95	6.04e-09	4.79e-05	-0.81	-0.69	Urate levels;	chr16:79701065	chr16:79715232~79770563:-
UVM	cis	rs7188445	1	rs7190187	ENSG00000261390.4	RP11-345M22.2	-6.95	6.04e-09	4.79e-05	-0.81	-0.69	Urate levels;	chr16:79701281	chr16:79715232~79770563:-
UVM	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-6.94	6.07e-09	4.8e-05	-0.82	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
UVM	cis	rs9549328	0.7	rs4907568	ENSG00000267868.1	RP11-120K24.3	6.94	6.13e-09	4.82e-05	0.84	0.69	Systolic blood pressure;	chr13:112963260	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.614	rs34306822	ENSG00000267868.1	RP11-120K24.3	-6.94	6.13e-09	4.82e-05	-0.84	-0.69	Systolic blood pressure;	chr13:112962185	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.67	rs61963562	ENSG00000267868.1	RP11-120K24.3	-6.94	6.13e-09	4.82e-05	-0.84	-0.69	Systolic blood pressure;	chr13:112962209	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.542	rs36172983	ENSG00000267868.1	RP11-120K24.3	-6.94	6.13e-09	4.82e-05	-0.84	-0.69	Systolic blood pressure;	chr13:112962268	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.52	rs36144023	ENSG00000267868.1	RP11-120K24.3	-6.94	6.13e-09	4.82e-05	-0.84	-0.69	Systolic blood pressure;	chr13:112962278	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.565	rs36145949	ENSG00000267868.1	RP11-120K24.3	-6.94	6.13e-09	4.82e-05	-0.84	-0.69	Systolic blood pressure;	chr13:112962294	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.565	rs35371379	ENSG00000267868.1	RP11-120K24.3	-6.94	6.13e-09	4.82e-05	-0.84	-0.69	Systolic blood pressure;	chr13:112962401	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.67	rs35992827	ENSG00000267868.1	RP11-120K24.3	-6.94	6.13e-09	4.82e-05	-0.84	-0.69	Systolic blood pressure;	chr13:112962438	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.642	rs2993343	ENSG00000267868.1	RP11-120K24.3	-6.94	6.13e-09	4.82e-05	-0.84	-0.69	Systolic blood pressure;	chr13:112962530	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.67	rs3011475	ENSG00000267868.1	RP11-120K24.3	-6.94	6.13e-09	4.82e-05	-0.84	-0.69	Systolic blood pressure;	chr13:112962552	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.67	rs2993344	ENSG00000267868.1	RP11-120K24.3	-6.94	6.13e-09	4.82e-05	-0.84	-0.69	Systolic blood pressure;	chr13:112962708	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.699	rs2993345	ENSG00000267868.1	RP11-120K24.3	-6.94	6.13e-09	4.82e-05	-0.84	-0.69	Systolic blood pressure;	chr13:112962772	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.614	rs35299896	ENSG00000267868.1	RP11-120K24.3	-6.94	6.13e-09	4.82e-05	-0.84	-0.69	Systolic blood pressure;	chr13:112962915	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.616	rs35086993	ENSG00000267868.1	RP11-120K24.3	-6.94	6.13e-09	4.82e-05	-0.84	-0.69	Systolic blood pressure;	chr13:112962991	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.589	rs34144481	ENSG00000267868.1	RP11-120K24.3	-6.94	6.13e-09	4.82e-05	-0.84	-0.69	Systolic blood pressure;	chr13:112963008	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.565	rs35988856	ENSG00000267868.1	RP11-120K24.3	-6.94	6.13e-09	4.82e-05	-0.84	-0.69	Systolic blood pressure;	chr13:112963113	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.564	rs34556022	ENSG00000267868.1	RP11-120K24.3	-6.94	6.13e-09	4.82e-05	-0.84	-0.69	Systolic blood pressure;	chr13:112963123	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.611	rs72661939	ENSG00000267868.1	RP11-120K24.3	-6.94	6.13e-09	4.82e-05	-0.84	-0.69	Systolic blood pressure;	chr13:112963184	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.544	rs66893681	ENSG00000267868.1	RP11-120K24.3	-6.94	6.13e-09	4.82e-05	-0.84	-0.69	Systolic blood pressure;	chr13:112963185	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.643	rs4907567	ENSG00000267868.1	RP11-120K24.3	-6.94	6.13e-09	4.82e-05	-0.84	-0.69	Systolic blood pressure;	chr13:112963219	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.7	rs4907570	ENSG00000267868.1	RP11-120K24.3	-6.94	6.13e-09	4.82e-05	-0.84	-0.69	Systolic blood pressure;	chr13:112963337	chr13:112964835~112966131:-
UVM	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	6.94	6.14e-09	4.83e-05	0.83	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
UVM	cis	rs9322193	0.923	rs9766004	ENSG00000231760.4	RP11-350J20.5	6.94	6.15e-09	4.83e-05	0.78	0.69	Lung cancer;	chr6:149754363	chr6:149796151~149826294:-
UVM	cis	rs1799949	0.757	rs9915489	ENSG00000198496.9	NBR2	-6.94	6.19e-09	4.86e-05	-0.95	-0.69	Menopause (age at onset);	chr17:43021209	chr17:43125610~43153671:+
UVM	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	6.94	6.22e-09	4.88e-05	1.1	0.69	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
UVM	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	6.94	6.22e-09	4.88e-05	1.1	0.69	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
UVM	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	6.94	6.22e-09	4.88e-05	1.1	0.69	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
UVM	cis	rs2455601	0.638	rs11042148	ENSG00000254860.4	TMEM9B-AS1	6.94	6.22e-09	4.88e-05	1.1	0.69	Schizophrenia;	chr11:8987127	chr11:8964675~8977527:+
UVM	cis	rs2455601	0.638	rs3815991	ENSG00000254860.4	TMEM9B-AS1	-6.94	6.22e-09	4.88e-05	-1.1	-0.69	Schizophrenia;	chr11:8986122	chr11:8964675~8977527:+
UVM	cis	rs3091242	0.933	rs28530483	ENSG00000261349.1	RP3-465N24.5	-6.93	6.38e-09	5e-05	-0.65	-0.69	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.933	rs28633797	ENSG00000261349.1	RP3-465N24.5	-6.93	6.44e-09	5.04e-05	-0.65	-0.69	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25266102~25267136:-
UVM	cis	rs2739330	0.703	rs5760112	ENSG00000218537.1	MIF-AS1	6.92	6.56e-09	5.12e-05	0.92	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-6.92	6.7e-09	5.23e-05	-0.92	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
UVM	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	6.92	6.7e-09	5.23e-05	1.01	0.69	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
UVM	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-6.91	6.98e-09	5.43e-05	-0.9	-0.69	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-6.91	6.98e-09	5.43e-05	-0.9	-0.69	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
UVM	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-6.9	7.11e-09	5.53e-05	-0.68	-0.69	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
UVM	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	6.89	7.3e-09	5.67e-05	0.8	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	6.89	7.3e-09	5.67e-05	0.8	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	6.88	7.65e-09	5.9e-05	0.77	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.628	rs13162420	ENSG00000253404.1	AC034243.1	6.88	7.7e-09	5.94e-05	0.98	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138839070	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.628	rs13167462	ENSG00000253404.1	AC034243.1	6.88	7.7e-09	5.94e-05	0.98	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841572	chr5:138744434~138753309:-
UVM	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-6.87	8.04e-09	6.19e-05	-1.06	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
UVM	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	6.85	8.43e-09	6.47e-05	0.81	0.69	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
UVM	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	6.85	8.56e-09	6.52e-05	0.87	0.69	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
UVM	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	6.85	8.56e-09	6.52e-05	0.87	0.69	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
UVM	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	6.85	8.56e-09	6.52e-05	0.87	0.69	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
UVM	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	6.85	8.56e-09	6.52e-05	0.87	0.69	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
UVM	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	6.85	8.56e-09	6.52e-05	0.87	0.69	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
UVM	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	6.85	8.56e-09	6.52e-05	0.87	0.69	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
UVM	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	6.85	8.56e-09	6.52e-05	0.87	0.69	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
UVM	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	6.85	8.56e-09	6.52e-05	0.87	0.69	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
UVM	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	6.85	8.56e-09	6.52e-05	0.87	0.69	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
UVM	cis	rs2487048	0.591	rs1800977	ENSG00000226334.1	RP11-217B7.2	-6.83	9.2e-09	6.92e-05	-0.78	-0.69	Intraocular pressure;	chr9:104928169	chr9:104927553~104928892:+
UVM	cis	rs2486288	0.656	rs9921025	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45254404	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs11629807	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45254839	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs8041702	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45254895	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs11629858	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45254916	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs11629859	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45254923	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.587	rs12899942	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45255082	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs12899058	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45255126	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs12904150	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45255407	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs9920290	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45255837	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs11854325	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45256761	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs10519018	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45257067	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs2413774	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45257225	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs2413772	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45257664	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs11632724	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45258593	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs11632651	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45258640	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs11637920	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45258707	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs11632777	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45258847	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs11632778	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45258858	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs11632752	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45258942	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs11632920	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45259066	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs12911186	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45259225	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs12915314	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45259293	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs8039138	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45259394	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs8039540	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45259644	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs8040185	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45259883	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs2413771	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45260942	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs11639420	ENSG00000259520.4	CTD-2651B20.3	6.83	9.25e-09	6.92e-05	0.87	0.69	Glomerular filtration rate;	chr15:45267070	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.656	rs8039354	ENSG00000259520.4	CTD-2651B20.3	-6.83	9.25e-09	6.92e-05	-0.87	-0.69	Glomerular filtration rate;	chr15:45259558	chr15:45251580~45279251:-
UVM	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-6.83	9.33e-09	6.98e-05	-0.8	-0.69	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
UVM	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-6.82	9.62e-09	7.19e-05	-0.77	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
UVM	cis	rs2739330	0.685	rs4822453	ENSG00000218537.1	MIF-AS1	6.82	9.64e-09	7.2e-05	1	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23894426~23898930:-
UVM	cis	rs1153858	0.668	rs63603561	ENSG00000259520.4	CTD-2651B20.3	6.81	9.99e-09	7.45e-05	1	0.69	Homoarginine levels;	chr15:45301125	chr15:45251580~45279251:-
UVM	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	6.8	1.01e-08	7.56e-05	0.77	0.69	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
UVM	cis	rs2739330	0.652	rs2000469	ENSG00000218537.1	MIF-AS1	6.78	1.1e-08	8.17e-05	1.07	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23894426~23898930:-
UVM	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	6.78	1.12e-08	8.22e-05	0.87	0.68	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
UVM	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	6.78	1.12e-08	8.22e-05	0.87	0.68	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
UVM	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	6.78	1.12e-08	8.22e-05	0.87	0.68	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-6.78	1.12e-08	8.22e-05	-0.87	-0.68	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
UVM	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-6.78	1.12e-08	8.22e-05	-0.87	-0.68	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
UVM	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-6.78	1.12e-08	8.22e-05	-0.87	-0.68	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
UVM	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-6.78	1.12e-08	8.22e-05	-0.87	-0.68	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
UVM	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-6.78	1.12e-08	8.22e-05	-0.87	-0.68	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
UVM	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-6.78	1.12e-08	8.22e-05	-0.87	-0.68	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
UVM	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-6.78	1.12e-08	8.22e-05	-0.87	-0.68	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
UVM	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-6.78	1.12e-08	8.22e-05	-0.87	-0.68	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
UVM	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-6.78	1.12e-08	8.22e-05	-0.87	-0.68	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
UVM	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	6.78	1.12e-08	8.22e-05	0.76	0.68	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	6.78	1.12e-08	8.22e-05	0.76	0.68	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
UVM	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	6.78	1.12e-08	8.22e-05	0.76	0.68	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	6.78	1.12e-08	8.22e-05	0.76	0.68	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	6.78	1.12e-08	8.22e-05	0.76	0.68	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	6.78	1.12e-08	8.22e-05	0.76	0.68	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	6.78	1.12e-08	8.22e-05	0.76	0.68	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	6.78	1.12e-08	8.22e-05	0.76	0.68	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
UVM	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	6.78	1.12e-08	8.22e-05	0.76	0.68	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	6.78	1.12e-08	8.22e-05	0.76	0.68	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	6.78	1.12e-08	8.22e-05	0.76	0.68	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
UVM	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	6.78	1.12e-08	8.22e-05	0.76	0.68	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
UVM	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	6.78	1.12e-08	8.22e-05	0.76	0.68	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	6.78	1.12e-08	8.22e-05	0.76	0.68	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	6.78	1.12e-08	8.22e-05	0.76	0.68	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	6.78	1.12e-08	8.22e-05	0.76	0.68	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	6.78	1.12e-08	8.22e-05	0.76	0.68	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
UVM	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	6.78	1.12e-08	8.22e-05	0.76	0.68	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	6.78	1.12e-08	8.22e-05	0.76	0.68	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	6.78	1.12e-08	8.22e-05	0.76	0.68	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
UVM	cis	rs9549328	0.7	rs3011474	ENSG00000267868.1	RP11-120K24.3	-6.77	1.14e-08	8.31e-05	-0.84	-0.68	Systolic blood pressure;	chr13:112963551	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.7	rs3011473	ENSG00000267868.1	RP11-120K24.3	-6.77	1.14e-08	8.31e-05	-0.84	-0.68	Systolic blood pressure;	chr13:112963782	chr13:112964835~112966131:-
UVM	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	6.77	1.16e-08	8.48e-05	0.86	0.68	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
UVM	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	6.77	1.16e-08	8.48e-05	0.86	0.68	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
UVM	cis	rs9322193	0.923	rs6913486	ENSG00000231760.4	RP11-350J20.5	-6.77	1.17e-08	8.5e-05	-0.88	-0.68	Lung cancer;	chr6:149705060	chr6:149796151~149826294:-
UVM	cis	rs1167827	0.901	rs6963105	ENSG00000127957.15	PMS2P3	-6.76	1.19e-08	8.61e-05	-0.61	-0.68	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75468222	chr7:75502930~75528148:-
UVM	cis	rs7188445	1	rs11150190	ENSG00000261390.4	RP11-345M22.2	-6.76	1.19e-08	8.61e-05	-0.74	-0.68	Urate levels;	chr16:79700352	chr16:79715232~79770563:-
UVM	cis	rs55794721	0.543	rs1293260	ENSG00000261349.1	RP3-465N24.5	-6.75	1.22e-08	8.83e-05	-0.66	-0.68	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25266102~25267136:-
UVM	cis	rs3091242	1	rs646867	ENSG00000261349.1	RP3-465N24.5	-6.75	1.22e-08	8.83e-05	-0.66	-0.68	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.967	rs1053438	ENSG00000261349.1	RP3-465N24.5	6.75	1.22e-08	8.83e-05	0.66	0.68	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.935	rs3093632	ENSG00000261349.1	RP3-465N24.5	-6.75	1.24e-08	8.94e-05	-0.66	-0.68	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25266102~25267136:-
UVM	cis	rs12541595	0.808	rs10105974	ENSG00000249816.5	LINC00964	-6.75	1.24e-08	8.96e-05	-0.65	-0.68	Left ventricle diastolic internal dimension;	chr8:124842273	chr8:124848737~124954328:+
UVM	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-6.74	1.27e-08	9.1e-05	-0.78	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.931	rs10077796	ENSG00000253404.1	AC034243.1	-6.74	1.27e-08	9.1e-05	-0.78	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	6.74	1.27e-08	9.1e-05	0.78	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	6.74	1.27e-08	9.1e-05	0.78	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	6.74	1.27e-08	9.1e-05	0.78	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	6.74	1.27e-08	9.1e-05	0.78	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
UVM	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-6.74	1.28e-08	9.13e-05	-0.86	-0.68	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
UVM	cis	rs11214589	0.747	rs11214582	ENSG00000270179.1	RP11-159N11.4	-6.74	1.3e-08	9.27e-05	-0.86	-0.68	Neuroticism;	chr11:113347328	chr11:113368478~113369117:+
UVM	cis	rs11214589	0.747	rs11493880	ENSG00000270179.1	RP11-159N11.4	-6.74	1.3e-08	9.27e-05	-0.86	-0.68	Neuroticism;	chr11:113354422	chr11:113368478~113369117:+
UVM	cis	rs11214589	0.747	rs7939992	ENSG00000270179.1	RP11-159N11.4	-6.74	1.3e-08	9.27e-05	-0.86	-0.68	Neuroticism;	chr11:113358943	chr11:113368478~113369117:+
UVM	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	6.73	1.33e-08	9.44e-05	0.78	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	6.73	1.33e-08	9.44e-05	0.78	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	6.73	1.33e-08	9.44e-05	0.78	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	6.73	1.33e-08	9.44e-05	0.78	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	6.73	1.33e-08	9.44e-05	0.78	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	6.73	1.33e-08	9.44e-05	0.78	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
UVM	cis	rs9660180	0.935	rs9786942	ENSG00000268575.1	RP1-283E3.8	-6.71	1.43e-08	0.000101	-0.69	-0.68	Body mass index;	chr1:1827774	chr1:1702736~1737688:-
UVM	cis	rs9660180	0.934	rs34849348	ENSG00000268575.1	RP1-283E3.8	-6.71	1.43e-08	0.000101	-0.69	-0.68	Body mass index;	chr1:1831318	chr1:1702736~1737688:-
UVM	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-6.71	1.44e-08	0.000101	-0.86	-0.68	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
UVM	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	6.71	1.44e-08	0.000101	0.86	0.68	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
UVM	cis	rs9660180	0.967	rs66701417	ENSG00000268575.1	RP1-283E3.8	-6.7	1.48e-08	0.000104	-0.72	-0.68	Body mass index;	chr1:1766653	chr1:1702736~1737688:-
UVM	cis	rs9660180	0.967	rs12040325	ENSG00000268575.1	RP1-283E3.8	-6.7	1.48e-08	0.000104	-0.72	-0.68	Body mass index;	chr1:1770997	chr1:1702736~1737688:-
UVM	cis	rs3091242	0.967	rs665372	ENSG00000261349.1	RP3-465N24.5	-6.7	1.48e-08	0.000104	-0.66	-0.68	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25266102~25267136:-
UVM	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	6.7	1.49e-08	0.000105	0.74	0.68	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
UVM	cis	rs11214589	0.747	rs10891536	ENSG00000270179.1	RP11-159N11.4	-6.69	1.52e-08	0.000106	-0.85	-0.68	Neuroticism;	chr11:113338706	chr11:113368478~113369117:+
UVM	cis	rs2739330	0.703	rs5760112	ENSG00000273295.1	AP000350.5	6.68	1.6e-08	0.000112	0.73	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-6.68	1.63e-08	0.000114	-0.73	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
UVM	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	6.64	1.86e-08	0.000129	0.76	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	6.63	1.92e-08	0.000133	0.93	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.628	rs13154573	ENSG00000253404.1	AC034243.1	6.63	1.92e-08	0.000133	0.93	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138812375	chr5:138744434~138753309:-
UVM	cis	rs7188445	0.871	rs8047723	ENSG00000261390.4	RP11-345M22.2	6.63	1.96e-08	0.000136	0.7	0.68	Urate levels;	chr16:79671018	chr16:79715232~79770563:-
UVM	cis	rs9660180	0.78	rs12038111	ENSG00000268575.1	RP1-283E3.8	-6.62	1.96e-08	0.000136	-0.71	-0.68	Body mass index;	chr1:1772410	chr1:1702736~1737688:-
UVM	cis	rs9660180	0.836	rs12038134	ENSG00000268575.1	RP1-283E3.8	-6.62	1.96e-08	0.000136	-0.71	-0.68	Body mass index;	chr1:1772426	chr1:1702736~1737688:-
UVM	cis	rs916888	0.61	rs142167	ENSG00000262539.1	RP11-259G18.3	-6.61	2.07e-08	0.000143	-0.91	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46259551~46260606:-
UVM	cis	rs1930961	1	rs6004675	ENSG00000100058.11	CRYBB2P1	6.61	2.09e-08	0.000145	1.49	0.68	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25448105~25520854:+
UVM	cis	rs916888	0.773	rs1378358	ENSG00000214401.4	KANSL1-AS1	6.6	2.11e-08	0.000146	1.3	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46193576~46196723:+
UVM	cis	rs916888	0.773	rs538628	ENSG00000214401.4	KANSL1-AS1	6.6	2.11e-08	0.000146	1.3	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46193576~46196723:+
UVM	cis	rs916888	0.773	rs169201	ENSG00000214401.4	KANSL1-AS1	6.6	2.11e-08	0.000146	1.3	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46193576~46196723:+
UVM	cis	rs916888	0.773	rs199439	ENSG00000214401.4	KANSL1-AS1	6.6	2.11e-08	0.000146	1.3	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46193576~46196723:+
UVM	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	6.6	2.14e-08	0.000147	0.78	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
UVM	cis	rs2486288	0.656	rs11637838	ENSG00000259520.4	CTD-2651B20.3	6.59	2.23e-08	0.000154	0.85	0.67	Glomerular filtration rate;	chr15:45258459	chr15:45251580~45279251:-
UVM	cis	rs9322193	0.923	rs2880436	ENSG00000231760.4	RP11-350J20.5	6.58	2.33e-08	0.00016	0.83	0.67	Lung cancer;	chr6:149859123	chr6:149796151~149826294:-
UVM	cis	rs7615952	0.932	rs7629977	ENSG00000171084.14	FAM86JP	6.58	2.35e-08	0.000161	0.94	0.67	Blood pressure (smoking interaction);	chr3:125930730	chr3:125916620~125930024:+
UVM	cis	rs9660180	0.967	rs6687065	ENSG00000268575.1	RP1-283E3.8	-6.57	2.44e-08	0.000166	-0.67	-0.67	Body mass index;	chr1:1847030	chr1:1702736~1737688:-
UVM	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-6.56	2.48e-08	0.000169	-0.96	-0.67	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
UVM	cis	rs3091242	0.933	rs9645452	ENSG00000261349.1	RP3-465N24.5	6.56	2.5e-08	0.00017	0.66	0.67	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-6.55	2.62e-08	0.000175	-0.63	-0.67	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-6.55	2.62e-08	0.000175	-0.63	-0.67	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
UVM	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-6.55	2.62e-08	0.000175	-0.63	-0.67	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.9	rs1811832	ENSG00000261349.1	RP3-465N24.5	-6.55	2.62e-08	0.000175	-0.63	-0.67	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.933	rs926438	ENSG00000261349.1	RP3-465N24.5	-6.55	2.62e-08	0.000175	-0.63	-0.67	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.933	rs909833	ENSG00000261349.1	RP3-465N24.5	-6.55	2.62e-08	0.000175	-0.63	-0.67	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25266102~25267136:-
UVM	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	6.54	2.69e-08	0.00018	0.71	0.67	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
UVM	cis	rs9660180	0.967	rs61422524	ENSG00000268575.1	RP1-283E3.8	-6.54	2.71e-08	0.000181	-0.67	-0.67	Body mass index;	chr1:1836126	chr1:1702736~1737688:-
UVM	cis	rs9660180	0.967	rs10907191	ENSG00000268575.1	RP1-283E3.8	-6.54	2.71e-08	0.000181	-0.67	-0.67	Body mass index;	chr1:1843381	chr1:1702736~1737688:-
UVM	cis	rs2486288	0.656	rs9921035	ENSG00000259520.4	CTD-2651B20.3	6.54	2.73e-08	0.000182	0.85	0.67	Glomerular filtration rate;	chr15:45254462	chr15:45251580~45279251:-
UVM	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
UVM	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
UVM	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
UVM	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
UVM	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
UVM	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
UVM	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
UVM	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
UVM	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
UVM	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
UVM	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
UVM	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
UVM	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
UVM	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
UVM	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
UVM	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
UVM	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
UVM	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
UVM	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
UVM	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
UVM	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
UVM	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
UVM	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-6.52	2.85e-08	0.000187	-0.92	-0.67	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
UVM	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	6.52	2.85e-08	0.000187	0.92	0.67	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
UVM	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	6.52	2.85e-08	0.000187	0.92	0.67	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
UVM	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	6.52	2.85e-08	0.000187	0.92	0.67	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
UVM	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	6.52	2.85e-08	0.000187	0.92	0.67	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
UVM	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	6.52	2.85e-08	0.000187	0.92	0.67	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
UVM	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	6.52	2.85e-08	0.000187	0.92	0.67	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
UVM	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	6.52	2.85e-08	0.000187	0.92	0.67	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
UVM	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	6.52	2.85e-08	0.000187	0.92	0.67	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
UVM	cis	rs875971	0.522	rs9530	ENSG00000226824.5	RP4-756H11.3	-6.52	2.88e-08	0.000189	-0.92	-0.67	Aortic root size;	chr7:65960907	chr7:66654538~66669855:+
UVM	cis	rs3091242	1	rs3091242	ENSG00000261349.1	RP3-465N24.5	-6.52	2.89e-08	0.000189	-0.65	-0.67	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.967	rs3091240	ENSG00000261349.1	RP3-465N24.5	-6.52	2.89e-08	0.000189	-0.65	-0.67	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.967	rs3093614	ENSG00000261349.1	RP3-465N24.5	6.52	2.89e-08	0.000189	0.65	0.67	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25266102~25267136:-
UVM	cis	rs2283792	0.846	rs240051	ENSG00000224086.5	LL22NC03-86G7.1	-6.51	2.95e-08	0.000192	-0.74	-0.67	Multiple sclerosis;	chr22:21909763	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.846	rs240053	ENSG00000224086.5	LL22NC03-86G7.1	-6.51	2.95e-08	0.000192	-0.74	-0.67	Multiple sclerosis;	chr22:21911000	chr22:21938293~21977632:+
UVM	cis	rs3091242	0.933	rs3093584	ENSG00000261349.1	RP3-465N24.5	6.51	2.96e-08	0.000193	0.66	0.67	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25266102~25267136:-
UVM	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	6.51	2.96e-08	0.000193	1.22	0.67	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
UVM	cis	rs3091242	0.934	rs686631	ENSG00000261349.1	RP3-465N24.5	-6.51	2.98e-08	0.000194	-0.64	-0.67	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25266102~25267136:-
UVM	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-6.51	3.01e-08	0.000196	-0.82	-0.67	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
UVM	cis	rs2455601	0.786	rs10279	ENSG00000254860.4	TMEM9B-AS1	6.51	3.04e-08	0.000198	0.95	0.67	Schizophrenia;	chr11:8947762	chr11:8964675~8977527:+
UVM	cis	rs2455601	0.744	rs7938995	ENSG00000254860.4	TMEM9B-AS1	6.51	3.04e-08	0.000198	0.95	0.67	Schizophrenia;	chr11:8954128	chr11:8964675~8977527:+
UVM	cis	rs2455601	0.786	rs2568070	ENSG00000254860.4	TMEM9B-AS1	6.51	3.04e-08	0.000198	0.95	0.67	Schizophrenia;	chr11:8955346	chr11:8964675~8977527:+
UVM	cis	rs2455601	0.786	rs2568068	ENSG00000254860.4	TMEM9B-AS1	6.51	3.04e-08	0.000198	0.95	0.67	Schizophrenia;	chr11:8956283	chr11:8964675~8977527:+
UVM	cis	rs12541595	0.754	rs3935882	ENSG00000249816.5	LINC00964	6.5	3.06e-08	0.000199	0.7	0.67	Left ventricle diastolic internal dimension;	chr8:124886015	chr8:124848737~124954328:+
UVM	cis	rs1155848	0.892	rs9565509	ENSG00000227354.5	RBM26-AS1	6.5	3.08e-08	0.000199	1.13	0.67	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79483696	chr13:79406309~79424328:+
UVM	cis	rs1155848	0.892	rs28546558	ENSG00000227354.5	RBM26-AS1	6.5	3.08e-08	0.000199	1.13	0.67	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79516024	chr13:79406309~79424328:+
UVM	cis	rs1155848	0.892	rs3759438	ENSG00000227354.5	RBM26-AS1	6.5	3.08e-08	0.000199	1.13	0.67	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79566863	chr13:79406309~79424328:+
UVM	cis	rs2283792	0.792	rs151680	ENSG00000224086.5	LL22NC03-86G7.1	-6.5	3.13e-08	0.000199	-0.74	-0.67	Multiple sclerosis;	chr22:21918869	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.812	rs240064	ENSG00000224086.5	LL22NC03-86G7.1	6.5	3.14e-08	2e-04	0.74	0.67	Multiple sclerosis;	chr22:21927265	chr22:21938293~21977632:+
UVM	cis	rs858239	0.636	rs7808488	ENSG00000230658.1	KLHL7-AS1	6.49	3.21e-08	0.000203	0.75	0.67	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23101228~23105703:-
UVM	cis	rs858239	0.669	rs1618339	ENSG00000230658.1	KLHL7-AS1	6.49	3.21e-08	0.000203	0.75	0.67	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23101228~23105703:-
UVM	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	6.49	3.21e-08	0.000203	0.75	0.67	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
UVM	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-6.49	3.21e-08	0.000203	-0.75	-0.67	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
UVM	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	6.49	3.21e-08	0.000203	0.75	0.67	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
UVM	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	6.49	3.21e-08	0.000203	0.75	0.67	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
UVM	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	6.49	3.21e-08	0.000203	0.75	0.67	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
UVM	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	6.49	3.21e-08	0.000203	0.75	0.67	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
UVM	cis	rs916888	0.773	rs199457	ENSG00000214401.4	KANSL1-AS1	6.49	3.21e-08	0.000203	1.27	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46193576~46196723:+
UVM	cis	rs916888	0.687	rs199456	ENSG00000214401.4	KANSL1-AS1	6.49	3.21e-08	0.000203	1.27	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46193576~46196723:+
UVM	cis	rs916888	0.773	rs199451	ENSG00000214401.4	KANSL1-AS1	6.49	3.21e-08	0.000203	1.27	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46193576~46196723:+
UVM	cis	rs916888	0.773	rs199448	ENSG00000214401.4	KANSL1-AS1	6.49	3.21e-08	0.000203	1.27	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46193576~46196723:+
UVM	cis	rs916888	0.773	rs199447	ENSG00000214401.4	KANSL1-AS1	6.49	3.21e-08	0.000203	1.27	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46193576~46196723:+
UVM	cis	rs916888	0.773	rs199445	ENSG00000214401.4	KANSL1-AS1	6.49	3.21e-08	0.000203	1.27	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46193576~46196723:+
UVM	cis	rs916888	0.773	rs199443	ENSG00000214401.4	KANSL1-AS1	6.49	3.21e-08	0.000203	1.27	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46193576~46196723:+
UVM	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	6.49	3.21e-08	0.000203	1.27	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
UVM	cis	rs916888	0.773	rs199534	ENSG00000214401.4	KANSL1-AS1	6.49	3.21e-08	0.000203	1.27	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46193576~46196723:+
UVM	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	6.49	3.21e-08	0.000203	1.27	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
UVM	cis	rs916888	0.773	rs199533	ENSG00000214401.4	KANSL1-AS1	6.49	3.21e-08	0.000203	1.27	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46193576~46196723:+
UVM	cis	rs2283792	0.812	rs94194	ENSG00000224086.5	LL22NC03-86G7.1	-6.49	3.25e-08	0.000205	-0.74	-0.67	Multiple sclerosis;	chr22:21933937	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.812	rs5995269	ENSG00000224086.5	LL22NC03-86G7.1	-6.49	3.25e-08	0.000205	-0.74	-0.67	Multiple sclerosis;	chr22:21935025	chr22:21938293~21977632:+
UVM	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	6.48	3.3e-08	0.000208	0.91	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
UVM	cis	rs7569084	0.905	rs13417564	ENSG00000204929.10	AC074391.1	-6.48	3.31e-08	0.000208	-1.01	-0.67	Sum eosinophil basophil counts;	chr2:65438139	chr2:65436711~66084639:+
UVM	cis	rs2486288	0.656	rs8037583	ENSG00000259520.4	CTD-2651B20.3	6.48	3.32e-08	0.000208	0.88	0.67	Glomerular filtration rate;	chr15:45254180	chr15:45251580~45279251:-
UVM	cis	rs916888	0.602	rs199508	ENSG00000262539.1	RP11-259G18.3	-6.47	3.42e-08	0.000214	-0.96	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781472	chr17:46259551~46260606:-
UVM	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	6.47	3.47e-08	0.000216	0.74	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
UVM	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	6.47	3.48e-08	0.000217	0.78	0.67	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
UVM	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-6.46	3.54e-08	0.000221	-0.91	-0.67	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
UVM	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-6.46	3.63e-08	0.000226	-0.91	-0.67	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
UVM	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-6.46	3.63e-08	0.000226	-0.91	-0.67	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
UVM	cis	rs7569084	1	rs7569084	ENSG00000204929.10	AC074391.1	-6.46	3.65e-08	0.000227	-1	-0.67	Sum eosinophil basophil counts;	chr2:65429835	chr2:65436711~66084639:+
UVM	cis	rs7569084	1	rs13385171	ENSG00000204929.10	AC074391.1	-6.46	3.65e-08	0.000227	-1	-0.67	Sum eosinophil basophil counts;	chr2:65434709	chr2:65436711~66084639:+
UVM	cis	rs916888	0.61	rs199529	ENSG00000214401.4	KANSL1-AS1	6.45	3.77e-08	0.000234	1.27	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46193576~46196723:+
UVM	cis	rs4889009	0.533	rs12596569	ENSG00000261390.4	RP11-345M22.2	6.44	3.83e-08	0.000238	0.76	0.67	Thyroid peroxidase antibody positivity;	chr16:79701354	chr16:79715232~79770563:-
UVM	cis	rs2455601	0.671	rs2568091	ENSG00000254860.4	TMEM9B-AS1	6.44	3.91e-08	0.00024	1.04	0.67	Schizophrenia;	chr11:8964501	chr11:8964675~8977527:+
UVM	cis	rs2455601	0.638	rs2742485	ENSG00000254860.4	TMEM9B-AS1	6.44	3.91e-08	0.00024	1.04	0.67	Schizophrenia;	chr11:8965240	chr11:8964675~8977527:+
UVM	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-6.44	3.91e-08	0.00024	-0.9	-0.67	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
UVM	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-6.44	3.93e-08	0.00024	-0.84	-0.67	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
UVM	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	6.43	4e-08	0.000244	0.91	0.67	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
UVM	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	6.43	4e-08	0.000244	0.91	0.67	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
UVM	cis	rs858239	0.669	rs12539467	ENSG00000230658.1	KLHL7-AS1	6.43	4e-08	0.000244	0.8	0.67	Cerebrospinal fluid biomarker levels;	chr7:23076240	chr7:23101228~23105703:-
UVM	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	6.43	4.03e-08	0.000246	0.9	0.67	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
UVM	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	6.43	4.03e-08	0.000246	0.9	0.67	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
UVM	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	6.43	4.03e-08	0.000246	0.9	0.67	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
UVM	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	6.43	4.03e-08	0.000246	0.9	0.67	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
UVM	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-6.43	4.06e-08	0.000247	-0.93	-0.67	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
UVM	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-6.43	4.06e-08	0.000247	-0.93	-0.67	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-6.43	4.06e-08	0.000247	-0.93	-0.67	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
UVM	cis	rs3091242	0.933	rs932372	ENSG00000261349.1	RP3-465N24.5	-6.43	4.07e-08	0.000247	-0.66	-0.67	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.933	rs9438904	ENSG00000261349.1	RP3-465N24.5	-6.43	4.07e-08	0.000247	-0.66	-0.67	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25266102~25267136:-
UVM	cis	rs55794721	0.509	rs909834	ENSG00000261349.1	RP3-465N24.5	-6.43	4.07e-08	0.000247	-0.66	-0.67	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.866	rs11249249	ENSG00000261349.1	RP3-465N24.5	-6.43	4.07e-08	0.000247	-0.66	-0.67	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25266102~25267136:-
UVM	cis	rs9660180	0.846	rs10907195	ENSG00000268575.1	RP1-283E3.8	6.42	4.2e-08	0.000253	0.72	0.66	Body mass index;	chr1:1781909	chr1:1702736~1737688:-
UVM	cis	rs9660180	0.783	rs1107910	ENSG00000268575.1	RP1-283E3.8	-6.41	4.36e-08	0.000262	-0.72	-0.66	Body mass index;	chr1:1760882	chr1:1702736~1737688:-
UVM	cis	rs1153858	0.723	rs1719238	ENSG00000259520.4	CTD-2651B20.3	6.39	4.72e-08	0.000283	0.95	0.66	Homoarginine levels;	chr15:45302568	chr15:45251580~45279251:-
UVM	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-6.38	4.73e-08	0.000283	-0.71	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
UVM	cis	rs12541595	0.836	rs6980573	ENSG00000249816.5	LINC00964	6.38	4.81e-08	0.000288	0.62	0.66	Left ventricle diastolic internal dimension;	chr8:124840111	chr8:124848737~124954328:+
UVM	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-6.37	4.92e-08	0.000294	-0.59	-0.66	Breast cancer;	chr11:743813	chr11:779617~780755:+
UVM	cis	rs1155848	0.892	rs1023293	ENSG00000227354.5	RBM26-AS1	6.36	5.12e-08	0.000305	1.12	0.66	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480285	chr13:79406309~79424328:+
UVM	cis	rs1155848	0.892	rs953005	ENSG00000227354.5	RBM26-AS1	6.36	5.12e-08	0.000305	1.12	0.66	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480544	chr13:79406309~79424328:+
UVM	cis	rs1155848	0.892	rs9565508	ENSG00000227354.5	RBM26-AS1	6.36	5.12e-08	0.000305	1.12	0.66	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79482451	chr13:79406309~79424328:+
UVM	cis	rs1155848	0.892	rs9574424	ENSG00000227354.5	RBM26-AS1	-6.36	5.12e-08	0.000305	-1.12	-0.66	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79448541	chr13:79406309~79424328:+
UVM	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	6.36	5.17e-08	0.000306	0.72	0.66	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	6.36	5.17e-08	0.000306	0.72	0.66	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	6.36	5.17e-08	0.000306	0.72	0.66	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	6.36	5.17e-08	0.000306	0.72	0.66	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	6.36	5.17e-08	0.000306	0.72	0.66	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	6.36	5.17e-08	0.000306	0.72	0.66	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
UVM	cis	rs2739330	0.731	rs4822450	ENSG00000273295.1	AP000350.5	6.35	5.39e-08	0.000317	0.71	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	6.35	5.39e-08	0.000317	0.71	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
UVM	cis	rs2739330	0.76	rs5760095	ENSG00000273295.1	AP000350.5	6.35	5.44e-08	0.00032	0.71	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23901432~23907068:-
UVM	cis	rs494459	0.726	rs1784300	ENSG00000255239.1	AP002954.6	6.34	5.56e-08	0.000326	0.63	0.66	Height;	chr11:118808920	chr11:118688039~118690600:-
UVM	cis	rs494459	0.691	rs607472	ENSG00000255239.1	AP002954.6	6.34	5.56e-08	0.000326	0.63	0.66	Height;	chr11:118809363	chr11:118688039~118690600:-
UVM	cis	rs2455601	0.574	rs2568094	ENSG00000254860.4	TMEM9B-AS1	6.34	5.58e-08	0.000326	1.04	0.66	Schizophrenia;	chr11:8970671	chr11:8964675~8977527:+
UVM	cis	rs9322193	0.923	rs2342765	ENSG00000231760.4	RP11-350J20.5	6.34	5.62e-08	0.000329	0.8	0.66	Lung cancer;	chr6:149858873	chr6:149796151~149826294:-
UVM	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-6.34	5.65e-08	0.00033	-0.69	-0.66	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
UVM	cis	rs1153858	0.621	rs2687512	ENSG00000259520.4	CTD-2651B20.3	6.33	5.75e-08	0.000336	0.95	0.66	Homoarginine levels;	chr15:45289297	chr15:45251580~45279251:-
UVM	cis	rs7615952	0.866	rs6438949	ENSG00000171084.14	FAM86JP	6.33	5.78e-08	0.000338	0.86	0.66	Blood pressure (smoking interaction);	chr3:125931221	chr3:125916620~125930024:+
UVM	cis	rs1930961	1	rs59226697	ENSG00000100058.11	CRYBB2P1	6.32	5.95e-08	0.000346	1.42	0.66	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25448105~25520854:+
UVM	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	6.31	6.18e-08	0.000359	0.67	0.66	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
UVM	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	6.31	6.21e-08	0.000361	0.88	0.66	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
UVM	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	6.31	6.21e-08	0.000361	0.88	0.66	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
UVM	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-6.3	6.38e-08	0.00037	-0.78	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
UVM	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-6.3	6.4e-08	0.000371	-0.84	-0.66	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
UVM	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-6.3	6.56e-08	0.000377	-1.01	-0.66	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
UVM	cis	rs1167827	0.805	rs809439	ENSG00000127957.15	PMS2P3	6.27	7.19e-08	0.00041	0.62	0.66	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75531992	chr7:75502930~75528148:-
UVM	cis	rs950027	0.549	rs11070452	ENSG00000259520.4	CTD-2651B20.3	6.27	7.2e-08	0.00041	0.85	0.66	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45251580~45279251:-
UVM	cis	rs950027	0.549	rs9920634	ENSG00000259520.4	CTD-2651B20.3	6.27	7.2e-08	0.00041	0.85	0.66	Response to fenofibrate (adiponectin levels);	chr15:45304348	chr15:45251580~45279251:-
UVM	cis	rs950027	0.549	rs2899375	ENSG00000259520.4	CTD-2651B20.3	6.27	7.2e-08	0.00041	0.85	0.66	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45251580~45279251:-
UVM	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	6.27	7.23e-08	0.000412	0.8	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
UVM	cis	rs2455601	0.638	rs2568092	ENSG00000254860.4	TMEM9B-AS1	-6.27	7.32e-08	0.000417	-1.02	-0.66	Schizophrenia;	chr11:8965891	chr11:8964675~8977527:+
UVM	cis	rs7569084	1	rs7583469	ENSG00000204929.10	AC074391.1	6.26	7.35e-08	0.000419	1.02	0.66	Sum eosinophil basophil counts;	chr2:65424222	chr2:65436711~66084639:+
UVM	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	6.26	7.37e-08	0.00042	0.9	0.66	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
UVM	cis	rs7188445	0.871	rs11150187	ENSG00000261390.4	RP11-345M22.2	6.26	7.43e-08	0.000423	0.69	0.66	Urate levels;	chr16:79670515	chr16:79715232~79770563:-
UVM	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-6.26	7.48e-08	0.000425	-0.75	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
UVM	cis	rs2455601	0.744	rs2568085	ENSG00000254860.4	TMEM9B-AS1	-6.26	7.6e-08	0.000431	-0.89	-0.66	Schizophrenia;	chr11:8954201	chr11:8964675~8977527:+
UVM	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	6.25	7.63e-08	0.000433	0.57	0.66	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
UVM	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	6.25	7.85e-08	0.000445	0.7	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
UVM	cis	rs7174755	0.923	rs9672383	ENSG00000260657.2	RP11-315D16.4	6.24	8.03e-08	0.000453	0.81	0.65	Major depressive disorder;	chr15:68306731	chr15:68267792~68277994:-
UVM	cis	rs7174755	0.961	rs11631030	ENSG00000260657.2	RP11-315D16.4	6.24	8.06e-08	0.000454	0.81	0.65	Major depressive disorder;	chr15:68303463	chr15:68267792~68277994:-
UVM	cis	rs2739330	0.731	rs4822450	ENSG00000218537.1	MIF-AS1	6.23	8.19e-08	0.000461	0.87	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23894426~23898930:-
UVM	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	6.23	8.19e-08	0.000461	0.87	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
UVM	cis	rs2283792	0.687	rs381849	ENSG00000224086.5	LL22NC03-86G7.1	-6.23	8.28e-08	0.000466	-0.71	-0.65	Multiple sclerosis;	chr22:21951341	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.718	rs239918	ENSG00000224086.5	LL22NC03-86G7.1	-6.23	8.28e-08	0.000466	-0.71	-0.65	Multiple sclerosis;	chr22:21959457	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.745	rs5756306	ENSG00000224086.5	LL22NC03-86G7.1	6.23	8.28e-08	0.000466	0.71	0.65	Multiple sclerosis;	chr22:21978846	chr22:21938293~21977632:+
UVM	cis	rs2882667	0.652	rs6596463	ENSG00000253404.1	AC034243.1	6.23	8.36e-08	0.00047	0.71	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138744434~138753309:-
UVM	cis	rs9549328	0.614	rs35872678	ENSG00000267868.1	RP11-120K24.3	-6.23	8.42e-08	0.000473	-0.85	-0.65	Systolic blood pressure;	chr13:112962917	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.7	rs34890317	ENSG00000267868.1	RP11-120K24.3	-6.23	8.42e-08	0.000473	-0.85	-0.65	Systolic blood pressure;	chr13:112962931	chr13:112964835~112966131:-
UVM	cis	rs916888	0.61	rs199452	ENSG00000262539.1	RP11-259G18.3	6.22	8.56e-08	0.000479	0.92	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46259551~46260606:-
UVM	cis	rs916888	0.647	rs199524	ENSG00000262539.1	RP11-259G18.3	-6.22	8.56e-08	0.000479	-0.92	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46259551~46260606:-
UVM	cis	rs916888	0.647	rs199523	ENSG00000262539.1	RP11-259G18.3	-6.22	8.56e-08	0.000479	-0.92	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46259551~46260606:-
UVM	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-6.21	8.82e-08	0.000494	-0.9	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
UVM	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	6.21	8.83e-08	0.000494	0.66	0.65	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
UVM	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	6.21	8.99e-08	5e-04	0.69	0.65	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
UVM	cis	rs2739330	0.76	rs5760095	ENSG00000218537.1	MIF-AS1	6.21	9.12e-08	0.000504	0.87	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23894426~23898930:-
UVM	cis	rs1153858	0.723	rs4580098	ENSG00000259520.4	CTD-2651B20.3	-6.2	9.19e-08	0.000508	-0.94	-0.65	Homoarginine levels;	chr15:45304711	chr15:45251580~45279251:-
UVM	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-6.2	9.3e-08	0.000512	-0.72	-0.65	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
UVM	cis	rs7188445	0.966	rs11150188	ENSG00000261390.4	RP11-345M22.2	-6.19	9.81e-08	0.000523	-0.72	-0.65	Urate levels;	chr16:79673401	chr16:79715232~79770563:-
UVM	cis	rs2882667	0.66	rs11951084	ENSG00000253404.1	AC034243.1	6.18	1e-07	0.000528	0.75	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:139125858	chr5:138744434~138753309:-
UVM	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	6.18	1.01e-07	0.000528	0.39	0.65	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
UVM	cis	rs9660180	1	rs3737628	ENSG00000268575.1	RP1-283E3.8	-6.17	1.02e-07	0.000528	-0.64	-0.65	Body mass index;	chr1:1791493	chr1:1702736~1737688:-
UVM	cis	rs9660180	1	rs9660180	ENSG00000268575.1	RP1-283E3.8	-6.17	1.02e-07	0.000528	-0.64	-0.65	Body mass index;	chr1:1791592	chr1:1702736~1737688:-
UVM	cis	rs9660180	0.935	rs2180311	ENSG00000268575.1	RP1-283E3.8	-6.17	1.02e-07	0.000528	-0.64	-0.65	Body mass index;	chr1:1817295	chr1:1702736~1737688:-
UVM	cis	rs9660180	0.967	rs6664664	ENSG00000268575.1	RP1-283E3.8	-6.17	1.02e-07	0.000528	-0.64	-0.65	Body mass index;	chr1:1819825	chr1:1702736~1737688:-
UVM	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	6.17	1.02e-07	0.000529	0.73	0.65	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
UVM	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	6.17	1.02e-07	0.000529	0.73	0.65	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
UVM	cis	rs2882667	0.505	rs6596465	ENSG00000253404.1	AC034243.1	-6.17	1.04e-07	0.000535	-0.77	-0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:139147337	chr5:138744434~138753309:-
UVM	cis	rs7174755	0.962	rs4777034	ENSG00000260657.2	RP11-315D16.4	-6.15	1.1e-07	0.000565	-0.8	-0.65	Major depressive disorder;	chr15:68309546	chr15:68267792~68277994:-
UVM	cis	rs7174755	0.962	rs1020842	ENSG00000260657.2	RP11-315D16.4	-6.15	1.1e-07	0.000565	-0.8	-0.65	Major depressive disorder;	chr15:68309840	chr15:68267792~68277994:-
UVM	cis	rs9660180	0.967	rs12034740	ENSG00000268575.1	RP1-283E3.8	-6.15	1.12e-07	0.000574	-0.64	-0.65	Body mass index;	chr1:1797530	chr1:1702736~1737688:-
UVM	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-6.15	1.13e-07	0.000577	-0.71	-0.65	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
UVM	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-6.14	1.18e-07	0.00059	-0.81	-0.65	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-6.14	1.18e-07	0.00059	-0.81	-0.65	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-6.14	1.18e-07	0.00059	-0.81	-0.65	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-6.14	1.18e-07	0.00059	-0.81	-0.65	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-6.14	1.18e-07	0.00059	-0.81	-0.65	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-6.14	1.18e-07	0.00059	-0.81	-0.65	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-6.14	1.18e-07	0.00059	-0.81	-0.65	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-6.14	1.18e-07	0.00059	-0.81	-0.65	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-6.14	1.18e-07	0.00059	-0.81	-0.65	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
UVM	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-6.14	1.18e-07	0.00059	-0.81	-0.65	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
UVM	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-6.14	1.18e-07	0.00059	-0.81	-0.65	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-6.14	1.18e-07	0.00059	-0.81	-0.65	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-6.14	1.18e-07	0.00059	-0.81	-0.65	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-6.14	1.18e-07	0.00059	-0.81	-0.65	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
UVM	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-6.14	1.18e-07	0.00059	-0.81	-0.65	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
UVM	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-6.14	1.18e-07	0.00059	-0.81	-0.65	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
UVM	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-6.14	1.18e-07	0.00059	-0.81	-0.65	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
UVM	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-6.14	1.18e-07	0.00059	-0.81	-0.65	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-6.14	1.18e-07	0.00059	-0.81	-0.65	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
UVM	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-6.14	1.18e-07	0.00059	-0.81	-0.65	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
UVM	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-6.14	1.18e-07	0.00059	-0.81	-0.65	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
UVM	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
UVM	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
UVM	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
UVM	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
UVM	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
UVM	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
UVM	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
UVM	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	6.14	1.18e-07	0.00059	0.81	0.65	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
UVM	cis	rs1155848	0.571	rs6563125	ENSG00000227354.5	RBM26-AS1	6.13	1.19e-07	0.000592	0.96	0.65	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79630618	chr13:79406309~79424328:+
UVM	cis	rs1155848	0.571	rs58739959	ENSG00000227354.5	RBM26-AS1	6.13	1.19e-07	0.000592	0.96	0.65	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79633468	chr13:79406309~79424328:+
UVM	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-6.13	1.19e-07	0.000592	-0.67	-0.65	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
UVM	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-6.13	1.2e-07	0.000597	-0.87	-0.65	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
UVM	cis	rs2455601	0.882	rs11042105	ENSG00000254860.4	TMEM9B-AS1	6.13	1.2e-07	0.000597	1	0.65	Schizophrenia;	chr11:8872963	chr11:8964675~8977527:+
UVM	cis	rs2455601	0.882	rs10840139	ENSG00000254860.4	TMEM9B-AS1	6.13	1.2e-07	0.000597	1	0.65	Schizophrenia;	chr11:8873291	chr11:8964675~8977527:+
UVM	cis	rs2455601	1	rs72632952	ENSG00000254860.4	TMEM9B-AS1	6.13	1.2e-07	0.000597	1	0.65	Schizophrenia;	chr11:8896429	chr11:8964675~8977527:+
UVM	cis	rs2455601	0.935	rs12049908	ENSG00000254860.4	TMEM9B-AS1	6.13	1.2e-07	0.000597	1	0.65	Schizophrenia;	chr11:8897762	chr11:8964675~8977527:+
UVM	cis	rs2455601	1	rs11042114	ENSG00000254860.4	TMEM9B-AS1	6.13	1.2e-07	0.000597	1	0.65	Schizophrenia;	chr11:8898342	chr11:8964675~8977527:+
UVM	cis	rs2455601	0.882	rs11042115	ENSG00000254860.4	TMEM9B-AS1	6.13	1.2e-07	0.000597	1	0.65	Schizophrenia;	chr11:8905132	chr11:8964675~8977527:+
UVM	cis	rs2455601	0.882	rs11042116	ENSG00000254860.4	TMEM9B-AS1	6.13	1.2e-07	0.000597	1	0.65	Schizophrenia;	chr11:8906925	chr11:8964675~8977527:+
UVM	cis	rs2455601	0.882	rs11042118	ENSG00000254860.4	TMEM9B-AS1	6.13	1.2e-07	0.000597	1	0.65	Schizophrenia;	chr11:8907244	chr11:8964675~8977527:+
UVM	cis	rs2455601	0.882	rs11042106	ENSG00000254860.4	TMEM9B-AS1	-6.13	1.2e-07	0.000597	-1	-0.65	Schizophrenia;	chr11:8874536	chr11:8964675~8977527:+
UVM	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	6.13	1.21e-07	0.000601	0.78	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
UVM	cis	rs7188445	0.871	rs8048928	ENSG00000261390.4	RP11-345M22.2	-6.12	1.22e-07	0.000607	-0.68	-0.65	Urate levels;	chr16:79671039	chr16:79715232~79770563:-
UVM	cis	rs950027	0.549	rs12909409	ENSG00000259520.4	CTD-2651B20.3	6.12	1.24e-07	0.000614	0.84	0.65	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45251580~45279251:-
UVM	cis	rs950027	0.572	rs12910764	ENSG00000259520.4	CTD-2651B20.3	6.12	1.24e-07	0.000614	0.84	0.65	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45251580~45279251:-
UVM	cis	rs7188445	0.871	rs7202770	ENSG00000261390.4	RP11-345M22.2	-6.12	1.24e-07	0.000614	-0.69	-0.65	Urate levels;	chr16:79672643	chr16:79715232~79770563:-
UVM	cis	rs7188445	0.835	rs1424231	ENSG00000261390.4	RP11-345M22.2	-6.12	1.24e-07	0.000614	-0.69	-0.65	Urate levels;	chr16:79672854	chr16:79715232~79770563:-
UVM	cis	rs7188445	0.871	rs16950997	ENSG00000261390.4	RP11-345M22.2	-6.12	1.24e-07	0.000614	-0.69	-0.65	Urate levels;	chr16:79673733	chr16:79715232~79770563:-
UVM	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	6.12	1.24e-07	0.000617	0.7	0.65	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
UVM	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	6.12	1.25e-07	0.00062	0.81	0.65	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-6.12	1.25e-07	0.00062	-0.81	-0.65	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
UVM	cis	rs9660180	0.967	rs2272908	ENSG00000268575.1	RP1-283E3.8	6.12	1.26e-07	0.000625	0.66	0.65	Body mass index;	chr1:1790040	chr1:1702736~1737688:-
UVM	cis	rs858239	0.669	rs1990365	ENSG00000230658.1	KLHL7-AS1	6.11	1.31e-07	0.000645	0.71	0.65	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23101228~23105703:-
UVM	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-6.1	1.35e-07	0.000661	-0.81	-0.65	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
UVM	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	6.09	1.38e-07	0.00067	0.71	0.65	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
UVM	cis	rs858239	0.73	rs858279	ENSG00000230658.1	KLHL7-AS1	6.09	1.41e-07	0.000685	0.74	0.64	Cerebrospinal fluid biomarker levels;	chr7:23211386	chr7:23101228~23105703:-
UVM	cis	rs1930961	1	rs760554	ENSG00000100058.11	CRYBB2P1	6.08	1.41e-07	0.000685	1.39	0.64	Bipolar disorder with mood-incongruent psychosis;	chr22:25476625	chr22:25448105~25520854:+
UVM	cis	rs1930961	1	rs760555	ENSG00000100058.11	CRYBB2P1	6.08	1.41e-07	0.000685	1.39	0.64	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25448105~25520854:+
UVM	cis	rs9660180	0.836	rs72634845	ENSG00000268575.1	RP1-283E3.8	-6.08	1.42e-07	0.000689	-0.66	-0.64	Body mass index;	chr1:1773460	chr1:1702736~1737688:-
UVM	cis	rs9660180	0.868	rs72634846	ENSG00000268575.1	RP1-283E3.8	-6.08	1.42e-07	0.000689	-0.66	-0.64	Body mass index;	chr1:1773476	chr1:1702736~1737688:-
UVM	cis	rs9660180	0.839	rs12040826	ENSG00000268575.1	RP1-283E3.8	-6.08	1.42e-07	0.000689	-0.66	-0.64	Body mass index;	chr1:1773848	chr1:1702736~1737688:-
UVM	cis	rs9660180	0.967	rs12044597	ENSG00000268575.1	RP1-283E3.8	-6.08	1.42e-07	0.000689	-0.66	-0.64	Body mass index;	chr1:1777362	chr1:1702736~1737688:-
UVM	cis	rs9660180	0.967	rs11260623	ENSG00000268575.1	RP1-283E3.8	-6.08	1.45e-07	0.000701	-0.63	-0.64	Body mass index;	chr1:1850017	chr1:1702736~1737688:-
UVM	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	6.07	1.48e-07	0.000714	0.65	0.64	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
UVM	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-6.07	1.51e-07	0.000726	-0.81	-0.64	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
UVM	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-6.07	1.51e-07	0.000726	-0.81	-0.64	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
UVM	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-6.07	1.51e-07	0.000726	-0.81	-0.64	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
UVM	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-6.07	1.51e-07	0.000726	-0.81	-0.64	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
UVM	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-6.07	1.51e-07	0.000726	-0.81	-0.64	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
UVM	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-6.07	1.51e-07	0.000726	-0.81	-0.64	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
UVM	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-6.07	1.51e-07	0.000726	-0.81	-0.64	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
UVM	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-6.07	1.51e-07	0.000726	-0.81	-0.64	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
UVM	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-6.07	1.51e-07	0.000726	-0.81	-0.64	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
UVM	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-6.07	1.51e-07	0.000726	-0.81	-0.64	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
UVM	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-6.07	1.51e-07	0.000726	-0.81	-0.64	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
UVM	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-6.07	1.51e-07	0.000726	-0.81	-0.64	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
UVM	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	6.06	1.56e-07	0.000746	0.81	0.64	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
UVM	cis	rs507080	0.501	rs494459	ENSG00000255239.1	AP002954.6	-6.06	1.57e-07	0.000749	-0.6	-0.64	Serum metabolite levels;	chr11:118703966	chr11:118688039~118690600:-
UVM	cis	rs507080	0.524	rs524409	ENSG00000255239.1	AP002954.6	6.06	1.57e-07	0.000749	0.6	0.64	Serum metabolite levels;	chr11:118703602	chr11:118688039~118690600:-
UVM	cis	rs507080	0.501	rs626645	ENSG00000255239.1	AP002954.6	6.06	1.57e-07	0.000749	0.6	0.64	Serum metabolite levels;	chr11:118704471	chr11:118688039~118690600:-
UVM	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	6.06	1.57e-07	0.000753	0.65	0.64	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.933	rs7541095	ENSG00000261349.1	RP3-465N24.5	-6.05	1.58e-07	0.000757	-0.65	-0.64	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25266102~25267136:-
UVM	cis	rs9322193	0.884	rs9383864	ENSG00000231760.4	RP11-350J20.5	6.05	1.6e-07	0.000763	0.81	0.64	Lung cancer;	chr6:149851969	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.884	rs7743823	ENSG00000231760.4	RP11-350J20.5	6.04	1.67e-07	0.000795	0.8	0.64	Lung cancer;	chr6:149849744	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.884	rs9397036	ENSG00000231760.4	RP11-350J20.5	6.04	1.67e-07	0.000795	0.8	0.64	Lung cancer;	chr6:149851787	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.884	rs9383865	ENSG00000231760.4	RP11-350J20.5	6.04	1.67e-07	0.000795	0.8	0.64	Lung cancer;	chr6:149852043	chr6:149796151~149826294:-
UVM	cis	rs2882667	0.505	rs7721110	ENSG00000253404.1	AC034243.1	6.04	1.67e-07	0.000796	0.75	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:139146817	chr5:138744434~138753309:-
UVM	cis	rs3750965	0.959	rs3168115	ENSG00000260895.1	RP11-554A11.7	-6.02	1.78e-07	0.000847	-0.89	-0.64	Hair color;	chr11:69090622	chr11:69103493~69109094:+
UVM	cis	rs3750965	0.959	rs4930265	ENSG00000260895.1	RP11-554A11.7	6.02	1.78e-07	0.000847	0.89	0.64	Hair color;	chr11:69088486	chr11:69103493~69109094:+
UVM	cis	rs3750965	0.959	rs3376	ENSG00000260895.1	RP11-554A11.7	6.02	1.78e-07	0.000847	0.89	0.64	Hair color;	chr11:69089212	chr11:69103493~69109094:+
UVM	cis	rs3750965	0.959	rs2253658	ENSG00000260895.1	RP11-554A11.7	6.02	1.78e-07	0.000847	0.89	0.64	Hair color;	chr11:69089336	chr11:69103493~69109094:+
UVM	cis	rs3750965	0.806	rs7107680	ENSG00000260895.1	RP11-554A11.7	6.02	1.78e-07	0.000847	0.89	0.64	Hair color;	chr11:69092426	chr11:69103493~69109094:+
UVM	cis	rs3750965	0.92	rs10896420	ENSG00000260895.1	RP11-554A11.7	6.02	1.78e-07	0.000847	0.89	0.64	Hair color;	chr11:69095579	chr11:69103493~69109094:+
UVM	cis	rs3750965	0.92	rs10896421	ENSG00000260895.1	RP11-554A11.7	6.02	1.78e-07	0.000847	0.89	0.64	Hair color;	chr11:69095580	chr11:69103493~69109094:+
UVM	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-6.02	1.78e-07	0.000847	-0.72	-0.64	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
UVM	cis	rs3750965	0.959	rs4930264	ENSG00000260895.1	RP11-554A11.7	6.01	1.86e-07	0.000882	0.88	0.64	Hair color;	chr11:69084713	chr11:69103493~69109094:+
UVM	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	6.01	1.87e-07	0.000887	0.66	0.64	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
UVM	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	6.01	1.87e-07	0.000887	0.66	0.64	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
UVM	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	6.01	1.88e-07	0.000892	0.92	0.64	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	6.01	1.88e-07	0.000892	0.92	0.64	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
UVM	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	6	1.91e-07	0.000894	0.7	0.64	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
UVM	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	6	1.91e-07	0.000894	0.7	0.64	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
UVM	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	6	1.91e-07	0.000894	0.7	0.64	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
UVM	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-6	1.93e-07	0.000901	-0.72	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
UVM	cis	rs6700559	0.935	rs10920001	ENSG00000260088.1	RP11-92G12.3	-6	1.96e-07	0.000911	-0.9	-0.64	Coronary artery disease;	chr1:200682420	chr1:200669507~200694250:+
UVM	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-5.99	1.99e-07	0.000916	-0.83	-0.64	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
UVM	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-5.99	1.99e-07	0.000918	-0.72	-0.64	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
UVM	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	5.99	2.02e-07	0.000931	0.65	0.64	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
UVM	cis	rs950027	0.549	rs11636114	ENSG00000259520.4	CTD-2651B20.3	-5.98	2.08e-07	0.000954	-0.83	-0.64	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45251580~45279251:-
UVM	cis	rs1930961	1	rs7285549	ENSG00000100058.11	CRYBB2P1	5.98	2.09e-07	0.000961	1.35	0.64	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25448105~25520854:+
UVM	cis	rs1930961	1	rs6004669	ENSG00000100058.11	CRYBB2P1	5.98	2.09e-07	0.000961	1.35	0.64	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25448105~25520854:+
UVM	cis	rs1930961	1	rs5996946	ENSG00000100058.11	CRYBB2P1	5.98	2.09e-07	0.000961	1.35	0.64	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25448105~25520854:+
UVM	cis	rs1930961	1	rs997873	ENSG00000100058.11	CRYBB2P1	5.98	2.09e-07	0.000961	1.35	0.64	Bipolar disorder with mood-incongruent psychosis;	chr22:25482315	chr22:25448105~25520854:+
UVM	cis	rs1930961	1	rs997872	ENSG00000100058.11	CRYBB2P1	5.98	2.09e-07	0.000961	1.35	0.64	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25448105~25520854:+
UVM	cis	rs1930961	1	rs6004671	ENSG00000100058.11	CRYBB2P1	5.98	2.09e-07	0.000961	1.35	0.64	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25448105~25520854:+
UVM	cis	rs1930961	1	rs6004672	ENSG00000100058.11	CRYBB2P1	5.98	2.09e-07	0.000961	1.35	0.64	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25448105~25520854:+
UVM	cis	rs1930961	1	rs6004667	ENSG00000100058.11	CRYBB2P1	-5.98	2.09e-07	0.000961	-1.35	-0.64	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25448105~25520854:+
UVM	cis	rs1930961	1	rs6004668	ENSG00000100058.11	CRYBB2P1	-5.98	2.09e-07	0.000961	-1.35	-0.64	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25448105~25520854:+
UVM	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	5.98	2.11e-07	0.000965	0.76	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	5.98	2.11e-07	0.000965	0.76	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
UVM	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-5.97	2.13e-07	0.000974	-0.71	-0.64	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
UVM	cis	rs7615952	0.932	rs6438948	ENSG00000171084.14	FAM86JP	-5.97	2.15e-07	0.000983	-0.84	-0.64	Blood pressure (smoking interaction);	chr3:125931202	chr3:125916620~125930024:+
UVM	cis	rs1930961	1	rs6519611	ENSG00000100058.11	CRYBB2P1	5.97	2.15e-07	0.000983	1.4	0.64	Bipolar disorder with mood-incongruent psychosis;	chr22:25449888	chr22:25448105~25520854:+
UVM	cis	rs1930961	1	rs9624834	ENSG00000100058.11	CRYBB2P1	5.97	2.15e-07	0.000983	1.4	0.64	Bipolar disorder with mood-incongruent psychosis;	chr22:25450048	chr22:25448105~25520854:+
UVM	cis	rs1930961	1	rs9624835	ENSG00000100058.11	CRYBB2P1	5.97	2.15e-07	0.000983	1.4	0.64	Bipolar disorder with mood-incongruent psychosis;	chr22:25450054	chr22:25448105~25520854:+
UVM	cis	rs1930961	1	rs9624836	ENSG00000100058.11	CRYBB2P1	5.97	2.15e-07	0.000983	1.4	0.64	Bipolar disorder with mood-incongruent psychosis;	chr22:25450120	chr22:25448105~25520854:+
UVM	cis	rs1930961	0.867	rs6423498	ENSG00000100058.11	CRYBB2P1	5.97	2.15e-07	0.000983	1.4	0.64	Bipolar disorder with mood-incongruent psychosis;	chr22:25457401	chr22:25448105~25520854:+
UVM	cis	rs858239	0.669	rs6461687	ENSG00000230658.1	KLHL7-AS1	5.97	2.17e-07	0.00099	0.7	0.64	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23101228~23105703:-
UVM	cis	rs858239	0.669	rs6461688	ENSG00000230658.1	KLHL7-AS1	5.97	2.17e-07	0.00099	0.7	0.64	Cerebrospinal fluid biomarker levels;	chr7:23076996	chr7:23101228~23105703:-
UVM	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	5.97	2.17e-07	0.000993	0.73	0.64	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
UVM	cis	rs9322193	0.847	rs868375	ENSG00000231760.4	RP11-350J20.5	5.95	2.32e-07	0.00105	0.83	0.64	Lung cancer;	chr6:149844905	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.847	rs880246	ENSG00000231760.4	RP11-350J20.5	5.95	2.32e-07	0.00105	0.83	0.64	Lung cancer;	chr6:149845972	chr6:149796151~149826294:-
UVM	cis	rs494459	0.964	rs576283	ENSG00000255239.1	AP002954.6	5.94	2.39e-07	0.00108	0.59	0.64	Height;	chr11:118703185	chr11:118688039~118690600:-
UVM	cis	rs494459	0.929	rs627391	ENSG00000255239.1	AP002954.6	5.94	2.39e-07	0.00108	0.59	0.64	Height;	chr11:118703207	chr11:118688039~118690600:-
UVM	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	5.94	2.42e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
UVM	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
UVM	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
UVM	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
UVM	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
UVM	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
UVM	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
UVM	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
UVM	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
UVM	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
UVM	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
UVM	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
UVM	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	5.94	2.43e-07	0.00108	0.79	0.64	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-5.94	2.43e-07	0.00108	-0.79	-0.64	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-5.94	2.43e-07	0.00108	-0.79	-0.64	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
UVM	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-5.94	2.43e-07	0.00108	-0.79	-0.64	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-5.94	2.43e-07	0.00108	-0.79	-0.64	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-5.94	2.43e-07	0.00108	-0.79	-0.64	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-5.94	2.43e-07	0.00108	-0.79	-0.64	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-5.94	2.43e-07	0.00108	-0.79	-0.64	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
UVM	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-5.94	2.43e-07	0.00108	-0.79	-0.64	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-5.94	2.43e-07	0.00108	-0.79	-0.64	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-5.94	2.43e-07	0.00108	-0.79	-0.64	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
UVM	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-5.94	2.43e-07	0.00108	-0.79	-0.64	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-5.94	2.43e-07	0.00108	-0.79	-0.64	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
UVM	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-5.94	2.43e-07	0.00108	-0.79	-0.64	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
UVM	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-5.94	2.43e-07	0.00108	-0.79	-0.64	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-5.94	2.43e-07	0.00108	-0.79	-0.64	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
UVM	cis	rs1153858	0.723	rs11855527	ENSG00000259520.4	CTD-2651B20.3	5.93	2.44e-07	0.00108	0.92	0.64	Homoarginine levels;	chr15:45314487	chr15:45251580~45279251:-
UVM	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	5.93	2.53e-07	0.00111	0.7	0.63	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
UVM	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	5.93	2.53e-07	0.00111	0.7	0.63	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
UVM	cis	rs11098499	0.954	rs11098524	ENSG00000245958.5	RP11-33B1.1	-5.92	2.55e-07	0.00112	-0.43	-0.63	Corneal astigmatism;	chr4:119468877	chr4:119454791~119552025:+
UVM	cis	rs2455601	0.786	rs3763914	ENSG00000254860.4	TMEM9B-AS1	5.92	2.58e-07	0.00113	1	0.63	Schizophrenia;	chr11:8919156	chr11:8964675~8977527:+
UVM	cis	rs2455601	0.786	rs11042127	ENSG00000254860.4	TMEM9B-AS1	5.92	2.58e-07	0.00113	1	0.63	Schizophrenia;	chr11:8926039	chr11:8964675~8977527:+
UVM	cis	rs2455601	0.786	rs3763913	ENSG00000254860.4	TMEM9B-AS1	5.92	2.58e-07	0.00113	1	0.63	Schizophrenia;	chr11:8929683	chr11:8964675~8977527:+
UVM	cis	rs2455601	0.766	rs1109304	ENSG00000254860.4	TMEM9B-AS1	5.92	2.58e-07	0.00113	1	0.63	Schizophrenia;	chr11:8933908	chr11:8964675~8977527:+
UVM	cis	rs2455601	0.786	rs3751064	ENSG00000254860.4	TMEM9B-AS1	5.92	2.58e-07	0.00113	1	0.63	Schizophrenia;	chr11:8937356	chr11:8964675~8977527:+
UVM	cis	rs2455601	0.744	rs11042133	ENSG00000254860.4	TMEM9B-AS1	5.92	2.58e-07	0.00113	1	0.63	Schizophrenia;	chr11:8944964	chr11:8964675~8977527:+
UVM	cis	rs2455601	0.786	rs56680262	ENSG00000254860.4	TMEM9B-AS1	5.92	2.58e-07	0.00113	1	0.63	Schizophrenia;	chr11:8950008	chr11:8964675~8977527:+
UVM	cis	rs2455601	0.744	rs2163626	ENSG00000254860.4	TMEM9B-AS1	5.92	2.58e-07	0.00113	1	0.63	Schizophrenia;	chr11:8962000	chr11:8964675~8977527:+
UVM	cis	rs916888	0.779	rs199528	ENSG00000214401.4	KANSL1-AS1	5.91	2.67e-07	0.00115	1.23	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46193576~46196723:+
UVM	cis	rs916888	0.821	rs199525	ENSG00000214401.4	KANSL1-AS1	5.91	2.67e-07	0.00115	1.23	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46193576~46196723:+
UVM	cis	rs916888	0.821	rs70600	ENSG00000214401.4	KANSL1-AS1	5.91	2.67e-07	0.00115	1.23	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46193576~46196723:+
UVM	cis	rs916888	0.697	rs199516	ENSG00000214401.4	KANSL1-AS1	-5.91	2.67e-07	0.00115	-1.23	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46193576~46196723:+
UVM	cis	rs916888	0.738	rs199515	ENSG00000214401.4	KANSL1-AS1	-5.91	2.67e-07	0.00115	-1.23	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46193576~46196723:+
UVM	cis	rs916888	0.821	rs199514	ENSG00000214401.4	KANSL1-AS1	-5.91	2.67e-07	0.00115	-1.23	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46193576~46196723:+
UVM	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-5.91	2.67e-07	0.00115	-1.23	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
UVM	cis	rs916888	0.821	rs199512	ENSG00000214401.4	KANSL1-AS1	-5.91	2.67e-07	0.00115	-1.23	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46193576~46196723:+
UVM	cis	rs916888	0.821	rs199509	ENSG00000214401.4	KANSL1-AS1	-5.91	2.67e-07	0.00115	-1.23	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46193576~46196723:+
UVM	cis	rs916888	0.821	rs199507	ENSG00000214401.4	KANSL1-AS1	-5.91	2.67e-07	0.00115	-1.23	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46193576~46196723:+
UVM	cis	rs916888	0.821	rs199506	ENSG00000214401.4	KANSL1-AS1	-5.91	2.67e-07	0.00115	-1.23	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46193576~46196723:+
UVM	cis	rs916888	0.821	rs415430	ENSG00000214401.4	KANSL1-AS1	-5.91	2.67e-07	0.00115	-1.23	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46193576~46196723:+
UVM	cis	rs916888	0.779	rs430685	ENSG00000214401.4	KANSL1-AS1	-5.91	2.67e-07	0.00115	-1.23	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46193576~46196723:+
UVM	cis	rs916888	0.821	rs199505	ENSG00000214401.4	KANSL1-AS1	-5.91	2.67e-07	0.00115	-1.23	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46193576~46196723:+
UVM	cis	rs916888	0.821	rs70602	ENSG00000214401.4	KANSL1-AS1	-5.91	2.67e-07	0.00115	-1.23	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46193576~46196723:+
UVM	cis	rs4423214	1	rs909217	ENSG00000254682.1	RP11-660L16.2	5.91	2.68e-07	0.00115	0.97	0.63	Vitamin D levels;	chr11:71435531	chr11:71448674~71452157:+
UVM	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	5.91	2.68e-07	0.00115	0.55	0.63	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
UVM	cis	rs3750965	1	rs3750965	ENSG00000260895.1	RP11-554A11.7	5.91	2.7e-07	0.00116	0.88	0.63	Hair color;	chr11:69072692	chr11:69103493~69109094:+
UVM	cis	rs3750965	1	rs7937006	ENSG00000260895.1	RP11-554A11.7	5.91	2.7e-07	0.00116	0.88	0.63	Hair color;	chr11:69076464	chr11:69103493~69109094:+
UVM	cis	rs3750965	1	rs731974	ENSG00000260895.1	RP11-554A11.7	5.91	2.7e-07	0.00116	0.88	0.63	Hair color;	chr11:69079688	chr11:69103493~69109094:+
UVM	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	5.9	2.74e-07	0.00117	0.37	0.63	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
UVM	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	5.9	2.75e-07	0.00117	0.79	0.63	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
UVM	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	5.9	2.75e-07	0.00117	0.79	0.63	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
UVM	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	5.9	2.75e-07	0.00117	0.79	0.63	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
UVM	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	5.9	2.75e-07	0.00117	0.79	0.63	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
UVM	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	5.9	2.75e-07	0.00117	0.79	0.63	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
UVM	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	5.9	2.75e-07	0.00117	0.79	0.63	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
UVM	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	5.9	2.75e-07	0.00117	0.79	0.63	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
UVM	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	5.9	2.75e-07	0.00117	0.79	0.63	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
UVM	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-5.9	2.75e-07	0.00117	-0.79	-0.63	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
UVM	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-5.9	2.75e-07	0.00117	-0.79	-0.63	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
UVM	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-5.9	2.75e-07	0.00117	-0.79	-0.63	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
UVM	cis	rs950027	0.62	rs872192	ENSG00000259520.4	CTD-2651B20.3	-5.9	2.76e-07	0.00118	-0.83	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:45251580~45279251:-
UVM	cis	rs7174755	1	rs68069953	ENSG00000260657.2	RP11-315D16.4	5.9	2.79e-07	0.00118	0.8	0.63	Major depressive disorder;	chr15:68304235	chr15:68267792~68277994:-
UVM	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-5.9	2.79e-07	0.00118	-0.78	-0.63	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-5.9	2.79e-07	0.00118	-0.78	-0.63	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-5.9	2.79e-07	0.00118	-0.78	-0.63	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-5.9	2.79e-07	0.00118	-0.78	-0.63	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-5.9	2.79e-07	0.00118	-0.78	-0.63	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
UVM	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-5.9	2.79e-07	0.00118	-0.78	-0.63	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
UVM	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	5.9	2.79e-07	0.00118	0.78	0.63	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
UVM	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	5.9	2.79e-07	0.00118	0.78	0.63	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	5.9	2.79e-07	0.00118	0.78	0.63	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	5.9	2.79e-07	0.00118	0.78	0.63	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	5.9	2.79e-07	0.00118	0.78	0.63	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	5.9	2.79e-07	0.00118	0.78	0.63	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	5.9	2.79e-07	0.00118	0.78	0.63	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
UVM	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	5.9	2.79e-07	0.00118	0.78	0.63	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
UVM	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	5.9	2.79e-07	0.00118	0.78	0.63	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
UVM	cis	rs9660180	0.967	rs6603803	ENSG00000268575.1	RP1-283E3.8	-5.9	2.8e-07	0.00118	-0.64	-0.63	Body mass index;	chr1:1881249	chr1:1702736~1737688:-
UVM	cis	rs9322193	0.923	rs7769101	ENSG00000231760.4	RP11-350J20.5	5.89	2.82e-07	0.00119	0.82	0.63	Lung cancer;	chr6:149848768	chr6:149796151~149826294:-
UVM	cis	rs9322193	0.772	rs7738696	ENSG00000231760.4	RP11-350J20.5	5.89	2.82e-07	0.00119	0.82	0.63	Lung cancer;	chr6:149848985	chr6:149796151~149826294:-
UVM	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	5.89	2.84e-07	0.0012	0.75	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
UVM	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	5.89	2.84e-07	0.0012	0.68	0.63	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
UVM	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-5.89	2.86e-07	0.00121	-0.91	-0.63	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
UVM	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	5.89	2.9e-07	0.00122	0.85	0.63	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
UVM	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	5.88	2.93e-07	0.00124	0.67	0.63	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
UVM	cis	rs916888	0.821	rs199504	ENSG00000214401.4	KANSL1-AS1	-5.88	2.95e-07	0.00124	-1.24	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46193576~46196723:+
UVM	cis	rs4853012	0.838	rs2177707	ENSG00000217702.2	RP11-287D1.4	5.88	2.96e-07	0.00125	1.05	0.63	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.887	rs2280642	ENSG00000217702.2	RP11-287D1.4	5.88	2.96e-07	0.00125	1.05	0.63	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74130583~74135395:+
UVM	cis	rs4853012	1	rs2280643	ENSG00000217702.2	RP11-287D1.4	5.88	2.96e-07	0.00125	1.05	0.63	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.887	rs2280644	ENSG00000217702.2	RP11-287D1.4	5.88	2.96e-07	0.00125	1.05	0.63	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74130583~74135395:+
UVM	cis	rs4853012	0.887	rs12478482	ENSG00000217702.2	RP11-287D1.4	5.88	2.96e-07	0.00125	1.05	0.63	Gestational age at birth (maternal effect);	chr2:74132293	chr2:74130583~74135395:+
UVM	cis	rs11673344	0.573	rs73039109	ENSG00000226686.6	LINC01535	5.88	2.98e-07	0.00126	0.85	0.63	Obesity-related traits;	chr19:36891073	chr19:37251912~37265535:+
UVM	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	5.88	2.99e-07	0.00126	0.73	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
UVM	cis	rs11155671	0.53	rs9397398	ENSG00000268592.3	RAET1E-AS1	5.87	3.04e-07	0.00128	0.7	0.63	Testicular germ cell tumor;	chr6:149872467	chr6:149863494~149919507:+
UVM	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	5.87	3.08e-07	0.0013	0.78	0.63	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
UVM	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	5.87	3.09e-07	0.0013	0.81	0.63	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
UVM	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	5.87	3.09e-07	0.0013	0.81	0.63	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
UVM	cis	rs6700559	0.654	rs2809345	ENSG00000260088.1	RP11-92G12.3	5.87	3.14e-07	0.00132	0.86	0.63	Coronary artery disease;	chr1:200627135	chr1:200669507~200694250:+
UVM	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-5.87	3.14e-07	0.00132	-0.68	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
UVM	cis	rs2882667	0.638	rs6895690	ENSG00000253404.1	AC034243.1	5.86	3.14e-07	0.00132	0.76	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:139130162	chr5:138744434~138753309:-
UVM	cis	rs7174755	0.961	rs12148843	ENSG00000260657.2	RP11-315D16.4	5.86	3.17e-07	0.00133	0.8	0.63	Major depressive disorder;	chr15:68302184	chr15:68267792~68277994:-
UVM	cis	rs7174755	0.961	rs1122247	ENSG00000260657.2	RP11-315D16.4	5.86	3.17e-07	0.00133	0.8	0.63	Major depressive disorder;	chr15:68302523	chr15:68267792~68277994:-
UVM	cis	rs9660180	0.837	rs915292	ENSG00000268575.1	RP1-283E3.8	-5.86	3.21e-07	0.00135	-0.64	-0.63	Body mass index;	chr1:1860718	chr1:1702736~1737688:-
UVM	cis	rs9660180	0.967	rs9660106	ENSG00000268575.1	RP1-283E3.8	-5.86	3.21e-07	0.00135	-0.64	-0.63	Body mass index;	chr1:1866508	chr1:1702736~1737688:-
UVM	cis	rs9660180	0.934	rs12729990	ENSG00000268575.1	RP1-283E3.8	-5.86	3.21e-07	0.00135	-0.64	-0.63	Body mass index;	chr1:1880596	chr1:1702736~1737688:-
UVM	cis	rs9660180	0.967	rs6603802	ENSG00000268575.1	RP1-283E3.8	-5.86	3.21e-07	0.00135	-0.64	-0.63	Body mass index;	chr1:1881082	chr1:1702736~1737688:-
UVM	cis	rs3091242	0.933	rs10903129	ENSG00000261349.1	RP3-465N24.5	-5.85	3.26e-07	0.00136	-0.62	-0.63	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25266102~25267136:-
UVM	cis	rs7188445	0.736	rs7500666	ENSG00000261390.4	RP11-345M22.2	5.85	3.31e-07	0.00138	0.65	0.63	Urate levels;	chr16:79672509	chr16:79715232~79770563:-
UVM	cis	rs9660180	0.875	rs4648727	ENSG00000268575.1	RP1-283E3.8	5.84	3.39e-07	0.00141	0.67	0.63	Body mass index;	chr1:1844830	chr1:1702736~1737688:-
UVM	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-5.84	3.39e-07	0.00141	-0.91	-0.63	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-5.84	3.39e-07	0.00141	-0.91	-0.63	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-5.84	3.39e-07	0.00141	-0.91	-0.63	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-5.84	3.39e-07	0.00141	-0.91	-0.63	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	5.84	3.39e-07	0.00141	0.91	0.63	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	5.84	3.39e-07	0.00141	0.91	0.63	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	5.84	3.39e-07	0.00141	0.91	0.63	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.81	rs7529962	ENSG00000260088.1	RP11-92G12.3	-5.84	3.39e-07	0.00141	-0.87	-0.63	Coronary artery disease;	chr1:200627849	chr1:200669507~200694250:+
UVM	cis	rs3091242	0.933	rs1534954	ENSG00000261349.1	RP3-465N24.5	-5.83	3.6e-07	0.00149	-0.64	-0.63	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25266102~25267136:-
UVM	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	5.83	3.62e-07	0.0015	0.75	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
UVM	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	5.83	3.62e-07	0.0015	0.75	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
UVM	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	5.83	3.62e-07	0.0015	0.75	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
UVM	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	5.82	3.69e-07	0.00151	0.64	0.63	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
UVM	cis	rs2882667	1	rs2882667	ENSG00000253404.1	AC034243.1	5.82	3.73e-07	0.00152	0.75	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138978417	chr5:138744434~138753309:-
UVM	cis	rs11098499	0.954	rs13145352	ENSG00000245958.5	RP11-33B1.1	5.82	3.75e-07	0.00153	0.43	0.63	Corneal astigmatism;	chr4:119488808	chr4:119454791~119552025:+
UVM	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	5.81	3.83e-07	0.00156	0.83	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
UVM	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-5.81	3.84e-07	0.00156	-0.66	-0.63	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
UVM	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-5.81	3.84e-07	0.00156	-0.66	-0.63	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
UVM	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-5.81	3.84e-07	0.00156	-0.66	-0.63	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
UVM	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-5.81	3.84e-07	0.00156	-0.66	-0.63	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
UVM	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-5.81	3.84e-07	0.00156	-0.66	-0.63	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
UVM	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-5.81	3.84e-07	0.00156	-0.66	-0.63	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
UVM	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-5.81	3.84e-07	0.00156	-0.66	-0.63	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
UVM	cis	rs10256972	0.539	rs2949174	ENSG00000229043.2	AC091729.9	-5.81	3.84e-07	0.00156	-0.66	-0.63	Endometriosis;Longevity;	chr7:1174287	chr7:1160374~1165267:+
UVM	cis	rs10256972	0.514	rs2140578	ENSG00000229043.2	AC091729.9	-5.81	3.84e-07	0.00156	-0.66	-0.63	Endometriosis;Longevity;	chr7:1174367	chr7:1160374~1165267:+
UVM	cis	rs858239	0.601	rs28673077	ENSG00000230658.1	KLHL7-AS1	5.8	3.93e-07	0.00158	0.72	0.63	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23101228~23105703:-
UVM	cis	rs7195287	0.779	rs2335454	ENSG00000276791.1	CTD-2270P14.5	5.79	4.12e-07	0.00164	0.77	0.63	Eosinophil counts;	chr16:2778156	chr16:2777319~2780568:+
UVM	cis	rs7195287	0.591	rs63744561	ENSG00000276791.1	CTD-2270P14.5	5.79	4.12e-07	0.00164	0.77	0.63	Eosinophil counts;	chr16:2778171	chr16:2777319~2780568:+
UVM	cis	rs2335455	1	rs2335455	ENSG00000276791.1	CTD-2270P14.5	5.79	4.12e-07	0.00164	0.77	0.63	Sum eosinophil basophil counts;	chr16:2778172	chr16:2777319~2780568:+
UVM	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-5.79	4.13e-07	0.00164	-0.65	-0.63	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
UVM	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	5.78	4.2e-07	0.00167	0.72	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	5.78	4.2e-07	0.00167	0.72	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	5.78	4.2e-07	0.00167	0.72	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
UVM	cis	rs8072100	0.905	rs8078686	ENSG00000228782.6	CTD-2026D20.3	-5.78	4.21e-07	0.00167	-0.72	-0.63	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47658340	chr17:47450568~47492492:-
UVM	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	5.78	4.22e-07	0.00168	0.71	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	5.78	4.22e-07	0.00168	0.71	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
UVM	cis	rs4423214	0.921	rs11603330	ENSG00000254682.1	RP11-660L16.2	5.78	4.25e-07	0.00169	0.92	0.63	Vitamin D levels;	chr11:71442413	chr11:71448674~71452157:+
UVM	cis	rs3091242	0.9	rs4649086	ENSG00000261349.1	RP3-465N24.5	-5.78	4.27e-07	0.00169	-0.63	-0.63	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25266102~25267136:-
UVM	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-5.78	4.27e-07	0.00169	-0.82	-0.63	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
UVM	cis	rs7174755	1	rs7174755	ENSG00000260657.2	RP11-315D16.4	-5.77	4.37e-07	0.00173	-0.77	-0.63	Major depressive disorder;	chr15:68304789	chr15:68267792~68277994:-
UVM	cis	rs9322193	0.923	rs4869750	ENSG00000231760.4	RP11-350J20.5	5.77	4.4e-07	0.00174	0.82	0.62	Lung cancer;	chr6:149855996	chr6:149796151~149826294:-
UVM	cis	rs507080	0.501	rs637563	ENSG00000255239.1	AP002954.6	5.77	4.47e-07	0.00177	0.59	0.62	Serum metabolite levels;	chr11:118704770	chr11:118688039~118690600:-
UVM	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	5.77	4.48e-07	0.00177	0.72	0.62	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
UVM	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	5.77	4.48e-07	0.00177	0.72	0.62	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
UVM	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	5.77	4.48e-07	0.00177	0.72	0.62	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
UVM	cis	rs858239	0.508	rs10242104	ENSG00000230658.1	KLHL7-AS1	5.77	4.48e-07	0.00177	0.72	0.62	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23101228~23105703:-
UVM	cis	rs858239	0.537	rs2286272	ENSG00000230658.1	KLHL7-AS1	5.77	4.48e-07	0.00177	0.72	0.62	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23101228~23105703:-
UVM	cis	rs858239	0.537	rs6955115	ENSG00000230658.1	KLHL7-AS1	5.77	4.48e-07	0.00177	0.72	0.62	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23101228~23105703:-
UVM	cis	rs858239	0.537	rs10279691	ENSG00000230658.1	KLHL7-AS1	5.77	4.48e-07	0.00177	0.72	0.62	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23101228~23105703:-
UVM	cis	rs858239	0.537	rs6942981	ENSG00000230658.1	KLHL7-AS1	5.77	4.48e-07	0.00177	0.72	0.62	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23101228~23105703:-
UVM	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	5.77	4.48e-07	0.00177	0.72	0.62	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
UVM	cis	rs858239	0.568	rs6970694	ENSG00000230658.1	KLHL7-AS1	5.77	4.48e-07	0.00177	0.72	0.62	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23101228~23105703:-
UVM	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	5.76	4.52e-07	0.00179	0.78	0.62	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
UVM	cis	rs9322193	0.884	rs1108889	ENSG00000231760.4	RP11-350J20.5	5.76	4.53e-07	0.00179	0.81	0.62	Lung cancer;	chr6:149845433	chr6:149796151~149826294:-
UVM	cis	rs3091242	0.933	rs11249250	ENSG00000261349.1	RP3-465N24.5	-5.76	4.54e-07	0.0018	-0.64	-0.62	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25266102~25267136:-
UVM	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-5.76	4.59e-07	0.00181	-0.79	-0.62	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
UVM	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-5.76	4.6e-07	0.00182	-0.36	-0.62	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
UVM	cis	rs4423214	1	rs12797951	ENSG00000254682.1	RP11-660L16.2	-5.75	4.75e-07	0.00186	-0.94	-0.62	Vitamin D levels;	chr11:71432220	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs2852853	ENSG00000254682.1	RP11-660L16.2	5.75	4.75e-07	0.00186	0.94	0.62	Vitamin D levels;	chr11:71439171	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.959	rs11606033	ENSG00000254682.1	RP11-660L16.2	5.75	4.75e-07	0.00186	0.94	0.62	Vitamin D levels;	chr11:71443158	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs1044482	ENSG00000254682.1	RP11-660L16.2	5.75	4.75e-07	0.00186	0.94	0.62	Vitamin D levels;	chr11:71444125	chr11:71448674~71452157:+
UVM	cis	rs3091242	0.933	rs34006994	ENSG00000261349.1	RP3-465N24.5	5.75	4.75e-07	0.00186	0.63	0.62	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.933	rs61775167	ENSG00000261349.1	RP3-465N24.5	5.75	4.75e-07	0.00186	0.63	0.62	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.933	rs35497030	ENSG00000261349.1	RP3-465N24.5	5.75	4.75e-07	0.00186	0.63	0.62	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.836	rs34997029	ENSG00000261349.1	RP3-465N24.5	5.75	4.75e-07	0.00186	0.63	0.62	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.902	rs36003018	ENSG00000261349.1	RP3-465N24.5	5.75	4.75e-07	0.00186	0.63	0.62	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.933	rs35403885	ENSG00000261349.1	RP3-465N24.5	5.75	4.75e-07	0.00186	0.63	0.62	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.933	rs35530120	ENSG00000261349.1	RP3-465N24.5	5.75	4.75e-07	0.00186	0.63	0.62	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.933	rs10903130	ENSG00000261349.1	RP3-465N24.5	-5.75	4.75e-07	0.00186	-0.63	-0.62	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.933	rs11249251	ENSG00000261349.1	RP3-465N24.5	-5.75	4.75e-07	0.00186	-0.63	-0.62	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.904	rs6661533	ENSG00000261349.1	RP3-465N24.5	-5.75	4.75e-07	0.00186	-0.63	-0.62	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25266102~25267136:-
UVM	cis	rs55794721	0.509	rs12027110	ENSG00000261349.1	RP3-465N24.5	-5.75	4.75e-07	0.00186	-0.63	-0.62	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25266102~25267136:-
UVM	cis	rs55794721	0.509	rs12027135	ENSG00000261349.1	RP3-465N24.5	-5.75	4.75e-07	0.00186	-0.63	-0.62	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25266102~25267136:-
UVM	cis	rs55794721	0.509	rs6699113	ENSG00000261349.1	RP3-465N24.5	-5.75	4.75e-07	0.00186	-0.63	-0.62	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25266102~25267136:-
UVM	cis	rs55794721	0.509	rs7554255	ENSG00000261349.1	RP3-465N24.5	-5.75	4.75e-07	0.00186	-0.63	-0.62	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25266102~25267136:-
UVM	cis	rs55794721	0.509	rs4649085	ENSG00000261349.1	RP3-465N24.5	-5.75	4.75e-07	0.00186	-0.63	-0.62	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25266102~25267136:-
UVM	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-5.75	4.75e-07	0.00186	-0.36	-0.62	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-5.75	4.75e-07	0.00186	-0.36	-0.62	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-5.75	4.75e-07	0.00186	-0.36	-0.62	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-5.75	4.75e-07	0.00186	-0.36	-0.62	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-5.75	4.75e-07	0.00186	-0.36	-0.62	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-5.75	4.75e-07	0.00186	-0.36	-0.62	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-5.75	4.75e-07	0.00186	-0.36	-0.62	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-5.75	4.75e-07	0.00186	-0.36	-0.62	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-5.75	4.75e-07	0.00186	-0.36	-0.62	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-5.75	4.75e-07	0.00186	-0.36	-0.62	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-5.75	4.75e-07	0.00186	-0.36	-0.62	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-5.75	4.75e-07	0.00186	-0.36	-0.62	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-5.75	4.75e-07	0.00186	-0.36	-0.62	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
UVM	cis	rs4423214	0.535	rs1540129	ENSG00000254682.1	RP11-660L16.2	5.75	4.8e-07	0.00188	0.96	0.62	Vitamin D levels;	chr11:71418477	chr11:71448674~71452157:+
UVM	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-5.75	4.83e-07	0.00189	-0.96	-0.62	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
UVM	cis	rs950027	0.62	rs1617634	ENSG00000259520.4	CTD-2651B20.3	-5.74	4.95e-07	0.00193	-0.82	-0.62	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:45251580~45279251:-
UVM	cis	rs950027	0.62	rs1617984	ENSG00000259520.4	CTD-2651B20.3	-5.74	4.95e-07	0.00193	-0.82	-0.62	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:45251580~45279251:-
UVM	cis	rs950027	0.62	rs1719245	ENSG00000259520.4	CTD-2651B20.3	-5.74	4.95e-07	0.00193	-0.82	-0.62	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:45251580~45279251:-
UVM	cis	rs950027	0.62	rs1719246	ENSG00000259520.4	CTD-2651B20.3	-5.74	4.95e-07	0.00193	-0.82	-0.62	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45251580~45279251:-
UVM	cis	rs950027	0.62	rs1153862	ENSG00000259520.4	CTD-2651B20.3	-5.74	4.95e-07	0.00193	-0.82	-0.62	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45251580~45279251:-
UVM	cis	rs4423214	1	rs12422045	ENSG00000254682.1	RP11-660L16.2	5.73	5.04e-07	0.00195	0.89	0.62	Vitamin D levels;	chr11:71443774	chr11:71448674~71452157:+
UVM	cis	rs11155671	0.53	rs6557133	ENSG00000268592.3	RAET1E-AS1	5.73	5.08e-07	0.00196	0.72	0.62	Testicular germ cell tumor;	chr6:149874248	chr6:149863494~149919507:+
UVM	cis	rs10256972	0.577	rs2949179	ENSG00000229043.2	AC091729.9	-5.73	5.1e-07	0.00197	-0.66	-0.62	Endometriosis;Longevity;	chr7:1170249	chr7:1160374~1165267:+
UVM	cis	rs10256972	0.504	rs2949178	ENSG00000229043.2	AC091729.9	-5.73	5.1e-07	0.00197	-0.66	-0.62	Endometriosis;Longevity;	chr7:1170289	chr7:1160374~1165267:+
UVM	cis	rs494459	0.688	rs1048040	ENSG00000255239.1	AP002954.6	5.73	5.15e-07	0.00199	0.58	0.62	Height;	chr11:118747911	chr11:118688039~118690600:-
UVM	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-5.73	5.21e-07	0.00201	-0.77	-0.62	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
UVM	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-5.72	5.24e-07	0.00202	-0.36	-0.62	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
UVM	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-5.72	5.25e-07	0.00202	-0.78	-0.62	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
UVM	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-5.72	5.27e-07	0.00202	-0.72	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-5.72	5.27e-07	0.00202	-0.72	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	5.72	5.27e-07	0.00202	0.72	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.858	rs11957633	ENSG00000253404.1	AC034243.1	5.72	5.27e-07	0.00202	0.72	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028705	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.822	rs11738376	ENSG00000253404.1	AC034243.1	5.72	5.27e-07	0.00202	0.72	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139062483	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.822	rs13187096	ENSG00000253404.1	AC034243.1	5.72	5.27e-07	0.00202	0.72	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139068399	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	5.72	5.27e-07	0.00202	0.72	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.858	rs11242444	ENSG00000253404.1	AC034243.1	5.72	5.27e-07	0.00202	0.72	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070690	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.858	rs11956159	ENSG00000253404.1	AC034243.1	5.72	5.27e-07	0.00202	0.72	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139072879	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	5.72	5.27e-07	0.00202	0.72	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	5.72	5.27e-07	0.00202	0.72	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	5.72	5.27e-07	0.00202	0.72	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	5.72	5.27e-07	0.00202	0.72	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	5.72	5.27e-07	0.00202	0.72	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
UVM	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	5.72	5.35e-07	0.00205	0.68	0.62	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
UVM	cis	rs4423214	1	rs1981412	ENSG00000254682.1	RP11-660L16.2	5.72	5.36e-07	0.00206	0.93	0.62	Vitamin D levels;	chr11:71427664	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs12419279	ENSG00000254682.1	RP11-660L16.2	5.72	5.36e-07	0.00206	0.93	0.62	Vitamin D levels;	chr11:71428015	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs12419334	ENSG00000254682.1	RP11-660L16.2	5.72	5.36e-07	0.00206	0.93	0.62	Vitamin D levels;	chr11:71428426	chr11:71448674~71452157:+
UVM	cis	rs10262624	0.528	rs722294	ENSG00000234286.1	AC006026.13	5.72	5.37e-07	0.00206	0.79	0.62	Schizophrenia;	chr7:23706966	chr7:23680195~23680786:-
UVM	cis	rs10262624	0.504	rs4722255	ENSG00000234286.1	AC006026.13	-5.72	5.37e-07	0.00206	-0.79	-0.62	Schizophrenia;	chr7:23706453	chr7:23680195~23680786:-
UVM	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	5.72	5.4e-07	0.00207	0.52	0.62	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
UVM	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-5.71	5.44e-07	0.00209	-0.83	-0.62	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
UVM	cis	rs507080	0.501	rs516503	ENSG00000255239.1	AP002954.6	5.71	5.57e-07	0.00213	0.59	0.62	Serum metabolite levels;	chr11:118709639	chr11:118688039~118690600:-
UVM	cis	rs494459	0.838	rs581045	ENSG00000255239.1	AP002954.6	5.71	5.57e-07	0.00213	0.58	0.62	Height;	chr11:118761813	chr11:118688039~118690600:-
UVM	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	5.71	5.58e-07	0.00213	0.68	0.62	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
UVM	cis	rs1153858	1	rs1613559	ENSG00000259520.4	CTD-2651B20.3	-5.71	5.6e-07	0.00214	-0.91	-0.62	Homoarginine levels;	chr15:45329918	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs1618874	ENSG00000259520.4	CTD-2651B20.3	-5.71	5.6e-07	0.00214	-0.91	-0.62	Homoarginine levels;	chr15:45330588	chr15:45251580~45279251:-
UVM	cis	rs7188445	0.736	rs4243177	ENSG00000261390.4	RP11-345M22.2	5.7	5.63e-07	0.00215	0.66	0.62	Urate levels;	chr16:79669932	chr16:79715232~79770563:-
UVM	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	5.7	5.68e-07	0.00217	0.91	0.62	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
UVM	cis	rs3750965	0.959	rs11228490	ENSG00000260895.1	RP11-554A11.7	-5.7	5.73e-07	0.00219	-0.86	-0.62	Hair color;	chr11:69093404	chr11:69103493~69109094:+
UVM	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-5.69	5.85e-07	0.00223	-0.9	-0.62	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
UVM	cis	rs1153858	1	rs28679834	ENSG00000259520.4	CTD-2651B20.3	-5.69	5.88e-07	0.00224	-0.91	-0.62	Homoarginine levels;	chr15:45324008	chr15:45251580~45279251:-
UVM	cis	rs1153858	0.895	rs12593402	ENSG00000259520.4	CTD-2651B20.3	-5.69	5.88e-07	0.00224	-0.91	-0.62	Homoarginine levels;	chr15:45325194	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs12593370	ENSG00000259520.4	CTD-2651B20.3	-5.69	5.88e-07	0.00224	-0.91	-0.62	Homoarginine levels;	chr15:45325219	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs4775895	ENSG00000259520.4	CTD-2651B20.3	-5.69	5.88e-07	0.00224	-0.91	-0.62	Homoarginine levels;	chr15:45325759	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs59889118	ENSG00000259520.4	CTD-2651B20.3	-5.69	5.88e-07	0.00224	-0.91	-0.62	Homoarginine levels;	chr15:45326532	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs1980288	ENSG00000259520.4	CTD-2651B20.3	-5.69	5.88e-07	0.00224	-0.91	-0.62	Homoarginine levels;	chr15:45328414	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs1719247	ENSG00000259520.4	CTD-2651B20.3	-5.69	5.88e-07	0.00224	-0.91	-0.62	Homoarginine levels;	chr15:45328787	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs12909158	ENSG00000259520.4	CTD-2651B20.3	-5.69	5.88e-07	0.00224	-0.91	-0.62	Homoarginine levels;	chr15:45328976	chr15:45251580~45279251:-
UVM	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	5.69	5.89e-07	0.00224	0.74	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
UVM	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	5.69	5.96e-07	0.00226	0.72	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
UVM	cis	rs494459	0.838	rs632124	ENSG00000255239.1	AP002954.6	5.68	6.22e-07	0.00236	0.59	0.62	Height;	chr11:118742526	chr11:118688039~118690600:-
UVM	cis	rs494459	0.838	rs607125	ENSG00000255239.1	AP002954.6	5.68	6.22e-07	0.00236	0.59	0.62	Height;	chr11:118746590	chr11:118688039~118690600:-
UVM	cis	rs494459	0.838	rs488219	ENSG00000255239.1	AP002954.6	5.67	6.38e-07	0.00242	0.57	0.62	Height;	chr11:118749988	chr11:118688039~118690600:-
UVM	cis	rs494459	0.838	rs555639	ENSG00000255239.1	AP002954.6	-5.67	6.38e-07	0.00242	-0.57	-0.62	Height;	chr11:118758322	chr11:118688039~118690600:-
UVM	cis	rs494459	0.838	rs1784543	ENSG00000255239.1	AP002954.6	5.67	6.38e-07	0.00242	0.57	0.62	Height;	chr11:118760944	chr11:118688039~118690600:-
UVM	cis	rs494459	0.657	rs614554	ENSG00000255239.1	AP002954.6	5.67	6.38e-07	0.00242	0.57	0.62	Height;	chr11:118764443	chr11:118688039~118690600:-
UVM	cis	rs494459	0.838	rs555649	ENSG00000255239.1	AP002954.6	5.67	6.38e-07	0.00242	0.57	0.62	Height;	chr11:118781100	chr11:118688039~118690600:-
UVM	cis	rs494459	0.756	rs570806	ENSG00000255239.1	AP002954.6	5.67	6.38e-07	0.00242	0.57	0.62	Height;	chr11:118786602	chr11:118688039~118690600:-
UVM	cis	rs494459	0.838	rs12796102	ENSG00000255239.1	AP002954.6	5.67	6.38e-07	0.00242	0.57	0.62	Height;	chr11:118791319	chr11:118688039~118690600:-
UVM	cis	rs11155671	0.53	rs6935829	ENSG00000268592.3	RAET1E-AS1	5.67	6.39e-07	0.00242	0.69	0.62	Testicular germ cell tumor;	chr6:149896675	chr6:149863494~149919507:+
UVM	cis	rs8072100	0.807	rs2175290	ENSG00000228782.6	CTD-2026D20.3	5.67	6.41e-07	0.00242	0.63	0.62	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402551	chr17:47450568~47492492:-
UVM	cis	rs4423214	0.879	rs12803256	ENSG00000254682.1	RP11-660L16.2	5.66	6.49e-07	0.00245	0.95	0.62	Vitamin D levels;	chr11:71421822	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	5.66	6.55e-07	0.00248	0.92	0.62	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
UVM	cis	rs1930961	1	rs1930961	ENSG00000100058.11	CRYBB2P1	5.66	6.56e-07	0.00248	1.3	0.62	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25448105~25520854:+
UVM	cis	rs2882667	0.537	rs6887866	ENSG00000253404.1	AC034243.1	5.65	6.74e-07	0.00254	0.66	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138744434~138753309:-
UVM	cis	rs11155671	0.53	rs1334510	ENSG00000268592.3	RAET1E-AS1	5.65	6.79e-07	0.00256	0.68	0.62	Testicular germ cell tumor;	chr6:149880043	chr6:149863494~149919507:+
UVM	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-5.65	6.86e-07	0.00259	-0.73	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
UVM	cis	rs9322193	0.884	rs7744105	ENSG00000231760.4	RP11-350J20.5	5.65	6.89e-07	0.0026	0.76	0.62	Lung cancer;	chr6:149849308	chr6:149796151~149826294:-
UVM	cis	rs858239	0.601	rs7809661	ENSG00000230658.1	KLHL7-AS1	5.65	6.95e-07	0.00262	0.72	0.62	Cerebrospinal fluid biomarker levels;	chr7:23142130	chr7:23101228~23105703:-
UVM	cis	rs9322193	0.884	rs7769115	ENSG00000231760.4	RP11-350J20.5	5.64	7.01e-07	0.00264	0.79	0.62	Lung cancer;	chr6:149848796	chr6:149796151~149826294:-
UVM	cis	rs5760092	0.627	rs6519489	ENSG00000273295.1	AP000350.5	-5.64	7.11e-07	0.00268	-0.8	-0.62	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23901432~23907068:-
UVM	cis	rs5760092	0.755	rs11090298	ENSG00000273295.1	AP000350.5	-5.64	7.11e-07	0.00268	-0.8	-0.62	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23901432~23907068:-
UVM	cis	rs8072100	0.84	rs12453233	ENSG00000228782.6	CTD-2026D20.3	5.64	7.21e-07	0.00269	0.63	0.62	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377204	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.84	rs1912482	ENSG00000228782.6	CTD-2026D20.3	5.64	7.21e-07	0.00269	0.63	0.62	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377517	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.84	rs2136751	ENSG00000228782.6	CTD-2026D20.3	5.64	7.21e-07	0.00269	0.63	0.62	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378727	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.84	rs4968319	ENSG00000228782.6	CTD-2026D20.3	5.64	7.21e-07	0.00269	0.63	0.62	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47387601	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.84	rs9895746	ENSG00000228782.6	CTD-2026D20.3	5.64	7.21e-07	0.00269	0.63	0.62	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47401733	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.84	rs11079774	ENSG00000228782.6	CTD-2026D20.3	5.64	7.21e-07	0.00269	0.63	0.62	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402340	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.84	rs9900360	ENSG00000228782.6	CTD-2026D20.3	5.64	7.21e-07	0.00269	0.63	0.62	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47414613	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.84	rs56952963	ENSG00000228782.6	CTD-2026D20.3	5.64	7.21e-07	0.00269	0.63	0.62	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416460	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.84	rs9893901	ENSG00000228782.6	CTD-2026D20.3	5.64	7.21e-07	0.00269	0.63	0.62	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47429316	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.744	rs34537623	ENSG00000228782.6	CTD-2026D20.3	5.64	7.21e-07	0.00269	0.63	0.62	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47452837	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.777	rs9914653	ENSG00000228782.6	CTD-2026D20.3	5.64	7.21e-07	0.00269	0.63	0.62	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47460029	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.84	rs9912311	ENSG00000228782.6	CTD-2026D20.3	5.64	7.21e-07	0.00269	0.63	0.62	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469766	chr17:47450568~47492492:-
UVM	cis	rs2882667	0.537	rs10057545	ENSG00000253404.1	AC034243.1	5.62	7.5e-07	0.0028	0.66	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095319	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	5.62	7.58e-07	0.00282	0.74	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
UVM	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-5.62	7.72e-07	0.00287	-1.12	-0.61	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
UVM	cis	rs1155848	0.892	rs9574421	ENSG00000227354.5	RBM26-AS1	5.61	7.83e-07	0.0029	1.15	0.61	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79406205	chr13:79406309~79424328:+
UVM	cis	rs1155848	0.892	rs2296286	ENSG00000227354.5	RBM26-AS1	5.61	7.83e-07	0.0029	1.15	0.61	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79406474	chr13:79406309~79424328:+
UVM	cis	rs507080	0.769	rs7389	ENSG00000255239.1	AP002954.6	-5.61	8.02e-07	0.00296	-0.67	-0.61	Serum metabolite levels;	chr11:118657756	chr11:118688039~118690600:-
UVM	cis	rs2455601	1	rs2455601	ENSG00000254860.4	TMEM9B-AS1	5.6	8.15e-07	0.003	1.08	0.61	Schizophrenia;	chr11:8877853	chr11:8964675~8977527:+
UVM	cis	rs2455601	1	rs12418190	ENSG00000254860.4	TMEM9B-AS1	5.6	8.15e-07	0.003	1.08	0.61	Schizophrenia;	chr11:8878271	chr11:8964675~8977527:+
UVM	cis	rs2455601	1	rs12223690	ENSG00000254860.4	TMEM9B-AS1	5.6	8.15e-07	0.003	1.08	0.61	Schizophrenia;	chr11:8880277	chr11:8964675~8977527:+
UVM	cis	rs2455601	1	rs7104661	ENSG00000254860.4	TMEM9B-AS1	5.6	8.15e-07	0.003	1.08	0.61	Schizophrenia;	chr11:8880954	chr11:8964675~8977527:+
UVM	cis	rs2455601	1	rs11042108	ENSG00000254860.4	TMEM9B-AS1	5.6	8.15e-07	0.003	1.08	0.61	Schizophrenia;	chr11:8884474	chr11:8964675~8977527:+
UVM	cis	rs2455601	1	rs56336128	ENSG00000254860.4	TMEM9B-AS1	5.6	8.15e-07	0.003	1.08	0.61	Schizophrenia;	chr11:8886752	chr11:8964675~8977527:+
UVM	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	5.59	8.36e-07	0.00304	0.69	0.61	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
UVM	cis	rs4423214	1	rs4944946	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71448383	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs28364617	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71448718	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs2002063	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71452430	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs11600860	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71452973	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.959	rs11606611	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71453000	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs11606612	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71453001	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs11606631	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71453075	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs12789751	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71453425	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs12791871	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71453498	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs7944926	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71454579	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs12792306	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71455946	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs12785878	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71456403	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs4944955	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71456631	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs4944956	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71456719	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs4944958	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71457027	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.959	rs12793224	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71457664	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.959	rs12794668	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71457669	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs12790010	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71459607	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs12806844	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71459724	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs12808368	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71459771	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs12790558	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71459859	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.959	rs11233747	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71460596	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs11600569	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71462701	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.918	rs11233789	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71470039	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs12278461	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71471139	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs2282621	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71472428	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs2282620	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71472431	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs7935125	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71473144	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs732934	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71475430	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs4944062	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71476248	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs3794060	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71476633	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.879	rs4945008	ENSG00000254682.1	RP11-660L16.2	5.59	8.43e-07	0.00305	0.91	0.61	Vitamin D levels;	chr11:71510202	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-5.59	8.43e-07	0.00305	-0.91	-0.61	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
UVM	cis	rs4423214	1	rs4944959	ENSG00000254682.1	RP11-660L16.2	-5.59	8.43e-07	0.00305	-0.91	-0.61	Vitamin D levels;	chr11:71457188	chr11:71448674~71452157:+
UVM	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	5.59	8.59e-07	0.0031	0.65	0.61	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
UVM	cis	rs7188445	0.736	rs8048539	ENSG00000261390.4	RP11-345M22.2	5.59	8.61e-07	0.0031	0.64	0.61	Urate levels;	chr16:79670255	chr16:79715232~79770563:-
UVM	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	5.58	8.67e-07	0.00313	0.78	0.61	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
UVM	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-5.58	8.67e-07	0.00313	-0.78	-0.61	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
UVM	cis	rs494459	0.838	rs2510897	ENSG00000255239.1	AP002954.6	5.58	8.67e-07	0.00313	0.59	0.61	Height;	chr11:118773873	chr11:118688039~118690600:-
UVM	cis	rs8072100	0.544	rs7214993	ENSG00000228782.6	CTD-2026D20.3	5.58	8.75e-07	0.00314	0.66	0.61	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309431	chr17:47450568~47492492:-
UVM	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-5.58	8.89e-07	0.00318	-0.65	-0.61	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
UVM	cis	rs8072100	0.846	rs6503796	ENSG00000228782.6	CTD-2026D20.3	5.57	9.07e-07	0.00321	0.64	0.61	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47687883	chr17:47450568~47492492:-
UVM	cis	rs3750965	0.734	rs11604251	ENSG00000260895.1	RP11-554A11.7	-5.57	9.11e-07	0.00321	-0.87	-0.61	Hair color;	chr11:69052961	chr11:69103493~69109094:+
UVM	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-5.57	9.12e-07	0.00321	-0.35	-0.61	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-5.57	9.12e-07	0.00321	-0.35	-0.61	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-5.57	9.12e-07	0.00321	-0.35	-0.61	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-5.57	9.12e-07	0.00321	-0.35	-0.61	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-5.57	9.12e-07	0.00321	-0.35	-0.61	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-5.57	9.12e-07	0.00321	-0.35	-0.61	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-5.57	9.12e-07	0.00321	-0.35	-0.61	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-5.57	9.12e-07	0.00321	-0.35	-0.61	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-5.57	9.12e-07	0.00321	-0.35	-0.61	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-5.57	9.12e-07	0.00321	-0.35	-0.61	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-5.57	9.12e-07	0.00321	-0.35	-0.61	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-5.57	9.12e-07	0.00321	-0.35	-0.61	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-5.57	9.12e-07	0.00321	-0.35	-0.61	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-5.57	9.12e-07	0.00321	-0.35	-0.61	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-5.57	9.12e-07	0.00321	-0.35	-0.61	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-5.57	9.12e-07	0.00321	-0.35	-0.61	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-5.57	9.12e-07	0.00321	-0.35	-0.61	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-5.57	9.12e-07	0.00321	-0.35	-0.61	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs35790435	ENSG00000272010.1	CTD-3025N20.3	-5.57	9.12e-07	0.00321	-0.35	-0.61	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65591850~65592472:-
UVM	cis	rs494459	0.838	rs567680	ENSG00000255239.1	AP002954.6	5.57	9.19e-07	0.00321	0.58	0.61	Height;	chr11:118737823	chr11:118688039~118690600:-
UVM	cis	rs494459	0.838	rs566733	ENSG00000255239.1	AP002954.6	5.57	9.19e-07	0.00321	0.58	0.61	Height;	chr11:118737916	chr11:118688039~118690600:-
UVM	cis	rs1799949	0.602	rs8176257	ENSG00000198496.9	NBR2	-5.56	9.37e-07	0.00321	-0.86	-0.61	Menopause (age at onset);	chr17:43064188	chr17:43125610~43153671:+
UVM	cis	rs9549328	0.577	rs4907477	ENSG00000267868.1	RP11-120K24.3	5.56	9.42e-07	0.00322	0.77	0.61	Systolic blood pressure;	chr13:112964170	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.577	rs4907478	ENSG00000267868.1	RP11-120K24.3	5.56	9.42e-07	0.00322	0.77	0.61	Systolic blood pressure;	chr13:112964173	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.577	rs4907571	ENSG00000267868.1	RP11-120K24.3	5.56	9.42e-07	0.00322	0.77	0.61	Systolic blood pressure;	chr13:112964182	chr13:112964835~112966131:-
UVM	cis	rs5760092	0.755	rs4585126	ENSG00000273295.1	AP000350.5	-5.56	9.45e-07	0.00323	-0.79	-0.61	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23901432~23907068:-
UVM	cis	rs2080501	0.601	rs12919799	ENSG00000279356.1	RP11-429P3.8	-5.56	9.47e-07	0.00324	-0.49	-0.61	IgG glycosylation;	chr16:49635044	chr16:50072862~50074986:+
UVM	cis	rs5760092	0.755	rs915589	ENSG00000273295.1	AP000350.5	-5.56	9.53e-07	0.00325	-0.8	-0.61	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23901432~23907068:-
UVM	cis	rs6003958	1	rs6003958	ENSG00000273295.1	AP000350.5	-5.56	9.53e-07	0.00325	-0.8	-0.61	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23901432~23907068:-
UVM	cis	rs5760092	0.755	rs6003959	ENSG00000273295.1	AP000350.5	-5.56	9.53e-07	0.00325	-0.8	-0.61	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23901432~23907068:-
UVM	cis	rs2283792	0.871	rs8136867	ENSG00000224086.5	LL22NC03-86G7.1	-5.55	9.65e-07	0.00329	-0.63	-0.61	Multiple sclerosis;	chr22:21850504	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.776	rs9610458	ENSG00000224086.5	LL22NC03-86G7.1	-5.55	9.65e-07	0.00329	-0.63	-0.61	Multiple sclerosis;	chr22:21851064	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.905	rs5755694	ENSG00000224086.5	LL22NC03-86G7.1	-5.55	9.7e-07	0.00331	-0.63	-0.61	Multiple sclerosis;	chr22:21846241	chr22:21938293~21977632:+
UVM	cis	rs1153858	1	rs7171577	ENSG00000259520.4	CTD-2651B20.3	-5.55	9.84e-07	0.00335	-0.9	-0.61	Homoarginine levels;	chr15:45335781	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs10519021	ENSG00000259520.4	CTD-2651B20.3	-5.55	9.84e-07	0.00335	-0.9	-0.61	Homoarginine levels;	chr15:45339597	chr15:45251580~45279251:-
UVM	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-5.55	9.84e-07	0.00335	-0.8	-0.61	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
UVM	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	5.55	9.96e-07	0.00338	0.8	0.61	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
UVM	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-5.54	1.01e-06	0.00343	-0.35	-0.61	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
UVM	cis	rs3931020	0.679	rs28671241	ENSG00000272864.1	RP11-17E13.2	-5.54	1.03e-06	0.00348	-0.62	-0.61	Resistin levels;	chr1:74716197	chr1:74698769~74699333:-
UVM	cis	rs8072100	0.967	rs9894905	ENSG00000228782.6	CTD-2026D20.3	5.53	1.04e-06	0.00351	0.64	0.61	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408616	chr17:47450568~47492492:-
UVM	cis	rs7847628	0.551	rs10818476	ENSG00000226752.6	PSMD5-AS1	-5.53	1.04e-06	0.00352	-0.52	-0.61	Birth weight;	chr9:120809760	chr9:120824828~120854385:+
UVM	cis	rs7847628	0.587	rs1060817	ENSG00000226752.6	PSMD5-AS1	-5.53	1.04e-06	0.00352	-0.52	-0.61	Birth weight;	chr9:120820914	chr9:120824828~120854385:+
UVM	cis	rs35058679	0.507	rs9556486	ENSG00000247400.3	DNAJC3-AS1	-5.53	1.06e-06	0.00355	-0.38	-0.61	Schizophrenia;	chr13:95524427	chr13:95648733~95676925:-
UVM	cis	rs6991838	0.584	rs7836349	ENSG00000272010.1	CTD-3025N20.3	-5.53	1.07e-06	0.00358	-0.35	-0.61	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65591850~65592472:-
UVM	cis	rs1153858	1	rs2668747	ENSG00000259520.4	CTD-2651B20.3	-5.52	1.1e-06	0.00367	-0.89	-0.61	Homoarginine levels;	chr15:45325018	chr15:45251580~45279251:-
UVM	cis	rs2487048	0.761	rs1800976	ENSG00000226334.1	RP11-217B7.2	-5.51	1.12e-06	0.00373	-0.71	-0.61	Intraocular pressure;	chr9:104928428	chr9:104927553~104928892:+
UVM	cis	rs2487048	0.725	rs2422493	ENSG00000226334.1	RP11-217B7.2	-5.51	1.12e-06	0.00373	-0.71	-0.61	Intraocular pressure;	chr9:104928714	chr9:104927553~104928892:+
UVM	cis	rs11098499	0.954	rs12510138	ENSG00000245958.5	RP11-33B1.1	-5.51	1.12e-06	0.00373	-0.43	-0.61	Corneal astigmatism;	chr4:119502780	chr4:119454791~119552025:+
UVM	cis	rs997154	1	rs997154	ENSG00000279656.1	RP11-298I3.6	-5.51	1.13e-06	0.00376	-0.84	-0.61	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22995273	chr14:23023083~23024217:-
UVM	cis	rs1153858	1	rs56850226	ENSG00000259520.4	CTD-2651B20.3	-5.51	1.14e-06	0.0038	-0.89	-0.61	Homoarginine levels;	chr15:45340920	chr15:45251580~45279251:-
UVM	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	5.5	1.17e-06	0.00388	0.8	0.61	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
UVM	cis	rs8072100	0.811	rs1912483	ENSG00000228782.6	CTD-2026D20.3	5.49	1.22e-06	0.00403	0.61	0.61	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366128	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.811	rs9889709	ENSG00000228782.6	CTD-2026D20.3	5.49	1.22e-06	0.00403	0.61	0.61	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47367863	chr17:47450568~47492492:-
UVM	cis	rs2283792	0.765	rs34550586	ENSG00000224086.5	LL22NC03-86G7.1	-5.48	1.24e-06	0.0041	-0.66	-0.61	Multiple sclerosis;	chr22:21791345	chr22:21938293~21977632:+
UVM	cis	rs1799949	0.628	rs4474733	ENSG00000198496.9	NBR2	-5.48	1.24e-06	0.00412	-0.8	-0.61	Menopause (age at onset);	chr17:43356292	chr17:43125610~43153671:+
UVM	cis	rs2455601	0.529	rs2653569	ENSG00000254860.4	TMEM9B-AS1	5.48	1.25e-06	0.00413	0.91	0.61	Schizophrenia;	chr11:8965431	chr11:8964675~8977527:+
UVM	cis	rs858239	0.932	rs1728320	ENSG00000230658.1	KLHL7-AS1	5.48	1.26e-06	0.00415	0.67	0.61	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23101228~23105703:-
UVM	cis	rs11155671	0.53	rs2342769	ENSG00000268592.3	RAET1E-AS1	5.48	1.26e-06	0.00418	0.7	0.6	Testicular germ cell tumor;	chr6:149895371	chr6:149863494~149919507:+
UVM	cis	rs8072100	0.84	rs12452796	ENSG00000228782.6	CTD-2026D20.3	-5.47	1.32e-06	0.00434	-0.62	-0.6	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402367	chr17:47450568~47492492:-
UVM	cis	rs2455601	0.507	rs2568044	ENSG00000254860.4	TMEM9B-AS1	-5.46	1.33e-06	0.00438	-0.9	-0.6	Schizophrenia;	chr11:8980930	chr11:8964675~8977527:+
UVM	cis	rs2455601	0.573	rs2653573	ENSG00000254860.4	TMEM9B-AS1	5.46	1.33e-06	0.00438	0.9	0.6	Schizophrenia;	chr11:8968327	chr11:8964675~8977527:+
UVM	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	5.46	1.36e-06	0.00441	0.35	0.6	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	5.46	1.36e-06	0.00441	0.35	0.6	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	5.46	1.36e-06	0.00441	0.35	0.6	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	5.46	1.36e-06	0.00441	0.35	0.6	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	5.46	1.36e-06	0.00441	0.35	0.6	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	5.46	1.36e-06	0.00441	0.35	0.6	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	5.46	1.36e-06	0.00441	0.35	0.6	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	5.46	1.36e-06	0.00441	0.35	0.6	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	5.46	1.36e-06	0.00441	0.35	0.6	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	5.46	1.36e-06	0.00441	0.35	0.6	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	5.46	1.36e-06	0.00441	0.35	0.6	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	5.46	1.36e-06	0.00441	0.35	0.6	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	5.46	1.36e-06	0.00441	0.35	0.6	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	5.46	1.36e-06	0.00441	0.35	0.6	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	5.46	1.36e-06	0.00441	0.35	0.6	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	5.46	1.36e-06	0.00441	0.35	0.6	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	5.46	1.36e-06	0.00441	0.35	0.6	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	5.46	1.36e-06	0.00441	0.35	0.6	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	5.46	1.36e-06	0.00441	0.35	0.6	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	5.46	1.36e-06	0.00441	0.35	0.6	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	5.46	1.36e-06	0.00441	0.35	0.6	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-5.46	1.36e-06	0.00441	-0.35	-0.6	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
UVM	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-5.46	1.36e-06	0.00441	-0.35	-0.6	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
UVM	cis	rs11098499	1	rs1011054	ENSG00000245958.5	RP11-33B1.1	5.46	1.37e-06	0.00442	0.39	0.6	Corneal astigmatism;	chr4:119281232	chr4:119454791~119552025:+
UVM	cis	rs2283792	0.967	rs5999823	ENSG00000224086.5	LL22NC03-86G7.1	-5.45	1.42e-06	0.00453	-0.63	-0.6	Multiple sclerosis;	chr22:21856587	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.935	rs2283794	ENSG00000224086.5	LL22NC03-86G7.1	-5.45	1.42e-06	0.00453	-0.63	-0.6	Multiple sclerosis;	chr22:21858180	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.967	rs4821402	ENSG00000224086.5	LL22NC03-86G7.1	-5.45	1.42e-06	0.00453	-0.63	-0.6	Multiple sclerosis;	chr22:21860457	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.935	rs5750113	ENSG00000224086.5	LL22NC03-86G7.1	-5.45	1.42e-06	0.00453	-0.63	-0.6	Multiple sclerosis;	chr22:21865784	chr22:21938293~21977632:+
UVM	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	5.44	1.43e-06	0.00457	0.73	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
UVM	cis	rs3750965	0.881	rs61057353	ENSG00000260895.1	RP11-554A11.7	5.44	1.44e-06	0.00461	0.88	0.6	Hair color;	chr11:69049582	chr11:69103493~69109094:+
UVM	cis	rs1930961	1	rs6004673	ENSG00000100058.11	CRYBB2P1	5.44	1.45e-06	0.00464	1.27	0.6	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25448105~25520854:+
UVM	cis	rs950027	0.595	rs2486288	ENSG00000259520.4	CTD-2651B20.3	-5.44	1.46e-06	0.00466	-0.81	-0.6	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45251580~45279251:-
UVM	cis	rs2486288	0.539	rs2433601	ENSG00000259520.4	CTD-2651B20.3	-5.44	1.46e-06	0.00466	-0.81	-0.6	Glomerular filtration rate;	chr15:45424227	chr15:45251580~45279251:-
UVM	cis	rs11155671	0.53	rs9371215	ENSG00000268592.3	RAET1E-AS1	5.44	1.48e-06	0.00471	0.67	0.6	Testicular germ cell tumor;	chr6:149873162	chr6:149863494~149919507:+
UVM	cis	rs507080	0.733	rs601318	ENSG00000255239.1	AP002954.6	5.43	1.49e-06	0.00474	0.64	0.6	Serum metabolite levels;	chr11:118648845	chr11:118688039~118690600:-
UVM	cis	rs1930961	0.85	rs5996945	ENSG00000100058.11	CRYBB2P1	-5.43	1.52e-06	0.00483	-1.27	-0.6	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25448105~25520854:+
UVM	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-5.43	1.52e-06	0.00484	-0.71	-0.6	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
UVM	cis	rs1858037	0.867	rs953312	ENSG00000204929.10	AC074391.1	5.43	1.52e-06	0.00485	0.98	0.6	Rheumatoid arthritis;	chr2:65340556	chr2:65436711~66084639:+
UVM	cis	rs1858037	0.867	rs9789444	ENSG00000204929.10	AC074391.1	5.43	1.52e-06	0.00485	0.98	0.6	Rheumatoid arthritis;	chr2:65342093	chr2:65436711~66084639:+
UVM	cis	rs1025688	0.561	rs7227542	ENSG00000267322.2	SNHG22	5.41	1.6e-06	0.00507	0.67	0.6	Neutrophil count;Sum basophil neutrophil counts;	chr18:50626552	chr18:49814023~49851059:+
UVM	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-5.41	1.6e-06	0.00507	-0.65	-0.6	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
UVM	cis	rs11155671	0.53	rs9968871	ENSG00000268592.3	RAET1E-AS1	5.41	1.64e-06	0.00519	0.69	0.6	Testicular germ cell tumor;	chr6:149888060	chr6:149863494~149919507:+
UVM	cis	rs11155671	0.53	rs9969044	ENSG00000268592.3	RAET1E-AS1	5.41	1.64e-06	0.00519	0.69	0.6	Testicular germ cell tumor;	chr6:149888068	chr6:149863494~149919507:+
UVM	cis	rs11155671	0.53	rs7756850	ENSG00000268592.3	RAET1E-AS1	5.41	1.64e-06	0.00519	0.69	0.6	Testicular germ cell tumor;	chr6:149891460	chr6:149863494~149919507:+
UVM	cis	rs11155671	0.53	rs9371542	ENSG00000268592.3	RAET1E-AS1	5.41	1.64e-06	0.00519	0.69	0.6	Testicular germ cell tumor;	chr6:149891949	chr6:149863494~149919507:+
UVM	cis	rs9322193	0.567	rs7747457	ENSG00000268592.3	RAET1E-AS1	5.41	1.64e-06	0.00519	0.69	0.6	Lung cancer;	chr6:149892366	chr6:149863494~149919507:+
UVM	cis	rs11155671	0.53	rs9371223	ENSG00000268592.3	RAET1E-AS1	5.41	1.64e-06	0.00519	0.69	0.6	Testicular germ cell tumor;	chr6:149893670	chr6:149863494~149919507:+
UVM	cis	rs5769765	0.728	rs6520064	ENSG00000229409.1	RP11-494O16.3	-5.4	1.65e-06	0.0052	-0.95	-0.6	Schizophrenia;	chr22:49900821	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.773	rs6520065	ENSG00000229409.1	RP11-494O16.3	-5.4	1.65e-06	0.0052	-0.95	-0.6	Schizophrenia;	chr22:49900822	chr22:49845929~49846090:+
UVM	cis	rs11155671	0.53	rs9371544	ENSG00000268592.3	RAET1E-AS1	5.4	1.66e-06	0.00525	0.68	0.6	Testicular germ cell tumor;	chr6:149896224	chr6:149863494~149919507:+
UVM	cis	rs3931020	0.772	rs1409785	ENSG00000272864.1	RP11-17E13.2	-5.4	1.66e-06	0.00525	-0.6	-0.6	Resistin levels;	chr1:74782438	chr1:74698769~74699333:-
UVM	cis	rs1858037	0.867	rs67817304	ENSG00000204929.10	AC074391.1	5.4	1.69e-06	0.0053	0.97	0.6	Rheumatoid arthritis;	chr2:65346982	chr2:65436711~66084639:+
UVM	cis	rs1858037	0.867	rs4671660	ENSG00000204929.10	AC074391.1	5.4	1.69e-06	0.0053	0.97	0.6	Rheumatoid arthritis;	chr2:65349302	chr2:65436711~66084639:+
UVM	cis	rs1858037	0.806	rs12612780	ENSG00000204929.10	AC074391.1	5.4	1.69e-06	0.0053	0.97	0.6	Rheumatoid arthritis;	chr2:65355967	chr2:65436711~66084639:+
UVM	cis	rs1858037	0.867	rs67453645	ENSG00000204929.10	AC074391.1	5.4	1.69e-06	0.0053	0.97	0.6	Rheumatoid arthritis;	chr2:65358908	chr2:65436711~66084639:+
UVM	cis	rs1858037	0.867	rs57913336	ENSG00000204929.10	AC074391.1	5.4	1.69e-06	0.0053	0.97	0.6	Rheumatoid arthritis;	chr2:65360485	chr2:65436711~66084639:+
UVM	cis	rs1858037	0.867	rs61226353	ENSG00000204929.10	AC074391.1	5.4	1.69e-06	0.0053	0.97	0.6	Rheumatoid arthritis;	chr2:65363637	chr2:65436711~66084639:+
UVM	cis	rs1858037	0.765	rs67404371	ENSG00000204929.10	AC074391.1	5.4	1.69e-06	0.0053	0.97	0.6	Rheumatoid arthritis;	chr2:65370137	chr2:65436711~66084639:+
UVM	cis	rs1858037	0.836	rs1396209	ENSG00000204929.10	AC074391.1	5.4	1.69e-06	0.0053	0.97	0.6	Rheumatoid arthritis;	chr2:65374100	chr2:65436711~66084639:+
UVM	cis	rs1858037	0.867	rs2118305	ENSG00000204929.10	AC074391.1	5.4	1.69e-06	0.0053	0.97	0.6	Rheumatoid arthritis;	chr2:65378086	chr2:65436711~66084639:+
UVM	cis	rs1858037	0.836	rs17475335	ENSG00000204929.10	AC074391.1	5.4	1.69e-06	0.0053	0.97	0.6	Rheumatoid arthritis;	chr2:65378646	chr2:65436711~66084639:+
UVM	cis	rs1858037	0.867	rs876933	ENSG00000204929.10	AC074391.1	5.4	1.69e-06	0.0053	0.97	0.6	Rheumatoid arthritis;	chr2:65382303	chr2:65436711~66084639:+
UVM	cis	rs1858037	0.867	rs72621551	ENSG00000204929.10	AC074391.1	5.4	1.69e-06	0.0053	0.97	0.6	Rheumatoid arthritis;	chr2:65388087	chr2:65436711~66084639:+
UVM	cis	rs1858037	0.867	rs55945621	ENSG00000204929.10	AC074391.1	5.4	1.69e-06	0.0053	0.97	0.6	Rheumatoid arthritis;	chr2:65388220	chr2:65436711~66084639:+
UVM	cis	rs1858037	0.867	rs964505	ENSG00000204929.10	AC074391.1	5.4	1.69e-06	0.0053	0.97	0.6	Rheumatoid arthritis;	chr2:65396055	chr2:65436711~66084639:+
UVM	cis	rs1858037	0.867	rs1553675	ENSG00000204929.10	AC074391.1	-5.4	1.69e-06	0.0053	-0.97	-0.6	Rheumatoid arthritis;	chr2:65343173	chr2:65436711~66084639:+
UVM	cis	rs1858037	0.836	rs2576923	ENSG00000204929.10	AC074391.1	-5.4	1.69e-06	0.0053	-0.97	-0.6	Rheumatoid arthritis;	chr2:65406750	chr2:65436711~66084639:+
UVM	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	5.39	1.73e-06	0.00543	0.6	0.6	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
UVM	cis	rs1799949	0.602	rs8176199	ENSG00000198496.9	NBR2	-5.39	1.74e-06	0.00545	-0.81	-0.6	Menopause (age at onset);	chr17:43078507	chr17:43125610~43153671:+
UVM	cis	rs507080	0.769	rs2077173	ENSG00000255239.1	AP002954.6	5.38	1.77e-06	0.00554	0.67	0.6	Serum metabolite levels;	chr11:118621876	chr11:118688039~118690600:-
UVM	cis	rs2935183	1	rs2935183	ENSG00000228782.6	CTD-2026D20.3	-5.38	1.78e-06	0.00557	-0.67	-0.6	Multiple sclerosis or amyotrophic lateral sclerosis;	chr17:47530206	chr17:47450568~47492492:-
UVM	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	5.38	1.82e-06	0.00568	0.7	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
UVM	cis	rs9322193	0.886	rs4870055	ENSG00000231760.4	RP11-350J20.5	5.38	1.82e-06	0.00568	0.77	0.6	Lung cancer;	chr6:149848433	chr6:149796151~149826294:-
UVM	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-5.38	1.83e-06	0.00571	-0.65	-0.6	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
UVM	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	5.37	1.86e-06	0.00573	0.54	0.6	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	5.37	1.86e-06	0.00573	0.54	0.6	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	5.37	1.86e-06	0.00573	0.54	0.6	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	5.37	1.86e-06	0.00573	0.54	0.6	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	5.37	1.86e-06	0.00573	0.54	0.6	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	5.37	1.86e-06	0.00573	0.54	0.6	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	5.37	1.86e-06	0.00573	0.54	0.6	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	5.37	1.86e-06	0.00573	0.54	0.6	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	5.37	1.86e-06	0.00573	0.54	0.6	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
UVM	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	5.37	1.88e-06	0.0058	0.63	0.6	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
UVM	cis	rs2882667	0.537	rs7704790	ENSG00000253404.1	AC034243.1	5.37	1.88e-06	0.00581	0.63	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139074407	chr5:138744434~138753309:-
UVM	cis	rs6597981	0.675	rs1138714	ENSG00000279672.1	CMB9-55F22.1	5.37	1.89e-06	0.00584	0.55	0.6	Breast cancer;	chr11:825110	chr11:779617~780755:+
UVM	cis	rs12439619	1	rs12439619	ENSG00000278603.1	RP13-608F4.5	5.36	1.91e-06	0.00588	0.77	0.6	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472203~82472426:+
UVM	cis	rs1930961	0.558	rs11090404	ENSG00000100058.11	CRYBB2P1	5.36	1.96e-06	0.00602	0.92	0.6	Bipolar disorder with mood-incongruent psychosis;	chr22:25527780	chr22:25448105~25520854:+
UVM	cis	rs1930961	0.558	rs5996951	ENSG00000100058.11	CRYBB2P1	5.36	1.96e-06	0.00602	0.92	0.6	Bipolar disorder with mood-incongruent psychosis;	chr22:25529032	chr22:25448105~25520854:+
UVM	cis	rs1930961	0.558	rs12160908	ENSG00000100058.11	CRYBB2P1	5.36	1.96e-06	0.00602	0.92	0.6	Bipolar disorder with mood-incongruent psychosis;	chr22:25532653	chr22:25448105~25520854:+
UVM	cis	rs1025688	1	rs745822	ENSG00000267322.2	SNHG22	5.35	1.99e-06	0.00612	0.63	0.6	Neutrophil count;Sum basophil neutrophil counts;	chr18:50616452	chr18:49814023~49851059:+
UVM	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	5.35	2e-06	0.00615	0.72	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
UVM	cis	rs9549328	0.731	rs55804996	ENSG00000267868.1	RP11-120K24.3	5.35	2.01e-06	0.00615	0.8	0.6	Systolic blood pressure;	chr13:112971053	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.8	rs9549616	ENSG00000267868.1	RP11-120K24.3	5.35	2.01e-06	0.00615	0.8	0.6	Systolic blood pressure;	chr13:112973448	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.8	rs9549617	ENSG00000267868.1	RP11-120K24.3	5.35	2.01e-06	0.00615	0.8	0.6	Systolic blood pressure;	chr13:112973756	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.837	rs9549618	ENSG00000267868.1	RP11-120K24.3	5.35	2.01e-06	0.00615	0.8	0.6	Systolic blood pressure;	chr13:112974334	chr13:112964835~112966131:-
UVM	cis	rs11155671	0.53	rs9322228	ENSG00000268592.3	RAET1E-AS1	5.35	2.01e-06	0.00616	0.67	0.6	Testicular germ cell tumor;	chr6:149888173	chr6:149863494~149919507:+
UVM	cis	rs11155671	0.53	rs7774787	ENSG00000268592.3	RAET1E-AS1	5.35	2.01e-06	0.00616	0.67	0.6	Testicular germ cell tumor;	chr6:149888296	chr6:149863494~149919507:+
UVM	cis	rs11155671	0.53	rs2342767	ENSG00000268592.3	RAET1E-AS1	5.35	2.01e-06	0.00616	0.67	0.6	Testicular germ cell tumor;	chr6:149888581	chr6:149863494~149919507:+
UVM	cis	rs11155671	0.53	rs7764376	ENSG00000268592.3	RAET1E-AS1	5.35	2.01e-06	0.00616	0.67	0.6	Testicular germ cell tumor;	chr6:149889208	chr6:149863494~149919507:+
UVM	cis	rs11155671	0.53	rs6933882	ENSG00000268592.3	RAET1E-AS1	5.35	2.01e-06	0.00616	0.67	0.6	Testicular germ cell tumor;	chr6:149889666	chr6:149863494~149919507:+
UVM	cis	rs11155671	0.53	rs6939761	ENSG00000268592.3	RAET1E-AS1	5.35	2.01e-06	0.00616	0.67	0.6	Testicular germ cell tumor;	chr6:149889858	chr6:149863494~149919507:+
UVM	cis	rs11155671	0.53	rs3823021	ENSG00000268592.3	RAET1E-AS1	5.35	2.01e-06	0.00616	0.67	0.6	Testicular germ cell tumor;	chr6:149889863	chr6:149863494~149919507:+
UVM	cis	rs11155671	0.53	rs4869763	ENSG00000268592.3	RAET1E-AS1	5.35	2.01e-06	0.00616	0.67	0.6	Testicular germ cell tumor;	chr6:149890548	chr6:149863494~149919507:+
UVM	cis	rs11155671	0.53	rs4869764	ENSG00000268592.3	RAET1E-AS1	5.35	2.01e-06	0.00616	0.67	0.6	Testicular germ cell tumor;	chr6:149890692	chr6:149863494~149919507:+
UVM	cis	rs9322193	0.567	rs7742692	ENSG00000268592.3	RAET1E-AS1	5.35	2.01e-06	0.00616	0.67	0.6	Lung cancer;	chr6:149892363	chr6:149863494~149919507:+
UVM	cis	rs8072100	0.967	rs4338849	ENSG00000228782.6	CTD-2026D20.3	5.35	2.02e-06	0.00618	0.64	0.6	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435117	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.905	rs9895274	ENSG00000228782.6	CTD-2026D20.3	5.35	2.02e-06	0.00618	0.64	0.6	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47461751	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.967	rs12452315	ENSG00000228782.6	CTD-2026D20.3	-5.35	2.02e-06	0.00618	-0.64	-0.6	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402080	chr17:47450568~47492492:-
UVM	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	5.35	2.02e-06	0.00618	0.34	0.6	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
UVM	cis	rs7174755	0.558	rs11071975	ENSG00000260657.2	RP11-315D16.4	-5.35	2.03e-06	0.00619	-0.94	-0.6	Major depressive disorder;	chr15:68037106	chr15:68267792~68277994:-
UVM	cis	rs8072100	0.875	rs4794047	ENSG00000228782.6	CTD-2026D20.3	-5.35	2.03e-06	0.00621	-0.63	-0.6	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685639	chr17:47450568~47492492:-
UVM	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	5.34	2.09e-06	0.00637	0.67	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	5.34	2.09e-06	0.00637	0.67	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	5.34	2.09e-06	0.00637	0.67	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
UVM	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-5.33	2.12e-06	0.00646	-0.88	-0.59	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
UVM	cis	rs950027	0.62	rs35861938	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.17e-06	0.00658	-0.8	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45251580~45279251:-
UVM	cis	rs950027	0.596	rs2467865	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.17e-06	0.00658	-0.8	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45251580~45279251:-
UVM	cis	rs950027	0.62	rs2461700	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.17e-06	0.00658	-0.8	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45251580~45279251:-
UVM	cis	rs950027	0.62	rs2453533	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.17e-06	0.00658	-0.8	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45251580~45279251:-
UVM	cis	rs950027	0.62	rs2467862	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.17e-06	0.00658	-0.8	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45251580~45279251:-
UVM	cis	rs950027	0.62	rs1145093	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.17e-06	0.00658	-0.8	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45251580~45279251:-
UVM	cis	rs950027	0.62	rs1145089	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.17e-06	0.00658	-0.8	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45251580~45279251:-
UVM	cis	rs950027	0.62	rs1049518	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.17e-06	0.00658	-0.8	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45251580~45279251:-
UVM	cis	rs950027	0.584	rs1145086	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.17e-06	0.00658	-0.8	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45251580~45279251:-
UVM	cis	rs950027	0.62	rs1153857	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.17e-06	0.00658	-0.8	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45251580~45279251:-
UVM	cis	rs950027	0.62	rs1153855	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.17e-06	0.00658	-0.8	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45251580~45279251:-
UVM	cis	rs950027	0.62	rs2486274	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.17e-06	0.00658	-0.8	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45251580~45279251:-
UVM	cis	rs950027	0.62	rs1145084	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.17e-06	0.00658	-0.8	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45251580~45279251:-
UVM	cis	rs950027	0.62	rs1145080	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.17e-06	0.00658	-0.8	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45251580~45279251:-
UVM	cis	rs950027	0.62	rs1145076	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.17e-06	0.00658	-0.8	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45251580~45279251:-
UVM	cis	rs950027	0.62	rs1426932	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.17e-06	0.00658	-0.8	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45251580~45279251:-
UVM	cis	rs950027	0.62	rs1346267	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.17e-06	0.00658	-0.8	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45251580~45279251:-
UVM	cis	rs950027	0.596	rs2467853	ENSG00000259520.4	CTD-2651B20.3	-5.33	2.17e-06	0.00658	-0.8	-0.59	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45251580~45279251:-
UVM	cis	rs950027	0.62	rs1153860	ENSG00000259520.4	CTD-2651B20.3	5.33	2.17e-06	0.00658	0.8	0.59	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45251580~45279251:-
UVM	cis	rs950027	0.62	rs1145077	ENSG00000259520.4	CTD-2651B20.3	5.33	2.17e-06	0.00658	0.8	0.59	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45251580~45279251:-
UVM	cis	rs3750965	0.839	rs921670	ENSG00000260895.1	RP11-554A11.7	5.32	2.21e-06	0.00667	0.8	0.59	Hair color;	chr11:69104171	chr11:69103493~69109094:+
UVM	cis	rs1858037	0.867	rs1039765	ENSG00000204929.10	AC074391.1	-5.32	2.21e-06	0.00669	-0.95	-0.59	Rheumatoid arthritis;	chr2:65387228	chr2:65436711~66084639:+
UVM	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-5.32	2.22e-06	0.0067	-0.61	-0.59	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
UVM	cis	rs8072100	0.875	rs7208530	ENSG00000228782.6	CTD-2026D20.3	5.32	2.24e-06	0.00676	0.61	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47466741	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.875	rs12451409	ENSG00000228782.6	CTD-2026D20.3	5.32	2.24e-06	0.00676	0.61	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47467490	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.817	rs9892497	ENSG00000228782.6	CTD-2026D20.3	5.32	2.24e-06	0.00676	0.61	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47468553	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.817	rs9905581	ENSG00000228782.6	CTD-2026D20.3	5.32	2.24e-06	0.00676	0.61	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469819	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.817	rs12449647	ENSG00000228782.6	CTD-2026D20.3	5.32	2.24e-06	0.00676	0.61	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471592	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.817	rs7213086	ENSG00000228782.6	CTD-2026D20.3	5.32	2.25e-06	0.00676	0.62	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47674944	chr17:47450568~47492492:-
UVM	cis	rs1040	0.646	rs7764005	ENSG00000226445.1	XXyac-YX65C7_A.2	5.31	2.27e-06	0.00681	0.63	0.59	Joint mobility (Beighton score);	chr6:169207623	chr6:169213254~169239565:+
UVM	cis	rs2882667	0.556	rs6873733	ENSG00000253404.1	AC034243.1	5.31	2.31e-06	0.00692	0.63	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139067628	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.537	rs7701338	ENSG00000253404.1	AC034243.1	5.31	2.31e-06	0.00692	0.63	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070305	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.537	rs7701116	ENSG00000253404.1	AC034243.1	5.31	2.31e-06	0.00692	0.63	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070389	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.537	rs13181793	ENSG00000253404.1	AC034243.1	5.31	2.31e-06	0.00692	0.63	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073267	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.537	rs11743534	ENSG00000253404.1	AC034243.1	5.31	2.31e-06	0.00692	0.63	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073318	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	5.31	2.31e-06	0.00692	0.63	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
UVM	cis	rs9487094	0.626	rs12215077	ENSG00000260273.1	RP11-425D10.10	-5.31	2.34e-06	0.00699	-0.65	-0.59	Height;	chr6:109731677	chr6:109382795~109383666:+
UVM	cis	rs5769765	0.908	rs138880	ENSG00000229409.1	RP11-494O16.3	-5.3	2.35e-06	0.00702	-0.93	-0.59	Schizophrenia;	chr22:49824963	chr22:49845929~49846090:+
UVM	cis	rs11155671	0.53	rs7757984	ENSG00000268592.3	RAET1E-AS1	5.3	2.4e-06	0.00717	0.66	0.59	Testicular germ cell tumor;	chr6:149887515	chr6:149863494~149919507:+
UVM	cis	rs8072100	0.688	rs12602134	ENSG00000228782.6	CTD-2026D20.3	-5.29	2.45e-06	0.00726	-0.65	-0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47504770	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.934	rs8067286	ENSG00000228782.6	CTD-2026D20.3	-5.29	2.45e-06	0.00726	-0.65	-0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47517224	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.875	rs62073966	ENSG00000228782.6	CTD-2026D20.3	-5.29	2.45e-06	0.00726	-0.65	-0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47522647	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.935	rs78551919	ENSG00000228782.6	CTD-2026D20.3	-5.29	2.45e-06	0.00726	-0.65	-0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47548636	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.539	rs36043200	ENSG00000228782.6	CTD-2026D20.3	-5.29	2.45e-06	0.00726	-0.65	-0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47552040	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.905	rs8077106	ENSG00000228782.6	CTD-2026D20.3	-5.29	2.45e-06	0.00726	-0.65	-0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575925	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.754	rs8081717	ENSG00000228782.6	CTD-2026D20.3	-5.29	2.45e-06	0.00726	-0.65	-0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47576555	chr17:47450568~47492492:-
UVM	cis	rs8072100	1	rs8072100	ENSG00000228782.6	CTD-2026D20.3	-5.29	2.45e-06	0.00726	-0.65	-0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597321	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.935	rs12150231	ENSG00000228782.6	CTD-2026D20.3	-5.29	2.45e-06	0.00726	-0.65	-0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47639725	chr17:47450568~47492492:-
UVM	cis	rs8072100	1	rs4794016	ENSG00000228782.6	CTD-2026D20.3	-5.29	2.45e-06	0.00726	-0.65	-0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47648565	chr17:47450568~47492492:-
UVM	cis	rs8072100	1	rs11870935	ENSG00000228782.6	CTD-2026D20.3	-5.29	2.45e-06	0.00726	-0.65	-0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655239	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.846	rs4264433	ENSG00000228782.6	CTD-2026D20.3	-5.29	2.45e-06	0.00726	-0.65	-0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47659909	chr17:47450568~47492492:-
UVM	cis	rs8072100	1	rs3809868	ENSG00000228782.6	CTD-2026D20.3	-5.29	2.45e-06	0.00726	-0.65	-0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47673230	chr17:47450568~47492492:-
UVM	cis	rs8072100	1	rs7210738	ENSG00000228782.6	CTD-2026D20.3	-5.29	2.45e-06	0.00726	-0.65	-0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47680232	chr17:47450568~47492492:-
UVM	cis	rs8072100	1	rs4375701	ENSG00000228782.6	CTD-2026D20.3	5.29	2.45e-06	0.00726	0.65	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47634852	chr17:47450568~47492492:-
UVM	cis	rs8072100	1	rs8065437	ENSG00000228782.6	CTD-2026D20.3	5.29	2.45e-06	0.00726	0.65	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644287	chr17:47450568~47492492:-
UVM	cis	rs8072100	1	rs11650372	ENSG00000228782.6	CTD-2026D20.3	5.29	2.45e-06	0.00726	0.65	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644429	chr17:47450568~47492492:-
UVM	cis	rs8072100	1	rs8065669	ENSG00000228782.6	CTD-2026D20.3	5.29	2.45e-06	0.00726	0.65	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47647630	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.967	rs2317826	ENSG00000228782.6	CTD-2026D20.3	5.29	2.45e-06	0.00726	0.65	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47653533	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.967	rs4580230	ENSG00000228782.6	CTD-2026D20.3	5.29	2.45e-06	0.00726	0.65	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47661495	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.934	rs9905583	ENSG00000228782.6	CTD-2026D20.3	5.29	2.45e-06	0.00726	0.65	0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47663650	chr17:47450568~47492492:-
UVM	cis	rs507080	0.697	rs653008	ENSG00000255239.1	AP002954.6	5.29	2.47e-06	0.0073	0.63	0.59	Serum metabolite levels;	chr11:118649775	chr11:118688039~118690600:-
UVM	cis	rs507080	0.769	rs745663	ENSG00000255239.1	AP002954.6	5.29	2.47e-06	0.0073	0.63	0.59	Serum metabolite levels;	chr11:118658886	chr11:118688039~118690600:-
UVM	cis	rs3750965	1	rs1466222	ENSG00000260895.1	RP11-554A11.7	5.29	2.48e-06	0.00732	0.86	0.59	Hair color;	chr11:69065380	chr11:69103493~69109094:+
UVM	cis	rs3750965	1	rs7950657	ENSG00000260895.1	RP11-554A11.7	5.29	2.48e-06	0.00732	0.86	0.59	Hair color;	chr11:69067363	chr11:69103493~69109094:+
UVM	cis	rs3750965	1	rs61881024	ENSG00000260895.1	RP11-554A11.7	5.29	2.48e-06	0.00732	0.86	0.59	Hair color;	chr11:69070326	chr11:69103493~69109094:+
UVM	cis	rs12439619	0.739	rs4778988	ENSG00000278603.1	RP13-608F4.5	5.29	2.49e-06	0.00735	0.8	0.59	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472203~82472426:+
UVM	cis	rs1153858	1	rs4774577	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45352487	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs11070453	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45352956	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs4774578	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45353853	chr15:45251580~45279251:-
UVM	cis	rs61524473	1	rs61524473	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs12593230	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45354770	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs10444821	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45355038	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs72623915	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45355235	chr15:45251580~45279251:-
UVM	cis	rs1153858	0.725	rs74572151	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45355328	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs66714503	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45355840	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs2056493	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45356074	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs67831559	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45357109	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs2066090	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45357820	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs61365925	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45358113	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs16952714	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45358160	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs12101539	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45358468	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs8032904	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45359111	chr15:45251580~45279251:-
UVM	cis	rs1153858	0.943	rs8038342	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45359339	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs4774579	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45359605	chr15:45251580~45279251:-
UVM	cis	rs1153858	0.943	rs4774580	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45359888	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs4271549	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45360532	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs4627277	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45360570	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs4395020	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45360691	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs4625670	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45360728	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs4534782	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45360735	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs1049503	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45361509	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs12595087	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45363034	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs3759899	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45363705	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs1890565	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45371101	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs10519022	ENSG00000259520.4	CTD-2651B20.3	5.29	2.51e-06	0.00737	0.87	0.59	Homoarginine levels;	chr15:45371486	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs1554521	ENSG00000259520.4	CTD-2651B20.3	5.29	2.51e-06	0.00737	0.87	0.59	Homoarginine levels;	chr15:45371991	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs12594857	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45374980	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs66528868	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45376349	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs7494956	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45376367	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs12437840	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45376857	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs12437887	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45376896	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs2114501	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45378118	chr15:45251580~45279251:-
UVM	cis	rs1153858	0.887	rs7164139	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45378653	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs7164602	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45379127	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs12441971	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45379759	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs1346268	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45380831	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs67461176	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45384621	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs66939267	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45384704	chr15:45251580~45279251:-
UVM	cis	rs1153858	0.943	rs67045941	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45384813	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs67744121	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45385039	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs16942568	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45385192	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs4775937	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45386416	chr15:45251580~45279251:-
UVM	cis	rs1153858	0.943	rs11070454	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45388054	chr15:45251580~45279251:-
UVM	cis	rs1153858	0.943	rs12439575	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45392618	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs9788780	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45393289	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs7181167	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45394038	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs11070456	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45394637	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs11070457	ENSG00000259520.4	CTD-2651B20.3	-5.29	2.51e-06	0.00737	-0.87	-0.59	Homoarginine levels;	chr15:45394745	chr15:45251580~45279251:-
UVM	cis	rs8072100	0.817	rs6505049	ENSG00000228782.6	CTD-2026D20.3	-5.27	2.63e-06	0.00765	-0.61	-0.59	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47598415	chr17:47450568~47492492:-
UVM	cis	rs7615952	1	rs7616044	ENSG00000171084.14	FAM86JP	5.27	2.66e-06	0.00772	0.76	0.59	Blood pressure (smoking interaction);	chr3:125930511	chr3:125916620~125930024:+
UVM	cis	rs7569084	0.663	rs6546150	ENSG00000281920.1	RP11-418H16.1	-5.27	2.66e-06	0.00772	-0.88	-0.59	Sum eosinophil basophil counts;	chr2:65415066	chr2:65623272~65628424:+
UVM	cis	rs7569084	0.687	rs963539	ENSG00000281920.1	RP11-418H16.1	-5.27	2.66e-06	0.00772	-0.88	-0.59	Sum eosinophil basophil counts;	chr2:65421413	chr2:65623272~65628424:+
UVM	cis	rs7569084	0.687	rs6755006	ENSG00000281920.1	RP11-418H16.1	-5.27	2.66e-06	0.00772	-0.88	-0.59	Sum eosinophil basophil counts;	chr2:65426008	chr2:65623272~65628424:+
UVM	cis	rs7569084	0.687	rs6755128	ENSG00000281920.1	RP11-418H16.1	-5.27	2.66e-06	0.00772	-0.88	-0.59	Sum eosinophil basophil counts;	chr2:65426065	chr2:65623272~65628424:+
UVM	cis	rs7569084	0.687	rs12993075	ENSG00000281920.1	RP11-418H16.1	5.27	2.66e-06	0.00772	0.88	0.59	Sum eosinophil basophil counts;	chr2:65431010	chr2:65623272~65628424:+
UVM	cis	rs7569084	0.687	rs4671663	ENSG00000281920.1	RP11-418H16.1	5.27	2.66e-06	0.00772	0.88	0.59	Sum eosinophil basophil counts;	chr2:65434400	chr2:65623272~65628424:+
UVM	cis	rs7569084	0.687	rs11692813	ENSG00000281920.1	RP11-418H16.1	5.27	2.66e-06	0.00772	0.88	0.59	Sum eosinophil basophil counts;	chr2:65435172	chr2:65623272~65628424:+
UVM	cis	rs7569084	0.663	rs11126037	ENSG00000281920.1	RP11-418H16.1	5.27	2.66e-06	0.00772	0.88	0.59	Sum eosinophil basophil counts;	chr2:65436024	chr2:65623272~65628424:+
UVM	cis	rs7569084	0.687	rs11126038	ENSG00000281920.1	RP11-418H16.1	5.27	2.66e-06	0.00772	0.88	0.59	Sum eosinophil basophil counts;	chr2:65436100	chr2:65623272~65628424:+
UVM	cis	rs7569084	0.663	rs11694714	ENSG00000281920.1	RP11-418H16.1	5.27	2.66e-06	0.00772	0.88	0.59	Sum eosinophil basophil counts;	chr2:65436802	chr2:65623272~65628424:+
UVM	cis	rs7569084	0.663	rs4671128	ENSG00000281920.1	RP11-418H16.1	5.27	2.66e-06	0.00772	0.88	0.59	Sum eosinophil basophil counts;	chr2:65438130	chr2:65623272~65628424:+
UVM	cis	rs7569084	0.687	rs35839762	ENSG00000281920.1	RP11-418H16.1	5.27	2.66e-06	0.00772	0.88	0.59	Sum eosinophil basophil counts;	chr2:65441318	chr2:65623272~65628424:+
UVM	cis	rs7569084	0.687	rs1437462	ENSG00000281920.1	RP11-418H16.1	5.27	2.66e-06	0.00772	0.88	0.59	Sum eosinophil basophil counts;	chr2:65449559	chr2:65623272~65628424:+
UVM	cis	rs7569084	0.663	rs1437461	ENSG00000281920.1	RP11-418H16.1	5.27	2.66e-06	0.00772	0.88	0.59	Sum eosinophil basophil counts;	chr2:65452578	chr2:65623272~65628424:+
UVM	cis	rs7569084	0.687	rs7562559	ENSG00000281920.1	RP11-418H16.1	5.27	2.66e-06	0.00772	0.88	0.59	Sum eosinophil basophil counts;	chr2:65452719	chr2:65623272~65628424:+
UVM	cis	rs7569084	0.687	rs1370394	ENSG00000281920.1	RP11-418H16.1	5.27	2.66e-06	0.00772	0.88	0.59	Sum eosinophil basophil counts;	chr2:65453176	chr2:65623272~65628424:+
UVM	cis	rs7569084	0.687	rs934731	ENSG00000281920.1	RP11-418H16.1	5.27	2.66e-06	0.00772	0.88	0.59	Sum eosinophil basophil counts;	chr2:65456353	chr2:65623272~65628424:+
UVM	cis	rs7569084	0.687	rs7577452	ENSG00000281920.1	RP11-418H16.1	5.27	2.66e-06	0.00772	0.88	0.59	Sum eosinophil basophil counts;	chr2:65456694	chr2:65623272~65628424:+
UVM	cis	rs7569084	0.64	rs11126039	ENSG00000281920.1	RP11-418H16.1	5.27	2.66e-06	0.00772	0.88	0.59	Sum eosinophil basophil counts;	chr2:65457953	chr2:65623272~65628424:+
UVM	cis	rs7569084	0.687	rs12614851	ENSG00000281920.1	RP11-418H16.1	5.27	2.66e-06	0.00772	0.88	0.59	Sum eosinophil basophil counts;	chr2:65458050	chr2:65623272~65628424:+
UVM	cis	rs7569084	0.687	rs1344891	ENSG00000281920.1	RP11-418H16.1	5.27	2.66e-06	0.00772	0.88	0.59	Sum eosinophil basophil counts;	chr2:65458890	chr2:65623272~65628424:+
UVM	cis	rs7569084	0.687	rs11675538	ENSG00000281920.1	RP11-418H16.1	5.27	2.66e-06	0.00772	0.88	0.59	Sum eosinophil basophil counts;	chr2:65459327	chr2:65623272~65628424:+
UVM	cis	rs1799949	0.587	rs1824890	ENSG00000198496.9	NBR2	-5.27	2.67e-06	0.00774	-0.78	-0.59	Menopause (age at onset);	chr17:43344536	chr17:43125610~43153671:+
UVM	cis	rs10262624	0.504	rs59865844	ENSG00000234286.1	AC006026.13	5.27	2.68e-06	0.00777	0.78	0.59	Schizophrenia;	chr7:23693421	chr7:23680195~23680786:-
UVM	cis	rs7615952	1	rs7615952	ENSG00000171084.14	FAM86JP	-5.27	2.69e-06	0.0078	-0.79	-0.59	Blood pressure (smoking interaction);	chr3:125930560	chr3:125916620~125930024:+
UVM	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	5.26	2.72e-06	0.00788	0.49	0.59	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	5.26	2.72e-06	0.00788	0.49	0.59	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	5.26	2.72e-06	0.00788	0.49	0.59	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	5.26	2.72e-06	0.00788	0.49	0.59	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	5.26	2.72e-06	0.00788	0.49	0.59	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	5.26	2.72e-06	0.00788	0.49	0.59	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	5.26	2.72e-06	0.00788	0.49	0.59	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	5.26	2.72e-06	0.00788	0.49	0.59	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
UVM	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	5.26	2.77e-06	0.00799	0.89	0.59	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
UVM	cis	rs11155671	0.53	rs2342770	ENSG00000268592.3	RAET1E-AS1	5.25	2.81e-06	0.00811	0.67	0.59	Testicular germ cell tumor;	chr6:149895549	chr6:149863494~149919507:+
UVM	cis	rs2283792	0.967	rs5755099	ENSG00000224086.5	LL22NC03-86G7.1	-5.25	2.87e-06	0.00827	-0.62	-0.59	Multiple sclerosis;	chr22:21770751	chr22:21938293~21977632:+
UVM	cis	rs2283792	1	rs5999515	ENSG00000224086.5	LL22NC03-86G7.1	5.25	2.9e-06	0.00831	0.62	0.59	Multiple sclerosis;	chr22:21790812	chr22:21938293~21977632:+
UVM	cis	rs2283792	1	rs5749986	ENSG00000224086.5	LL22NC03-86G7.1	5.25	2.9e-06	0.00831	0.62	0.59	Multiple sclerosis;	chr22:21803372	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.967	rs3810609	ENSG00000224086.5	LL22NC03-86G7.1	-5.25	2.9e-06	0.00831	-0.62	-0.59	Multiple sclerosis;	chr22:21758513	chr22:21938293~21977632:+
UVM	cis	rs2283792	1	rs6928	ENSG00000224086.5	LL22NC03-86G7.1	-5.25	2.9e-06	0.00831	-0.62	-0.59	Multiple sclerosis;	chr22:21760715	chr22:21938293~21977632:+
UVM	cis	rs2283792	1	rs2006893	ENSG00000224086.5	LL22NC03-86G7.1	-5.25	2.9e-06	0.00831	-0.62	-0.59	Multiple sclerosis;	chr22:21774389	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.967	rs743409	ENSG00000224086.5	LL22NC03-86G7.1	-5.25	2.9e-06	0.00831	-0.62	-0.59	Multiple sclerosis;	chr22:21774926	chr22:21938293~21977632:+
UVM	cis	rs2283792	1	rs2283792	ENSG00000224086.5	LL22NC03-86G7.1	-5.25	2.9e-06	0.00831	-0.62	-0.59	Multiple sclerosis;	chr22:21776836	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.967	rs11704205	ENSG00000224086.5	LL22NC03-86G7.1	-5.25	2.9e-06	0.00831	-0.62	-0.59	Multiple sclerosis;	chr22:21790964	chr22:21938293~21977632:+
UVM	cis	rs2283792	1	rs5999521	ENSG00000224086.5	LL22NC03-86G7.1	-5.25	2.9e-06	0.00831	-0.62	-0.59	Multiple sclerosis;	chr22:21792110	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.967	rs5999550	ENSG00000224086.5	LL22NC03-86G7.1	-5.25	2.9e-06	0.00831	-0.62	-0.59	Multiple sclerosis;	chr22:21796997	chr22:21938293~21977632:+
UVM	cis	rs2283792	1	rs2266967	ENSG00000224086.5	LL22NC03-86G7.1	-5.25	2.9e-06	0.00831	-0.62	-0.59	Multiple sclerosis;	chr22:21802500	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.967	rs5749998	ENSG00000224086.5	LL22NC03-86G7.1	-5.25	2.9e-06	0.00831	-0.62	-0.59	Multiple sclerosis;	chr22:21808085	chr22:21938293~21977632:+
UVM	cis	rs2283792	1	rs9607287	ENSG00000224086.5	LL22NC03-86G7.1	-5.25	2.9e-06	0.00831	-0.62	-0.59	Multiple sclerosis;	chr22:21809136	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.935	rs8141851	ENSG00000224086.5	LL22NC03-86G7.1	-5.25	2.9e-06	0.00831	-0.62	-0.59	Multiple sclerosis;	chr22:21812161	chr22:21938293~21977632:+
UVM	cis	rs2283792	1	rs3788332	ENSG00000224086.5	LL22NC03-86G7.1	-5.25	2.9e-06	0.00831	-0.62	-0.59	Multiple sclerosis;	chr22:21817278	chr22:21938293~21977632:+
UVM	cis	rs2283792	1	rs6518986	ENSG00000224086.5	LL22NC03-86G7.1	-5.25	2.9e-06	0.00831	-0.62	-0.59	Multiple sclerosis;	chr22:21831058	chr22:21938293~21977632:+
UVM	cis	rs2283792	1	rs1892846	ENSG00000224086.5	LL22NC03-86G7.1	-5.25	2.9e-06	0.00831	-0.62	-0.59	Multiple sclerosis;	chr22:21832190	chr22:21938293~21977632:+
UVM	cis	rs2283792	1	rs1892848	ENSG00000224086.5	LL22NC03-86G7.1	-5.25	2.9e-06	0.00831	-0.62	-0.59	Multiple sclerosis;	chr22:21832273	chr22:21938293~21977632:+
UVM	cis	rs2283792	1	rs5999750	ENSG00000224086.5	LL22NC03-86G7.1	-5.25	2.9e-06	0.00831	-0.62	-0.59	Multiple sclerosis;	chr22:21833720	chr22:21938293~21977632:+
UVM	cis	rs12237653	1	rs12237653	ENSG00000236404.7	VLDLR-AS1	5.25	2.9e-06	0.00833	0.92	0.59	Gambling;	chr9:2551654	chr9:2422702~2643359:-
UVM	cis	rs8135665	0.6	rs3952	ENSG00000233739.1	RP5-1039K5.13	5.25	2.91e-06	0.00834	0.87	0.59	Advanced age-related macular degeneration;Age-related macular degeneration;	chr22:38060591	chr22:38057180~38073940:-
UVM	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	5.24	2.91e-06	0.00835	0.82	0.59	Shingles;	chr7:38346957	chr7:38343894~38350022:-
UVM	cis	rs801193	0.742	rs9969300	ENSG00000226824.5	RP4-756H11.3	5.24	2.94e-06	0.00842	0.79	0.59	Aortic root size;	chr7:66316659	chr7:66654538~66669855:+
UVM	cis	rs7174755	0.772	rs75395345	ENSG00000260657.2	RP11-315D16.4	5.24	2.95e-06	0.00844	0.89	0.59	Major depressive disorder;	chr15:68081380	chr15:68267792~68277994:-
UVM	cis	rs2739330	0.791	rs4822458	ENSG00000250470.1	AP000351.3	5.24	2.96e-06	0.00844	0.82	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23976904~23977585:-
UVM	cis	rs7615952	0.611	rs2947646	ENSG00000171084.14	FAM86JP	-5.24	2.96e-06	0.00845	-0.92	-0.59	Blood pressure (smoking interaction);	chr3:125874759	chr3:125916620~125930024:+
UVM	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-5.24	2.97e-06	0.00846	-0.87	-0.59	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-5.24	2.97e-06	0.00846	-0.87	-0.59	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-5.24	2.97e-06	0.00846	-0.87	-0.59	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-5.24	2.97e-06	0.00846	-0.87	-0.59	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-5.24	2.97e-06	0.00846	-0.87	-0.59	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-5.24	2.97e-06	0.00846	-0.87	-0.59	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-5.24	2.97e-06	0.00846	-0.87	-0.59	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-5.24	2.97e-06	0.00846	-0.87	-0.59	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-5.24	2.97e-06	0.00846	-0.87	-0.59	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-5.24	2.97e-06	0.00846	-0.87	-0.59	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-5.24	2.97e-06	0.00846	-0.87	-0.59	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-5.24	2.97e-06	0.00846	-0.87	-0.59	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-5.24	2.97e-06	0.00846	-0.87	-0.59	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-5.24	2.97e-06	0.00846	-0.87	-0.59	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-5.24	2.97e-06	0.00846	-0.87	-0.59	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-5.24	2.97e-06	0.00846	-0.87	-0.59	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
UVM	cis	rs1858037	0.867	rs4671658	ENSG00000204929.10	AC074391.1	-5.24	2.98e-06	0.00847	-0.95	-0.59	Rheumatoid arthritis;	chr2:65334258	chr2:65436711~66084639:+
UVM	cis	rs7174755	0.743	rs4777035	ENSG00000260657.2	RP11-315D16.4	-5.23	3.09e-06	0.00878	-0.69	-0.59	Major depressive disorder;	chr15:68312831	chr15:68267792~68277994:-
UVM	cis	rs3091242	0.933	rs61775174	ENSG00000261349.1	RP3-465N24.5	5.22	3.16e-06	0.00895	0.59	0.59	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25266102~25267136:-
UVM	cis	rs3091242	0.933	rs34933589	ENSG00000261349.1	RP3-465N24.5	5.22	3.16e-06	0.00895	0.59	0.59	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25266102~25267136:-
UVM	cis	rs3750965	0.92	rs11828017	ENSG00000260895.1	RP11-554A11.7	5.22	3.2e-06	0.00904	0.86	0.59	Hair color;	chr11:69051149	chr11:69103493~69109094:+
UVM	cis	rs3750965	1	rs4930643	ENSG00000260895.1	RP11-554A11.7	5.22	3.2e-06	0.00904	0.86	0.59	Hair color;	chr11:69051468	chr11:69103493~69109094:+
UVM	cis	rs3750965	0.92	rs4930644	ENSG00000260895.1	RP11-554A11.7	5.22	3.2e-06	0.00904	0.86	0.59	Hair color;	chr11:69051629	chr11:69103493~69109094:+
UVM	cis	rs1799949	0.602	rs8176235	ENSG00000198496.9	NBR2	-5.22	3.2e-06	0.00905	-0.83	-0.59	Menopause (age at onset);	chr17:43067543	chr17:43125610~43153671:+
UVM	cis	rs11214589	0.747	rs10891537	ENSG00000270179.1	RP11-159N11.4	-5.21	3.24e-06	0.00915	-0.71	-0.59	Neuroticism;	chr11:113340648	chr11:113368478~113369117:+
UVM	cis	rs2739330	0.791	rs9612520	ENSG00000250470.1	AP000351.3	5.21	3.29e-06	0.00926	0.82	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23976904~23977585:-
UVM	cis	rs875971	0.564	rs313804	ENSG00000226824.5	RP4-756H11.3	-5.21	3.34e-06	0.00928	-0.8	-0.59	Aortic root size;	chr7:66049635	chr7:66654538~66669855:+
UVM	cis	rs875971	0.662	rs448725	ENSG00000226824.5	RP4-756H11.3	-5.21	3.34e-06	0.00928	-0.8	-0.59	Aortic root size;	chr7:66049641	chr7:66654538~66669855:+
UVM	cis	rs875971	0.658	rs432667	ENSG00000226824.5	RP4-756H11.3	-5.21	3.34e-06	0.00928	-0.8	-0.59	Aortic root size;	chr7:66049646	chr7:66654538~66669855:+
UVM	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-5.21	3.34e-06	0.00928	-0.8	-0.59	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
UVM	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-5.21	3.34e-06	0.00928	-0.8	-0.59	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
UVM	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-5.21	3.34e-06	0.00928	-0.8	-0.59	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
UVM	cis	rs2283792	1	rs5749806	ENSG00000224086.5	LL22NC03-86G7.1	-5.21	3.35e-06	0.00928	-0.62	-0.59	Multiple sclerosis;	chr22:21752329	chr22:21938293~21977632:+
UVM	cis	rs7174755	0.923	rs4777036	ENSG00000260657.2	RP11-315D16.4	-5.2	3.4e-06	0.00938	-0.73	-0.58	Major depressive disorder;	chr15:68313230	chr15:68267792~68277994:-
UVM	cis	rs5769765	0.955	rs1321	ENSG00000229409.1	RP11-494O16.3	-5.2	3.41e-06	0.00941	-0.89	-0.58	Schizophrenia;	chr22:49903787	chr22:49845929~49846090:+
UVM	cis	rs916888	0.531	rs183211	ENSG00000214401.4	KANSL1-AS1	5.2	3.41e-06	0.00942	1.01	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46193576~46196723:+
UVM	cis	rs916888	0.61	rs199438	ENSG00000214401.4	KANSL1-AS1	5.2	3.41e-06	0.00942	1.01	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46193576~46196723:+
UVM	cis	rs1823874	0.581	rs12910401	ENSG00000182397.13	DNM1P46	-5.19	3.53e-06	0.00971	-0.69	-0.58	IgG glycosylation;	chr15:99799692	chr15:99790156~99806927:-
UVM	cis	rs1823874	0.581	rs12905599	ENSG00000182397.13	DNM1P46	-5.19	3.53e-06	0.00971	-0.69	-0.58	IgG glycosylation;	chr15:99799733	chr15:99790156~99806927:-
UVM	cis	rs1823874	0.581	rs11855419	ENSG00000182397.13	DNM1P46	5.19	3.53e-06	0.00971	0.69	0.58	IgG glycosylation;	chr15:99787275	chr15:99790156~99806927:-
UVM	cis	rs1823874	0.581	rs9920347	ENSG00000182397.13	DNM1P46	5.19	3.53e-06	0.00971	0.69	0.58	IgG glycosylation;	chr15:99799126	chr15:99790156~99806927:-
UVM	cis	rs8072100	0.871	rs7206971	ENSG00000228782.6	CTD-2026D20.3	-5.19	3.55e-06	0.00978	-0.61	-0.58	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347749	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.934	rs6504872	ENSG00000228782.6	CTD-2026D20.3	5.19	3.55e-06	0.00978	0.61	0.58	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47361586	chr17:47450568~47492492:-
UVM	cis	rs5769765	0.817	rs8142561	ENSG00000229409.1	RP11-494O16.3	-5.18	3.6e-06	0.0099	-0.94	-0.58	Schizophrenia;	chr22:49898102	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.955	rs8138687	ENSG00000229409.1	RP11-494O16.3	-5.18	3.6e-06	0.0099	-0.94	-0.58	Schizophrenia;	chr22:49898221	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.837	rs8142737	ENSG00000229409.1	RP11-494O16.3	-5.18	3.6e-06	0.0099	-0.94	-0.58	Schizophrenia;	chr22:49898241	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.955	rs8135816	ENSG00000229409.1	RP11-494O16.3	-5.18	3.6e-06	0.0099	-0.94	-0.58	Schizophrenia;	chr22:49898328	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.818	rs8140681	ENSG00000229409.1	RP11-494O16.3	-5.18	3.6e-06	0.0099	-0.94	-0.58	Schizophrenia;	chr22:49898433	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.825	rs9616780	ENSG00000229409.1	RP11-494O16.3	-5.18	3.6e-06	0.0099	-0.94	-0.58	Schizophrenia;	chr22:49899115	chr22:49845929~49846090:+
UVM	cis	rs467650	0.517	rs469491	ENSG00000246763.5	RGMB-AS1	5.18	3.61e-06	0.00992	0.79	0.58	Venous thromboembolism (SNP x SNP interaction);	chr5:98599799	chr5:98769618~98773469:-
UVM	cis	rs467650	0.534	rs466366	ENSG00000246763.5	RGMB-AS1	5.18	3.61e-06	0.00992	0.79	0.58	Venous thromboembolism (SNP x SNP interaction);	chr5:98600506	chr5:98769618~98773469:-
UVM	cis	rs11098499	0.863	rs1010739	ENSG00000245958.5	RP11-33B1.1	-5.18	3.66e-06	0.01	-0.4	-0.58	Corneal astigmatism;	chr4:119542316	chr4:119454791~119552025:+
UVM	cis	rs916888	0.779	rs199526	ENSG00000214401.4	KANSL1-AS1	-5.17	3.77e-06	0.0103	-1.09	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46193576~46196723:+
UVM	cis	rs3091242	0.933	rs7541095	ENSG00000224183.1	SDHDP6	-5.17	3.79e-06	0.0104	-0.65	-0.58	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25294164~25294643:-
UVM	cis	rs8072100	0.817	rs9912101	ENSG00000228782.6	CTD-2026D20.3	5.17	3.85e-06	0.0105	0.61	0.58	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469712	chr17:47450568~47492492:-
UVM	cis	rs467650	0.5	rs13160853	ENSG00000246763.5	RGMB-AS1	-5.16	3.89e-06	0.0106	-0.79	-0.58	Venous thromboembolism (SNP x SNP interaction);	chr5:98585193	chr5:98769618~98773469:-
UVM	cis	rs9487094	0.626	rs1322124	ENSG00000260273.1	RP11-425D10.10	5.15	4e-06	0.0108	0.63	0.58	Height;	chr6:109741670	chr6:109382795~109383666:+
UVM	cis	rs2188561	0.697	rs739518	ENSG00000241764.3	AC002467.7	5.15	4.04e-06	0.0109	0.67	0.58	Alcohol consumption;	chr7:107743682	chr7:107742817~107744581:-
UVM	cis	rs2188561	0.697	rs3735606	ENSG00000241764.3	AC002467.7	5.15	4.04e-06	0.0109	0.67	0.58	Alcohol consumption;	chr7:107743864	chr7:107742817~107744581:-
UVM	cis	rs2188561	0.697	rs7782475	ENSG00000241764.3	AC002467.7	-5.15	4.04e-06	0.0109	-0.67	-0.58	Alcohol consumption;	chr7:107745806	chr7:107742817~107744581:-
UVM	cis	rs2188561	0.697	rs4730258	ENSG00000241764.3	AC002467.7	5.15	4.04e-06	0.0109	0.67	0.58	Alcohol consumption;	chr7:107755787	chr7:107742817~107744581:-
UVM	cis	rs2188561	0.697	rs7787927	ENSG00000241764.3	AC002467.7	5.15	4.04e-06	0.0109	0.67	0.58	Alcohol consumption;	chr7:107763915	chr7:107742817~107744581:-
UVM	cis	rs507080	0.769	rs11603616	ENSG00000255239.1	AP002954.6	5.15	4.12e-06	0.011	0.62	0.58	Serum metabolite levels;	chr11:118625350	chr11:118688039~118690600:-
UVM	cis	rs507080	0.769	rs571001	ENSG00000255239.1	AP002954.6	5.15	4.12e-06	0.011	0.62	0.58	Serum metabolite levels;	chr11:118629457	chr11:118688039~118690600:-
UVM	cis	rs507080	0.769	rs570952	ENSG00000255239.1	AP002954.6	5.15	4.12e-06	0.011	0.62	0.58	Serum metabolite levels;	chr11:118629477	chr11:118688039~118690600:-
UVM	cis	rs507080	0.769	rs645637	ENSG00000255239.1	AP002954.6	5.15	4.12e-06	0.011	0.62	0.58	Serum metabolite levels;	chr11:118634373	chr11:118688039~118690600:-
UVM	cis	rs507080	0.769	rs483283	ENSG00000255239.1	AP002954.6	5.15	4.12e-06	0.011	0.62	0.58	Serum metabolite levels;	chr11:118635684	chr11:118688039~118690600:-
UVM	cis	rs507080	0.769	rs570836	ENSG00000255239.1	AP002954.6	5.15	4.12e-06	0.011	0.62	0.58	Serum metabolite levels;	chr11:118641444	chr11:118688039~118690600:-
UVM	cis	rs507080	0.769	rs527290	ENSG00000255239.1	AP002954.6	5.15	4.12e-06	0.011	0.62	0.58	Serum metabolite levels;	chr11:118644898	chr11:118688039~118690600:-
UVM	cis	rs8135665	0.6	rs6519097	ENSG00000233739.1	RP5-1039K5.13	5.14	4.15e-06	0.0111	0.84	0.58	Advanced age-related macular degeneration;Age-related macular degeneration;	chr22:38055458	chr22:38057180~38073940:-
UVM	cis	rs8135665	0.6	rs737662	ENSG00000233739.1	RP5-1039K5.13	5.14	4.15e-06	0.0111	0.84	0.58	Advanced age-related macular degeneration;Age-related macular degeneration;	chr22:38056358	chr22:38057180~38073940:-
UVM	cis	rs8135665	0.6	rs3026682	ENSG00000233739.1	RP5-1039K5.13	5.14	4.15e-06	0.0111	0.84	0.58	Advanced age-related macular degeneration;Age-related macular degeneration;	chr22:38056475	chr22:38057180~38073940:-
UVM	cis	rs8135665	0.6	rs3948	ENSG00000233739.1	RP5-1039K5.13	5.14	4.15e-06	0.0111	0.84	0.58	Advanced age-related macular degeneration;Age-related macular degeneration;	chr22:38060673	chr22:38057180~38073940:-
UVM	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	5.14	4.19e-06	0.0112	0.63	0.58	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
UVM	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	5.14	4.19e-06	0.0112	0.63	0.58	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
UVM	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	5.14	4.19e-06	0.0112	0.63	0.58	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
UVM	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	5.14	4.19e-06	0.0112	0.63	0.58	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
UVM	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	5.14	4.19e-06	0.0112	0.63	0.58	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
UVM	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	5.14	4.19e-06	0.0112	0.63	0.58	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
UVM	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	5.14	4.19e-06	0.0112	0.63	0.58	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
UVM	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-5.14	4.19e-06	0.0112	-0.63	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
UVM	cis	rs1858037	0.867	rs6727013	ENSG00000204929.10	AC074391.1	5.14	4.2e-06	0.0112	0.94	0.58	Rheumatoid arthritis;	chr2:65331241	chr2:65436711~66084639:+
UVM	cis	rs1510272	0.515	rs2089735	ENSG00000243926.1	TIPARP-AS1	-5.14	4.2e-06	0.0112	-0.56	-0.58	Testicular germ cell tumor;	chr3:156624763	chr3:156671862~156674378:-
UVM	cis	rs11155671	0.53	rs9397420	ENSG00000268592.3	RAET1E-AS1	-5.14	4.26e-06	0.0113	-0.63	-0.58	Testicular germ cell tumor;	chr6:149885645	chr6:149863494~149919507:+
UVM	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	5.14	4.27e-06	0.0113	0.86	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
UVM	cis	rs9595066	1	rs4942281	ENSG00000227258.4	SMIM2-AS1	5.14	4.28e-06	0.0113	1.11	0.58	Schizophrenia;	chr13:44133990	chr13:44110451~44240517:+
UVM	cis	rs9595066	1	rs4942282	ENSG00000227258.4	SMIM2-AS1	5.14	4.28e-06	0.0113	1.11	0.58	Schizophrenia;	chr13:44134280	chr13:44110451~44240517:+
UVM	cis	rs9595066	1	rs7981575	ENSG00000227258.4	SMIM2-AS1	5.14	4.28e-06	0.0113	1.11	0.58	Schizophrenia;	chr13:44136811	chr13:44110451~44240517:+
UVM	cis	rs9595066	1	rs66786230	ENSG00000227258.4	SMIM2-AS1	5.14	4.28e-06	0.0113	1.11	0.58	Schizophrenia;	chr13:44137489	chr13:44110451~44240517:+
UVM	cis	rs7174755	0.608	rs10162905	ENSG00000260657.2	RP11-315D16.4	5.13	4.33e-06	0.0113	0.84	0.58	Major depressive disorder;	chr15:68103709	chr15:68267792~68277994:-
UVM	cis	rs7174755	0.608	rs62004789	ENSG00000260657.2	RP11-315D16.4	5.13	4.33e-06	0.0113	0.84	0.58	Major depressive disorder;	chr15:68148268	chr15:68267792~68277994:-
UVM	cis	rs7174755	0.637	rs113002386	ENSG00000260657.2	RP11-315D16.4	5.13	4.33e-06	0.0113	0.84	0.58	Major depressive disorder;	chr15:68172375	chr15:68267792~68277994:-
UVM	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	5.13	4.34e-06	0.0113	0.87	0.58	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.57	rs7118246	ENSG00000254682.1	RP11-660L16.2	5.13	4.34e-06	0.0113	0.87	0.58	Vitamin D levels;	chr11:71520078	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.65	rs7940244	ENSG00000254682.1	RP11-660L16.2	-5.13	4.34e-06	0.0113	-0.87	-0.58	Vitamin D levels;	chr11:71510528	chr11:71448674~71452157:+
UVM	cis	rs5769765	1	rs761879	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49847562	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.954	rs1569954	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49850423	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.954	rs5770707	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49850885	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.954	rs5770709	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49851548	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.778	rs4574208	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49863090	chr22:49845929~49846090:+
UVM	cis	rs5769765	1	rs5769760	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49866048	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.955	rs2295406	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49866521	chr22:49845929~49846090:+
UVM	cis	rs5769765	1	rs2295408	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49867403	chr22:49845929~49846090:+
UVM	cis	rs5769765	1	rs2295409	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49867412	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.955	rs8139758	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49867475	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.913	rs2319462	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49869722	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.955	rs5769761	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49869993	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.954	rs5769762	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49870394	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.908	rs2319464	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49872129	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.955	rs2319465	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49872136	chr22:49845929~49846090:+
UVM	cis	rs5769765	1	rs34774661	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49873860	chr22:49845929~49846090:+
UVM	cis	rs5769765	1	rs4824106	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49874174	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.954	rs5770739	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49874366	chr22:49845929~49846090:+
UVM	cis	rs5769765	1	rs5770741	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49876567	chr22:49845929~49846090:+
UVM	cis	rs5769765	1	rs5770742	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49876661	chr22:49845929~49846090:+
UVM	cis	rs5769765	1	rs4597652	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49876922	chr22:49845929~49846090:+
UVM	cis	rs5769765	1	rs5769764	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49877136	chr22:49845929~49846090:+
UVM	cis	rs5769765	1	rs5769765	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49877528	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.865	rs4824108	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49877780	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.908	rs4824109	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49877812	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.837	rs4824110	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49877983	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.74	rs2103932	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49878867	chr22:49845929~49846090:+
UVM	cis	rs5769765	1	rs8184990	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49879526	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.955	rs5770750	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49883180	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.955	rs5769767	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49883261	chr22:49845929~49846090:+
UVM	cis	rs5769765	1	rs910800	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49884994	chr22:49845929~49846090:+
UVM	cis	rs5769765	1	rs5770755	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49886488	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.874	rs4624	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49888269	chr22:49845929~49846090:+
UVM	cis	rs5769765	1	rs2092982	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49888556	chr22:49845929~49846090:+
UVM	cis	rs5769765	1	rs738711	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49888955	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.913	rs4824111	ENSG00000229409.1	RP11-494O16.3	5.13	4.35e-06	0.0113	0.92	0.58	Schizophrenia;	chr22:49890657	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.908	rs138889	ENSG00000229409.1	RP11-494O16.3	-5.13	4.35e-06	0.0113	-0.92	-0.58	Schizophrenia;	chr22:49833025	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.908	rs138891	ENSG00000229409.1	RP11-494O16.3	-5.13	4.35e-06	0.0113	-0.92	-0.58	Schizophrenia;	chr22:49834093	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.862	rs138897	ENSG00000229409.1	RP11-494O16.3	-5.13	4.35e-06	0.0113	-0.92	-0.58	Schizophrenia;	chr22:49837419	chr22:49845929~49846090:+
UVM	cis	rs5769765	1	rs2319458	ENSG00000229409.1	RP11-494O16.3	-5.13	4.35e-06	0.0113	-0.92	-0.58	Schizophrenia;	chr22:49842658	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.954	rs6009900	ENSG00000229409.1	RP11-494O16.3	-5.13	4.35e-06	0.0113	-0.92	-0.58	Schizophrenia;	chr22:49842962	chr22:49845929~49846090:+
UVM	cis	rs5769765	1	rs1033665	ENSG00000229409.1	RP11-494O16.3	-5.13	4.35e-06	0.0113	-0.92	-0.58	Schizophrenia;	chr22:49858479	chr22:49845929~49846090:+
UVM	cis	rs5769765	1	rs4824112	ENSG00000229409.1	RP11-494O16.3	-5.13	4.35e-06	0.0113	-0.92	-0.58	Schizophrenia;	chr22:49890697	chr22:49845929~49846090:+
UVM	cis	rs5769765	1	rs764813	ENSG00000229409.1	RP11-494O16.3	-5.13	4.35e-06	0.0113	-0.92	-0.58	Schizophrenia;	chr22:49892524	chr22:49845929~49846090:+
UVM	cis	rs5769765	1	rs768618	ENSG00000229409.1	RP11-494O16.3	-5.13	4.35e-06	0.0113	-0.92	-0.58	Schizophrenia;	chr22:49893179	chr22:49845929~49846090:+
UVM	cis	rs5769765	1	rs768619	ENSG00000229409.1	RP11-494O16.3	-5.13	4.35e-06	0.0113	-0.92	-0.58	Schizophrenia;	chr22:49893618	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.862	rs9616774	ENSG00000229409.1	RP11-494O16.3	-5.13	4.35e-06	0.0113	-0.92	-0.58	Schizophrenia;	chr22:49896951	chr22:49845929~49846090:+
UVM	cis	rs5769765	1	rs8138941	ENSG00000229409.1	RP11-494O16.3	-5.13	4.35e-06	0.0113	-0.92	-0.58	Schizophrenia;	chr22:49897030	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.955	rs6520066	ENSG00000229409.1	RP11-494O16.3	-5.13	4.35e-06	0.0113	-0.92	-0.58	Schizophrenia;	chr22:49901340	chr22:49845929~49846090:+
UVM	cis	rs1153858	1	rs4775911	ENSG00000259520.4	CTD-2651B20.3	5.13	4.37e-06	0.0113	0.86	0.58	Homoarginine levels;	chr15:45357589	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs3809472	ENSG00000259520.4	CTD-2651B20.3	-5.13	4.42e-06	0.0113	-0.86	-0.58	Homoarginine levels;	chr15:45402120	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs1820518	ENSG00000259520.4	CTD-2651B20.3	-5.13	4.42e-06	0.0113	-0.86	-0.58	Homoarginine levels;	chr15:45402381	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs1365610	ENSG00000259520.4	CTD-2651B20.3	-5.13	4.42e-06	0.0113	-0.86	-0.58	Homoarginine levels;	chr15:45402412	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs7402650	ENSG00000259520.4	CTD-2651B20.3	-5.13	4.42e-06	0.0113	-0.86	-0.58	Homoarginine levels;	chr15:45409697	chr15:45251580~45279251:-
UVM	cis	rs1153858	0.943	rs7402632	ENSG00000259520.4	CTD-2651B20.3	-5.13	4.42e-06	0.0113	-0.86	-0.58	Homoarginine levels;	chr15:45409715	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs8042786	ENSG00000259520.4	CTD-2651B20.3	-5.13	4.42e-06	0.0113	-0.86	-0.58	Homoarginine levels;	chr15:45411341	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs12440038	ENSG00000259520.4	CTD-2651B20.3	-5.13	4.42e-06	0.0113	-0.86	-0.58	Homoarginine levels;	chr15:45414541	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs2467858	ENSG00000259520.4	CTD-2651B20.3	-5.13	4.42e-06	0.0113	-0.86	-0.58	Homoarginine levels;	chr15:45419294	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs60476496	ENSG00000259520.4	CTD-2651B20.3	-5.13	4.42e-06	0.0113	-0.86	-0.58	Homoarginine levels;	chr15:45421603	chr15:45251580~45279251:-
UVM	cis	rs8072100	0.748	rs9908016	ENSG00000228782.6	CTD-2026D20.3	5.12	4.46e-06	0.0113	0.6	0.58	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47473995	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.782	rs28507314	ENSG00000228782.6	CTD-2026D20.3	5.12	4.46e-06	0.0113	0.6	0.58	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47474036	chr17:47450568~47492492:-
UVM	cis	rs2882667	0.858	rs11951899	ENSG00000253404.1	AC034243.1	5.12	4.52e-06	0.0114	0.72	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038621	chr5:138744434~138753309:-
UVM	cis	rs916888	0.61	rs199436	ENSG00000214401.4	KANSL1-AS1	-5.12	4.54e-06	0.0114	-0.99	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46193576~46196723:+
UVM	cis	rs916888	0.61	rs199454	ENSG00000214401.4	KANSL1-AS1	-5.12	4.54e-06	0.0114	-0.99	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46193576~46196723:+
UVM	cis	rs916888	0.61	rs199446	ENSG00000214401.4	KANSL1-AS1	-5.12	4.54e-06	0.0114	-0.99	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46193576~46196723:+
UVM	cis	rs916888	0.61	rs199536	ENSG00000214401.4	KANSL1-AS1	-5.12	4.54e-06	0.0114	-0.99	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46193576~46196723:+
UVM	cis	rs916888	0.61	rs199530	ENSG00000214401.4	KANSL1-AS1	-5.12	4.54e-06	0.0114	-0.99	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46193576~46196723:+
UVM	cis	rs916888	0.61	rs199453	ENSG00000214401.4	KANSL1-AS1	5.12	4.54e-06	0.0114	0.99	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46193576~46196723:+
UVM	cis	rs916888	0.647	rs199449	ENSG00000214401.4	KANSL1-AS1	5.12	4.54e-06	0.0114	0.99	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46193576~46196723:+
UVM	cis	rs916888	0.61	rs199444	ENSG00000214401.4	KANSL1-AS1	5.12	4.54e-06	0.0114	0.99	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46193576~46196723:+
UVM	cis	rs916888	0.61	rs199442	ENSG00000214401.4	KANSL1-AS1	5.12	4.54e-06	0.0114	0.99	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46193576~46196723:+
UVM	cis	rs8072100	0.745	rs7214410	ENSG00000228782.6	CTD-2026D20.3	5.12	4.58e-06	0.0116	0.59	0.58	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47345262	chr17:47450568~47492492:-
UVM	cis	rs1025688	1	rs8084255	ENSG00000267322.2	SNHG22	5.11	4.6e-06	0.0116	0.63	0.58	Neutrophil count;Sum basophil neutrophil counts;	chr18:50618384	chr18:49814023~49851059:+
UVM	cis	rs5769765	1	rs5770728	ENSG00000229409.1	RP11-494O16.3	5.11	4.65e-06	0.0117	0.91	0.58	Schizophrenia;	chr22:49866336	chr22:49845929~49846090:+
UVM	cis	rs9322193	0.884	rs880245	ENSG00000231760.4	RP11-350J20.5	-5.11	4.69e-06	0.0118	-0.75	-0.58	Lung cancer;	chr6:149846262	chr6:149796151~149826294:-
UVM	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	5.11	4.69e-06	0.0118	0.72	0.58	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
UVM	cis	rs7617773	0.851	rs13068288	ENSG00000229759.1	MRPS18AP1	5.1	4.79e-06	0.012	0.48	0.58	Coronary artery disease;	chr3:48290261	chr3:48256350~48256938:-
UVM	cis	rs1025688	1	rs1025687	ENSG00000267322.2	SNHG22	-5.1	4.82e-06	0.0121	-0.62	-0.58	Neutrophil count;Sum basophil neutrophil counts;	chr18:50621423	chr18:49814023~49851059:+
UVM	cis	rs1025688	1	rs1025688	ENSG00000267322.2	SNHG22	-5.1	4.82e-06	0.0121	-0.62	-0.58	Neutrophil count;Sum basophil neutrophil counts;	chr18:50621506	chr18:49814023~49851059:+
UVM	cis	rs1025688	1	rs2053248	ENSG00000267322.2	SNHG22	5.1	4.82e-06	0.0121	0.62	0.58	Neutrophil count;Sum basophil neutrophil counts;	chr18:50621825	chr18:49814023~49851059:+
UVM	cis	rs1025688	1	rs2053249	ENSG00000267322.2	SNHG22	5.1	4.82e-06	0.0121	0.62	0.58	Neutrophil count;Sum basophil neutrophil counts;	chr18:50621889	chr18:49814023~49851059:+
UVM	cis	rs1025688	1	rs9947760	ENSG00000267322.2	SNHG22	5.1	4.82e-06	0.0121	0.62	0.58	Neutrophil count;Sum basophil neutrophil counts;	chr18:50622371	chr18:49814023~49851059:+
UVM	cis	rs7195303	0.773	rs2325828	ENSG00000276408.1	RP11-490B18.5	-5.1	4.85e-06	0.0121	-1.37	-0.58	Crohn's disease (time to surgery);	chr16:75166098	chr16:75556392~75557059:+
UVM	cis	rs7195303	0.773	rs7188165	ENSG00000276408.1	RP11-490B18.5	5.1	4.85e-06	0.0121	1.37	0.58	Crohn's disease (time to surgery);	chr16:75164651	chr16:75556392~75557059:+
UVM	cis	rs7195303	0.773	rs2325829	ENSG00000276408.1	RP11-490B18.5	5.1	4.85e-06	0.0121	1.37	0.58	Crohn's disease (time to surgery);	chr16:75166004	chr16:75556392~75557059:+
UVM	cis	rs7195303	0.73	rs9929570	ENSG00000276408.1	RP11-490B18.5	5.1	4.85e-06	0.0121	1.37	0.58	Crohn's disease (time to surgery);	chr16:75166480	chr16:75556392~75557059:+
UVM	cis	rs7195303	0.73	rs7200789	ENSG00000276408.1	RP11-490B18.5	5.1	4.85e-06	0.0121	1.37	0.58	Crohn's disease (time to surgery);	chr16:75166518	chr16:75556392~75557059:+
UVM	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	5.1	4.86e-06	0.0121	0.47	0.58	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
UVM	cis	rs1040	0.646	rs6605528	ENSG00000226445.1	XXyac-YX65C7_A.2	5.1	4.89e-06	0.0121	0.62	0.58	Joint mobility (Beighton score);	chr6:169208712	chr6:169213254~169239565:+
UVM	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	5.09	4.94e-06	0.0122	0.64	0.58	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
UVM	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	5.09	4.94e-06	0.0122	0.64	0.58	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
UVM	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	5.09	4.94e-06	0.0122	0.64	0.58	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
UVM	cis	rs2283792	0.73	rs738858	ENSG00000224086.5	LL22NC03-86G7.1	-5.09	4.95e-06	0.0122	-0.64	-0.58	Multiple sclerosis;	chr22:21926544	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.73	rs2329884	ENSG00000224086.5	LL22NC03-86G7.1	-5.09	4.95e-06	0.0122	-0.64	-0.58	Multiple sclerosis;	chr22:21927890	chr22:21938293~21977632:+
UVM	cis	rs9322193	0.543	rs9371533	ENSG00000268592.3	RAET1E-AS1	5.09	5e-06	0.0122	0.65	0.58	Lung cancer;	chr6:149889545	chr6:149863494~149919507:+
UVM	cis	rs7615952	0.932	rs13065725	ENSG00000171084.14	FAM86JP	5.09	5.03e-06	0.0122	0.74	0.58	Blood pressure (smoking interaction);	chr3:125913446	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.8	rs11915699	ENSG00000171084.14	FAM86JP	5.09	5.03e-06	0.0122	0.74	0.58	Blood pressure (smoking interaction);	chr3:125913841	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.551	rs6438945	ENSG00000171084.14	FAM86JP	5.09	5.03e-06	0.0122	0.74	0.58	Blood pressure (smoking interaction);	chr3:125915630	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.673	rs7632557	ENSG00000171084.14	FAM86JP	5.09	5.03e-06	0.0122	0.74	0.58	Blood pressure (smoking interaction);	chr3:125916038	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.932	rs9841157	ENSG00000171084.14	FAM86JP	5.09	5.03e-06	0.0122	0.74	0.58	Blood pressure (smoking interaction);	chr3:125916812	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.551	rs12695470	ENSG00000171084.14	FAM86JP	5.09	5.03e-06	0.0122	0.74	0.58	Blood pressure (smoking interaction);	chr3:125916875	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.932	rs13325495	ENSG00000171084.14	FAM86JP	5.09	5.03e-06	0.0122	0.74	0.58	Blood pressure (smoking interaction);	chr3:125918573	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.8	rs2062773	ENSG00000171084.14	FAM86JP	5.09	5.03e-06	0.0122	0.74	0.58	Blood pressure (smoking interaction);	chr3:125920805	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.799	rs13315434	ENSG00000171084.14	FAM86JP	5.09	5.03e-06	0.0122	0.74	0.58	Blood pressure (smoking interaction);	chr3:125922551	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.736	rs11921945	ENSG00000171084.14	FAM86JP	5.09	5.03e-06	0.0122	0.74	0.58	Blood pressure (smoking interaction);	chr3:125924876	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.866	rs13063119	ENSG00000171084.14	FAM86JP	5.09	5.03e-06	0.0122	0.74	0.58	Blood pressure (smoking interaction);	chr3:125925004	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.736	rs13063122	ENSG00000171084.14	FAM86JP	5.09	5.03e-06	0.0122	0.74	0.58	Blood pressure (smoking interaction);	chr3:125925017	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.8	rs12489350	ENSG00000171084.14	FAM86JP	5.09	5.03e-06	0.0122	0.74	0.58	Blood pressure (smoking interaction);	chr3:125925273	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.741	rs13314845	ENSG00000171084.14	FAM86JP	5.09	5.03e-06	0.0122	0.74	0.58	Blood pressure (smoking interaction);	chr3:125925939	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.733	rs13314847	ENSG00000171084.14	FAM86JP	5.09	5.03e-06	0.0122	0.74	0.58	Blood pressure (smoking interaction);	chr3:125925945	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.932	rs13086087	ENSG00000171084.14	FAM86JP	5.09	5.03e-06	0.0122	0.74	0.58	Blood pressure (smoking interaction);	chr3:125927438	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.8	rs13086460	ENSG00000171084.14	FAM86JP	5.09	5.03e-06	0.0122	0.74	0.58	Blood pressure (smoking interaction);	chr3:125927574	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.866	rs1976459	ENSG00000171084.14	FAM86JP	5.09	5.03e-06	0.0122	0.74	0.58	Blood pressure (smoking interaction);	chr3:125928643	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.932	rs1976458	ENSG00000171084.14	FAM86JP	5.09	5.03e-06	0.0122	0.74	0.58	Blood pressure (smoking interaction);	chr3:125928669	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.673	rs3811677	ENSG00000171084.14	FAM86JP	5.09	5.03e-06	0.0122	0.74	0.58	Blood pressure (smoking interaction);	chr3:125929237	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.932	rs3811679	ENSG00000171084.14	FAM86JP	5.09	5.03e-06	0.0122	0.74	0.58	Blood pressure (smoking interaction);	chr3:125929440	chr3:125916620~125930024:+
UVM	cis	rs6991838	0.612	rs7842162	ENSG00000272010.1	CTD-3025N20.3	5.09	5.08e-06	0.0123	0.33	0.58	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65591850~65592472:-
UVM	cis	rs2149351	0.515	rs7870029	ENSG00000234782.3	TPT1P9	5.08	5.18e-06	0.0125	0.76	0.58	Neuroticism;Neuroticism (multi-trait analysis);	chr9:117740396	chr9:118082869~118083382:-
UVM	cis	rs2149351	0.515	rs1927888	ENSG00000234782.3	TPT1P9	5.08	5.18e-06	0.0125	0.76	0.58	Neuroticism;Neuroticism (multi-trait analysis);	chr9:117740530	chr9:118082869~118083382:-
UVM	cis	rs2882667	0.858	rs35812969	ENSG00000253404.1	AC034243.1	5.08	5.2e-06	0.0126	0.69	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041861	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.858	rs11242442	ENSG00000253404.1	AC034243.1	5.08	5.2e-06	0.0126	0.69	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044800	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.858	rs17207870	ENSG00000253404.1	AC034243.1	5.08	5.2e-06	0.0126	0.69	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139052048	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.858	rs11949916	ENSG00000253404.1	AC034243.1	5.08	5.2e-06	0.0126	0.69	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139060588	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	5.08	5.2e-06	0.0126	0.69	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
UVM	cis	rs12237653	1	rs1331455	ENSG00000236404.7	VLDLR-AS1	5.07	5.32e-06	0.0128	0.92	0.58	Gambling;	chr9:2557493	chr9:2422702~2643359:-
UVM	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	5.07	5.33e-06	0.0128	0.67	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
UVM	cis	rs9322193	0.504	rs7771014	ENSG00000268592.3	RAET1E-AS1	5.07	5.4e-06	0.013	0.63	0.58	Lung cancer;	chr6:149884310	chr6:149863494~149919507:+
UVM	cis	rs3091242	0.934	rs666686	ENSG00000224183.1	SDHDP6	-5.07	5.45e-06	0.0131	-0.63	-0.57	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25294164~25294643:-
UVM	cis	rs8072100	0.817	rs11869940	ENSG00000228782.6	CTD-2026D20.3	-5.07	5.48e-06	0.0131	-0.61	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47501069	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.967	rs62076549	ENSG00000228782.6	CTD-2026D20.3	-5.07	5.48e-06	0.0131	-0.61	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47502189	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.902	rs12051716	ENSG00000228782.6	CTD-2026D20.3	-5.07	5.48e-06	0.0131	-0.61	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505029	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.967	rs7221548	ENSG00000228782.6	CTD-2026D20.3	-5.07	5.48e-06	0.0131	-0.61	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505586	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.967	rs8074149	ENSG00000228782.6	CTD-2026D20.3	-5.07	5.48e-06	0.0131	-0.61	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47506009	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.967	rs4794058	ENSG00000228782.6	CTD-2026D20.3	-5.07	5.48e-06	0.0131	-0.61	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47519732	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.87	rs10432035	ENSG00000228782.6	CTD-2026D20.3	-5.07	5.48e-06	0.0131	-0.61	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47547547	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.935	rs8070759	ENSG00000228782.6	CTD-2026D20.3	-5.07	5.48e-06	0.0131	-0.61	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47561394	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.764	rs2644349	ENSG00000228782.6	CTD-2026D20.3	-5.07	5.48e-06	0.0131	-0.61	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47564377	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.875	rs9635762	ENSG00000228782.6	CTD-2026D20.3	-5.07	5.48e-06	0.0131	-0.61	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47571080	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.967	rs4793842	ENSG00000228782.6	CTD-2026D20.3	-5.07	5.48e-06	0.0131	-0.61	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47594140	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.967	rs8078880	ENSG00000228782.6	CTD-2026D20.3	-5.07	5.48e-06	0.0131	-0.61	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599160	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.967	rs8075411	ENSG00000228782.6	CTD-2026D20.3	-5.07	5.48e-06	0.0131	-0.61	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599394	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.701	rs10163469	ENSG00000228782.6	CTD-2026D20.3	-5.07	5.48e-06	0.0131	-0.61	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47610401	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.935	rs12943464	ENSG00000228782.6	CTD-2026D20.3	-5.07	5.48e-06	0.0131	-0.61	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47612985	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.967	rs3760370	ENSG00000228782.6	CTD-2026D20.3	-5.07	5.48e-06	0.0131	-0.61	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618466	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.935	rs4793978	ENSG00000228782.6	CTD-2026D20.3	-5.07	5.48e-06	0.0131	-0.61	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47620809	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.967	rs11079784	ENSG00000228782.6	CTD-2026D20.3	-5.07	5.48e-06	0.0131	-0.61	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47624914	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.967	rs11656855	ENSG00000228782.6	CTD-2026D20.3	-5.07	5.48e-06	0.0131	-0.61	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637289	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.967	rs11871606	ENSG00000228782.6	CTD-2026D20.3	-5.07	5.48e-06	0.0131	-0.61	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655408	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.967	rs7219303	ENSG00000228782.6	CTD-2026D20.3	-5.07	5.48e-06	0.0131	-0.61	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47660335	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.967	rs4289035	ENSG00000228782.6	CTD-2026D20.3	5.07	5.48e-06	0.0131	0.61	0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47629845	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.967	rs4794001	ENSG00000228782.6	CTD-2026D20.3	5.07	5.48e-06	0.0131	0.61	0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47643483	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.967	rs4239162	ENSG00000228782.6	CTD-2026D20.3	5.07	5.48e-06	0.0131	0.61	0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678444	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.967	rs4239163	ENSG00000228782.6	CTD-2026D20.3	5.07	5.48e-06	0.0131	0.61	0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678588	chr17:47450568~47492492:-
UVM	cis	rs7819412	0.811	rs2409691	ENSG00000255310.2	AF131215.2	-5.06	5.5e-06	0.0131	-0.49	-0.57	Triglycerides;	chr8:11085766	chr8:11107788~11109726:-
UVM	cis	rs1153858	1	rs16942000	ENSG00000259520.4	CTD-2651B20.3	-5.06	5.51e-06	0.0132	-0.84	-0.57	Homoarginine levels;	chr15:45340805	chr15:45251580~45279251:-
UVM	cis	rs1153858	0.945	rs7182300	ENSG00000259520.4	CTD-2651B20.3	-5.06	5.51e-06	0.0132	-0.84	-0.57	Homoarginine levels;	chr15:45342730	chr15:45251580~45279251:-
UVM	cis	rs1153858	0.887	rs7171163	ENSG00000259520.4	CTD-2651B20.3	-5.06	5.51e-06	0.0132	-0.84	-0.57	Homoarginine levels;	chr15:45344197	chr15:45251580~45279251:-
UVM	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-5.06	5.52e-06	0.0132	-0.59	-0.57	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
UVM	cis	rs5760092	0.755	rs915589	ENSG00000218537.1	MIF-AS1	-5.06	5.62e-06	0.0133	-0.93	-0.57	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23894426~23898930:-
UVM	cis	rs6003958	1	rs6003958	ENSG00000218537.1	MIF-AS1	-5.06	5.62e-06	0.0133	-0.93	-0.57	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23894426~23898930:-
UVM	cis	rs5760092	0.755	rs6003959	ENSG00000218537.1	MIF-AS1	-5.06	5.62e-06	0.0133	-0.93	-0.57	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23894426~23898930:-
UVM	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-5.06	5.64e-06	0.0134	-0.6	-0.57	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
UVM	cis	rs35058679	0.526	rs7995308	ENSG00000247400.3	DNAJC3-AS1	-5.06	5.64e-06	0.0134	-0.36	-0.57	Schizophrenia;	chr13:95510059	chr13:95648733~95676925:-
UVM	cis	rs35058679	0.526	rs2389354	ENSG00000247400.3	DNAJC3-AS1	-5.06	5.64e-06	0.0134	-0.36	-0.57	Schizophrenia;	chr13:95510205	chr13:95648733~95676925:-
UVM	cis	rs35058679	0.526	rs2389355	ENSG00000247400.3	DNAJC3-AS1	-5.06	5.64e-06	0.0134	-0.36	-0.57	Schizophrenia;	chr13:95510448	chr13:95648733~95676925:-
UVM	cis	rs35058679	0.526	rs980094	ENSG00000247400.3	DNAJC3-AS1	-5.06	5.64e-06	0.0134	-0.36	-0.57	Schizophrenia;	chr13:95510470	chr13:95648733~95676925:-
UVM	cis	rs35058679	0.526	rs9302077	ENSG00000247400.3	DNAJC3-AS1	-5.06	5.64e-06	0.0134	-0.36	-0.57	Schizophrenia;	chr13:95511134	chr13:95648733~95676925:-
UVM	cis	rs35058679	0.547	rs9561893	ENSG00000247400.3	DNAJC3-AS1	-5.06	5.64e-06	0.0134	-0.36	-0.57	Schizophrenia;	chr13:95517370	chr13:95648733~95676925:-
UVM	cis	rs35058679	0.526	rs9302078	ENSG00000247400.3	DNAJC3-AS1	-5.06	5.64e-06	0.0134	-0.36	-0.57	Schizophrenia;	chr13:95519685	chr13:95648733~95676925:-
UVM	cis	rs35058679	0.526	rs9302079	ENSG00000247400.3	DNAJC3-AS1	-5.06	5.64e-06	0.0134	-0.36	-0.57	Schizophrenia;	chr13:95519736	chr13:95648733~95676925:-
UVM	cis	rs35058679	0.526	rs9556484	ENSG00000247400.3	DNAJC3-AS1	-5.06	5.64e-06	0.0134	-0.36	-0.57	Schizophrenia;	chr13:95522203	chr13:95648733~95676925:-
UVM	cis	rs35058679	0.526	rs9556485	ENSG00000247400.3	DNAJC3-AS1	-5.06	5.64e-06	0.0134	-0.36	-0.57	Schizophrenia;	chr13:95522840	chr13:95648733~95676925:-
UVM	cis	rs35058679	0.526	rs9561895	ENSG00000247400.3	DNAJC3-AS1	-5.06	5.64e-06	0.0134	-0.36	-0.57	Schizophrenia;	chr13:95523141	chr13:95648733~95676925:-
UVM	cis	rs35058679	0.526	rs9590296	ENSG00000247400.3	DNAJC3-AS1	-5.06	5.64e-06	0.0134	-0.36	-0.57	Schizophrenia;	chr13:95528466	chr13:95648733~95676925:-
UVM	cis	rs35058679	0.526	rs9590298	ENSG00000247400.3	DNAJC3-AS1	-5.06	5.64e-06	0.0134	-0.36	-0.57	Schizophrenia;	chr13:95531649	chr13:95648733~95676925:-
UVM	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-5.06	5.65e-06	0.0134	-0.49	-0.57	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
UVM	cis	rs17711722	0.565	rs4275112	ENSG00000164669.11	INTS4P1	5.06	5.66e-06	0.0134	0.65	0.57	Calcium levels;	chr7:65733651	chr7:65141225~65234216:+
UVM	cis	rs17711722	0.522	rs4642526	ENSG00000164669.11	INTS4P1	-5.06	5.66e-06	0.0134	-0.65	-0.57	Calcium levels;	chr7:65751755	chr7:65141225~65234216:+
UVM	cis	rs11155671	0.53	rs9383577	ENSG00000268592.3	RAET1E-AS1	5.05	5.69e-06	0.0134	0.63	0.57	Testicular germ cell tumor;	chr6:149886059	chr6:149863494~149919507:+
UVM	cis	rs11155671	0.53	rs9383914	ENSG00000268592.3	RAET1E-AS1	5.05	5.69e-06	0.0134	0.63	0.57	Testicular germ cell tumor;	chr6:149886098	chr6:149863494~149919507:+
UVM	cis	rs11155671	0.517	rs9397058	ENSG00000268592.3	RAET1E-AS1	5.05	5.69e-06	0.0134	0.63	0.57	Testicular germ cell tumor;	chr6:149886113	chr6:149863494~149919507:+
UVM	cis	rs11155671	0.53	rs7768626	ENSG00000268592.3	RAET1E-AS1	5.05	5.69e-06	0.0134	0.63	0.57	Testicular germ cell tumor;	chr6:149886826	chr6:149863494~149919507:+
UVM	cis	rs11155671	0.53	rs7768665	ENSG00000268592.3	RAET1E-AS1	5.05	5.69e-06	0.0134	0.63	0.57	Testicular germ cell tumor;	chr6:149886888	chr6:149863494~149919507:+
UVM	cis	rs11155671	0.53	rs7758020	ENSG00000268592.3	RAET1E-AS1	5.05	5.69e-06	0.0134	0.63	0.57	Testicular germ cell tumor;	chr6:149886975	chr6:149863494~149919507:+
UVM	cis	rs11155671	0.53	rs7758033	ENSG00000268592.3	RAET1E-AS1	5.05	5.69e-06	0.0134	0.63	0.57	Testicular germ cell tumor;	chr6:149886999	chr6:149863494~149919507:+
UVM	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-5.05	5.7e-06	0.0135	-0.64	-0.57	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-5.05	5.7e-06	0.0135	-0.64	-0.57	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-5.05	5.7e-06	0.0135	-0.64	-0.57	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
UVM	cis	rs507080	0.501	rs625735	ENSG00000255239.1	AP002954.6	5.05	5.76e-06	0.0136	0.54	0.57	Serum metabolite levels;	chr11:118704710	chr11:118688039~118690600:-
UVM	cis	rs7174755	0.772	rs8025474	ENSG00000260657.2	RP11-315D16.4	5.05	5.81e-06	0.0137	0.87	0.57	Major depressive disorder;	chr15:68094185	chr15:68267792~68277994:-
UVM	cis	rs8072100	0.79	rs11079783	ENSG00000228782.6	CTD-2026D20.3	-5.04	5.97e-06	0.014	-0.6	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47608650	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.79	rs7222225	ENSG00000228782.6	CTD-2026D20.3	-5.04	5.97e-06	0.014	-0.6	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47616131	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.79	rs3760371	ENSG00000228782.6	CTD-2026D20.3	-5.04	5.97e-06	0.014	-0.6	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618548	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.79	rs34200664	ENSG00000228782.6	CTD-2026D20.3	-5.04	5.97e-06	0.014	-0.6	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47667286	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.79	rs11656856	ENSG00000228782.6	CTD-2026D20.3	-5.04	6.03e-06	0.0141	-0.6	-0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637305	chr17:47450568~47492492:-
UVM	cis	rs6570726	0.791	rs1509214	ENSG00000235652.6	RP11-545I5.3	-5.03	6.14e-06	0.0143	-0.52	-0.57	Lobe attachment (rater-scored or self-reported);	chr6:145463470	chr6:145799409~145886585:+
UVM	cis	rs8072100	0.79	rs1962307	ENSG00000228782.6	CTD-2026D20.3	5.03	6.17e-06	0.0143	0.6	0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47630505	chr17:47450568~47492492:-
UVM	cis	rs5760092	0.627	rs6519489	ENSG00000218537.1	MIF-AS1	-5.03	6.18e-06	0.0143	-0.92	-0.57	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23894426~23898930:-
UVM	cis	rs5760092	0.755	rs11090298	ENSG00000218537.1	MIF-AS1	-5.03	6.18e-06	0.0143	-0.92	-0.57	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23894426~23898930:-
UVM	cis	rs2283792	0.73	rs894095	ENSG00000224086.5	LL22NC03-86G7.1	-5.03	6.25e-06	0.0145	-0.64	-0.57	Multiple sclerosis;	chr22:21928404	chr22:21938293~21977632:+
UVM	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-5.03	6.28e-06	0.0145	-0.51	-0.57	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
UVM	cis	rs7772486	0.754	rs9390356	ENSG00000235652.6	RP11-545I5.3	-5.02	6.39e-06	0.0148	-0.53	-0.57	Lobe attachment (rater-scored or self-reported);	chr6:145797847	chr6:145799409~145886585:+
UVM	cis	rs916888	0.602	rs199508	ENSG00000214401.4	KANSL1-AS1	-5.02	6.47e-06	0.0149	-1.02	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781472	chr17:46193576~46196723:+
UVM	cis	rs7772486	0.686	rs9376961	ENSG00000235652.6	RP11-545I5.3	5.02	6.47e-06	0.0149	0.55	0.57	Lobe attachment (rater-scored or self-reported);	chr6:145727601	chr6:145799409~145886585:+
UVM	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	5.02	6.5e-06	0.015	0.49	0.57	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
UVM	cis	rs9399135	0.636	rs7749106	ENSG00000232876.1	CTA-212D2.2	-5.02	6.5e-06	0.015	-0.66	-0.57	Red blood cell count;	chr6:134947004	chr6:135055033~135060550:+
UVM	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-5.01	6.57e-06	0.0151	-0.63	-0.57	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
UVM	cis	rs4789452	0.573	rs312872	ENSG00000267065.2	CTD-2246P4.1	-5.01	6.6e-06	0.0152	-0.76	-0.57	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;	chr17:77371245	chr17:76799044~76807102:+
UVM	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	5.01	6.62e-06	0.0152	0.63	0.57	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-5.01	6.62e-06	0.0152	-0.63	-0.57	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
UVM	cis	rs3931020	0.548	rs17618340	ENSG00000272864.1	RP11-17E13.2	-5.01	6.66e-06	0.0153	-0.58	-0.57	Resistin levels;	chr1:74781933	chr1:74698769~74699333:-
UVM	cis	rs5769765	0.865	rs3788730	ENSG00000229409.1	RP11-494O16.3	5.01	6.67e-06	0.0153	0.93	0.57	Schizophrenia;	chr22:49851047	chr22:49845929~49846090:+
UVM	cis	rs11673344	0.75	rs78241494	ENSG00000226686.6	LINC01535	5.01	6.7e-06	0.0153	0.79	0.57	Obesity-related traits;	chr19:37158846	chr19:37251912~37265535:+
UVM	cis	rs11673344	0.838	rs111827672	ENSG00000226686.6	LINC01535	5.01	6.7e-06	0.0153	0.79	0.57	Obesity-related traits;	chr19:37158964	chr19:37251912~37265535:+
UVM	cis	rs11673344	0.636	rs7255595	ENSG00000226686.6	LINC01535	5.01	6.73e-06	0.0154	0.77	0.57	Obesity-related traits;	chr19:36896260	chr19:37251912~37265535:+
UVM	cis	rs7847628	0.765	rs10985024	ENSG00000226752.6	PSMD5-AS1	-5.01	6.77e-06	0.0154	-0.49	-0.57	Birth weight;	chr9:120754534	chr9:120824828~120854385:+
UVM	cis	rs2283792	0.73	rs2083565	ENSG00000224086.5	LL22NC03-86G7.1	-5	6.84e-06	0.0156	-0.63	-0.57	Multiple sclerosis;	chr22:21929985	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.73	rs2027790	ENSG00000224086.5	LL22NC03-86G7.1	-5	6.84e-06	0.0156	-0.63	-0.57	Multiple sclerosis;	chr22:21933592	chr22:21938293~21977632:+
UVM	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	5	6.92e-06	0.0157	0.49	0.57	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
UVM	cis	rs7847628	0.666	rs2031974	ENSG00000226752.6	PSMD5-AS1	-5	6.92e-06	0.0157	-0.49	-0.57	Birth weight;	chr9:120765243	chr9:120824828~120854385:+
UVM	cis	rs6570726	0.526	rs9403699	ENSG00000235652.6	RP11-545I5.3	5	6.93e-06	0.0157	0.64	0.57	Lobe attachment (rater-scored or self-reported);	chr6:145409549	chr6:145799409~145886585:+
UVM	cis	rs5769765	0.632	rs13056783	ENSG00000229409.1	RP11-494O16.3	5	6.96e-06	0.0158	0.91	0.57	Schizophrenia;	chr22:49865504	chr22:49845929~49846090:+
UVM	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-4.99	7.11e-06	0.0161	-0.63	-0.57	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
UVM	cis	rs916888	0.779	rs199498	ENSG00000214401.4	KANSL1-AS1	4.99	7.17e-06	0.0162	1.18	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46193576~46196723:+
UVM	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	4.99	7.19e-06	0.0162	0.65	0.57	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
UVM	cis	rs11673344	0.838	rs55856280	ENSG00000226686.6	LINC01535	4.99	7.23e-06	0.0163	0.79	0.57	Obesity-related traits;	chr19:37150747	chr19:37251912~37265535:+
UVM	cis	rs875971	0.545	rs1796222	ENSG00000226824.5	RP4-756H11.3	4.99	7.25e-06	0.0163	0.87	0.57	Aortic root size;	chr7:66592167	chr7:66654538~66669855:+
UVM	cis	rs12237653	0.929	rs10812227	ENSG00000236404.7	VLDLR-AS1	4.98	7.27e-06	0.0164	0.96	0.57	Gambling;	chr9:2548556	chr9:2422702~2643359:-
UVM	cis	rs11673344	0.838	rs112401881	ENSG00000226686.6	LINC01535	4.98	7.29e-06	0.0164	0.78	0.57	Obesity-related traits;	chr19:37156092	chr19:37251912~37265535:+
UVM	cis	rs997154	0.655	rs2008345	ENSG00000279656.1	RP11-298I3.6	4.97	7.52e-06	0.0169	0.81	0.57	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22932233	chr14:23023083~23024217:-
UVM	cis	rs8072100	0.748	rs9912592	ENSG00000228782.6	CTD-2026D20.3	4.97	7.53e-06	0.0169	0.6	0.57	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47479579	chr17:47450568~47492492:-
UVM	cis	rs1153858	0.945	rs1974981	ENSG00000259520.4	CTD-2651B20.3	4.97	7.71e-06	0.0173	0.83	0.57	Homoarginine levels;	chr15:45436925	chr15:45251580~45279251:-
UVM	cis	rs1153858	0.887	rs28569043	ENSG00000259520.4	CTD-2651B20.3	-4.97	7.71e-06	0.0173	-0.83	-0.57	Homoarginine levels;	chr15:45438728	chr15:45251580~45279251:-
UVM	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	4.97	7.73e-06	0.0173	0.47	0.57	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	4.97	7.73e-06	0.0173	0.47	0.57	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
UVM	cis	rs12439619	0.508	rs17354842	ENSG00000278603.1	RP13-608F4.5	-4.97	7.77e-06	0.0174	-0.68	-0.57	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82472203~82472426:+
UVM	cis	rs10771431	0.713	rs17794353	ENSG00000111788.10	RP11-22B23.1	-4.96	7.83e-06	0.0175	-0.49	-0.57	Breast size;	chr12:9209187	chr12:9277235~9313241:+
UVM	cis	rs10771431	0.738	rs11049697	ENSG00000111788.10	RP11-22B23.1	4.96	7.83e-06	0.0175	0.49	0.57	Breast size;	chr12:9232743	chr12:9277235~9313241:+
UVM	cis	rs12439619	0.508	rs8032033	ENSG00000278603.1	RP13-608F4.5	4.96	7.84e-06	0.0175	0.67	0.57	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472203~82472426:+
UVM	cis	rs6991838	0.584	rs7842085	ENSG00000272010.1	CTD-3025N20.3	4.96	7.87e-06	0.0176	0.33	0.57	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65591850~65592472:-
UVM	cis	rs5760092	0.755	rs4585126	ENSG00000218537.1	MIF-AS1	-4.96	7.91e-06	0.0177	-0.9	-0.57	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23894426~23898930:-
UVM	cis	rs1040	0.625	rs9505936	ENSG00000226445.1	XXyac-YX65C7_A.2	4.96	7.92e-06	0.0177	0.61	0.57	Joint mobility (Beighton score);	chr6:169211724	chr6:169213254~169239565:+
UVM	cis	rs1040	0.625	rs9505937	ENSG00000226445.1	XXyac-YX65C7_A.2	4.96	7.92e-06	0.0177	0.61	0.57	Joint mobility (Beighton score);	chr6:169211725	chr6:169213254~169239565:+
UVM	cis	rs1040	0.646	rs9505938	ENSG00000226445.1	XXyac-YX65C7_A.2	4.96	7.92e-06	0.0177	0.61	0.57	Joint mobility (Beighton score);	chr6:169211837	chr6:169213254~169239565:+
UVM	cis	rs7647973	0.925	rs6446257	ENSG00000223343.1	RP13-131K19.2	4.96	7.96e-06	0.0178	0.86	0.57	Menarche (age at onset);	chr3:49216059	chr3:48985049~48989988:-
UVM	cis	rs6570726	0.846	rs7773939	ENSG00000235652.6	RP11-545I5.3	-4.95	8.08e-06	0.018	-0.55	-0.57	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145799409~145886585:+
UVM	cis	rs11673344	0.801	rs17707446	ENSG00000226686.6	LINC01535	-4.95	8.13e-06	0.0181	-0.78	-0.57	Obesity-related traits;	chr19:37092140	chr19:37251912~37265535:+
UVM	cis	rs6991838	1	rs6991838	ENSG00000272010.1	CTD-3025N20.3	-4.94	8.38e-06	0.0186	-0.32	-0.57	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65591850~65592472:-
UVM	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	4.94	8.4e-06	0.0186	0.52	0.57	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
UVM	cis	rs12237653	0.929	rs10966858	ENSG00000236404.7	VLDLR-AS1	4.94	8.47e-06	0.0188	0.95	0.57	Gambling;	chr9:2541910	chr9:2422702~2643359:-
UVM	cis	rs12237653	0.929	rs13298979	ENSG00000236404.7	VLDLR-AS1	4.94	8.47e-06	0.0188	0.95	0.57	Gambling;	chr9:2543199	chr9:2422702~2643359:-
UVM	cis	rs12237653	0.929	rs13284385	ENSG00000236404.7	VLDLR-AS1	4.94	8.47e-06	0.0188	0.95	0.57	Gambling;	chr9:2544001	chr9:2422702~2643359:-
UVM	cis	rs12237653	0.929	rs10966874	ENSG00000236404.7	VLDLR-AS1	4.94	8.47e-06	0.0188	0.95	0.57	Gambling;	chr9:2545581	chr9:2422702~2643359:-
UVM	cis	rs12237653	0.929	rs12685652	ENSG00000236404.7	VLDLR-AS1	4.94	8.47e-06	0.0188	0.95	0.57	Gambling;	chr9:2546525	chr9:2422702~2643359:-
UVM	cis	rs12237653	0.929	rs4741731	ENSG00000236404.7	VLDLR-AS1	4.94	8.47e-06	0.0188	0.95	0.57	Gambling;	chr9:2547959	chr9:2422702~2643359:-
UVM	cis	rs12237653	0.929	rs4740695	ENSG00000236404.7	VLDLR-AS1	4.94	8.47e-06	0.0188	0.95	0.57	Gambling;	chr9:2547987	chr9:2422702~2643359:-
UVM	cis	rs12237653	0.929	rs4741732	ENSG00000236404.7	VLDLR-AS1	4.94	8.47e-06	0.0188	0.95	0.57	Gambling;	chr9:2548026	chr9:2422702~2643359:-
UVM	cis	rs12237653	0.929	rs4740696	ENSG00000236404.7	VLDLR-AS1	4.94	8.47e-06	0.0188	0.95	0.57	Gambling;	chr9:2548106	chr9:2422702~2643359:-
UVM	cis	rs9399135	0.66	rs9389248	ENSG00000232876.1	CTA-212D2.2	-4.94	8.59e-06	0.019	-0.63	-0.56	Red blood cell count;	chr6:134961518	chr6:135055033~135060550:+
UVM	cis	rs11098499	0.954	rs12502423	ENSG00000245958.5	RP11-33B1.1	-4.93	8.68e-06	0.0192	-0.38	-0.56	Corneal astigmatism;	chr4:119503017	chr4:119454791~119552025:+
UVM	cis	rs3091242	0.933	rs1534954	ENSG00000224183.1	SDHDP6	-4.93	8.7e-06	0.0192	-0.64	-0.56	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25294164~25294643:-
UVM	cis	rs72840196	0.597	rs77142204	ENSG00000226708.1	AC073409.1	4.93	8.91e-06	0.0196	0.87	0.56	Pediatric areal bone mineral density (radius);	chr2:123735716	chr2:123443266~123444445:-
UVM	cis	rs72840196	0.597	rs76099382	ENSG00000226708.1	AC073409.1	4.93	8.91e-06	0.0196	0.87	0.56	Pediatric areal bone mineral density (radius);	chr2:123738237	chr2:123443266~123444445:-
UVM	cis	rs997154	0.655	rs7147394	ENSG00000279656.1	RP11-298I3.6	4.93	8.92e-06	0.0196	0.81	0.56	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:23023083~23024217:-
UVM	cis	rs997154	0.655	rs4981454	ENSG00000279656.1	RP11-298I3.6	4.93	8.92e-06	0.0196	0.81	0.56	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22952977	chr14:23023083~23024217:-
UVM	cis	rs9399135	0.684	rs1135205	ENSG00000232876.1	CTA-212D2.2	-4.92	9.06e-06	0.0198	-0.63	-0.56	Red blood cell count;	chr6:134960657	chr6:135055033~135060550:+
UVM	cis	rs2749592	0.531	rs1208559	ENSG00000263064.2	RP11-291L22.7	-4.92	9.06e-06	0.0198	-0.73	-0.56	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:38448689~38448949:+
UVM	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-4.92	9.07e-06	0.0199	-0.63	-0.56	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
UVM	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	4.92	9.07e-06	0.0199	0.7	0.56	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
UVM	cis	rs9549328	0.878	rs9577407	ENSG00000267868.1	RP11-120K24.3	4.92	9.09e-06	0.0199	0.73	0.56	Systolic blood pressure;	chr13:112985357	chr13:112964835~112966131:-
UVM	cis	rs7569084	0.663	rs10190233	ENSG00000281920.1	RP11-418H16.1	-4.92	9.13e-06	0.02	-0.83	-0.56	Sum eosinophil basophil counts;	chr2:65413095	chr2:65623272~65628424:+
UVM	cis	rs8135665	0.6	rs3026685	ENSG00000233739.1	RP5-1039K5.13	4.92	9.19e-06	0.02	0.82	0.56	Advanced age-related macular degeneration;Age-related macular degeneration;	chr22:38066673	chr22:38057180~38073940:-
UVM	cis	rs7615952	1	rs9289275	ENSG00000171084.14	FAM86JP	4.92	9.22e-06	0.0201	0.74	0.56	Blood pressure (smoking interaction);	chr3:125929816	chr3:125916620~125930024:+
UVM	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-4.92	9.26e-06	0.0201	-0.63	-0.56	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
UVM	cis	rs9549328	0.8	rs9549326	ENSG00000267868.1	RP11-120K24.3	4.91	9.31e-06	0.0202	0.74	0.56	Systolic blood pressure;	chr13:112976139	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.8	rs9549619	ENSG00000267868.1	RP11-120K24.3	4.91	9.31e-06	0.0202	0.74	0.56	Systolic blood pressure;	chr13:112978306	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.8	rs9549620	ENSG00000267868.1	RP11-120K24.3	4.91	9.31e-06	0.0202	0.74	0.56	Systolic blood pressure;	chr13:112979107	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.8	rs9549621	ENSG00000267868.1	RP11-120K24.3	4.91	9.31e-06	0.0202	0.74	0.56	Systolic blood pressure;	chr13:112979265	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.842	rs6577024	ENSG00000267868.1	RP11-120K24.3	4.91	9.31e-06	0.0202	0.74	0.56	Systolic blood pressure;	chr13:112979777	chr13:112964835~112966131:-
UVM	cis	rs9549328	0.718	rs7139939	ENSG00000267868.1	RP11-120K24.3	4.91	9.31e-06	0.0202	0.74	0.56	Systolic blood pressure;	chr13:112980095	chr13:112964835~112966131:-
UVM	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-4.91	9.33e-06	0.0203	-0.61	-0.56	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
UVM	cis	rs35058679	0.526	rs4540944	ENSG00000247400.3	DNAJC3-AS1	4.91	9.36e-06	0.0203	0.36	0.56	Schizophrenia;	chr13:95529871	chr13:95648733~95676925:-
UVM	cis	rs12237653	0.929	rs10812238	ENSG00000236404.7	VLDLR-AS1	4.91	9.38e-06	0.0204	0.94	0.56	Gambling;	chr9:2551089	chr9:2422702~2643359:-
UVM	cis	rs4296977	0.516	rs58731747	ENSG00000213542.3	RP11-467H10.1	-4.91	9.46e-06	0.0205	-0.61	-0.56	Allergic disease (asthma, hay fever or eczema);	chr7:77306175	chr7:77115399~77116192:-
UVM	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	4.91	9.51e-06	0.0206	0.61	0.56	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
UVM	cis	rs17511627	0.591	rs2147561	ENSG00000235315.2	RPL23AP69	-4.91	9.52e-06	0.0206	-0.73	-0.56	Alzheimer's disease;	chr13:26069038	chr13:25206049~25206506:+
UVM	cis	rs8072100	0.764	rs4794371	ENSG00000228782.6	CTD-2026D20.3	-4.9	9.64e-06	0.0208	-0.58	-0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47550327	chr17:47450568~47492492:-
UVM	cis	rs3091242	0.933	rs11249250	ENSG00000224183.1	SDHDP6	-4.9	9.74e-06	0.021	-0.64	-0.56	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25294164~25294643:-
UVM	cis	rs2080501	0.628	rs1344530	ENSG00000279356.1	RP11-429P3.8	4.9	9.79e-06	0.0211	0.43	0.56	IgG glycosylation;	chr16:49631211	chr16:50072862~50074986:+
UVM	cis	rs875971	0.545	rs12670811	ENSG00000226824.5	RP4-756H11.3	-4.9	9.91e-06	0.0213	-0.86	-0.56	Aortic root size;	chr7:66358032	chr7:66654538~66669855:+
UVM	cis	rs3091242	0.933	rs10903129	ENSG00000224183.1	SDHDP6	-4.9	9.93e-06	0.0213	-0.61	-0.56	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25294164~25294643:-
UVM	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	4.89	1e-05	0.0215	0.52	0.56	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
UVM	cis	rs9595066	0.941	rs9533777	ENSG00000227258.4	SMIM2-AS1	-4.89	1.01e-05	0.0216	-1.08	-0.56	Schizophrenia;	chr13:44134584	chr13:44110451~44240517:+
UVM	cis	rs3091242	0.9	rs669063	ENSG00000224183.1	SDHDP6	-4.89	1.02e-05	0.0218	-0.58	-0.56	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25294164~25294643:-
UVM	cis	rs3091242	0.867	rs602052	ENSG00000224183.1	SDHDP6	-4.89	1.02e-05	0.0218	-0.58	-0.56	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25294164~25294643:-
UVM	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	4.89	1.02e-05	0.0218	0.6	0.56	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
UVM	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	4.89	1.02e-05	0.0218	0.6	0.56	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
UVM	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	4.89	1.02e-05	0.0218	0.6	0.56	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
UVM	cis	rs74054849	0.717	rs3856275	ENSG00000271742.1	RP4-680D5.9	-4.89	1.02e-05	0.0219	-1.16	-0.56	Alcoholic chronic pancreatitis;	chr1:15592181	chr1:15682873~15683128:-
UVM	cis	rs74054849	0.717	rs1547032	ENSG00000271742.1	RP4-680D5.9	4.89	1.02e-05	0.0219	1.16	0.56	Alcoholic chronic pancreatitis;	chr1:15592479	chr1:15682873~15683128:-
UVM	cis	rs74054849	0.717	rs61348093	ENSG00000271742.1	RP4-680D5.9	4.89	1.02e-05	0.0219	1.16	0.56	Alcoholic chronic pancreatitis;	chr1:15596247	chr1:15682873~15683128:-
UVM	cis	rs74054849	0.717	rs75387567	ENSG00000271742.1	RP4-680D5.9	4.89	1.02e-05	0.0219	1.16	0.56	Alcoholic chronic pancreatitis;	chr1:15599585	chr1:15682873~15683128:-
UVM	cis	rs74054849	0.717	rs74054799	ENSG00000271742.1	RP4-680D5.9	4.89	1.02e-05	0.0219	1.16	0.56	Alcoholic chronic pancreatitis;	chr1:15599855	chr1:15682873~15683128:-
UVM	cis	rs77808099	0.59	rs74654914	ENSG00000271742.1	RP4-680D5.9	4.89	1.02e-05	0.0219	1.16	0.56	Alcoholic chronic pancreatitis;	chr1:15609624	chr1:15682873~15683128:-
UVM	cis	rs74054849	0.717	rs80042126	ENSG00000271742.1	RP4-680D5.9	4.89	1.02e-05	0.0219	1.16	0.56	Alcoholic chronic pancreatitis;	chr1:15611613	chr1:15682873~15683128:-
UVM	cis	rs74054849	0.85	rs78132144	ENSG00000271742.1	RP4-680D5.9	4.89	1.02e-05	0.0219	1.16	0.56	Alcoholic chronic pancreatitis;	chr1:15613388	chr1:15682873~15683128:-
UVM	cis	rs74054849	0.571	rs77157441	ENSG00000271742.1	RP4-680D5.9	4.89	1.02e-05	0.0219	1.16	0.56	Alcoholic chronic pancreatitis;	chr1:15615013	chr1:15682873~15683128:-
UVM	cis	rs74054849	0.85	rs55764623	ENSG00000271742.1	RP4-680D5.9	4.89	1.02e-05	0.0219	1.16	0.56	Alcoholic chronic pancreatitis;	chr1:15627888	chr1:15682873~15683128:-
UVM	cis	rs74054849	0.85	rs16851878	ENSG00000271742.1	RP4-680D5.9	4.89	1.02e-05	0.0219	1.16	0.56	Alcoholic chronic pancreatitis;	chr1:15629115	chr1:15682873~15683128:-
UVM	cis	rs74054849	0.85	rs41270277	ENSG00000271742.1	RP4-680D5.9	4.89	1.02e-05	0.0219	1.16	0.56	Alcoholic chronic pancreatitis;	chr1:15633869	chr1:15682873~15683128:-
UVM	cis	rs74054849	0.85	rs75348249	ENSG00000271742.1	RP4-680D5.9	4.89	1.02e-05	0.0219	1.16	0.56	Alcoholic chronic pancreatitis;	chr1:15634769	chr1:15682873~15683128:-
UVM	cis	rs74054849	0.85	rs60513147	ENSG00000271742.1	RP4-680D5.9	4.89	1.02e-05	0.0219	1.16	0.56	Alcoholic chronic pancreatitis;	chr1:15636479	chr1:15682873~15683128:-
UVM	cis	rs74054849	0.85	rs76291985	ENSG00000271742.1	RP4-680D5.9	4.89	1.02e-05	0.0219	1.16	0.56	Alcoholic chronic pancreatitis;	chr1:15642262	chr1:15682873~15683128:-
UVM	cis	rs74054849	0.717	rs12240198	ENSG00000271742.1	RP4-680D5.9	4.89	1.02e-05	0.0219	1.16	0.56	Alcoholic chronic pancreatitis;	chr1:15645964	chr1:15682873~15683128:-
UVM	cis	rs74054849	0.85	rs113809420	ENSG00000271742.1	RP4-680D5.9	4.89	1.02e-05	0.0219	1.16	0.56	Alcoholic chronic pancreatitis;	chr1:15652334	chr1:15682873~15683128:-
UVM	cis	rs74054849	0.85	rs74707777	ENSG00000271742.1	RP4-680D5.9	4.89	1.02e-05	0.0219	1.16	0.56	Alcoholic chronic pancreatitis;	chr1:15653106	chr1:15682873~15683128:-
UVM	cis	rs74054849	0.85	rs79208691	ENSG00000271742.1	RP4-680D5.9	4.89	1.02e-05	0.0219	1.16	0.56	Alcoholic chronic pancreatitis;	chr1:15653319	chr1:15682873~15683128:-
UVM	cis	rs74054849	0.85	rs35001035	ENSG00000271742.1	RP4-680D5.9	4.89	1.02e-05	0.0219	1.16	0.56	Alcoholic chronic pancreatitis;	chr1:15655222	chr1:15682873~15683128:-
UVM	cis	rs494459	0.536	rs7103067	ENSG00000255239.1	AP002954.6	4.89	1.03e-05	0.0219	0.51	0.56	Height;	chr11:118852670	chr11:118688039~118690600:-
UVM	cis	rs494459	0.536	rs57719838	ENSG00000255239.1	AP002954.6	4.89	1.03e-05	0.0219	0.51	0.56	Height;	chr11:118854014	chr11:118688039~118690600:-
UVM	cis	rs494459	0.536	rs11217063	ENSG00000255239.1	AP002954.6	4.89	1.03e-05	0.0219	0.51	0.56	Height;	chr11:118855233	chr11:118688039~118690600:-
UVM	cis	rs494459	0.536	rs11217065	ENSG00000255239.1	AP002954.6	4.89	1.03e-05	0.0219	0.51	0.56	Height;	chr11:118855938	chr11:118688039~118690600:-
UVM	cis	rs494459	0.536	rs10790267	ENSG00000255239.1	AP002954.6	4.89	1.03e-05	0.0219	0.51	0.56	Height;	chr11:118856460	chr11:118688039~118690600:-
UVM	cis	rs494459	0.536	rs11217067	ENSG00000255239.1	AP002954.6	4.89	1.03e-05	0.0219	0.51	0.56	Height;	chr11:118856623	chr11:118688039~118690600:-
UVM	cis	rs2510897	0.675	rs4936442	ENSG00000255239.1	AP002954.6	4.89	1.03e-05	0.0219	0.51	0.56	Height;	chr11:118857611	chr11:118688039~118690600:-
UVM	cis	rs494459	0.504	rs7929520	ENSG00000255239.1	AP002954.6	4.89	1.03e-05	0.0219	0.51	0.56	Height;	chr11:118859432	chr11:118688039~118690600:-
UVM	cis	rs57368286	1	rs57368286	ENSG00000281920.1	RP11-418H16.1	-4.88	1.03e-05	0.022	-0.88	-0.56	Granulocyte percentage of myeloid white cells;	chr2:65415453	chr2:65623272~65628424:+
UVM	cis	rs4963124	0.962	rs11246306	ENSG00000279672.1	CMB9-55F22.1	4.88	1.05e-05	0.0222	0.57	0.56	Proteinuria and chronic kidney disease;	chr11:761525	chr11:779617~780755:+
UVM	cis	rs5769707	0.777	rs739243	ENSG00000272821.1	CTA-384D8.36	4.88	1.05e-05	0.0222	0.61	0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49663563	chr22:50523926~50524780:+
UVM	cis	rs5769707	0.749	rs7286706	ENSG00000272821.1	CTA-384D8.36	4.88	1.05e-05	0.0222	0.61	0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49664698	chr22:50523926~50524780:+
UVM	cis	rs2283792	0.691	rs11913721	ENSG00000224086.5	LL22NC03-86G7.1	-4.88	1.05e-05	0.0223	-0.65	-0.56	Multiple sclerosis;	chr22:21855846	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.715	rs56036797	ENSG00000224086.5	LL22NC03-86G7.1	-4.88	1.05e-05	0.0223	-0.65	-0.56	Multiple sclerosis;	chr22:21860875	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.74	rs11912377	ENSG00000224086.5	LL22NC03-86G7.1	-4.88	1.05e-05	0.0223	-0.65	-0.56	Multiple sclerosis;	chr22:21864332	chr22:21938293~21977632:+
UVM	cis	rs7772486	0.754	rs697054	ENSG00000235652.6	RP11-545I5.3	4.88	1.05e-05	0.0223	0.52	0.56	Lobe attachment (rater-scored or self-reported);	chr6:145682634	chr6:145799409~145886585:+
UVM	cis	rs6142618	0.811	rs6058597	ENSG00000230613.1	HM13-AS1	-4.87	1.09e-05	0.023	-0.88	-0.56	Inflammatory bowel disease;	chr20:32254836	chr20:31567707~31573263:-
UVM	cis	rs2919917	1	rs1384804	ENSG00000254352.1	RP11-578O24.2	4.87	1.09e-05	0.023	0.41	0.56	Lymphocyte counts;	chr8:78659987	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs10093654	ENSG00000254352.1	RP11-578O24.2	4.87	1.09e-05	0.023	0.41	0.56	Lymphocyte counts;	chr8:78660360	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs10093797	ENSG00000254352.1	RP11-578O24.2	4.87	1.09e-05	0.023	0.41	0.56	Lymphocyte counts;	chr8:78660478	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs1021156	ENSG00000254352.1	RP11-578O24.2	4.87	1.09e-05	0.023	0.41	0.56	Lymphocyte counts;	chr8:78663569	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs3808619	ENSG00000254352.1	RP11-578O24.2	4.87	1.09e-05	0.023	0.41	0.56	Lymphocyte counts;	chr8:78665491	chr8:78723796~78724136:-
UVM	cis	rs6918152	0.738	rs9378896	ENSG00000230433.1	RP1-20B11.2	-4.87	1.09e-05	0.0231	-0.62	-0.56	Black vs. red hair color;Black vs. blond hair color;	chr6:521147	chr6:524171~525581:+
UVM	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-4.87	1.09e-05	0.0231	-0.79	-0.56	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
UVM	cis	rs12506630	0.563	rs66506011	ENSG00000226950.5	DANCR	4.86	1.1e-05	0.0233	0.58	0.56	Breast cancer;	chr4:53118817	chr4:52712404~52720351:+
UVM	cis	rs12439619	0.53	rs7162177	ENSG00000278603.1	RP13-608F4.5	4.86	1.1e-05	0.0233	0.66	0.56	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472203~82472426:+
UVM	cis	rs12439619	0.508	rs8042665	ENSG00000278603.1	RP13-608F4.5	4.86	1.1e-05	0.0233	0.66	0.56	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472203~82472426:+
UVM	cis	rs12439619	0.508	rs8023960	ENSG00000278603.1	RP13-608F4.5	4.86	1.1e-05	0.0233	0.66	0.56	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472203~82472426:+
UVM	cis	rs12439619	0.53	rs28883606	ENSG00000278603.1	RP13-608F4.5	4.86	1.11e-05	0.0235	0.65	0.56	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472203~82472426:+
UVM	cis	rs12439619	0.693	rs28665836	ENSG00000278603.1	RP13-608F4.5	4.86	1.11e-05	0.0235	0.65	0.56	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472203~82472426:+
UVM	cis	rs10262624	0.528	rs5029444	ENSG00000234286.1	AC006026.13	4.86	1.11e-05	0.0235	0.72	0.56	Schizophrenia;	chr7:23698176	chr7:23680195~23680786:-
UVM	cis	rs1040	0.646	rs7450201	ENSG00000226445.1	XXyac-YX65C7_A.2	4.86	1.12e-05	0.0235	0.59	0.56	Joint mobility (Beighton score);	chr6:169205497	chr6:169213254~169239565:+
UVM	cis	rs1153858	1	rs11852800	ENSG00000259520.4	CTD-2651B20.3	4.86	1.12e-05	0.0235	0.83	0.56	Homoarginine levels;	chr15:45346933	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs2467864	ENSG00000259520.4	CTD-2651B20.3	4.86	1.12e-05	0.0235	0.83	0.56	Homoarginine levels;	chr15:45348900	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs9783731	ENSG00000259520.4	CTD-2651B20.3	4.86	1.12e-05	0.0235	0.83	0.56	Homoarginine levels;	chr15:45350686	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs1153858	ENSG00000259520.4	CTD-2651B20.3	4.86	1.12e-05	0.0235	0.83	0.56	Homoarginine levels;	chr15:45360505	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs12439274	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45344469	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs56669689	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45345531	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs56806728	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45345616	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs4775906	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45346096	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs7179743	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45346133	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs4775907	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45346449	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs7163720	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45347176	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs7167900	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45347273	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs12591058	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45347974	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs7169818	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45347993	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs7169587	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45348181	chr15:45251580~45279251:-
UVM	cis	rs1153858	0.943	rs28605551	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45349522	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs2467863	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45349682	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs4775909	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45350844	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs2453541	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45353180	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs2461702	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45355229	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs1145091	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45357798	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs1049508	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45361394	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs1145085	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45365606	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs1288775	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45369480	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs1145081	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45387469	chr15:45251580~45279251:-
UVM	cis	rs1153858	0.943	rs1145079	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45389563	chr15:45251580~45279251:-
UVM	cis	rs1153858	0.832	rs1145078	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45390079	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs1346266	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45402318	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs1153849	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45403497	chr15:45251580~45279251:-
UVM	cis	rs1153858	0.945	rs2467854	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45409399	chr15:45251580~45279251:-
UVM	cis	rs1153858	1	rs2461701	ENSG00000259520.4	CTD-2651B20.3	-4.86	1.12e-05	0.0235	-0.83	-0.56	Homoarginine levels;	chr15:45411193	chr15:45251580~45279251:-
UVM	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-4.86	1.13e-05	0.0236	-0.61	-0.56	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
UVM	cis	rs1858037	0.867	rs871974	ENSG00000204929.10	AC074391.1	-4.86	1.13e-05	0.0236	-0.95	-0.56	Rheumatoid arthritis;	chr2:65330153	chr2:65436711~66084639:+
UVM	cis	rs617219	0.591	rs1840805	ENSG00000213757.3	CTC-451P13.1	-4.86	1.14e-05	0.0238	-0.6	-0.56	Betaine levels in individuals undergoing cardiac evaluation;	chr5:79269740	chr5:79284132~79284918:-
UVM	cis	rs7829975	0.582	rs448231	ENSG00000248538.5	RP11-10A14.5	4.85	1.16e-05	0.0242	0.54	0.56	Mood instability;	chr8:8932549	chr8:9189011~9202854:+
UVM	cis	rs4963124	0.924	rs7478765	ENSG00000279672.1	CMB9-55F22.1	4.85	1.17e-05	0.0243	0.55	0.56	Proteinuria and chronic kidney disease;	chr11:752059	chr11:779617~780755:+
UVM	cis	rs3091242	0.809	rs660129	ENSG00000224183.1	SDHDP6	-4.85	1.17e-05	0.0243	-0.58	-0.56	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25294164~25294643:-
UVM	cis	rs3091242	0.728	rs706845	ENSG00000224183.1	SDHDP6	-4.85	1.17e-05	0.0243	-0.58	-0.56	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25294164~25294643:-
UVM	cis	rs3091242	0.9	rs1883427	ENSG00000224183.1	SDHDP6	-4.85	1.17e-05	0.0243	-0.58	-0.56	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25294164~25294643:-
UVM	cis	rs55794721	0.509	rs2982358	ENSG00000224183.1	SDHDP6	-4.85	1.17e-05	0.0243	-0.58	-0.56	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25294164~25294643:-
UVM	cis	rs55794721	0.509	rs2375313	ENSG00000224183.1	SDHDP6	-4.85	1.17e-05	0.0243	-0.58	-0.56	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25294164~25294643:-
UVM	cis	rs5769765	0.773	rs9616751	ENSG00000229409.1	RP11-494O16.3	-4.84	1.19e-05	0.0246	-0.88	-0.56	Schizophrenia;	chr22:49828588	chr22:49845929~49846090:+
UVM	cis	rs9487094	0.626	rs12204548	ENSG00000260273.1	RP11-425D10.10	4.84	1.19e-05	0.0246	0.62	0.56	Height;	chr6:109715504	chr6:109382795~109383666:+
UVM	cis	rs9487094	0.626	rs3799849	ENSG00000260273.1	RP11-425D10.10	4.84	1.19e-05	0.0246	0.62	0.56	Height;	chr6:109715560	chr6:109382795~109383666:+
UVM	cis	rs2749592	0.513	rs1208708	ENSG00000263064.2	RP11-291L22.7	4.84	1.21e-05	0.0251	0.74	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:38448689~38448949:+
UVM	cis	rs10751647	0.804	rs3809112	ENSG00000251661.3	RP11-326C3.11	-4.84	1.22e-05	0.0252	-0.58	-0.56	Monocyte count;	chr11:307036	chr11:318640~325631:+
UVM	cis	rs6026584	0.931	rs6026580	ENSG00000270951.1	RP1-309F20.4	-4.84	1.22e-05	0.0253	-0.61	-0.56	Renal function-related traits (BUN);	chr20:58893095	chr20:58876592~58876981:-
UVM	cis	rs2283792	0.73	rs56398890	ENSG00000224086.5	LL22NC03-86G7.1	-4.84	1.22e-05	0.0253	-0.63	-0.56	Multiple sclerosis;	chr22:21836496	chr22:21938293~21977632:+
UVM	cis	rs9549328	0.879	rs12428058	ENSG00000267868.1	RP11-120K24.3	4.83	1.22e-05	0.0253	0.71	0.56	Systolic blood pressure;	chr13:112982190	chr13:112964835~112966131:-
UVM	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	4.83	1.23e-05	0.0255	0.6	0.56	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
UVM	cis	rs11098499	0.913	rs67073020	ENSG00000245958.5	RP11-33B1.1	-4.83	1.23e-05	0.0255	-0.36	-0.56	Corneal astigmatism;	chr4:119231402	chr4:119454791~119552025:+
UVM	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-4.83	1.23e-05	0.0255	-0.62	-0.56	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-4.83	1.23e-05	0.0255	-0.62	-0.56	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-4.83	1.23e-05	0.0255	-0.62	-0.56	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs4895434	ENSG00000232876.1	CTA-212D2.2	-4.83	1.23e-05	0.0255	-0.62	-0.56	Red blood cell count;	chr6:134972227	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-4.83	1.23e-05	0.0255	-0.62	-0.56	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
UVM	cis	rs9399135	1	rs4895435	ENSG00000232876.1	CTA-212D2.2	-4.83	1.23e-05	0.0255	-0.62	-0.56	Red blood cell count;	chr6:134972325	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs4896120	ENSG00000232876.1	CTA-212D2.2	-4.83	1.23e-05	0.0255	-0.62	-0.56	Red blood cell count;	chr6:134972374	chr6:135055033~135060550:+
UVM	cis	rs3091242	0.933	rs28633797	ENSG00000224183.1	SDHDP6	-4.83	1.24e-05	0.0255	-0.58	-0.56	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25294164~25294643:-
UVM	cis	rs875971	0.545	rs73378304	ENSG00000226824.5	RP4-756H11.3	-4.83	1.24e-05	0.0256	-0.86	-0.56	Aortic root size;	chr7:66175760	chr7:66654538~66669855:+
UVM	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-4.83	1.25e-05	0.0257	-0.55	-0.56	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
UVM	cis	rs7615952	0.673	rs9821905	ENSG00000171084.14	FAM86JP	-4.83	1.26e-05	0.0259	-0.85	-0.56	Blood pressure (smoking interaction);	chr3:125902007	chr3:125916620~125930024:+
UVM	cis	rs9487094	0.626	rs11153215	ENSG00000260273.1	RP11-425D10.10	4.83	1.26e-05	0.0259	0.62	0.56	Height;	chr6:109732518	chr6:109382795~109383666:+
UVM	cis	rs10751647	0.767	rs4758639	ENSG00000251661.3	RP11-326C3.11	4.83	1.26e-05	0.026	0.59	0.56	Monocyte count;	chr11:305406	chr11:318640~325631:+
UVM	cis	rs9487094	0.626	rs3799845	ENSG00000260273.1	RP11-425D10.10	4.82	1.28e-05	0.0263	0.61	0.56	Height;	chr6:109706514	chr6:109382795~109383666:+
UVM	cis	rs3091242	0.933	rs28530483	ENSG00000224183.1	SDHDP6	-4.82	1.29e-05	0.0264	-0.57	-0.56	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25294164~25294643:-
UVM	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-4.82	1.29e-05	0.0264	-0.92	-0.56	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-4.82	1.29e-05	0.0264	-0.92	-0.56	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-4.82	1.29e-05	0.0264	-0.92	-0.56	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
UVM	cis	rs2283792	1	rs3810610	ENSG00000224086.5	LL22NC03-86G7.1	-4.82	1.3e-05	0.0266	-0.59	-0.56	Multiple sclerosis;	chr22:21761209	chr22:21938293~21977632:+
UVM	cis	rs2283792	1	rs13943	ENSG00000224086.5	LL22NC03-86G7.1	-4.82	1.3e-05	0.0266	-0.59	-0.56	Multiple sclerosis;	chr22:21761913	chr22:21938293~21977632:+
UVM	cis	rs11155671	0.53	rs9383912	ENSG00000268592.3	RAET1E-AS1	4.82	1.3e-05	0.0267	0.62	0.56	Testicular germ cell tumor;	chr6:149885479	chr6:149863494~149919507:+
UVM	cis	rs11148252	0.532	rs9536185	ENSG00000235660.1	LINC00345	-4.82	1.31e-05	0.0268	-0.64	-0.56	Lewy body disease;	chr13:52605666	chr13:52484161~52484680:-
UVM	cis	rs11148252	0.532	rs9536190	ENSG00000235660.1	LINC00345	-4.82	1.31e-05	0.0268	-0.64	-0.56	Lewy body disease;	chr13:52606909	chr13:52484161~52484680:-
UVM	cis	rs11155671	0.53	rs9383940	ENSG00000268592.3	RAET1E-AS1	4.81	1.32e-05	0.0269	0.65	0.56	Testicular germ cell tumor;	chr6:149904923	chr6:149863494~149919507:+
UVM	cis	rs8072100	0.512	rs9303533	ENSG00000228782.6	CTD-2026D20.3	4.81	1.32e-05	0.0269	0.61	0.56	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309174	chr17:47450568~47492492:-
UVM	cis	rs7772486	0.754	rs9497419	ENSG00000235652.6	RP11-545I5.3	4.81	1.32e-05	0.0269	0.51	0.56	Lobe attachment (rater-scored or self-reported);	chr6:145821473	chr6:145799409~145886585:+
UVM	cis	rs7772486	0.754	rs6921073	ENSG00000235652.6	RP11-545I5.3	4.81	1.32e-05	0.0269	0.51	0.56	Lobe attachment (rater-scored or self-reported);	chr6:145823241	chr6:145799409~145886585:+
UVM	cis	rs7772486	0.754	rs9386134	ENSG00000235652.6	RP11-545I5.3	4.81	1.32e-05	0.0269	0.51	0.56	Lobe attachment (rater-scored or self-reported);	chr6:145824372	chr6:145799409~145886585:+
UVM	cis	rs7772486	0.754	rs9390358	ENSG00000235652.6	RP11-545I5.3	4.81	1.32e-05	0.0269	0.51	0.56	Lobe attachment (rater-scored or self-reported);	chr6:145824542	chr6:145799409~145886585:+
UVM	cis	rs7772486	0.727	rs12190966	ENSG00000235652.6	RP11-545I5.3	4.81	1.32e-05	0.0269	0.51	0.56	Lobe attachment (rater-scored or self-reported);	chr6:145825684	chr6:145799409~145886585:+
UVM	cis	rs11098499	0.954	rs2389802	ENSG00000245958.5	RP11-33B1.1	-4.81	1.33e-05	0.027	-0.38	-0.56	Corneal astigmatism;	chr4:119404577	chr4:119454791~119552025:+
UVM	cis	rs7615952	0.688	rs7624806	ENSG00000171084.14	FAM86JP	4.81	1.33e-05	0.0271	0.7	0.55	Blood pressure (smoking interaction);	chr3:125880231	chr3:125916620~125930024:+
UVM	cis	rs3091242	0.933	rs11802413	ENSG00000224183.1	SDHDP6	4.81	1.33e-05	0.0272	0.62	0.55	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25294164~25294643:-
UVM	cis	rs1510272	0.515	rs6762762	ENSG00000243926.1	TIPARP-AS1	-4.81	1.34e-05	0.0273	-0.61	-0.55	Testicular germ cell tumor;	chr3:156625194	chr3:156671862~156674378:-
UVM	cis	rs4862750	0.874	rs6553027	ENSG00000251008.1	ORAOV1P1	4.81	1.35e-05	0.0274	0.67	0.55	Lobe attachment (rater-scored or self-reported);	chr4:186954623	chr4:186170863~186171257:-
UVM	cis	rs5769765	0.913	rs28670284	ENSG00000229409.1	RP11-494O16.3	-4.81	1.36e-05	0.0276	-0.93	-0.55	Schizophrenia;	chr22:49828325	chr22:49845929~49846090:+
UVM	cis	rs875971	0.545	rs73376394	ENSG00000226824.5	RP4-756H11.3	-4.8	1.36e-05	0.0277	-0.84	-0.55	Aortic root size;	chr7:66172694	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs10261710	ENSG00000226824.5	RP4-756H11.3	-4.8	1.36e-05	0.0277	-0.84	-0.55	Aortic root size;	chr7:66249202	chr7:66654538~66669855:+
UVM	cis	rs1153858	0.945	rs16943246	ENSG00000259520.4	CTD-2651B20.3	-4.8	1.36e-05	0.0277	-0.81	-0.55	Homoarginine levels;	chr15:45428399	chr15:45251580~45279251:-
UVM	cis	rs4862750	0.881	rs6813866	ENSG00000251008.1	ORAOV1P1	4.8	1.37e-05	0.0278	0.67	0.55	Lobe attachment (rater-scored or self-reported);	chr4:186951007	chr4:186170863~186171257:-
UVM	cis	rs3750965	0.919	rs12280942	ENSG00000260895.1	RP11-554A11.7	-4.8	1.38e-05	0.028	-0.75	-0.55	Hair color;	chr11:69092215	chr11:69103493~69109094:+
UVM	cis	rs17711722	0.565	rs4717276	ENSG00000164669.11	INTS4P1	-4.8	1.38e-05	0.028	-0.64	-0.55	Calcium levels;	chr7:65829754	chr7:65141225~65234216:+
UVM	cis	rs6991838	0.584	rs6993876	ENSG00000200714.1	Y_RNA	4.8	1.39e-05	0.0281	0.34	0.55	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65592731~65592820:+
UVM	cis	rs494459	0.536	rs34561290	ENSG00000255239.1	AP002954.6	4.8	1.4e-05	0.0284	0.5	0.55	Height;	chr11:118860890	chr11:118688039~118690600:-
UVM	cis	rs494459	0.536	rs11217072	ENSG00000255239.1	AP002954.6	4.8	1.4e-05	0.0284	0.5	0.55	Height;	chr11:118861053	chr11:118688039~118690600:-
UVM	cis	rs7104764	1	rs10400248	ENSG00000277290.1	RP11-326C3.16	-4.79	1.41e-05	0.0285	-0.47	-0.55	Menarche (age at onset);	chr11:247029	chr11:243099~243483:-
UVM	cis	rs17711722	0.522	rs62469933	ENSG00000164669.11	INTS4P1	-4.79	1.41e-05	0.0285	-0.64	-0.55	Calcium levels;	chr7:65800652	chr7:65141225~65234216:+
UVM	cis	rs17711722	0.523	rs313812	ENSG00000164669.11	INTS4P1	4.79	1.41e-05	0.0285	0.64	0.55	Calcium levels;	chr7:66040056	chr7:65141225~65234216:+
UVM	cis	rs17711722	0.523	rs365896	ENSG00000164669.11	INTS4P1	4.79	1.41e-05	0.0285	0.64	0.55	Calcium levels;	chr7:66045710	chr7:65141225~65234216:+
UVM	cis	rs875971	0.502	rs2465121	ENSG00000226824.5	RP4-756H11.3	4.79	1.41e-05	0.0285	0.84	0.55	Aortic root size;	chr7:66156017	chr7:66654538~66669855:+
UVM	cis	rs2080501	0.601	rs3803665	ENSG00000279356.1	RP11-429P3.8	4.79	1.41e-05	0.0285	0.42	0.55	IgG glycosylation;	chr16:49638609	chr16:50072862~50074986:+
UVM	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-4.79	1.42e-05	0.0286	-0.47	-0.55	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
UVM	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-4.79	1.42e-05	0.0286	-0.47	-0.55	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
UVM	cis	rs2080501	0.628	rs28971165	ENSG00000279356.1	RP11-429P3.8	4.79	1.44e-05	0.029	0.42	0.55	IgG glycosylation;	chr16:49627792	chr16:50072862~50074986:+
UVM	cis	rs6570726	0.791	rs12208019	ENSG00000235652.6	RP11-545I5.3	4.79	1.44e-05	0.029	0.51	0.55	Lobe attachment (rater-scored or self-reported);	chr6:145614436	chr6:145799409~145886585:+
UVM	cis	rs6570726	0.643	rs9403735	ENSG00000235652.6	RP11-545I5.3	4.79	1.44e-05	0.029	0.51	0.55	Lobe attachment (rater-scored or self-reported);	chr6:145615455	chr6:145799409~145886585:+
UVM	cis	rs6570726	0.791	rs11155435	ENSG00000235652.6	RP11-545I5.3	4.79	1.44e-05	0.029	0.51	0.55	Lobe attachment (rater-scored or self-reported);	chr6:145617409	chr6:145799409~145886585:+
UVM	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-4.79	1.44e-05	0.0291	-0.61	-0.55	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-4.79	1.44e-05	0.0291	-0.61	-0.55	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
UVM	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-4.79	1.45e-05	0.0291	-0.61	-0.55	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
UVM	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	4.79	1.45e-05	0.0291	0.92	0.55	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-4.79	1.45e-05	0.0291	-0.92	-0.55	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-4.79	1.45e-05	0.0291	-0.92	-0.55	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-4.79	1.45e-05	0.0291	-0.92	-0.55	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-4.79	1.45e-05	0.0291	-0.92	-0.55	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-4.79	1.45e-05	0.0291	-0.92	-0.55	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-4.79	1.45e-05	0.0291	-0.92	-0.55	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-4.79	1.45e-05	0.0291	-0.92	-0.55	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-4.79	1.45e-05	0.0291	-0.92	-0.55	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-4.79	1.45e-05	0.0291	-0.92	-0.55	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	4.79	1.45e-05	0.0291	0.92	0.55	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
UVM	cis	rs4862750	0.914	rs11943333	ENSG00000251008.1	ORAOV1P1	4.79	1.45e-05	0.0292	0.68	0.55	Lobe attachment (rater-scored or self-reported);	chr4:186951301	chr4:186170863~186171257:-
UVM	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-4.79	1.45e-05	0.0292	-0.59	-0.55	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
UVM	cis	rs12568771	0.505	rs2477134	ENSG00000272426.1	RP11-108M9.6	-4.78	1.46e-05	0.0293	-0.64	-0.55	IgA nephropathy;	chr1:17307077	chr1:16904339~16904776:-
UVM	cis	rs73086581	0.787	rs67633417	ENSG00000229539.1	RP11-119B16.2	4.78	1.47e-05	0.0294	1.06	0.55	Response to antidepressants in depression;	chr20:3887610	chr20:3888239~3888868:-
UVM	cis	rs73086581	0.787	rs68127408	ENSG00000229539.1	RP11-119B16.2	4.78	1.47e-05	0.0294	1.06	0.55	Response to antidepressants in depression;	chr20:3887800	chr20:3888239~3888868:-
UVM	cis	rs73086581	0.787	rs67724338	ENSG00000229539.1	RP11-119B16.2	4.78	1.47e-05	0.0294	1.06	0.55	Response to antidepressants in depression;	chr20:3888410	chr20:3888239~3888868:-
UVM	cis	rs73086581	0.787	rs67202952	ENSG00000229539.1	RP11-119B16.2	4.78	1.47e-05	0.0294	1.06	0.55	Response to antidepressants in depression;	chr20:3888452	chr20:3888239~3888868:-
UVM	cis	rs934734	0.544	rs4671127	ENSG00000204929.10	AC074391.1	4.78	1.47e-05	0.0295	0.93	0.55	Rheumatoid arthritis;	chr2:65335836	chr2:65436711~66084639:+
UVM	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	4.78	1.47e-05	0.0295	0.42	0.55	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	4.78	1.47e-05	0.0295	0.42	0.55	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs9846818	ENSG00000229759.1	MRPS18AP1	4.78	1.47e-05	0.0295	0.42	0.55	Coronary artery disease;	chr3:48334195	chr3:48256350~48256938:-
UVM	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	4.78	1.48e-05	0.0297	0.59	0.55	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
UVM	cis	rs6570726	0.791	rs9403734	ENSG00000235652.6	RP11-545I5.3	4.78	1.49e-05	0.0298	0.51	0.55	Lobe attachment (rater-scored or self-reported);	chr6:145610323	chr6:145799409~145886585:+
UVM	cis	rs6570726	0.791	rs2096201	ENSG00000235652.6	RP11-545I5.3	4.78	1.49e-05	0.0298	0.51	0.55	Lobe attachment (rater-scored or self-reported);	chr6:145613137	chr6:145799409~145886585:+
UVM	cis	rs7615952	0.673	rs34209763	ENSG00000171084.14	FAM86JP	4.78	1.49e-05	0.0298	0.86	0.55	Blood pressure (smoking interaction);	chr3:125880752	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.8	rs35390120	ENSG00000171084.14	FAM86JP	4.78	1.49e-05	0.0298	0.86	0.55	Blood pressure (smoking interaction);	chr3:125880966	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.611	rs2971298	ENSG00000171084.14	FAM86JP	4.78	1.49e-05	0.0298	0.86	0.55	Blood pressure (smoking interaction);	chr3:125883870	chr3:125916620~125930024:+
UVM	cis	rs858239	0.931	rs9690941	ENSG00000230658.1	KLHL7-AS1	4.78	1.49e-05	0.0298	0.59	0.55	Cerebrospinal fluid biomarker levels;	chr7:23242134	chr7:23101228~23105703:-
UVM	cis	rs10256972	0.567	rs2960850	ENSG00000229043.2	AC091729.9	-4.78	1.5e-05	0.03	-0.59	-0.55	Endometriosis;Longevity;	chr7:1172013	chr7:1160374~1165267:+
UVM	cis	rs3091242	0.804	rs631133	ENSG00000224183.1	SDHDP6	-4.78	1.5e-05	0.03	-0.57	-0.55	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25294164~25294643:-
UVM	cis	rs4862750	0.83	rs13152425	ENSG00000251008.1	ORAOV1P1	4.77	1.51e-05	0.0302	0.66	0.55	Lobe attachment (rater-scored or self-reported);	chr4:186973572	chr4:186170863~186171257:-
UVM	cis	rs2739330	0.76	rs1002286	ENSG00000250470.1	AP000351.3	-4.77	1.51e-05	0.0302	-0.73	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23976904~23977585:-
UVM	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-4.77	1.52e-05	0.0303	-0.6	-0.55	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
UVM	cis	rs7104764	0.957	rs10794301	ENSG00000277290.1	RP11-326C3.16	-4.77	1.52e-05	0.0303	-0.47	-0.55	Menarche (age at onset);	chr11:220401	chr11:243099~243483:-
UVM	cis	rs7104764	0.879	rs6421986	ENSG00000277290.1	RP11-326C3.16	-4.77	1.52e-05	0.0303	-0.47	-0.55	Menarche (age at onset);	chr11:221659	chr11:243099~243483:-
UVM	cis	rs6473252	0.522	rs11779701	ENSG00000231942.3	HNRNPA1P36	-4.77	1.53e-05	0.0305	-0.68	-0.55	Breast cancer;	chr8:80913091	chr8:81807772~81808726:+
UVM	cis	rs2919917	1	rs1483573	ENSG00000254352.1	RP11-578O24.2	4.77	1.54e-05	0.0308	0.4	0.55	Lymphocyte counts;	chr8:78711382	chr8:78723796~78724136:-
UVM	cis	rs934734	0.563	rs11126034	ENSG00000204929.10	AC074391.1	-4.77	1.55e-05	0.0308	-0.93	-0.55	Rheumatoid arthritis;	chr2:65353087	chr2:65436711~66084639:+
UVM	cis	rs934734	0.563	rs955903	ENSG00000204929.10	AC074391.1	4.77	1.55e-05	0.0308	0.93	0.55	Rheumatoid arthritis;	chr2:65348419	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.566	rs7584295	ENSG00000204929.10	AC074391.1	4.77	1.55e-05	0.0308	0.93	0.55	Sum eosinophil basophil counts;	chr2:65353940	chr2:65436711~66084639:+
UVM	cis	rs934734	0.563	rs11695373	ENSG00000204929.10	AC074391.1	4.77	1.55e-05	0.0308	0.93	0.55	Rheumatoid arthritis;	chr2:65354066	chr2:65436711~66084639:+
UVM	cis	rs934734	0.563	rs11684155	ENSG00000204929.10	AC074391.1	4.77	1.55e-05	0.0308	0.93	0.55	Rheumatoid arthritis;	chr2:65354166	chr2:65436711~66084639:+
UVM	cis	rs7569084	0.522	rs906577	ENSG00000204929.10	AC074391.1	4.77	1.55e-05	0.0308	0.93	0.55	Sum eosinophil basophil counts;	chr2:65369523	chr2:65436711~66084639:+
UVM	cis	rs934734	0.563	rs11126035	ENSG00000204929.10	AC074391.1	4.77	1.55e-05	0.0308	0.93	0.55	Rheumatoid arthritis;	chr2:65369932	chr2:65436711~66084639:+
UVM	cis	rs934734	0.563	rs11673956	ENSG00000204929.10	AC074391.1	4.77	1.55e-05	0.0308	0.93	0.55	Rheumatoid arthritis;	chr2:65370523	chr2:65436711~66084639:+
UVM	cis	rs934734	0.563	rs11673987	ENSG00000204929.10	AC074391.1	4.77	1.55e-05	0.0308	0.93	0.55	Rheumatoid arthritis;	chr2:65370537	chr2:65436711~66084639:+
UVM	cis	rs934734	0.563	rs1858036	ENSG00000204929.10	AC074391.1	4.77	1.55e-05	0.0308	0.93	0.55	Rheumatoid arthritis;	chr2:65371107	chr2:65436711~66084639:+
UVM	cis	rs934734	0.563	rs1858037	ENSG00000204929.10	AC074391.1	4.77	1.55e-05	0.0308	0.93	0.55	Rheumatoid arthritis;	chr2:65371166	chr2:65436711~66084639:+
UVM	cis	rs3091242	0.933	rs9645452	ENSG00000224183.1	SDHDP6	4.77	1.55e-05	0.0309	0.6	0.55	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25294164~25294643:-
UVM	cis	rs2919917	0.915	rs3899796	ENSG00000254352.1	RP11-578O24.2	4.77	1.56e-05	0.031	0.4	0.55	Lymphocyte counts;	chr8:78655847	chr8:78723796~78724136:-
UVM	cis	rs17711722	0.522	rs6957759	ENSG00000164669.11	INTS4P1	-4.77	1.56e-05	0.031	-0.64	-0.55	Calcium levels;	chr7:65806798	chr7:65141225~65234216:+
UVM	cis	rs3892715	0.581	rs2676889	ENSG00000242086.7	LINC00969	-4.76	1.56e-05	0.0311	-0.29	-0.55	Attention deficit hyperactivity disorder (time to onset);	chr3:195042872	chr3:195658062~195739964:+
UVM	cis	rs12237653	0.72	rs10812210	ENSG00000236404.7	VLDLR-AS1	-4.76	1.56e-05	0.0311	-0.9	-0.55	Gambling;	chr9:2536828	chr9:2422702~2643359:-
UVM	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	4.76	1.57e-05	0.0311	0.55	0.55	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
UVM	cis	rs10256972	0.678	rs6962989	ENSG00000229043.2	AC091729.9	-4.76	1.57e-05	0.0312	-0.61	-0.55	Endometriosis;Longevity;	chr7:977876	chr7:1160374~1165267:+
UVM	cis	rs4862750	0.914	rs6814259	ENSG00000251008.1	ORAOV1P1	4.76	1.57e-05	0.0312	0.67	0.55	Lobe attachment (rater-scored or self-reported);	chr4:186951183	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.914	rs6837117	ENSG00000251008.1	ORAOV1P1	4.76	1.57e-05	0.0312	0.67	0.55	Lobe attachment (rater-scored or self-reported);	chr4:186951225	chr4:186170863~186171257:-
UVM	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	4.76	1.59e-05	0.0316	0.57	0.55	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
UVM	cis	rs5769765	0.671	rs138844	ENSG00000229409.1	RP11-494O16.3	-4.76	1.6e-05	0.0316	-0.87	-0.55	Schizophrenia;	chr22:49790836	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.624	rs2285187	ENSG00000229409.1	RP11-494O16.3	-4.76	1.6e-05	0.0316	-0.87	-0.55	Schizophrenia;	chr22:49791784	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.658	rs2157536	ENSG00000229409.1	RP11-494O16.3	-4.76	1.6e-05	0.0316	-0.87	-0.55	Schizophrenia;	chr22:49796532	chr22:49845929~49846090:+
UVM	cis	rs12237653	0.929	rs10812239	ENSG00000236404.7	VLDLR-AS1	4.76	1.6e-05	0.0317	0.95	0.55	Gambling;	chr9:2551136	chr9:2422702~2643359:-
UVM	cis	rs7615952	0.673	rs16834637	ENSG00000171084.14	FAM86JP	4.76	1.6e-05	0.0317	0.85	0.55	Blood pressure (smoking interaction);	chr3:125886628	chr3:125916620~125930024:+
UVM	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	4.76	1.6e-05	0.0317	0.7	0.55	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
UVM	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	4.76	1.6e-05	0.0317	0.7	0.55	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
UVM	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-4.76	1.6e-05	0.0317	-0.7	-0.55	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
UVM	cis	rs11673344	0.642	rs11083420	ENSG00000226686.6	LINC01535	4.76	1.6e-05	0.0317	0.7	0.55	Obesity-related traits;	chr19:37317901	chr19:37251912~37265535:+
UVM	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-4.76	1.6e-05	0.0317	-0.6	-0.55	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
UVM	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-4.76	1.6e-05	0.0317	-0.6	-0.55	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-4.75	1.61e-05	0.0319	-0.6	-0.55	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-4.75	1.61e-05	0.0319	-0.6	-0.55	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-4.75	1.61e-05	0.0319	-0.6	-0.55	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-4.75	1.61e-05	0.0319	-0.6	-0.55	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
UVM	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-4.75	1.61e-05	0.0319	-0.6	-0.55	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-4.75	1.61e-05	0.0319	-0.6	-0.55	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-4.75	1.61e-05	0.0319	-0.6	-0.55	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-4.75	1.61e-05	0.0319	-0.6	-0.55	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-4.75	1.61e-05	0.0319	-0.6	-0.55	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-4.75	1.61e-05	0.0319	-0.6	-0.55	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-4.75	1.61e-05	0.0319	-0.6	-0.55	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-4.75	1.61e-05	0.0319	-0.6	-0.55	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
UVM	cis	rs6991838	0.806	rs11781358	ENSG00000272010.1	CTD-3025N20.3	4.75	1.62e-05	0.0319	0.3	0.55	Intelligence (multi-trait analysis);	chr8:65557691	chr8:65591850~65592472:-
UVM	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-4.75	1.62e-05	0.032	-0.6	-0.55	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
UVM	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-4.75	1.62e-05	0.032	-0.6	-0.55	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-4.75	1.62e-05	0.032	-0.6	-0.55	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-4.75	1.62e-05	0.032	-0.6	-0.55	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-4.75	1.62e-05	0.032	-0.6	-0.55	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-4.75	1.62e-05	0.032	-0.6	-0.55	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-4.75	1.62e-05	0.032	-0.6	-0.55	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-4.75	1.62e-05	0.032	-0.6	-0.55	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
UVM	cis	rs7772486	0.754	rs697055	ENSG00000235652.6	RP11-545I5.3	4.75	1.62e-05	0.032	0.53	0.55	Lobe attachment (rater-scored or self-reported);	chr6:145682654	chr6:145799409~145886585:+
UVM	cis	rs11098499	0.909	rs10026736	ENSG00000245958.5	RP11-33B1.1	-4.75	1.63e-05	0.0322	-0.38	-0.55	Corneal astigmatism;	chr4:119463167	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.913	rs12186259	ENSG00000245958.5	RP11-33B1.1	-4.75	1.63e-05	0.0322	-0.36	-0.55	Corneal astigmatism;	chr4:119230884	chr4:119454791~119552025:+
UVM	cis	rs2729354	0.903	rs2729371	ENSG00000265566.2	RN7SL605P	-4.75	1.64e-05	0.0323	-0.79	-0.55	Blood protein levels;	chr11:57553849	chr11:57528085~57528365:-
UVM	cis	rs2729354	0.909	rs2729374	ENSG00000265566.2	RN7SL605P	-4.75	1.64e-05	0.0323	-0.79	-0.55	Blood protein levels;	chr11:57559454	chr11:57528085~57528365:-
UVM	cis	rs6964833	0.935	rs34762099	ENSG00000123965.13	PMS2P5	4.75	1.65e-05	0.0324	0.94	0.55	Menarche (age at onset);	chr7:74636378	chr7:74894116~74897835:+
UVM	cis	rs6964833	0.786	rs35633336	ENSG00000123965.13	PMS2P5	4.75	1.65e-05	0.0324	0.94	0.55	Menarche (age at onset);	chr7:74643961	chr7:74894116~74897835:+
UVM	cis	rs6964833	0.935	rs34630792	ENSG00000123965.13	PMS2P5	4.75	1.65e-05	0.0324	0.94	0.55	Menarche (age at onset);	chr7:74646869	chr7:74894116~74897835:+
UVM	cis	rs6964833	0.935	rs35735900	ENSG00000123965.13	PMS2P5	4.75	1.65e-05	0.0324	0.94	0.55	Menarche (age at onset);	chr7:74651887	chr7:74894116~74897835:+
UVM	cis	rs6964833	0.872	rs4717903	ENSG00000123965.13	PMS2P5	4.75	1.65e-05	0.0324	0.94	0.55	Menarche (age at onset);	chr7:74653827	chr7:74894116~74897835:+
UVM	cis	rs6964833	1	rs4717906	ENSG00000123965.13	PMS2P5	4.75	1.65e-05	0.0324	0.94	0.55	Menarche (age at onset);	chr7:74671923	chr7:74894116~74897835:+
UVM	cis	rs6964833	1	rs13227433	ENSG00000123965.13	PMS2P5	4.75	1.65e-05	0.0324	0.94	0.55	Menarche (age at onset);	chr7:74680386	chr7:74894116~74897835:+
UVM	cis	rs6964833	1	rs6967152	ENSG00000123965.13	PMS2P5	4.75	1.65e-05	0.0324	0.94	0.55	Menarche (age at onset);	chr7:74684983	chr7:74894116~74897835:+
UVM	cis	rs6964833	1	rs6964833	ENSG00000123965.13	PMS2P5	4.75	1.65e-05	0.0324	0.94	0.55	Menarche (age at onset);	chr7:74687575	chr7:74894116~74897835:+
UVM	cis	rs6964833	1	rs35203738	ENSG00000123965.13	PMS2P5	4.75	1.65e-05	0.0324	0.94	0.55	Menarche (age at onset);	chr7:74690864	chr7:74894116~74897835:+
UVM	cis	rs6964833	1	rs2301907	ENSG00000123965.13	PMS2P5	4.75	1.65e-05	0.0324	0.94	0.55	Menarche (age at onset);	chr7:74700517	chr7:74894116~74897835:+
UVM	cis	rs6964833	0.935	rs7795281	ENSG00000123965.13	PMS2P5	4.75	1.65e-05	0.0324	0.94	0.55	Menarche (age at onset);	chr7:74708523	chr7:74894116~74897835:+
UVM	cis	rs6964833	0.935	rs7795282	ENSG00000123965.13	PMS2P5	4.75	1.65e-05	0.0324	0.94	0.55	Menarche (age at onset);	chr7:74708526	chr7:74894116~74897835:+
UVM	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	4.75	1.65e-05	0.0324	0.5	0.55	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	4.75	1.65e-05	0.0324	0.5	0.55	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	4.75	1.65e-05	0.0324	0.5	0.55	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	4.75	1.65e-05	0.0324	0.5	0.55	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	4.75	1.65e-05	0.0324	0.5	0.55	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
UVM	cis	rs4862750	0.914	rs9995391	ENSG00000251008.1	ORAOV1P1	-4.75	1.65e-05	0.0325	-0.65	-0.55	Lobe attachment (rater-scored or self-reported);	chr4:186952595	chr4:186170863~186171257:-
UVM	cis	rs7772486	0.79	rs9485024	ENSG00000235652.6	RP11-545I5.3	-4.75	1.66e-05	0.0327	-0.51	-0.55	Lobe attachment (rater-scored or self-reported);	chr6:145821351	chr6:145799409~145886585:+
UVM	cis	rs7819412	0.783	rs28722721	ENSG00000255310.2	AF131215.2	-4.75	1.66e-05	0.0327	-0.46	-0.55	Triglycerides;	chr8:11091458	chr8:11107788~11109726:-
UVM	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	4.75	1.67e-05	0.0328	0.69	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
UVM	cis	rs11673344	0.864	rs1533736	ENSG00000226686.6	LINC01535	4.74	1.67e-05	0.0328	0.72	0.55	Obesity-related traits;	chr19:37164074	chr19:37251912~37265535:+
UVM	cis	rs11673344	0.801	rs56343212	ENSG00000226686.6	LINC01535	4.74	1.67e-05	0.0328	0.72	0.55	Obesity-related traits;	chr19:37167684	chr19:37251912~37265535:+
UVM	cis	rs8072100	0.79	rs6505048	ENSG00000228782.6	CTD-2026D20.3	-4.74	1.67e-05	0.0328	-0.57	-0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597632	chr17:47450568~47492492:-
UVM	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	4.74	1.68e-05	0.0328	0.62	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
UVM	cis	rs7615952	0.611	rs35321002	ENSG00000171084.14	FAM86JP	4.74	1.68e-05	0.0328	0.85	0.55	Blood pressure (smoking interaction);	chr3:125893222	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.611	rs9681518	ENSG00000171084.14	FAM86JP	4.74	1.68e-05	0.0328	0.85	0.55	Blood pressure (smoking interaction);	chr3:125896287	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.604	rs9837847	ENSG00000171084.14	FAM86JP	4.74	1.68e-05	0.0328	0.85	0.55	Blood pressure (smoking interaction);	chr3:125905076	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.673	rs35955861	ENSG00000171084.14	FAM86JP	4.74	1.68e-05	0.0328	0.85	0.55	Blood pressure (smoking interaction);	chr3:125907358	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.673	rs35001498	ENSG00000171084.14	FAM86JP	4.74	1.68e-05	0.0328	0.85	0.55	Blood pressure (smoking interaction);	chr3:125909801	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.611	rs7632305	ENSG00000171084.14	FAM86JP	4.74	1.68e-05	0.0328	0.85	0.55	Blood pressure (smoking interaction);	chr3:125915924	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.673	rs9841194	ENSG00000171084.14	FAM86JP	4.74	1.68e-05	0.0328	0.85	0.55	Blood pressure (smoking interaction);	chr3:125916896	chr3:125916620~125930024:+
UVM	cis	rs7615952	0.673	rs9289270	ENSG00000171084.14	FAM86JP	4.74	1.68e-05	0.0328	0.85	0.55	Blood pressure (smoking interaction);	chr3:125918136	chr3:125916620~125930024:+
UVM	cis	rs10771431	0.782	rs10771415	ENSG00000111788.10	RP11-22B23.1	4.74	1.68e-05	0.0329	0.48	0.55	Breast size;	chr12:9205627	chr12:9277235~9313241:+
UVM	cis	rs10771431	0.81	rs10771418	ENSG00000111788.10	RP11-22B23.1	4.74	1.68e-05	0.0329	0.48	0.55	Breast size;	chr12:9206399	chr12:9277235~9313241:+
UVM	cis	rs10771431	0.817	rs17202253	ENSG00000111788.10	RP11-22B23.1	4.74	1.68e-05	0.0329	0.48	0.55	Breast size;	chr12:9209254	chr12:9277235~9313241:+
UVM	cis	rs10771431	0.817	rs10843149	ENSG00000111788.10	RP11-22B23.1	4.74	1.68e-05	0.0329	0.48	0.55	Breast size;	chr12:9209471	chr12:9277235~9313241:+
UVM	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-4.74	1.69e-05	0.0331	-0.64	-0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-4.74	1.69e-05	0.0331	-0.64	-0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	4.74	1.69e-05	0.0331	0.64	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
UVM	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	4.74	1.69e-05	0.0331	0.64	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
UVM	cis	rs11673344	0.58	rs320881	ENSG00000226686.6	LINC01535	4.74	1.69e-05	0.0331	0.7	0.55	Obesity-related traits;	chr19:37246948	chr19:37251912~37265535:+
UVM	cis	rs35660623	0.542	rs10110552	ENSG00000253649.2	PRSS51	-4.74	1.72e-05	0.0336	-0.78	-0.55	3-hydroxypropylmercapturic acid levels in smokers;	chr8:10757949	chr8:10482878~10547585:-
UVM	cis	rs1167827	0.68	rs1167796	ENSG00000127957.15	PMS2P3	4.74	1.73e-05	0.0337	0.46	0.55	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75502930~75528148:-
UVM	cis	rs11155671	0.53	rs7742993	ENSG00000268592.3	RAET1E-AS1	4.73	1.73e-05	0.0338	0.61	0.55	Testicular germ cell tumor;	chr6:149883959	chr6:149863494~149919507:+
UVM	cis	rs8072100	0.905	rs11651766	ENSG00000228782.6	CTD-2026D20.3	4.73	1.74e-05	0.0339	0.58	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47497565	chr17:47450568~47492492:-
UVM	cis	rs8072100	0.905	rs9901869	ENSG00000228782.6	CTD-2026D20.3	4.73	1.74e-05	0.0339	0.58	0.55	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47497840	chr17:47450568~47492492:-
UVM	cis	rs9487094	0.626	rs2273752	ENSG00000260273.1	RP11-425D10.10	4.73	1.74e-05	0.0339	0.62	0.55	Height;	chr6:109738307	chr6:109382795~109383666:+
UVM	cis	rs9487094	0.626	rs12201444	ENSG00000260273.1	RP11-425D10.10	4.73	1.74e-05	0.0339	0.62	0.55	Height;	chr6:109738751	chr6:109382795~109383666:+
UVM	cis	rs9487094	0.626	rs4141930	ENSG00000260273.1	RP11-425D10.10	4.73	1.74e-05	0.0339	0.62	0.55	Height;	chr6:109739615	chr6:109382795~109383666:+
UVM	cis	rs2080501	0.628	rs28542020	ENSG00000279356.1	RP11-429P3.8	4.73	1.75e-05	0.034	0.42	0.55	IgG glycosylation;	chr16:49626677	chr16:50072862~50074986:+
UVM	cis	rs11148252	0.557	rs9536223	ENSG00000235660.1	LINC00345	-4.73	1.75e-05	0.0341	-0.61	-0.55	Lewy body disease;	chr13:52659059	chr13:52484161~52484680:-
UVM	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-4.73	1.76e-05	0.0341	-0.6	-0.55	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-4.73	1.76e-05	0.0341	-0.6	-0.55	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-4.73	1.76e-05	0.0341	-0.6	-0.55	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-4.73	1.76e-05	0.0341	-0.6	-0.55	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs4896123	ENSG00000232876.1	CTA-212D2.2	-4.73	1.76e-05	0.0341	-0.6	-0.55	Red blood cell count;	chr6:134974272	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-4.73	1.76e-05	0.0341	-0.6	-0.55	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-4.73	1.76e-05	0.0341	-0.6	-0.55	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-4.73	1.76e-05	0.0341	-0.6	-0.55	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-4.73	1.76e-05	0.0341	-0.6	-0.55	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
UVM	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-4.73	1.76e-05	0.0341	-0.6	-0.55	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-4.73	1.76e-05	0.0341	-0.6	-0.55	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-4.73	1.76e-05	0.0341	-0.6	-0.55	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-4.73	1.76e-05	0.0341	-0.6	-0.55	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-4.73	1.76e-05	0.0341	-0.6	-0.55	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
UVM	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-4.73	1.76e-05	0.0341	-0.6	-0.55	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
UVM	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-4.73	1.76e-05	0.0342	-0.92	-0.55	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
UVM	cis	rs11673344	0.832	rs112380313	ENSG00000226686.6	LINC01535	4.73	1.77e-05	0.0344	0.77	0.55	Obesity-related traits;	chr19:37027979	chr19:37251912~37265535:+
UVM	cis	rs11673344	0.832	rs76470527	ENSG00000226686.6	LINC01535	4.73	1.77e-05	0.0344	0.77	0.55	Obesity-related traits;	chr19:37035981	chr19:37251912~37265535:+
UVM	cis	rs11673344	0.832	rs56080874	ENSG00000226686.6	LINC01535	4.73	1.77e-05	0.0344	0.77	0.55	Obesity-related traits;	chr19:37085487	chr19:37251912~37265535:+
UVM	cis	rs11673344	0.77	rs7257135	ENSG00000226686.6	LINC01535	4.73	1.77e-05	0.0344	0.77	0.55	Obesity-related traits;	chr19:37088726	chr19:37251912~37265535:+
UVM	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	4.73	1.78e-05	0.0345	0.55	0.55	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
UVM	cis	rs34198350	0.683	rs3136337	ENSG00000272663.1	RP11-191L17.1	4.73	1.78e-05	0.0345	1.22	0.55	QT interval in Tripanosoma cruzi seropositivity;	chr2:47801326	chr2:48440043~48440597:-
UVM	cis	rs5769765	0.72	rs138820	ENSG00000229409.1	RP11-494O16.3	-4.72	1.79e-05	0.0347	-0.89	-0.55	Schizophrenia;	chr22:49770430	chr22:49845929~49846090:+
UVM	cis	rs9549328	0.807	rs3011548	ENSG00000267868.1	RP11-120K24.3	-4.72	1.79e-05	0.0347	-0.71	-0.55	Systolic blood pressure;	chr13:112980817	chr13:112964835~112966131:-
UVM	cis	rs11673344	0.74	rs113752815	ENSG00000226686.6	LINC01535	4.72	1.8e-05	0.0347	0.76	0.55	Obesity-related traits;	chr19:37043829	chr19:37251912~37265535:+
UVM	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	4.72	1.8e-05	0.0347	0.46	0.55	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
UVM	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-4.72	1.8e-05	0.0347	-0.46	-0.55	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
UVM	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-4.72	1.8e-05	0.0347	-0.46	-0.55	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
UVM	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-4.72	1.8e-05	0.0347	-0.46	-0.55	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
UVM	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-4.72	1.8e-05	0.0347	-0.46	-0.55	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
UVM	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-4.72	1.8e-05	0.0347	-0.46	-0.55	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
UVM	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-4.72	1.8e-05	0.0347	-0.46	-0.55	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
UVM	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-4.72	1.8e-05	0.0347	-0.46	-0.55	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
UVM	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-4.72	1.8e-05	0.0347	-0.46	-0.55	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
UVM	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-4.72	1.8e-05	0.0347	-0.46	-0.55	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
UVM	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-4.72	1.8e-05	0.0347	-0.46	-0.55	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
UVM	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-4.72	1.8e-05	0.0347	-0.46	-0.55	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
UVM	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-4.72	1.8e-05	0.0347	-0.46	-0.55	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
UVM	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-4.72	1.8e-05	0.0347	-0.46	-0.55	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
UVM	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-4.72	1.8e-05	0.0347	-0.46	-0.55	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
UVM	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-4.72	1.8e-05	0.0347	-0.46	-0.55	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
UVM	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-4.72	1.8e-05	0.0347	-0.46	-0.55	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
UVM	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-4.72	1.8e-05	0.0347	-0.46	-0.55	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
UVM	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-4.72	1.8e-05	0.0347	-0.46	-0.55	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
UVM	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-4.72	1.8e-05	0.0347	-0.46	-0.55	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
UVM	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-4.72	1.8e-05	0.0347	-0.46	-0.55	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
UVM	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-4.72	1.8e-05	0.0347	-0.46	-0.55	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
UVM	cis	rs11673344	0.642	rs73025481	ENSG00000226686.6	LINC01535	4.72	1.83e-05	0.0352	0.7	0.55	Obesity-related traits;	chr19:37346437	chr19:37251912~37265535:+
UVM	cis	rs11673344	0.642	rs55755939	ENSG00000226686.6	LINC01535	4.72	1.83e-05	0.0352	0.7	0.55	Obesity-related traits;	chr19:37353723	chr19:37251912~37265535:+
UVM	cis	rs11673344	0.555	rs502546	ENSG00000226686.6	LINC01535	-4.72	1.83e-05	0.0352	-0.7	-0.55	Obesity-related traits;	chr19:37361788	chr19:37251912~37265535:+
UVM	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	4.72	1.83e-05	0.0353	0.59	0.55	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
UVM	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	4.72	1.83e-05	0.0353	0.59	0.55	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
UVM	cis	rs12439619	0.508	rs11856561	ENSG00000278603.1	RP13-608F4.5	4.72	1.84e-05	0.0354	0.66	0.55	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472203~82472426:+
UVM	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	4.72	1.84e-05	0.0354	0.58	0.55	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
UVM	cis	rs3091242	0.933	rs3093584	ENSG00000224183.1	SDHDP6	4.72	1.84e-05	0.0355	0.59	0.55	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25294164~25294643:-
UVM	cis	rs9595066	1	rs9595066	ENSG00000227258.4	SMIM2-AS1	4.71	1.86e-05	0.0357	1.03	0.55	Schizophrenia;	chr13:44132132	chr13:44110451~44240517:+
UVM	cis	rs2739330	0.703	rs5760112	ENSG00000250470.1	AP000351.3	4.71	1.87e-05	0.0359	0.72	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23976904~23977585:-
UVM	cis	rs6570726	0.791	rs1509213	ENSG00000235652.6	RP11-545I5.3	-4.71	1.88e-05	0.036	-0.5	-0.55	Lobe attachment (rater-scored or self-reported);	chr6:145462224	chr6:145799409~145886585:+
UVM	cis	rs11148252	0.595	rs9526968	ENSG00000235660.1	LINC00345	-4.71	1.89e-05	0.0362	-0.6	-0.55	Lewy body disease;	chr13:52666048	chr13:52484161~52484680:-
UVM	cis	rs11148252	0.553	rs7999849	ENSG00000235660.1	LINC00345	-4.71	1.89e-05	0.0362	-0.6	-0.55	Lewy body disease;	chr13:52675279	chr13:52484161~52484680:-
UVM	cis	rs11148252	0.574	rs2038826	ENSG00000235660.1	LINC00345	-4.71	1.89e-05	0.0362	-0.6	-0.55	Lewy body disease;	chr13:52705878	chr13:52484161~52484680:-
UVM	cis	rs11148252	0.574	rs7139495	ENSG00000235660.1	LINC00345	-4.71	1.89e-05	0.0362	-0.6	-0.55	Lewy body disease;	chr13:52709183	chr13:52484161~52484680:-
UVM	cis	rs5769765	0.908	rs138866	ENSG00000229409.1	RP11-494O16.3	4.7	1.92e-05	0.0364	0.84	0.55	Schizophrenia;	chr22:49812255	chr22:49845929~49846090:+
UVM	cis	rs10256972	0.527	rs2949170	ENSG00000229043.2	AC091729.9	-4.7	1.92e-05	0.0364	-0.6	-0.55	Endometriosis;Longevity;	chr7:1176802	chr7:1160374~1165267:+
UVM	cis	rs2919917	1	rs3736169	ENSG00000254352.1	RP11-578O24.2	4.7	1.93e-05	0.0364	0.4	0.55	Lymphocyte counts;	chr8:78675620	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs7839152	ENSG00000254352.1	RP11-578O24.2	4.7	1.93e-05	0.0364	0.4	0.55	Lymphocyte counts;	chr8:78677777	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs28429528	ENSG00000254352.1	RP11-578O24.2	4.7	1.93e-05	0.0364	0.4	0.55	Lymphocyte counts;	chr8:78678782	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs9298316	ENSG00000254352.1	RP11-578O24.2	4.7	1.93e-05	0.0364	0.4	0.55	Lymphocyte counts;	chr8:78680191	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs7842142	ENSG00000254352.1	RP11-578O24.2	4.7	1.93e-05	0.0364	0.4	0.55	Lymphocyte counts;	chr8:78681501	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs11785966	ENSG00000254352.1	RP11-578O24.2	4.7	1.93e-05	0.0364	0.4	0.55	Lymphocyte counts;	chr8:78681851	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs10092335	ENSG00000254352.1	RP11-578O24.2	4.7	1.93e-05	0.0364	0.4	0.55	Lymphocyte counts;	chr8:78686218	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs10093127	ENSG00000254352.1	RP11-578O24.2	4.7	1.93e-05	0.0364	0.4	0.55	Lymphocyte counts;	chr8:78686869	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs1872072	ENSG00000254352.1	RP11-578O24.2	4.7	1.93e-05	0.0364	0.4	0.55	Lymphocyte counts;	chr8:78689185	chr8:78723796~78724136:-
UVM	cis	rs2919917	0.956	rs10112388	ENSG00000254352.1	RP11-578O24.2	4.7	1.93e-05	0.0364	0.4	0.55	Lymphocyte counts;	chr8:78691512	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs6980663	ENSG00000254352.1	RP11-578O24.2	4.7	1.93e-05	0.0364	0.4	0.55	Lymphocyte counts;	chr8:78691589	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs7001074	ENSG00000254352.1	RP11-578O24.2	4.7	1.93e-05	0.0364	0.4	0.55	Lymphocyte counts;	chr8:78691689	chr8:78723796~78724136:-
UVM	cis	rs11098499	0.69	rs34818745	ENSG00000245958.5	RP11-33B1.1	-4.7	1.94e-05	0.0364	-0.39	-0.55	Corneal astigmatism;	chr4:119335900	chr4:119454791~119552025:+
UVM	cis	rs210918	0.675	rs9380503	ENSG00000212802.4	RPL15P3	4.7	1.94e-05	0.0364	0.4	0.55	Neuroticism;	chr6:11750899	chr6:12514110~12514724:+
UVM	cis	rs2188561	0.697	rs2237679	ENSG00000241764.3	AC002467.7	4.7	1.95e-05	0.0364	0.63	0.55	Alcohol consumption;	chr7:107693581	chr7:107742817~107744581:-
UVM	cis	rs2188561	0.697	rs2072064	ENSG00000241764.3	AC002467.7	4.7	1.95e-05	0.0364	0.63	0.55	Alcohol consumption;	chr7:107694068	chr7:107742817~107744581:-
UVM	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	4.7	1.95e-05	0.0364	0.63	0.55	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
UVM	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	4.7	1.95e-05	0.0364	0.63	0.55	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
UVM	cis	rs2188561	0.708	rs9718496	ENSG00000241764.3	AC002467.7	4.7	1.95e-05	0.0364	0.63	0.55	Alcohol consumption;	chr7:107730187	chr7:107742817~107744581:-
UVM	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	4.7	1.95e-05	0.0364	0.63	0.55	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
UVM	cis	rs2188561	0.697	rs34986332	ENSG00000241764.3	AC002467.7	4.7	1.95e-05	0.0364	0.63	0.55	Alcohol consumption;	chr7:107739010	chr7:107742817~107744581:-
UVM	cis	rs2188561	0.638	rs28690459	ENSG00000241764.3	AC002467.7	4.7	1.95e-05	0.0364	0.63	0.55	Alcohol consumption;	chr7:107740258	chr7:107742817~107744581:-
UVM	cis	rs2188561	0.638	rs3735609	ENSG00000241764.3	AC002467.7	4.7	1.95e-05	0.0364	0.63	0.55	Alcohol consumption;	chr7:107743299	chr7:107742817~107744581:-
UVM	cis	rs2188561	0.697	rs3735607	ENSG00000241764.3	AC002467.7	4.7	1.95e-05	0.0364	0.63	0.55	Alcohol consumption;	chr7:107743833	chr7:107742817~107744581:-
UVM	cis	rs2188561	0.697	rs10808154	ENSG00000241764.3	AC002467.7	4.7	1.95e-05	0.0364	0.63	0.55	Alcohol consumption;	chr7:107745951	chr7:107742817~107744581:-
UVM	cis	rs2188561	0.697	rs6956243	ENSG00000241764.3	AC002467.7	4.7	1.95e-05	0.0364	0.63	0.55	Alcohol consumption;	chr7:107748466	chr7:107742817~107744581:-
UVM	cis	rs2188561	0.666	rs13231387	ENSG00000241764.3	AC002467.7	4.7	1.95e-05	0.0364	0.63	0.55	Alcohol consumption;	chr7:107749534	chr7:107742817~107744581:-
UVM	cis	rs2188561	0.615	rs13226711	ENSG00000241764.3	AC002467.7	4.7	1.95e-05	0.0364	0.63	0.55	Alcohol consumption;	chr7:107754897	chr7:107742817~107744581:-
UVM	cis	rs2188561	0.697	rs12705421	ENSG00000241764.3	AC002467.7	4.7	1.95e-05	0.0364	0.63	0.55	Alcohol consumption;	chr7:107760984	chr7:107742817~107744581:-
UVM	cis	rs2188561	0.697	rs12539555	ENSG00000241764.3	AC002467.7	4.7	1.95e-05	0.0364	0.63	0.55	Alcohol consumption;	chr7:107764028	chr7:107742817~107744581:-
UVM	cis	rs11098499	0.955	rs13113112	ENSG00000245958.5	RP11-33B1.1	-4.7	1.95e-05	0.0364	-0.35	-0.55	Corneal astigmatism;	chr4:119234885	chr4:119454791~119552025:+
UVM	cis	rs35660623	0.619	rs1118537	ENSG00000253649.2	PRSS51	-4.7	1.95e-05	0.0364	-0.83	-0.55	3-hydroxypropylmercapturic acid levels in smokers;	chr8:10742892	chr8:10482878~10547585:-
UVM	cis	rs35660623	0.867	rs35385650	ENSG00000253649.2	PRSS51	-4.7	1.95e-05	0.0364	-0.83	-0.55	3-hydroxypropylmercapturic acid levels in smokers;	chr8:10745030	chr8:10482878~10547585:-
UVM	cis	rs35660623	0.867	rs35120358	ENSG00000253649.2	PRSS51	-4.7	1.95e-05	0.0364	-0.83	-0.55	3-hydroxypropylmercapturic acid levels in smokers;	chr8:10745032	chr8:10482878~10547585:-
UVM	cis	rs6487679	0.543	rs11612110	ENSG00000111788.10	RP11-22B23.1	-4.7	1.95e-05	0.0364	-0.62	-0.55	Non-alcoholic fatty liver disease histology (AST);	chr12:9200195	chr12:9277235~9313241:+
UVM	cis	rs916888	0.61	rs199452	ENSG00000214401.4	KANSL1-AS1	4.7	1.96e-05	0.0364	0.95	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46193576~46196723:+
UVM	cis	rs916888	0.647	rs199524	ENSG00000214401.4	KANSL1-AS1	-4.7	1.96e-05	0.0364	-0.95	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46193576~46196723:+
UVM	cis	rs916888	0.647	rs199523	ENSG00000214401.4	KANSL1-AS1	-4.7	1.96e-05	0.0364	-0.95	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46193576~46196723:+
UVM	cis	rs11098499	0.909	rs10020034	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119373176	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.618	rs28491261	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119373745	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs59394118	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119374396	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.865	rs9996417	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119374707	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs59866101	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119375436	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.618	rs6858383	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119375617	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.697	rs6832410	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119375645	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.865	rs1112817	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119376645	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.779	rs10016060	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119377257	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs10005644	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119377322	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.697	rs10016448	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119377690	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.657	rs9996569	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119377849	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs11723757	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119378514	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs11723839	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119378518	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.908	rs11729050	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119378911	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs28429722	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119378938	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs10014845	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119379922	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs12506546	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119380463	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.779	rs7674500	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119382438	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs28884220	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119386056	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs28793658	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119386059	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.865	rs4507344	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119386330	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.697	rs4373140	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119386543	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs13113483	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119387884	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.542	rs10440343	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119388632	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs28668716	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119388720	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.779	rs10011097	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119389204	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.779	rs7699346	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119389387	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.542	rs7677836	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119389483	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs10002083	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119389997	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs10024844	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119390373	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs7437420	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119391748	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs4345162	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119391804	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.657	rs4463052	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119392103	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.697	rs4560394	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119392280	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs13151285	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119393586	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs28572238	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119395531	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs28714195	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119395795	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.863	rs12508173	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119397371	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.908	rs12504149	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119397422	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs10008392	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119397684	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.58	rs12509234	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119398279	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs10014719	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119399560	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.908	rs9995234	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119400672	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.908	rs7695996	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119400878	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.908	rs7696649	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119401022	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs10518331	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119402440	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs13133522	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119403269	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs35091806	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119404374	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs35165976	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119404475	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs3890049	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119405128	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs6846442	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119405168	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.738	rs72918577	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119405546	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.865	rs4001305	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119438081	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs67265404	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119438115	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs71614422	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119438185	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.738	rs34566984	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119440115	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.738	rs34965784	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119440431	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs17009122	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119441248	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.505	rs75122014	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119441271	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs9685777	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119444810	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs9759478	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119446843	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs71614438	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119450097	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs66506550	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119450290	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs7659501	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119450397	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs71629403	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119451412	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.697	rs28655325	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119451844	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.779	rs80242894	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119454597	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.865	rs28634456	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119454623	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs78332141	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119454627	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.779	rs28495013	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119454676	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs28571712	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119454825	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.738	rs28408407	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119454875	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs1809406	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119455967	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.865	rs2389809	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119456244	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.657	rs71614442	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119458191	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs2892848	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119460186	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.865	rs9994730	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119460409	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs9994810	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119460435	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.697	rs10020027	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119460724	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.779	rs7356491	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119460819	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.697	rs11941899	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119461603	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs7681978	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119462620	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.821	rs28665282	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119463031	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.738	rs10026493	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119463039	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs7681214	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119464165	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.908	rs28559989	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119465472	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.908	rs28499576	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119465522	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs28632018	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119465575	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.908	rs71614449	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119465900	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs35063680	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119465947	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs34858317	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119465955	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs17046116	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119466104	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs17046118	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119466341	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs7654587	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119467251	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs11098525	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119468997	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs11098526	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119469204	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.821	rs10032151	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119470473	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.865	rs10032158	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119470477	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs6838814	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119471288	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs13107475	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119471856	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs7436506	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119472614	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs12499324	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119472631	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs10008459	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119473076	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs2127821	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119473380	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs1480931	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119474654	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs9998585	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119475647	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs10034623	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119476674	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs6842762	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119477081	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.908	rs11098527	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119478751	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs10518328	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119480624	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs6848389	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119481467	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs6822679	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119481547	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs4577559	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119482888	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs7656252	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119483113	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.865	rs28845498	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119484031	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.865	rs28753180	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119484212	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs56270433	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119484875	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs10006525	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119487776	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs6849171	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119488394	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs12508504	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119489452	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs7681544	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119490100	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs17005535	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119490407	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs11940028	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119490752	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs11935596	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119491302	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs12507964	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119491906	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.909	rs11098530	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119491999	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs6834796	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119493538	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs11729521	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119495633	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs11734241	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119495717	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs17006190	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119497683	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs28685688	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119499179	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs7687843	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119500056	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs2306455	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119500814	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs10031483	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119501481	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs10031665	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119501697	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs3733519	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119502293	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs3733520	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119502325	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs3733523	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119502564	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs3733524	ENSG00000245958.5	RP11-33B1.1	-4.7	1.97e-05	0.0364	-0.37	-0.55	Corneal astigmatism;	chr4:119502574	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs4309825	ENSG00000245958.5	RP11-33B1.1	4.7	1.97e-05	0.0364	0.37	0.55	Corneal astigmatism;	chr4:119393726	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs9993199	ENSG00000245958.5	RP11-33B1.1	4.7	1.97e-05	0.0364	0.37	0.55	Corneal astigmatism;	chr4:119471718	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs6849561	ENSG00000245958.5	RP11-33B1.1	4.7	1.97e-05	0.0364	0.37	0.55	Corneal astigmatism;	chr4:119488539	chr4:119454791~119552025:+
UVM	cis	rs875971	0.545	rs4718325	ENSG00000226824.5	RP4-756H11.3	-4.7	1.97e-05	0.0365	-0.83	-0.55	Aortic root size;	chr7:66215323	chr7:66654538~66669855:+
UVM	cis	rs11098499	0.955	rs6815725	ENSG00000245958.5	RP11-33B1.1	-4.69	2.01e-05	0.037	-0.35	-0.55	Corneal astigmatism;	chr4:119237255	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.955	rs1551	ENSG00000245958.5	RP11-33B1.1	-4.69	2.01e-05	0.037	-0.35	-0.55	Corneal astigmatism;	chr4:119237345	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.955	rs11931312	ENSG00000245958.5	RP11-33B1.1	-4.69	2.01e-05	0.037	-0.35	-0.55	Corneal astigmatism;	chr4:119237868	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.955	rs1511018	ENSG00000245958.5	RP11-33B1.1	-4.69	2.01e-05	0.037	-0.35	-0.55	Corneal astigmatism;	chr4:119240425	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.955	rs1397608	ENSG00000245958.5	RP11-33B1.1	-4.69	2.01e-05	0.037	-0.35	-0.55	Corneal astigmatism;	chr4:119240589	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.955	rs7685268	ENSG00000245958.5	RP11-33B1.1	-4.69	2.01e-05	0.037	-0.35	-0.55	Corneal astigmatism;	chr4:119241033	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.955	rs7684942	ENSG00000245958.5	RP11-33B1.1	-4.69	2.01e-05	0.037	-0.35	-0.55	Corneal astigmatism;	chr4:119241046	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.913	rs10010696	ENSG00000245958.5	RP11-33B1.1	-4.69	2.01e-05	0.037	-0.35	-0.55	Corneal astigmatism;	chr4:119243148	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.955	rs1511019	ENSG00000245958.5	RP11-33B1.1	-4.69	2.01e-05	0.037	-0.35	-0.55	Corneal astigmatism;	chr4:119244852	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.913	rs11098496	ENSG00000245958.5	RP11-33B1.1	-4.69	2.01e-05	0.037	-0.35	-0.55	Corneal astigmatism;	chr4:119246311	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.955	rs35197422	ENSG00000245958.5	RP11-33B1.1	-4.69	2.01e-05	0.037	-0.35	-0.55	Corneal astigmatism;	chr4:119248159	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.955	rs35434465	ENSG00000245958.5	RP11-33B1.1	-4.69	2.01e-05	0.037	-0.35	-0.55	Corneal astigmatism;	chr4:119248223	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.955	rs1511015	ENSG00000245958.5	RP11-33B1.1	-4.69	2.01e-05	0.037	-0.35	-0.55	Corneal astigmatism;	chr4:119249318	chr4:119454791~119552025:+
UVM	cis	rs11098499	1	rs10029750	ENSG00000245958.5	RP11-33B1.1	-4.69	2.01e-05	0.037	-0.35	-0.55	Corneal astigmatism;	chr4:119251388	chr4:119454791~119552025:+
UVM	cis	rs11098499	1	rs13435802	ENSG00000245958.5	RP11-33B1.1	4.69	2.01e-05	0.037	0.35	0.55	Corneal astigmatism;	chr4:119256805	chr4:119454791~119552025:+
UVM	cis	rs11098499	1	rs6837898	ENSG00000245958.5	RP11-33B1.1	-4.69	2.01e-05	0.037	-0.35	-0.55	Corneal astigmatism;	chr4:119257999	chr4:119454791~119552025:+
UVM	cis	rs11098499	1	rs28374891	ENSG00000245958.5	RP11-33B1.1	-4.69	2.01e-05	0.037	-0.35	-0.55	Corneal astigmatism;	chr4:119262395	chr4:119454791~119552025:+
UVM	cis	rs11098499	1	rs35643470	ENSG00000245958.5	RP11-33B1.1	-4.69	2.01e-05	0.037	-0.35	-0.55	Corneal astigmatism;	chr4:119263793	chr4:119454791~119552025:+
UVM	cis	rs11098499	1	rs12506395	ENSG00000245958.5	RP11-33B1.1	-4.69	2.01e-05	0.037	-0.35	-0.55	Corneal astigmatism;	chr4:119263939	chr4:119454791~119552025:+
UVM	cis	rs11098499	1	rs6849889	ENSG00000245958.5	RP11-33B1.1	-4.69	2.01e-05	0.037	-0.35	-0.55	Corneal astigmatism;	chr4:119265193	chr4:119454791~119552025:+
UVM	cis	rs11098499	1	rs58601355	ENSG00000245958.5	RP11-33B1.1	-4.69	2.01e-05	0.037	-0.35	-0.55	Corneal astigmatism;	chr4:119265212	chr4:119454791~119552025:+
UVM	cis	rs11098499	1	rs7659194	ENSG00000245958.5	RP11-33B1.1	-4.69	2.01e-05	0.037	-0.35	-0.55	Corneal astigmatism;	chr4:119285992	chr4:119454791~119552025:+
UVM	cis	rs10256972	0.527	rs12538544	ENSG00000229043.2	AC091729.9	4.69	2.01e-05	0.037	0.6	0.55	Endometriosis;Longevity;	chr7:1177804	chr7:1160374~1165267:+
UVM	cis	rs11098499	0.954	rs10017543	ENSG00000245958.5	RP11-33B1.1	-4.69	2.02e-05	0.0373	-0.37	-0.55	Corneal astigmatism;	chr4:119400265	chr4:119454791~119552025:+
UVM	cis	rs2253762	1	rs2253762	ENSG00000276742.1	RP11-500G22.4	4.69	2.04e-05	0.0375	0.59	0.54	Breast cancer;	chr10:122041907	chr10:121956782~121957098:+
UVM	cis	rs4660261	0.561	rs11210934	ENSG00000237950.1	RP11-7O11.3	4.68	2.06e-05	0.0378	0.57	0.54	Intelligence (multi-trait analysis);	chr1:43903763	chr1:43944370~43946551:-
UVM	cis	rs10256972	0.553	rs4724424	ENSG00000229043.2	AC091729.9	-4.68	2.06e-05	0.0379	-0.63	-0.54	Endometriosis;Longevity;	chr7:1114570	chr7:1160374~1165267:+
UVM	cis	rs12237653	0.799	rs12684409	ENSG00000236404.7	VLDLR-AS1	-4.68	2.08e-05	0.0381	-0.92	-0.54	Gambling;	chr9:2546716	chr9:2422702~2643359:-
UVM	cis	rs11098499	0.618	rs35265692	ENSG00000245958.5	RP11-33B1.1	-4.68	2.08e-05	0.0382	-0.37	-0.54	Corneal astigmatism;	chr4:119403980	chr4:119454791~119552025:+
UVM	cis	rs1879352	0.642	rs9303906	ENSG00000264235.4	RP13-270P17.1	4.68	2.08e-05	0.0382	0.8	0.54	Acute lymphoblastic leukemia (childhood);	chr18:2503030	chr18:3255436~3261850:-
UVM	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	4.68	2.08e-05	0.0382	0.48	0.54	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
UVM	cis	rs11098499	1	rs11098499	ENSG00000245958.5	RP11-33B1.1	-4.68	2.09e-05	0.0383	-0.35	-0.54	Corneal astigmatism;	chr4:119266456	chr4:119454791~119552025:+
UVM	cis	rs4862750	0.914	rs1991256	ENSG00000251008.1	ORAOV1P1	4.68	2.1e-05	0.0385	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186954176	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.914	rs1991255	ENSG00000251008.1	ORAOV1P1	4.68	2.1e-05	0.0385	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186954186	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs1991254	ENSG00000251008.1	ORAOV1P1	4.68	2.1e-05	0.0385	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186954221	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.914	rs6553026	ENSG00000251008.1	ORAOV1P1	4.68	2.1e-05	0.0385	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186954494	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.914	rs7658351	ENSG00000251008.1	ORAOV1P1	4.68	2.1e-05	0.0385	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186954526	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.914	rs6553028	ENSG00000251008.1	ORAOV1P1	4.68	2.1e-05	0.0385	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186954892	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs7664463	ENSG00000251008.1	ORAOV1P1	4.68	2.1e-05	0.0385	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186955532	chr4:186170863~186171257:-
UVM	cis	rs11148252	0.553	rs9536219	ENSG00000235660.1	LINC00345	-4.67	2.18e-05	0.0398	-0.6	-0.54	Lewy body disease;	chr13:52653166	chr13:52484161~52484680:-
UVM	cis	rs8062405	0.757	rs2411453	ENSG00000259982.1	CDC37P1	-4.67	2.19e-05	0.04	-0.58	-0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28700294~28701540:-
UVM	cis	rs8072100	0.967	rs8072644	ENSG00000228782.6	CTD-2026D20.3	-4.66	2.2e-05	0.0401	-0.57	-0.54	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575998	chr17:47450568~47492492:-
UVM	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-4.66	2.21e-05	0.0402	-0.76	-0.54	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
UVM	cis	rs4862750	0.794	rs7672272	ENSG00000251008.1	ORAOV1P1	4.66	2.21e-05	0.0402	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186975620	chr4:186170863~186171257:-
UVM	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	4.66	2.21e-05	0.0402	0.56	0.54	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
UVM	cis	rs9549328	0.837	rs3742239	ENSG00000267868.1	RP11-120K24.3	4.66	2.21e-05	0.0403	0.74	0.54	Systolic blood pressure;	chr13:113001322	chr13:112964835~112966131:-
UVM	cis	rs7104764	0.957	rs1045454	ENSG00000277290.1	RP11-326C3.16	4.66	2.22e-05	0.0404	0.45	0.54	Menarche (age at onset);	chr11:204228	chr11:243099~243483:-
UVM	cis	rs7104764	0.957	rs56357554	ENSG00000277290.1	RP11-326C3.16	4.66	2.22e-05	0.0404	0.45	0.54	Menarche (age at onset);	chr11:204715	chr11:243099~243483:-
UVM	cis	rs7104764	0.957	rs3782120	ENSG00000277290.1	RP11-326C3.16	4.66	2.22e-05	0.0404	0.45	0.54	Menarche (age at onset);	chr11:206089	chr11:243099~243483:-
UVM	cis	rs7104764	0.957	rs6598075	ENSG00000277290.1	RP11-326C3.16	4.66	2.22e-05	0.0404	0.45	0.54	Menarche (age at onset);	chr11:207275	chr11:243099~243483:-
UVM	cis	rs7104764	0.957	rs58692051	ENSG00000277290.1	RP11-326C3.16	4.66	2.22e-05	0.0404	0.45	0.54	Menarche (age at onset);	chr11:207410	chr11:243099~243483:-
UVM	cis	rs3091242	0.933	rs10903130	ENSG00000224183.1	SDHDP6	-4.66	2.23e-05	0.0405	-0.61	-0.54	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25294164~25294643:-
UVM	cis	rs3091242	0.933	rs11249251	ENSG00000224183.1	SDHDP6	-4.66	2.23e-05	0.0405	-0.61	-0.54	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25294164~25294643:-
UVM	cis	rs3091242	0.904	rs6661533	ENSG00000224183.1	SDHDP6	-4.66	2.23e-05	0.0405	-0.61	-0.54	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25294164~25294643:-
UVM	cis	rs55794721	0.509	rs12027110	ENSG00000224183.1	SDHDP6	-4.66	2.23e-05	0.0405	-0.61	-0.54	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25294164~25294643:-
UVM	cis	rs55794721	0.509	rs12027135	ENSG00000224183.1	SDHDP6	-4.66	2.23e-05	0.0405	-0.61	-0.54	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25294164~25294643:-
UVM	cis	rs55794721	0.509	rs6699113	ENSG00000224183.1	SDHDP6	-4.66	2.23e-05	0.0405	-0.61	-0.54	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25294164~25294643:-
UVM	cis	rs55794721	0.509	rs7554255	ENSG00000224183.1	SDHDP6	-4.66	2.23e-05	0.0405	-0.61	-0.54	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25294164~25294643:-
UVM	cis	rs55794721	0.509	rs4649085	ENSG00000224183.1	SDHDP6	-4.66	2.23e-05	0.0405	-0.61	-0.54	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25294164~25294643:-
UVM	cis	rs3091242	0.933	rs34006994	ENSG00000224183.1	SDHDP6	4.66	2.23e-05	0.0405	0.61	0.54	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25294164~25294643:-
UVM	cis	rs3091242	0.933	rs61775167	ENSG00000224183.1	SDHDP6	4.66	2.23e-05	0.0405	0.61	0.54	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25294164~25294643:-
UVM	cis	rs3091242	0.933	rs35497030	ENSG00000224183.1	SDHDP6	4.66	2.23e-05	0.0405	0.61	0.54	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25294164~25294643:-
UVM	cis	rs3091242	0.836	rs34997029	ENSG00000224183.1	SDHDP6	4.66	2.23e-05	0.0405	0.61	0.54	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25294164~25294643:-
UVM	cis	rs3091242	0.902	rs36003018	ENSG00000224183.1	SDHDP6	4.66	2.23e-05	0.0405	0.61	0.54	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25294164~25294643:-
UVM	cis	rs3091242	0.933	rs35403885	ENSG00000224183.1	SDHDP6	4.66	2.23e-05	0.0405	0.61	0.54	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25294164~25294643:-
UVM	cis	rs3091242	0.933	rs35530120	ENSG00000224183.1	SDHDP6	4.66	2.23e-05	0.0405	0.61	0.54	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25294164~25294643:-
UVM	cis	rs10170846	0.8	rs10194743	ENSG00000261428.2	RP11-16P6.1	4.66	2.23e-05	0.0405	0.64	0.54	Schizophrenia (inflammation and infection response interaction);	chr2:222653432	chr2:222566899~222569719:-
UVM	cis	rs2283792	0.765	rs9607298	ENSG00000224086.5	LL22NC03-86G7.1	-4.66	2.24e-05	0.0407	-0.66	-0.54	Multiple sclerosis;	chr22:21829844	chr22:21938293~21977632:+
UVM	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	4.66	2.25e-05	0.0407	0.46	0.54	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
UVM	cis	rs875971	0.571	rs160641	ENSG00000226824.5	RP4-756H11.3	4.65	2.29e-05	0.0411	0.82	0.54	Aortic root size;	chr7:66112359	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs4441996	ENSG00000226824.5	RP4-756H11.3	4.65	2.29e-05	0.0411	0.82	0.54	Aortic root size;	chr7:66123233	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs316328	ENSG00000226824.5	RP4-756H11.3	4.65	2.29e-05	0.0411	0.82	0.54	Aortic root size;	chr7:66143851	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs316324	ENSG00000226824.5	RP4-756H11.3	4.65	2.29e-05	0.0411	0.82	0.54	Aortic root size;	chr7:66145627	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs316323	ENSG00000226824.5	RP4-756H11.3	4.65	2.29e-05	0.0411	0.82	0.54	Aortic root size;	chr7:66146002	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs316316	ENSG00000226824.5	RP4-756H11.3	4.65	2.29e-05	0.0411	0.82	0.54	Aortic root size;	chr7:66149270	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs316305	ENSG00000226824.5	RP4-756H11.3	4.65	2.29e-05	0.0411	0.82	0.54	Aortic root size;	chr7:66152984	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs2460427	ENSG00000226824.5	RP4-756H11.3	4.65	2.29e-05	0.0411	0.82	0.54	Aortic root size;	chr7:66154218	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs10950025	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66158946	chr7:66654538~66669855:+
UVM	cis	rs875971	0.52	rs12666485	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66160135	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs67688847	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66161064	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs7787063	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66164012	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs12673308	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66166374	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs67397473	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66168318	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs10950027	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66169164	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs10950029	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66169334	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs73376401	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66174841	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs6460276	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66182290	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs67775320	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66193792	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs6460281	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66216128	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs73142233	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66221293	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs73142245	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66226662	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs17138149	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66228193	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs73142265	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66234510	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs17138156	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66249708	chr7:66654538~66669855:+
UVM	cis	rs875971	0.502	rs11769702	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66255529	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs1547529	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66258859	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs6970498	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66275908	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs6979636	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66276638	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs2420456	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66280619	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs7783889	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66283366	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs1909508	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66301366	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs11767262	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66302237	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs73146609	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66302477	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs2173571	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66305392	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs11770063	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66318029	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs3936065	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66325577	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs66594357	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66327797	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs4718335	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66339619	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs10950036	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66353241	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs2279757	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66363676	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs6969224	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66370011	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs11766183	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66374173	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs1065265	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66376216	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs75840613	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66376399	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs7811204	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66387213	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs73148639	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66390342	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs6460298	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66442783	chr7:66654538~66669855:+
UVM	cis	rs875971	0.571	rs78668714	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66474464	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs35459055	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66479399	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs73150604	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66480545	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs7810213	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66481592	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs75577046	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66493729	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs3735147	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66505541	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs6950988	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66511428	chr7:66654538~66669855:+
UVM	cis	rs875971	0.597	rs11763224	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66518628	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs73152714	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66534641	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs4718364	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66536353	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs2420612	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66536825	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs6961853	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66537035	chr7:66654538~66669855:+
UVM	cis	rs875971	0.528	rs801213	ENSG00000226824.5	RP4-756H11.3	4.65	2.29e-05	0.0411	0.82	0.54	Aortic root size;	chr7:66549931	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs801212	ENSG00000226824.5	RP4-756H11.3	4.65	2.29e-05	0.0411	0.82	0.54	Aortic root size;	chr7:66550643	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs801199	ENSG00000226824.5	RP4-756H11.3	4.65	2.29e-05	0.0411	0.82	0.54	Aortic root size;	chr7:66560286	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs1638724	ENSG00000226824.5	RP4-756H11.3	4.65	2.29e-05	0.0411	0.82	0.54	Aortic root size;	chr7:66575494	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs1267814	ENSG00000226824.5	RP4-756H11.3	4.65	2.29e-05	0.0411	0.82	0.54	Aortic root size;	chr7:66579422	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs1796217	ENSG00000226824.5	RP4-756H11.3	4.65	2.29e-05	0.0411	0.82	0.54	Aortic root size;	chr7:66620931	chr7:66654538~66669855:+
UVM	cis	rs875971	0.502	rs1796227	ENSG00000226824.5	RP4-756H11.3	4.65	2.29e-05	0.0411	0.82	0.54	Aortic root size;	chr7:66622032	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs2707851	ENSG00000226824.5	RP4-756H11.3	4.65	2.29e-05	0.0411	0.82	0.54	Aortic root size;	chr7:66624178	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs1638735	ENSG00000226824.5	RP4-756H11.3	-4.65	2.29e-05	0.0411	-0.82	-0.54	Aortic root size;	chr7:66630751	chr7:66654538~66669855:+
UVM	cis	rs875971	0.545	rs1796219	ENSG00000226824.5	RP4-756H11.3	4.65	2.29e-05	0.0411	0.82	0.54	Aortic root size;	chr7:66645977	chr7:66654538~66669855:+
UVM	cis	rs875971	0.502	rs6460311	ENSG00000226824.5	RP4-756H11.3	4.65	2.29e-05	0.0411	0.82	0.54	Aortic root size;	chr7:66646886	chr7:66654538~66669855:+
UVM	cis	rs6964833	0.873	rs4717905	ENSG00000123965.13	PMS2P5	4.65	2.3e-05	0.0411	0.94	0.54	Menarche (age at onset);	chr7:74668903	chr7:74894116~74897835:+
UVM	cis	rs3091242	0.9	rs4649086	ENSG00000224183.1	SDHDP6	-4.65	2.3e-05	0.0411	-0.61	-0.54	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25294164~25294643:-
UVM	cis	rs2739330	1	rs2739330	ENSG00000250470.1	AP000351.3	4.65	2.3e-05	0.0411	0.81	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23953099	chr22:23976904~23977585:-
UVM	cis	rs2739330	0.729	rs9612523	ENSG00000250470.1	AP000351.3	4.65	2.3e-05	0.0411	0.81	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23954339	chr22:23976904~23977585:-
UVM	cis	rs2739330	0.964	rs2739338	ENSG00000250470.1	AP000351.3	4.65	2.3e-05	0.0411	0.81	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23954943	chr22:23976904~23977585:-
UVM	cis	rs2739330	0.615	rs2858911	ENSG00000250470.1	AP000351.3	4.65	2.3e-05	0.0411	0.81	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23955008	chr22:23976904~23977585:-
UVM	cis	rs2739330	0.576	rs2858912	ENSG00000250470.1	AP000351.3	4.65	2.3e-05	0.0411	0.81	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23955010	chr22:23976904~23977585:-
UVM	cis	rs11673344	0.77	rs34729406	ENSG00000226686.6	LINC01535	4.65	2.32e-05	0.0415	0.77	0.54	Obesity-related traits;	chr19:37012764	chr19:37251912~37265535:+
UVM	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	4.65	2.33e-05	0.0415	0.6	0.54	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
UVM	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	4.65	2.33e-05	0.0415	0.6	0.54	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
UVM	cis	rs5769765	0.671	rs138833	ENSG00000229409.1	RP11-494O16.3	-4.65	2.33e-05	0.0415	-0.85	-0.54	Schizophrenia;	chr22:49785269	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.704	rs138837	ENSG00000229409.1	RP11-494O16.3	-4.65	2.33e-05	0.0415	-0.85	-0.54	Schizophrenia;	chr22:49787066	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.671	rs138841	ENSG00000229409.1	RP11-494O16.3	-4.65	2.33e-05	0.0415	-0.85	-0.54	Schizophrenia;	chr22:49788312	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.862	rs138856	ENSG00000229409.1	RP11-494O16.3	-4.65	2.33e-05	0.0415	-0.85	-0.54	Schizophrenia;	chr22:49805730	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.862	rs138857	ENSG00000229409.1	RP11-494O16.3	-4.65	2.33e-05	0.0415	-0.85	-0.54	Schizophrenia;	chr22:49805941	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.908	rs138864	ENSG00000229409.1	RP11-494O16.3	-4.65	2.33e-05	0.0415	-0.85	-0.54	Schizophrenia;	chr22:49811064	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.908	rs138867	ENSG00000229409.1	RP11-494O16.3	4.65	2.33e-05	0.0415	0.85	0.54	Schizophrenia;	chr22:49814055	chr22:49845929~49846090:+
UVM	cis	rs5769765	0.862	rs138870	ENSG00000229409.1	RP11-494O16.3	-4.65	2.33e-05	0.0415	-0.85	-0.54	Schizophrenia;	chr22:49816089	chr22:49845929~49846090:+
UVM	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	4.65	2.33e-05	0.0415	0.55	0.54	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
UVM	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	4.65	2.33e-05	0.0415	0.55	0.54	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
UVM	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	4.65	2.33e-05	0.0415	0.55	0.54	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
UVM	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	4.65	2.33e-05	0.0415	0.55	0.54	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
UVM	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	4.65	2.33e-05	0.0415	0.55	0.54	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
UVM	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	4.65	2.33e-05	0.0415	0.55	0.54	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
UVM	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-4.65	2.33e-05	0.0415	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
UVM	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-4.65	2.33e-05	0.0415	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
UVM	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-4.65	2.33e-05	0.0415	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
UVM	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-4.65	2.33e-05	0.0415	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
UVM	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-4.65	2.33e-05	0.0415	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
UVM	cis	rs1577917	0.74	rs2758845	ENSG00000203875.9	SNHG5	-4.65	2.33e-05	0.0415	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85625130	chr6:85660950~85678736:-
UVM	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-4.65	2.33e-05	0.0415	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
UVM	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-4.65	2.33e-05	0.0415	-0.55	-0.54	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
UVM	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.84	rs1792233	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71471133	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
UVM	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-4.65	2.33e-05	0.0415	-0.88	-0.54	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
UVM	cis	rs11098499	0.863	rs3736115	ENSG00000245958.5	RP11-33B1.1	4.65	2.33e-05	0.0415	0.37	0.54	Corneal astigmatism;	chr4:119567548	chr4:119454791~119552025:+
UVM	cis	rs5769765	0.671	rs138817	ENSG00000229409.1	RP11-494O16.3	-4.65	2.35e-05	0.0418	-0.88	-0.54	Schizophrenia;	chr22:49769410	chr22:49845929~49846090:+
UVM	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-4.64	2.36e-05	0.0419	-0.6	-0.54	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
UVM	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-4.64	2.36e-05	0.0419	-0.6	-0.54	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
UVM	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-4.64	2.36e-05	0.0419	-0.6	-0.54	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
UVM	cis	rs4862750	0.914	rs11945845	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186952982	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.837	rs1863404	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186953500	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.914	rs9998558	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186953537	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.832	rs10007858	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186956338	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs9997374	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186956395	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs13143414	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186957059	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs13110072	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186957370	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs6825289	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186957955	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs13101380	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186973590	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs13101408	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186973623	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs56389997	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186973642	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.874	rs6822062	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186974399	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.758	rs2375915	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186975101	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs6852907	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186975940	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs6830426	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186976116	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs6830828	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186976318	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.832	rs6836426	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186976683	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs6811837	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186977008	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs9998172	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186977619	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs9998173	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186977624	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs7672831	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186977728	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs6553030	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186978080	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.832	rs6836076	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186978506	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs6836781	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186978547	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs11947595	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186978673	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs7679956	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186979075	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs7658314	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186979202	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.832	rs6419953	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186979355	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.794	rs7692427	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186980573	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.832	rs9995958	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186980610	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.915	rs6835681	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186982322	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.957	rs1030381	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186982414	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.794	rs1030382	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186982628	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.957	rs2375916	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186982769	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.957	rs4861733	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186982779	chr4:186170863~186171257:-
UVM	cis	rs4862750	1	rs4862750	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186982889	chr4:186170863~186171257:-
UVM	cis	rs4862750	1	rs4862751	ENSG00000251008.1	ORAOV1P1	4.64	2.36e-05	0.0419	0.65	0.54	Lobe attachment (rater-scored or self-reported);	chr4:186982896	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.914	rs1863405	ENSG00000251008.1	ORAOV1P1	-4.64	2.36e-05	0.0419	-0.65	-0.54	Lobe attachment (rater-scored or self-reported);	chr4:186953374	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs6821507	ENSG00000251008.1	ORAOV1P1	-4.64	2.36e-05	0.0419	-0.65	-0.54	Lobe attachment (rater-scored or self-reported);	chr4:186955675	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs4862747	ENSG00000251008.1	ORAOV1P1	-4.64	2.36e-05	0.0419	-0.65	-0.54	Lobe attachment (rater-scored or self-reported);	chr4:186956082	chr4:186170863~186171257:-
UVM	cis	rs4862750	0.872	rs6811569	ENSG00000251008.1	ORAOV1P1	-4.64	2.36e-05	0.0419	-0.65	-0.54	Lobe attachment (rater-scored or self-reported);	chr4:186976834	chr4:186170863~186171257:-
UVM	cis	rs11673344	0.563	rs256744	ENSG00000226686.6	LINC01535	-4.64	2.36e-05	0.0419	-0.69	-0.54	Obesity-related traits;	chr19:37364586	chr19:37251912~37265535:+
UVM	cis	rs11673344	0.562	rs256740	ENSG00000226686.6	LINC01535	-4.64	2.36e-05	0.0419	-0.69	-0.54	Obesity-related traits;	chr19:37365451	chr19:37251912~37265535:+
UVM	cis	rs11098499	0.955	rs13129661	ENSG00000245958.5	RP11-33B1.1	-4.64	2.4e-05	0.0422	-0.35	-0.54	Corneal astigmatism;	chr4:119231754	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.955	rs56386062	ENSG00000245958.5	RP11-33B1.1	-4.64	2.4e-05	0.0422	-0.35	-0.54	Corneal astigmatism;	chr4:119233980	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.955	rs4145951	ENSG00000245958.5	RP11-33B1.1	-4.64	2.4e-05	0.0422	-0.35	-0.54	Corneal astigmatism;	chr4:119234662	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.955	rs35916640	ENSG00000245958.5	RP11-33B1.1	-4.64	2.4e-05	0.0422	-0.35	-0.54	Corneal astigmatism;	chr4:119234697	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.955	rs13114751	ENSG00000245958.5	RP11-33B1.1	-4.64	2.4e-05	0.0422	-0.35	-0.54	Corneal astigmatism;	chr4:119235462	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.913	rs35271032	ENSG00000245958.5	RP11-33B1.1	-4.64	2.4e-05	0.0422	-0.35	-0.54	Corneal astigmatism;	chr4:119235504	chr4:119454791~119552025:+
UVM	cis	rs832187	0.776	rs854622	ENSG00000280620.1	SCAANT1	4.64	2.4e-05	0.0422	0.58	0.54	Schizophrenia;	chr3:63877166	chr3:63911518~63911772:-
UVM	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
UVM	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	4.64	2.4e-05	0.0422	0.45	0.54	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
UVM	cis	rs7104764	0.879	rs6598072	ENSG00000277290.1	RP11-326C3.16	-4.63	2.45e-05	0.0428	-0.44	-0.54	Menarche (age at onset);	chr11:219793	chr11:243099~243483:-
UVM	cis	rs7104764	0.957	rs6598071	ENSG00000277290.1	RP11-326C3.16	-4.63	2.45e-05	0.0428	-0.44	-0.54	Menarche (age at onset);	chr11:219800	chr11:243099~243483:-
UVM	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	4.63	2.47e-05	0.0432	0.47	0.54	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
UVM	cis	rs5760092	0.618	rs4461358	ENSG00000218537.1	MIF-AS1	-4.63	2.5e-05	0.0437	-0.79	-0.54	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23894426~23898930:-
UVM	cis	rs6700559	0.716	rs12140579	ENSG00000260088.1	RP11-92G12.3	4.63	2.51e-05	0.0437	0.77	0.54	Coronary artery disease;	chr1:200655368	chr1:200669507~200694250:+
UVM	cis	rs11098499	0.866	rs72676074	ENSG00000245958.5	RP11-33B1.1	-4.63	2.52e-05	0.0439	-0.37	-0.54	Corneal astigmatism;	chr4:119438686	chr4:119454791~119552025:+
UVM	cis	rs2080501	0.628	rs1861656	ENSG00000279356.1	RP11-429P3.8	-4.63	2.52e-05	0.0439	-0.42	-0.54	IgG glycosylation;	chr16:49629108	chr16:50072862~50074986:+
UVM	cis	rs74054849	0.85	rs10927835	ENSG00000271742.1	RP4-680D5.9	4.62	2.53e-05	0.0441	1.19	0.54	Alcoholic chronic pancreatitis;	chr1:15707706	chr1:15682873~15683128:-
UVM	cis	rs5760092	0.618	rs4461358	ENSG00000273295.1	AP000350.5	-4.62	2.53e-05	0.0441	-0.64	-0.54	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23901432~23907068:-
UVM	cis	rs9487094	0.626	rs11153213	ENSG00000260273.1	RP11-425D10.10	4.62	2.55e-05	0.0444	0.6	0.54	Height;	chr6:109693890	chr6:109382795~109383666:+
UVM	cis	rs9487094	0.67	rs12201356	ENSG00000260273.1	RP11-425D10.10	4.62	2.55e-05	0.0444	0.6	0.54	Height;	chr6:109694672	chr6:109382795~109383666:+
UVM	cis	rs9549328	0.885	rs3011545	ENSG00000267868.1	RP11-120K24.3	-4.62	2.55e-05	0.0444	-0.71	-0.54	Systolic blood pressure;	chr13:112982696	chr13:112964835~112966131:-
UVM	cis	rs875971	0.545	rs221986	ENSG00000226824.5	RP4-756H11.3	4.62	2.55e-05	0.0445	0.82	0.54	Aortic root size;	chr7:66105323	chr7:66654538~66669855:+
UVM	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-4.62	2.56e-05	0.0446	-0.6	-0.54	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
UVM	cis	rs73086581	0.687	rs16989002	ENSG00000229539.1	RP11-119B16.2	4.62	2.6e-05	0.0451	1.08	0.54	Response to antidepressants in depression;	chr20:3870056	chr20:3888239~3888868:-
UVM	cis	rs73086581	0.741	rs17212649	ENSG00000229539.1	RP11-119B16.2	4.62	2.6e-05	0.0451	1.08	0.54	Response to antidepressants in depression;	chr20:3872446	chr20:3888239~3888868:-
UVM	cis	rs73086581	0.787	rs73084505	ENSG00000229539.1	RP11-119B16.2	4.62	2.6e-05	0.0451	1.08	0.54	Response to antidepressants in depression;	chr20:3876227	chr20:3888239~3888868:-
UVM	cis	rs7104764	1	rs2293167	ENSG00000277290.1	RP11-326C3.16	4.61	2.61e-05	0.0454	0.44	0.54	Menarche (age at onset);	chr11:211644	chr11:243099~243483:-
UVM	cis	rs6700559	0.74	rs4387211	ENSG00000260088.1	RP11-92G12.3	-4.61	2.63e-05	0.0455	-0.75	-0.54	Coronary artery disease;	chr1:200676810	chr1:200669507~200694250:+
UVM	cis	rs1930961	1	rs6519611	ENSG00000272977.1	CTA-390C10.10	-4.61	2.64e-05	0.0457	-1.01	-0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25449888	chr22:25476218~25479971:+
UVM	cis	rs1930961	1	rs9624834	ENSG00000272977.1	CTA-390C10.10	-4.61	2.64e-05	0.0457	-1.01	-0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25450048	chr22:25476218~25479971:+
UVM	cis	rs1930961	1	rs9624835	ENSG00000272977.1	CTA-390C10.10	-4.61	2.64e-05	0.0457	-1.01	-0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25450054	chr22:25476218~25479971:+
UVM	cis	rs1930961	1	rs9624836	ENSG00000272977.1	CTA-390C10.10	-4.61	2.64e-05	0.0457	-1.01	-0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25450120	chr22:25476218~25479971:+
UVM	cis	rs1930961	0.867	rs6423498	ENSG00000272977.1	CTA-390C10.10	-4.61	2.64e-05	0.0457	-1.01	-0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25457401	chr22:25476218~25479971:+
UVM	cis	rs7772486	0.754	rs6570708	ENSG00000235652.6	RP11-545I5.3	-4.61	2.65e-05	0.0458	-0.5	-0.54	Lobe attachment (rater-scored or self-reported);	chr6:145668292	chr6:145799409~145886585:+
UVM	cis	rs858239	0.614	rs2014816	ENSG00000230658.1	KLHL7-AS1	4.61	2.65e-05	0.0458	0.63	0.54	Cerebrospinal fluid biomarker levels;	chr7:23083417	chr7:23101228~23105703:-
UVM	cis	rs858239	0.669	rs56400441	ENSG00000230658.1	KLHL7-AS1	4.61	2.65e-05	0.0458	0.63	0.54	Cerebrospinal fluid biomarker levels;	chr7:23103945	chr7:23101228~23105703:-
UVM	cis	rs6674176	0.66	rs3791112	ENSG00000237950.1	RP11-7O11.3	4.61	2.66e-05	0.0459	0.56	0.54	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43913576	chr1:43944370~43946551:-
UVM	cis	rs11098499	0.909	rs1546504	ENSG00000245958.5	RP11-33B1.1	-4.61	2.66e-05	0.0459	-0.37	-0.54	Corneal astigmatism;	chr4:119320024	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs1546505	ENSG00000245958.5	RP11-33B1.1	-4.61	2.66e-05	0.0459	-0.37	-0.54	Corneal astigmatism;	chr4:119320069	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.908	rs1002152	ENSG00000245958.5	RP11-33B1.1	-4.61	2.66e-05	0.0459	-0.37	-0.54	Corneal astigmatism;	chr4:119352232	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.865	rs11722183	ENSG00000245958.5	RP11-33B1.1	-4.61	2.66e-05	0.0459	-0.37	-0.54	Corneal astigmatism;	chr4:119359442	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.954	rs10017371	ENSG00000245958.5	RP11-33B1.1	-4.61	2.66e-05	0.0459	-0.37	-0.54	Corneal astigmatism;	chr4:119372621	chr4:119454791~119552025:+
UVM	cis	rs11098499	0.865	rs11098513	ENSG00000245958.5	RP11-33B1.1	-4.61	2.66e-05	0.0459	-0.37	-0.54	Corneal astigmatism;	chr4:119394920	chr4:119454791~119552025:+
UVM	cis	rs9468199	0.523	rs9468152	ENSG00000261839.1	RP1-265C24.8	4.6	2.71e-05	0.0467	0.8	0.54	Parkinson's disease;	chr6:27525127	chr6:28136849~28139678:+
UVM	cis	rs6700559	0.74	rs11582610	ENSG00000260088.1	RP11-92G12.3	4.6	2.72e-05	0.0468	0.75	0.54	Coronary artery disease;	chr1:200675973	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.74	rs10919997	ENSG00000260088.1	RP11-92G12.3	4.6	2.72e-05	0.0468	0.75	0.54	Coronary artery disease;	chr1:200677522	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.74	rs4437908	ENSG00000260088.1	RP11-92G12.3	4.6	2.72e-05	0.0468	0.75	0.54	Coronary artery disease;	chr1:200679311	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.74	rs4072551	ENSG00000260088.1	RP11-92G12.3	4.6	2.72e-05	0.0468	0.75	0.54	Coronary artery disease;	chr1:200679993	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.74	rs4072554	ENSG00000260088.1	RP11-92G12.3	4.6	2.72e-05	0.0468	0.75	0.54	Coronary artery disease;	chr1:200680238	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.74	rs10919999	ENSG00000260088.1	RP11-92G12.3	4.6	2.72e-05	0.0468	0.75	0.54	Coronary artery disease;	chr1:200680631	chr1:200669507~200694250:+
UVM	cis	rs6700559	0.654	rs12061556	ENSG00000260088.1	RP11-92G12.3	4.6	2.72e-05	0.0468	0.75	0.54	Coronary artery disease;	chr1:200681111	chr1:200669507~200694250:+
UVM	cis	rs11148252	0.574	rs73186430	ENSG00000235660.1	LINC00345	-4.6	2.73e-05	0.0469	-0.59	-0.54	Lewy body disease;	chr13:52658756	chr13:52484161~52484680:-
UVM	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-4.6	2.75e-05	0.0472	-0.46	-0.54	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
UVM	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-4.6	2.75e-05	0.0472	-0.46	-0.54	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
UVM	cis	rs11673344	0.67	rs73039188	ENSG00000226686.6	LINC01535	4.6	2.76e-05	0.0475	0.73	0.54	Obesity-related traits;	chr19:36922449	chr19:37251912~37265535:+
UVM	cis	rs34375054	0.525	rs7133614	ENSG00000279233.1	RP11-158L12.4	4.6	2.77e-05	0.0475	0.49	0.54	Post bronchodilator FEV1/FVC ratio;	chr12:125121411	chr12:125138245~125141711:+
UVM	cis	rs11673344	0.9	rs11671112	ENSG00000226686.6	LINC01535	4.6	2.78e-05	0.0478	0.71	0.54	Obesity-related traits;	chr19:37169384	chr19:37251912~37265535:+
UVM	cis	rs4296977	0.516	rs79761449	ENSG00000213542.3	RP11-467H10.1	-4.59	2.82e-05	0.0484	-0.58	-0.54	Allergic disease (asthma, hay fever or eczema);	chr7:77296176	chr7:77115399~77116192:-
UVM	cis	rs7615952	0.736	rs9862893	ENSG00000171084.14	FAM86JP	4.59	2.83e-05	0.0485	0.79	0.54	Blood pressure (smoking interaction);	chr3:125968131	chr3:125916620~125930024:+
UVM	cis	rs2442825	0.72	rs2648561	ENSG00000206573.7	THUMPD3-AS1	4.59	2.84e-05	0.0486	0.3	0.54	Cerebrospinal fluid clusterin levels;	chr3:9376399	chr3:9349689~9398579:-
UVM	cis	rs2283792	0.765	rs9340	ENSG00000224086.5	LL22NC03-86G7.1	-4.59	2.84e-05	0.0486	-0.63	-0.54	Multiple sclerosis;	chr22:21761064	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.765	rs1063311	ENSG00000224086.5	LL22NC03-86G7.1	-4.59	2.84e-05	0.0486	-0.63	-0.54	Multiple sclerosis;	chr22:21762178	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.765	rs2266966	ENSG00000224086.5	LL22NC03-86G7.1	-4.59	2.84e-05	0.0486	-0.63	-0.54	Multiple sclerosis;	chr22:21767265	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.74	rs2283791	ENSG00000224086.5	LL22NC03-86G7.1	-4.59	2.84e-05	0.0486	-0.63	-0.54	Multiple sclerosis;	chr22:21776656	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.715	rs56227348	ENSG00000224086.5	LL22NC03-86G7.1	-4.59	2.84e-05	0.0486	-0.63	-0.54	Multiple sclerosis;	chr22:21791443	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.765	rs9610328	ENSG00000224086.5	LL22NC03-86G7.1	-4.59	2.84e-05	0.0486	-0.63	-0.54	Multiple sclerosis;	chr22:21793085	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.765	rs6518968	ENSG00000224086.5	LL22NC03-86G7.1	-4.59	2.84e-05	0.0486	-0.63	-0.54	Multiple sclerosis;	chr22:21793327	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.765	rs7290469	ENSG00000224086.5	LL22NC03-86G7.1	-4.59	2.84e-05	0.0486	-0.63	-0.54	Multiple sclerosis;	chr22:21796693	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.765	rs9610338	ENSG00000224086.5	LL22NC03-86G7.1	4.59	2.84e-05	0.0486	0.63	0.54	Multiple sclerosis;	chr22:21797532	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.765	rs9607285	ENSG00000224086.5	LL22NC03-86G7.1	-4.59	2.84e-05	0.0486	-0.63	-0.54	Multiple sclerosis;	chr22:21808704	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.765	rs2266969	ENSG00000224086.5	LL22NC03-86G7.1	-4.59	2.84e-05	0.0486	-0.63	-0.54	Multiple sclerosis;	chr22:21819618	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.765	rs2283793	ENSG00000224086.5	LL22NC03-86G7.1	-4.59	2.84e-05	0.0486	-0.63	-0.54	Multiple sclerosis;	chr22:21827189	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.765	rs9610374	ENSG00000224086.5	LL22NC03-86G7.1	-4.59	2.84e-05	0.0486	-0.63	-0.54	Multiple sclerosis;	chr22:21832514	chr22:21938293~21977632:+
UVM	cis	rs2283792	0.765	rs5999752	ENSG00000224086.5	LL22NC03-86G7.1	-4.59	2.84e-05	0.0486	-0.63	-0.54	Multiple sclerosis;	chr22:21833894	chr22:21938293~21977632:+
UVM	cis	rs76935404	0.868	rs73034462	ENSG00000256612.6	CYP2B7P	-4.59	2.85e-05	0.0487	-0.67	-0.54	nicotine metabolite ratio in current smokers;	chr19:40912229	chr19:40924219~40950660:+
UVM	cis	rs76935404	0.899	rs73034465	ENSG00000256612.6	CYP2B7P	-4.59	2.85e-05	0.0487	-0.67	-0.54	nicotine metabolite ratio in current smokers;	chr19:40913170	chr19:40924219~40950660:+
UVM	cis	rs76935404	1	rs76935404	ENSG00000256612.6	CYP2B7P	-4.59	2.85e-05	0.0487	-0.67	-0.54	nicotine metabolite ratio in current smokers;	chr19:40913389	chr19:40924219~40950660:+
UVM	cis	rs76935404	0.811	rs28417358	ENSG00000256612.6	CYP2B7P	-4.59	2.85e-05	0.0487	-0.67	-0.54	nicotine metabolite ratio in current smokers;	chr19:40922200	chr19:40924219~40950660:+
UVM	cis	rs76935404	0.811	rs11083589	ENSG00000256612.6	CYP2B7P	-4.59	2.85e-05	0.0487	-0.67	-0.54	nicotine metabolite ratio in current smokers;	chr19:40922511	chr19:40924219~40950660:+
UVM	cis	rs76935404	0.811	rs4609955	ENSG00000256612.6	CYP2B7P	-4.59	2.85e-05	0.0487	-0.67	-0.54	nicotine metabolite ratio in current smokers;	chr19:40927708	chr19:40924219~40950660:+
UVM	cis	rs76935404	0.811	rs12151139	ENSG00000256612.6	CYP2B7P	4.59	2.85e-05	0.0487	0.67	0.54	nicotine metabolite ratio in current smokers;	chr19:40927638	chr19:40924219~40950660:+
UVM	cis	rs76935404	0.811	rs8100418	ENSG00000256612.6	CYP2B7P	-4.59	2.86e-05	0.0488	-0.67	-0.54	nicotine metabolite ratio in current smokers;	chr19:40908458	chr19:40924219~40950660:+
UVM	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	4.59	2.87e-05	0.0489	0.58	0.54	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
UVM	cis	rs853679	0.527	rs9461443	ENSG00000216676.2	RP1-15D7.1	-4.59	2.87e-05	0.0489	-0.91	-0.54	Depression;	chr6:28226851	chr6:27652602~27652825:-
UVM	cis	rs853679	0.55	rs34477097	ENSG00000216676.2	RP1-15D7.1	-4.59	2.87e-05	0.0489	-0.91	-0.54	Depression;	chr6:28229408	chr6:27652602~27652825:-
UVM	cis	rs741738	1	rs741738	ENSG00000251661.3	RP11-326C3.11	-4.59	2.89e-05	0.0492	-0.71	-0.54	Granulocyte percentage of myeloid white cells;	chr11:309508	chr11:318640~325631:+
UVM	cis	rs6142102	0.812	rs725478	ENSG00000275784.1	RP5-1125A11.6	4.58	2.93e-05	0.0498	0.66	0.54	Skin pigmentation;	chr20:33930548	chr20:33989480~33991818:-
UVM	cis	rs6142102	0.812	rs761238	ENSG00000275784.1	RP5-1125A11.6	4.58	2.93e-05	0.0498	0.66	0.54	Skin pigmentation;	chr20:33932182	chr20:33989480~33991818:-
UVM	cis	rs6142102	0.961	rs6059587	ENSG00000275784.1	RP5-1125A11.6	-4.58	2.93e-05	0.0498	-0.66	-0.54	Skin pigmentation;	chr20:33955120	chr20:33989480~33991818:-
UVM	cis	rs2919917	1	rs2953475	ENSG00000254352.1	RP11-578O24.2	-4.58	2.93e-05	0.0498	-0.39	-0.54	Lymphocyte counts;	chr8:78725903	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs1441438	ENSG00000254352.1	RP11-578O24.2	-4.58	2.93e-05	0.0498	-0.39	-0.54	Lymphocyte counts;	chr8:78729534	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs894221	ENSG00000254352.1	RP11-578O24.2	-4.58	2.93e-05	0.0498	-0.39	-0.54	Lymphocyte counts;	chr8:78736822	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs13269243	ENSG00000254352.1	RP11-578O24.2	4.58	2.93e-05	0.0498	0.39	0.54	Lymphocyte counts;	chr8:78669501	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs1054283	ENSG00000254352.1	RP11-578O24.2	4.58	2.93e-05	0.0498	0.39	0.54	Lymphocyte counts;	chr8:78698475	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs7010897	ENSG00000254352.1	RP11-578O24.2	4.58	2.93e-05	0.0498	0.39	0.54	Lymphocyte counts;	chr8:78708119	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs11986947	ENSG00000254352.1	RP11-578O24.2	4.58	2.93e-05	0.0498	0.39	0.54	Lymphocyte counts;	chr8:78708957	chr8:78723796~78724136:-
UVM	cis	rs2919917	0.915	rs2953477	ENSG00000254352.1	RP11-578O24.2	4.58	2.93e-05	0.0498	0.39	0.54	Lymphocyte counts;	chr8:78712370	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs2717539	ENSG00000254352.1	RP11-578O24.2	4.58	2.93e-05	0.0498	0.39	0.54	Lymphocyte counts;	chr8:78716804	chr8:78723796~78724136:-
UVM	cis	rs2919917	0.793	rs2625664	ENSG00000254352.1	RP11-578O24.2	4.58	2.93e-05	0.0498	0.39	0.54	Lymphocyte counts;	chr8:78718373	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs1026920	ENSG00000254352.1	RP11-578O24.2	4.58	2.93e-05	0.0498	0.39	0.54	Lymphocyte counts;	chr8:78719775	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs2717538	ENSG00000254352.1	RP11-578O24.2	4.58	2.93e-05	0.0498	0.39	0.54	Lymphocyte counts;	chr8:78720914	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs2919936	ENSG00000254352.1	RP11-578O24.2	4.58	2.93e-05	0.0498	0.39	0.54	Lymphocyte counts;	chr8:78721772	chr8:78723796~78724136:-
UVM	cis	rs2919917	1	rs2046338	ENSG00000254352.1	RP11-578O24.2	4.58	2.93e-05	0.0498	0.39	0.54	Lymphocyte counts;	chr8:78723734	chr8:78723796~78724136:-
UVM	cis	rs2919917	0.915	rs2046339	ENSG00000254352.1	RP11-578O24.2	4.58	2.93e-05	0.0498	0.39	0.54	Lymphocyte counts;	chr8:78724283	chr8:78723796~78724136:-
UVM	cis	rs11148252	0.574	rs3742297	ENSG00000235660.1	LINC00345	-4.58	2.93e-05	0.0498	-0.59	-0.54	Lewy body disease;	chr13:52703932	chr13:52484161~52484680:-
UVM	cis	rs11148252	0.574	rs9536247	ENSG00000235660.1	LINC00345	-4.58	2.93e-05	0.0498	-0.59	-0.54	Lewy body disease;	chr13:52705407	chr13:52484161~52484680:-
UVM	cis	rs11148252	0.553	rs2147692	ENSG00000235660.1	LINC00345	-4.58	2.93e-05	0.0498	-0.59	-0.54	Lewy body disease;	chr13:52712888	chr13:52484161~52484680:-
UVM	trans	rs6477998	0.58	rs12343629	ENSG00000238072.1	RP11-305M3.2	13.8	5.07e-19	2.55e-09	1.15	0.89	Hematology traits;	chr9:113279301	chr7:129410113~129410370:-
UVM	trans	rs6477998	0.58	rs11552582	ENSG00000238072.1	RP11-305M3.2	13.8	5.07e-19	2.55e-09	1.15	0.89	Hematology traits;	chr9:113282718	chr7:129410113~129410370:-
UVM	trans	rs6477998	0.58	rs10981715	ENSG00000238072.1	RP11-305M3.2	13.8	5.07e-19	2.55e-09	1.15	0.89	Hematology traits;	chr9:113287218	chr7:129410113~129410370:-
UVM	trans	rs6477998	0.58	rs10759638	ENSG00000238072.1	RP11-305M3.2	-13.8	5.07e-19	2.55e-09	-1.15	-0.89	Hematology traits;	chr9:113280212	chr7:129410113~129410370:-
UVM	trans	rs6477998	0.58	rs9299214	ENSG00000238072.1	RP11-305M3.2	13.46	1.41e-18	2.55e-09	1.2	0.88	Hematology traits;	chr9:113273416	chr7:129410113~129410370:-
UVM	trans	rs6477998	0.603	rs10117451	ENSG00000238072.1	RP11-305M3.2	13.46	1.41e-18	2.55e-09	1.2	0.88	Hematology traits;	chr9:113273610	chr7:129410113~129410370:-
UVM	trans	rs941207	0.756	rs7978685	ENSG00000121089.4	NACA3P	13.4	1.7e-18	2.55e-09	1.29	0.88	Platelet count;	chr12:56709370	chr4:164943290~164943937:+
UVM	trans	rs941207	0.724	rs4788	ENSG00000121089.4	NACA3P	13.4	1.7e-18	2.55e-09	1.29	0.88	Platelet count;	chr12:56712876	chr4:164943290~164943937:+
UVM	trans	rs941207	0.756	rs2958149	ENSG00000121089.4	NACA3P	13.4	1.7e-18	2.55e-09	1.29	0.88	Platelet count;	chr12:56716008	chr4:164943290~164943937:+
UVM	trans	rs941207	0.756	rs2926743	ENSG00000121089.4	NACA3P	13.4	1.7e-18	2.55e-09	1.29	0.88	Platelet count;	chr12:56720316	chr4:164943290~164943937:+
UVM	trans	rs941207	0.724	rs1979325	ENSG00000121089.4	NACA3P	13.4	1.7e-18	2.55e-09	1.29	0.88	Platelet count;	chr12:56728152	chr4:164943290~164943937:+
UVM	trans	rs941207	0.756	rs7313074	ENSG00000121089.4	NACA3P	-13.4	1.7e-18	2.55e-09	-1.29	-0.88	Platelet count;	chr12:56760705	chr4:164943290~164943937:+
UVM	trans	rs6477998	0.58	rs4979233	ENSG00000238072.1	RP11-305M3.2	13.34	2.06e-18	2.55e-09	1.13	0.88	Hematology traits;	chr9:113295501	chr7:129410113~129410370:-
UVM	trans	rs13177918	0.677	rs3857421	ENSG00000239528.1	RPS14P8	-13.18	3.32e-18	2.55e-09	-1.37	-0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.677	rs57890152	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.75	rs58256223	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.75	rs59354956	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.686	rs12654827	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.677	rs13160685	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.677	rs13161099	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.629	rs13161261	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.677	rs13161417	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.677	rs13161156	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.677	rs13181401	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.677	rs4541646	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.677	rs3900644	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.677	rs2070844	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.677	rs2073472	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.629	rs2070842	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.677	rs13171800	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.677	rs2070841	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.677	rs13177951	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.677	rs13177970	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.677	rs13164105	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.677	rs4841	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.677	rs13183077	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.677	rs3797622	ENSG00000239528.1	RPS14P8	13.18	3.32e-18	2.55e-09	1.37	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr5:116562562~116562930:+
UVM	trans	rs941207	0.789	rs2958145	ENSG00000121089.4	NACA3P	-12.95	6.61e-18	4.31e-09	-1.28	-0.87	Platelet count;	chr12:56662290	chr4:164943290~164943937:+
UVM	trans	rs941207	0.756	rs2958153	ENSG00000121089.4	NACA3P	12.95	6.61e-18	4.31e-09	1.28	0.87	Platelet count;	chr12:56687733	chr4:164943290~164943937:+
UVM	trans	rs6477998	0.557	rs11789755	ENSG00000238072.1	RP11-305M3.2	12.89	8.1e-18	5.21e-09	1.14	0.87	Hematology traits;	chr9:113292796	chr7:129410113~129410370:-
UVM	trans	rs13177918	0.626	rs3819332	ENSG00000239528.1	RPS14P8	12.78	1.12e-17	6.98e-09	1.36	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.626	rs13170300	ENSG00000239528.1	RPS14P8	12.78	1.12e-17	6.98e-09	1.36	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.557	rs12520101	ENSG00000239528.1	RPS14P8	12.69	1.52e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.677	rs3857421	ENSG00000224114.1	RP11-343H5.4	-12.62	1.89e-17	8e-09	-1.38	-0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.677	rs57890152	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.75	rs58256223	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.75	rs59354956	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.686	rs12654827	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.677	rs13160685	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.677	rs13161099	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.629	rs13161261	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.677	rs13161417	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.677	rs13161156	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.677	rs13181401	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.677	rs4541646	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.677	rs3900644	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.677	rs2070844	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.677	rs2073472	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.629	rs2070842	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.677	rs13171800	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.677	rs2070841	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.677	rs13177951	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.677	rs13177970	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.677	rs13164105	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.677	rs4841	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.677	rs13183077	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.677	rs3797622	ENSG00000224114.1	RP11-343H5.4	12.62	1.89e-17	8e-09	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.626	rs13175436	ENSG00000239528.1	RPS14P8	12.51	2.61e-17	1.06e-08	1.36	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.603	rs13175992	ENSG00000239528.1	RPS14P8	12.51	2.61e-17	1.06e-08	1.36	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.626	rs67026795	ENSG00000239528.1	RPS14P8	12.51	2.61e-17	1.06e-08	1.36	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.626	rs3819332	ENSG00000224114.1	RP11-343H5.4	12.48	2.91e-17	1.15e-08	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.626	rs13170300	ENSG00000224114.1	RP11-343H5.4	12.48	2.91e-17	1.15e-08	1.38	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:206695837~206696269:-
UVM	trans	rs6477998	0.58	rs4979231	ENSG00000238072.1	RP11-305M3.2	12.47	3.02e-17	1.17e-08	1.11	0.87	Hematology traits;	chr9:113286475	chr7:129410113~129410370:-
UVM	trans	rs7949030	0.596	rs11231138	ENSG00000186676.3	EEF1GP1	12.47	3.03e-17	1.17e-08	1.14	0.87	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548723	chr7:125033453~125035301:+
UVM	trans	rs13177918	0.626	rs13175436	ENSG00000224114.1	RP11-343H5.4	12.39	3.9e-17	1.46e-08	1.38	0.86	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.603	rs13175992	ENSG00000224114.1	RP11-343H5.4	12.39	3.9e-17	1.46e-08	1.38	0.86	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.626	rs67026795	ENSG00000224114.1	RP11-343H5.4	12.39	3.9e-17	1.46e-08	1.38	0.86	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:206695837~206696269:-
UVM	trans	rs7949030	0.626	rs11231144	ENSG00000186676.3	EEF1GP1	12.35	4.32e-17	1.6e-08	1.18	0.86	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62560566	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.626	rs7930896	ENSG00000186676.3	EEF1GP1	12.28	5.38e-17	1.92e-08	1.15	0.86	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62557800	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.626	rs11231141	ENSG00000186676.3	EEF1GP1	12.28	5.38e-17	1.92e-08	1.15	0.86	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62558793	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.626	rs7943191	ENSG00000186676.3	EEF1GP1	12.28	5.38e-17	1.92e-08	1.15	0.86	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561079	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.626	rs11231145	ENSG00000186676.3	EEF1GP1	12.28	5.38e-17	1.92e-08	1.15	0.86	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561382	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.626	rs61296092	ENSG00000186676.3	EEF1GP1	12.21	6.77e-17	2.28e-08	1.15	0.86	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62553366	chr7:125033453~125035301:+
UVM	trans	rs13177918	0.651	rs13184111	ENSG00000239528.1	RPS14P8	12.04	1.15e-16	3.78e-08	1.37	0.86	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.626	rs12186649	ENSG00000239528.1	RPS14P8	12.04	1.15e-16	3.78e-08	1.37	0.86	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr5:116562562~116562930:+
UVM	trans	rs12291225	0.679	rs11238	ENSG00000236360.2	RP11-334A14.2	-11.98	1.41e-16	4.09e-08	-1.03	-0.86	Sense of smell;	chr11:14266582	chr1:52993201~52993702:-
UVM	trans	rs12291225	0.645	rs3763950	ENSG00000236360.2	RP11-334A14.2	11.98	1.41e-16	4.09e-08	1.03	0.86	Sense of smell;	chr11:14256503	chr1:52993201~52993702:-
UVM	trans	rs12291225	0.679	rs4756786	ENSG00000236360.2	RP11-334A14.2	11.98	1.41e-16	4.09e-08	1.03	0.86	Sense of smell;	chr11:14264354	chr1:52993201~52993702:-
UVM	trans	rs12291225	0.679	rs11369	ENSG00000236360.2	RP11-334A14.2	11.98	1.41e-16	4.09e-08	1.03	0.86	Sense of smell;	chr11:14266550	chr1:52993201~52993702:-
UVM	trans	rs12291225	0.679	rs11605531	ENSG00000236360.2	RP11-334A14.2	11.98	1.41e-16	4.09e-08	1.03	0.86	Sense of smell;	chr11:14270048	chr1:52993201~52993702:-
UVM	trans	rs12291225	0.639	rs61883858	ENSG00000236360.2	RP11-334A14.2	11.98	1.41e-16	4.09e-08	1.03	0.86	Sense of smell;	chr11:14273162	chr1:52993201~52993702:-
UVM	trans	rs12291225	0.679	rs11023170	ENSG00000236360.2	RP11-334A14.2	11.98	1.41e-16	4.09e-08	1.03	0.86	Sense of smell;	chr11:14273363	chr1:52993201~52993702:-
UVM	trans	rs12291225	0.679	rs11023172	ENSG00000236360.2	RP11-334A14.2	11.98	1.41e-16	4.09e-08	1.03	0.86	Sense of smell;	chr11:14273821	chr1:52993201~52993702:-
UVM	trans	rs12291225	0.679	rs4757245	ENSG00000236360.2	RP11-334A14.2	11.98	1.41e-16	4.09e-08	1.03	0.86	Sense of smell;	chr11:14276326	chr1:52993201~52993702:-
UVM	trans	rs12291225	0.637	rs8570	ENSG00000236360.2	RP11-334A14.2	11.98	1.41e-16	4.09e-08	1.03	0.86	Sense of smell;	chr11:14279213	chr1:52993201~52993702:-
UVM	trans	rs12291225	0.753	rs1431374	ENSG00000236360.2	RP11-334A14.2	11.98	1.41e-16	4.09e-08	1.03	0.86	Sense of smell;	chr11:14282429	chr1:52993201~52993702:-
UVM	trans	rs12291225	0.679	rs10832240	ENSG00000236360.2	RP11-334A14.2	11.98	1.41e-16	4.09e-08	1.03	0.86	Sense of smell;	chr11:14283198	chr1:52993201~52993702:-
UVM	trans	rs12291225	0.679	rs7934671	ENSG00000236360.2	RP11-334A14.2	11.98	1.41e-16	4.09e-08	1.03	0.86	Sense of smell;	chr11:14283555	chr1:52993201~52993702:-
UVM	trans	rs12291225	0.679	rs11023178	ENSG00000236360.2	RP11-334A14.2	11.98	1.41e-16	4.09e-08	1.03	0.86	Sense of smell;	chr11:14288736	chr1:52993201~52993702:-
UVM	trans	rs12291225	0.679	rs34238445	ENSG00000236360.2	RP11-334A14.2	11.98	1.41e-16	4.09e-08	1.03	0.86	Sense of smell;	chr11:14294369	chr1:52993201~52993702:-
UVM	trans	rs928391	0.681	rs12145743	ENSG00000227183.3	HDGFP1	11.88	1.93e-16	5.39e-08	1.22	0.85	Platelet count;	chr1:156730859	chrX:131646639~131646890:+
UVM	trans	rs7949030	0.695	rs11231161	ENSG00000186676.3	EEF1GP1	11.86	2.12e-16	5.88e-08	1.19	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62610749	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.688	rs2849031	ENSG00000186676.3	EEF1GP1	-11.57	5.4e-16	1.22e-07	-1.18	-0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598193	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.653	rs2849030	ENSG00000186676.3	EEF1GP1	-11.57	5.4e-16	1.22e-07	-1.18	-0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599514	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.653	rs2516634	ENSG00000186676.3	EEF1GP1	-11.57	5.4e-16	1.22e-07	-1.18	-0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599714	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.626	rs71490390	ENSG00000186676.3	EEF1GP1	11.57	5.4e-16	1.22e-07	1.18	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561713	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.626	rs7124057	ENSG00000186676.3	EEF1GP1	11.57	5.4e-16	1.22e-07	1.18	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62566624	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.626	rs1061093	ENSG00000186676.3	EEF1GP1	11.57	5.4e-16	1.22e-07	1.18	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62567436	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.626	rs72927213	ENSG00000186676.3	EEF1GP1	11.57	5.4e-16	1.22e-07	1.18	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62583726	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.626	rs11231154	ENSG00000186676.3	EEF1GP1	11.57	5.4e-16	1.22e-07	1.18	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62594821	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.688	rs11231155	ENSG00000186676.3	EEF1GP1	11.57	5.4e-16	1.22e-07	1.18	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598147	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.591	rs11231156	ENSG00000186676.3	EEF1GP1	11.57	5.4e-16	1.22e-07	1.18	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598982	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.591	rs12049914	ENSG00000186676.3	EEF1GP1	11.57	5.4e-16	1.22e-07	1.18	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601964	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.591	rs35156678	ENSG00000186676.3	EEF1GP1	11.57	5.4e-16	1.22e-07	1.18	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602409	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.591	rs35880596	ENSG00000186676.3	EEF1GP1	11.57	5.4e-16	1.22e-07	1.18	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602412	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.596	rs71490394	ENSG00000186676.3	EEF1GP1	11.57	5.4e-16	1.22e-07	1.18	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602683	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.653	rs17773169	ENSG00000186676.3	EEF1GP1	11.54	5.95e-16	1.32e-07	1.12	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551058	chr7:125033453~125035301:+
UVM	trans	rs13177918	0.581	rs2245384	ENSG00000239528.1	RPS14P8	11.51	6.54e-16	1.43e-07	1.34	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437705	chr5:116562562~116562930:+
UVM	trans	rs7949030	0.622	rs34894392	ENSG00000186676.3	EEF1GP1	11.5	6.68e-16	1.45e-07	1.19	0.85	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62607349	chr7:125033453~125035301:+
UVM	trans	rs928391	0.681	rs12161427	ENSG00000227183.3	HDGFP1	11.4	9.24e-16	1.78e-07	1.23	0.85	Platelet count;	chr1:156736030	chrX:131646639~131646890:+
UVM	trans	rs928391	0.681	rs3806417	ENSG00000227183.3	HDGFP1	11.4	9.24e-16	1.78e-07	1.23	0.85	Platelet count;	chr1:156741831	chrX:131646639~131646890:+
UVM	trans	rs13177918	0.677	rs3857421	ENSG00000213058.3	RP4-765C7.2	-11.39	9.71e-16	1.78e-07	-1.3	-0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.677	rs57890152	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.75	rs58256223	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.75	rs59354956	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.686	rs12654827	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.677	rs13160685	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.677	rs13161099	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.629	rs13161261	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.677	rs13161417	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.677	rs13161156	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.677	rs13181401	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.677	rs4541646	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.677	rs3900644	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.677	rs2070844	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.677	rs2073472	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.629	rs2070842	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.677	rs13171800	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.677	rs2070841	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.677	rs13177951	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.677	rs13177970	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.677	rs13164105	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.677	rs4841	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.677	rs13183077	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.677	rs3797622	ENSG00000213058.3	RP4-765C7.2	11.39	9.71e-16	1.78e-07	1.3	0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:178411616~178411972:+
UVM	trans	rs6477998	0.535	rs3750535	ENSG00000238072.1	RP11-305M3.2	11.34	1.14e-15	2.04e-07	1.08	0.84	Hematology traits;	chr9:113297453	chr7:129410113~129410370:-
UVM	trans	rs6477998	0.557	rs3750534	ENSG00000238072.1	RP11-305M3.2	11.34	1.14e-15	2.04e-07	1.08	0.84	Hematology traits;	chr9:113297844	chr7:129410113~129410370:-
UVM	trans	rs6477998	0.58	rs3750532	ENSG00000238072.1	RP11-305M3.2	11.34	1.14e-15	2.04e-07	1.08	0.84	Hematology traits;	chr9:113298207	chr7:129410113~129410370:-
UVM	trans	rs6477998	0.58	rs2296073	ENSG00000238072.1	RP11-305M3.2	11.34	1.14e-15	2.04e-07	1.08	0.84	Hematology traits;	chr9:113299348	chr7:129410113~129410370:-
UVM	trans	rs6477998	0.58	rs7027833	ENSG00000238072.1	RP11-305M3.2	11.34	1.14e-15	2.04e-07	1.08	0.84	Hematology traits;	chr9:113301377	chr7:129410113~129410370:-
UVM	trans	rs941207	0.756	rs2950394	ENSG00000121089.4	NACA3P	-11.22	1.66e-15	2.58e-07	-1.29	-0.84	Platelet count;	chr12:56644548	chr4:164943290~164943937:+
UVM	trans	rs941207	0.756	rs7315472	ENSG00000121089.4	NACA3P	-11.22	1.66e-15	2.58e-07	-1.29	-0.84	Platelet count;	chr12:56648276	chr4:164943290~164943937:+
UVM	trans	rs941207	0.756	rs67046307	ENSG00000121089.4	NACA3P	-11.22	1.66e-15	2.58e-07	-1.29	-0.84	Platelet count;	chr12:56651152	chr4:164943290~164943937:+
UVM	trans	rs941207	0.756	rs10876915	ENSG00000121089.4	NACA3P	-11.22	1.66e-15	2.58e-07	-1.29	-0.84	Platelet count;	chr12:56655280	chr4:164943290~164943937:+
UVM	trans	rs941207	0.756	rs1465081	ENSG00000121089.4	NACA3P	-11.22	1.66e-15	2.58e-07	-1.29	-0.84	Platelet count;	chr12:56656390	chr4:164943290~164943937:+
UVM	trans	rs116095464	0.558	rs6878087	ENSG00000185986.11	SDHAP3	-11.2	1.78e-15	2.58e-07	-1.03	-0.84	Breast cancer;	chr5:223002	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10079760	ENSG00000185986.11	SDHAP3	11.2	1.78e-15	2.58e-07	1.03	0.84	Breast cancer;	chr5:230663	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs1541822	ENSG00000185986.11	SDHAP3	-11.2	1.78e-15	2.58e-07	-1.03	-0.84	Breast cancer;	chr5:269119	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs7714335	ENSG00000185986.11	SDHAP3	11.2	1.79e-15	2.58e-07	1.05	0.84	Breast cancer;	chr5:263398	chr5:1572222~1594620:-
UVM	trans	rs6477998	0.535	rs4979232	ENSG00000238072.1	RP11-305M3.2	-11.03	3.18e-15	2.58e-07	-1.15	-0.84	Hematology traits;	chr9:113286594	chr7:129410113~129410370:-
UVM	trans	rs6477998	0.535	rs10981712	ENSG00000238072.1	RP11-305M3.2	11.03	3.18e-15	2.58e-07	1.15	0.84	Hematology traits;	chr9:113283846	chr7:129410113~129410370:-
UVM	trans	rs116095464	0.558	rs6555058	ENSG00000185986.11	SDHAP3	-11.01	3.4e-15	2.58e-07	-1.04	-0.84	Breast cancer;	chr5:226261	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs12173015	ENSG00000185986.11	SDHAP3	-11.01	3.4e-15	2.58e-07	-1.04	-0.84	Breast cancer;	chr5:269852	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs7713524	ENSG00000185986.11	SDHAP3	-11.01	3.4e-15	2.58e-07	-1.04	-0.84	Breast cancer;	chr5:276085	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs9312956	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:201697	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs9312957	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:202079	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs62346508	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:203553	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10059907	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:205245	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10060089	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:205450	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10068203	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:206503	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs73029475	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:206854	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs6872854	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:208923	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.867	rs7726582	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:215234	chr5:1572222~1594620:-
UVM	trans	rs116095464	1	rs28416084	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:217525	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.619	rs2303741	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:218241	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.614	rs10067482	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:219213	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.614	rs56299325	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:220479	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs62346526	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:220499	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs56043030	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:220802	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10067021	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:221375	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs9312977	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:221801	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs9312978	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:221815	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs9312979	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:221942	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs6881920	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:222296	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs6878061	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:222957	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs6882584	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:223296	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs3213838	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:223775	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs6555052	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:224153	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs61689490	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:224789	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs61492827	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:225659	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs56342538	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:225681	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs6555055	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:226045	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs6555056	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:226107	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10043002	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:226638	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs62347677	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:227338	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs62347678	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:227381	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs73031482	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:227479	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs2162870	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:228014	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs28729548	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:228910	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs9687621	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:229079	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.681	rs9687745	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:229194	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs9688136	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:229233	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs62347683	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:230216	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.51	rs55750776	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:230352	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.764	rs10069197	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:230707	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.867	rs10074958	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:230713	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs2288459	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:231028	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs2288458	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:231145	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs2288457	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:231155	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs7736600	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:231222	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.51	rs7714944	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:231650	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10052012	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:231793	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10077076	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:231825	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10080225	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:232060	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10475136	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:232681	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs7725227	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:233402	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs7710005	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:233457	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs7708182	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:234673	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10058428	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:235493	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10036253	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:238404	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10075018	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:239060	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10076655	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:239349	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10057492	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:239388	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs28418643	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:240744	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.681	rs10060016	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:240985	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10057299	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:242020	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs13357299	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:242096	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs13354585	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:242148	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs13356367	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:242280	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.614	rs10059220	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:242698	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.85	rs10055295	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:243634	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10055354	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:243679	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.614	rs62344292	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:244515	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs60251075	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:245177	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs62344300	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:246221	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs56081398	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:247203	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.614	rs62344339	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:252880	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs9687898	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:253837	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10065584	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:253882	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs9688045	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:253920	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs112343653	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:257059	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs73024831	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:257077	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs62344345	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:257305	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs57335027	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:262792	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs6869925	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:263921	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs6875291	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:264077	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10055993	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:264181	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs6879656	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:264313	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs6866632	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:264314	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs6866776	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:264380	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs6874745	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:264412	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs7715108	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:264546	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs7730700	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:264598	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10057674	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:266698	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs1812843	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:267543	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs1971229	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:268072	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.614	rs4371799	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:268077	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs12173244	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:269409	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs56127718	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:270158	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs55664502	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:270370	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.51	rs7723883	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:270683	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.614	rs10061564	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:271214	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs55776650	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:273711	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.542	rs28650039	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:273839	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.614	rs28736753	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:273966	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10065239	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:275173	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs28635197	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:278956	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10056628	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:279397	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs59113266	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:279850	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs56298907	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:283165	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs11959126	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:283765	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs7356535	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:284002	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs7356696	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:284136	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs7356561	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:284266	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs59284383	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:284410	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs28558836	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:285633	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs55833259	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:286613	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs7731089	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:290307	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs7703803	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:292196	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs9654452	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:299446	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs9654453	ENSG00000185986.11	SDHAP3	11.01	3.4e-15	2.58e-07	1.04	0.84	Breast cancer;	chr5:299506	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs7708515	ENSG00000185986.11	SDHAP3	10.98	3.73e-15	2.82e-07	0.95	0.84	Breast cancer;	chr5:234874	chr5:1572222~1594620:-
UVM	trans	rs7949030	0.62	rs2428551	ENSG00000186676.3	EEF1GP1	10.91	4.65e-15	3.48e-07	1.16	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62562286	chr7:125033453~125035301:+
UVM	trans	rs13177918	0.557	rs12520101	ENSG00000224114.1	RP11-343H5.4	10.91	4.67e-15	3.48e-07	1.35	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:206695837~206696269:-
UVM	trans	rs116095464	0.558	rs113796397	ENSG00000185986.11	SDHAP3	10.86	5.53e-15	4.06e-07	1.03	0.83	Breast cancer;	chr5:246388	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.614	rs78905930	ENSG00000185986.11	SDHAP3	10.86	5.53e-15	4.06e-07	1.03	0.83	Breast cancer;	chr5:246445	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10462754	ENSG00000185986.11	SDHAP3	10.86	5.53e-15	4.06e-07	1.03	0.83	Breast cancer;	chr5:246554	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs10462755	ENSG00000185986.11	SDHAP3	10.86	5.53e-15	4.06e-07	1.03	0.83	Breast cancer;	chr5:246633	chr5:1572222~1594620:-
UVM	trans	rs6732160	0.691	rs6728147	ENSG00000236165.1	PRADC1P1	-10.85	5.69e-15	4.16e-07	-1.03	-0.83	Intelligence (multi-trait analysis);	chr2:73196362	chr3:36976316~36976840:+
UVM	trans	rs13177918	0.798	rs12514700	ENSG00000224114.1	RP11-343H5.4	10.83	6.14e-15	4.47e-07	1.45	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:206695837~206696269:-
UVM	trans	rs7949030	0.635	rs1801144	ENSG00000186676.3	EEF1GP1	10.79	7.01e-15	5.09e-07	1.17	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62614336	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.725	rs12808829	ENSG00000186676.3	EEF1GP1	10.71	9.12e-15	6.42e-07	1.16	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62611188	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.765	rs11553576	ENSG00000186676.3	EEF1GP1	10.71	9.12e-15	6.42e-07	1.16	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62611329	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.688	rs12798970	ENSG00000186676.3	EEF1GP1	-10.71	9.12e-15	6.42e-07	-1.16	-0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62612647	chr7:125033453~125035301:+
UVM	trans	rs116095464	0.51	rs60844864	ENSG00000185986.11	SDHAP3	10.71	9.14e-15	6.42e-07	1.03	0.83	Breast cancer;	chr5:266885	chr5:1572222~1594620:-
UVM	trans	rs6477998	0.513	rs10981720	ENSG00000238072.1	RP11-305M3.2	10.64	1.16e-14	8.09e-07	1.14	0.83	Hematology traits;	chr9:113293831	chr7:129410113~129410370:-
UVM	trans	rs116095464	0.558	rs28636067	ENSG00000185986.11	SDHAP3	10.59	1.4e-14	9.58e-07	1.04	0.83	Breast cancer;	chr5:199300	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs34629844	ENSG00000185986.11	SDHAP3	10.59	1.4e-14	9.58e-07	1.04	0.83	Breast cancer;	chr5:200714	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.558	rs62346506	ENSG00000185986.11	SDHAP3	10.59	1.4e-14	9.58e-07	1.04	0.83	Breast cancer;	chr5:201479	chr5:1572222~1594620:-
UVM	trans	rs6732160	0.691	rs7599223	ENSG00000236165.1	PRADC1P1	10.57	1.47e-14	1.01e-06	1.03	0.83	Intelligence (multi-trait analysis);	chr2:73199975	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.691	rs4536673	ENSG00000236165.1	PRADC1P1	10.51	1.83e-14	1.23e-06	1.03	0.82	Intelligence (multi-trait analysis);	chr2:73186334	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.691	rs11886257	ENSG00000236165.1	PRADC1P1	10.51	1.83e-14	1.23e-06	1.03	0.82	Intelligence (multi-trait analysis);	chr2:73189745	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.691	rs13402225	ENSG00000236165.1	PRADC1P1	10.51	1.83e-14	1.23e-06	1.03	0.82	Intelligence (multi-trait analysis);	chr2:73189778	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.691	rs1960233	ENSG00000236165.1	PRADC1P1	10.51	1.83e-14	1.23e-06	1.03	0.82	Intelligence (multi-trait analysis);	chr2:73194250	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.691	rs2007191	ENSG00000236165.1	PRADC1P1	10.51	1.83e-14	1.23e-06	1.03	0.82	Intelligence (multi-trait analysis);	chr2:73194335	chr3:36976316~36976840:+
UVM	trans	rs13177918	0.557	rs12520101	ENSG00000213058.3	RP4-765C7.2	10.49	1.93e-14	1.28e-06	1.28	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.626	rs3819332	ENSG00000213058.3	RP4-765C7.2	10.45	2.25e-14	1.49e-06	1.26	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.626	rs13170300	ENSG00000213058.3	RP4-765C7.2	10.45	2.25e-14	1.49e-06	1.26	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:178411616~178411972:+
UVM	trans	rs12291225	0.546	rs12795545	ENSG00000236360.2	RP11-334A14.2	10.39	2.74e-14	1.81e-06	0.89	0.82	Sense of smell;	chr11:14334018	chr1:52993201~52993702:-
UVM	trans	rs7949030	0.59	rs12225213	ENSG00000186676.3	EEF1GP1	10.38	2.84e-14	1.87e-06	1.16	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62582776	chr7:125033453~125035301:+
UVM	trans	rs13177918	0.651	rs13184111	ENSG00000224114.1	RP11-343H5.4	10.3	3.7e-14	2.41e-06	1.33	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.626	rs12186649	ENSG00000224114.1	RP11-343H5.4	10.3	3.7e-14	2.41e-06	1.33	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.626	rs2748240	ENSG00000239528.1	RPS14P8	10.27	4.07e-14	2.63e-06	1.22	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr5:116562562~116562930:+
UVM	trans	rs6477998	0.58	rs3750533	ENSG00000238072.1	RP11-305M3.2	10.26	4.23e-14	2.73e-06	1.08	0.82	Hematology traits;	chr9:113297941	chr7:129410113~129410370:-
UVM	trans	rs13177918	0.651	rs13184111	ENSG00000213058.3	RP4-765C7.2	10.25	4.45e-14	2.86e-06	1.28	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.626	rs12186649	ENSG00000213058.3	RP4-765C7.2	10.25	4.45e-14	2.86e-06	1.28	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr1:178411616~178411972:+
UVM	trans	rs928391	0.681	rs9427242	ENSG00000227183.3	HDGFP1	-10.2	5.22e-14	3.3e-06	-1.23	-0.82	Platelet count;	chr1:156755209	chrX:131646639~131646890:+
UVM	trans	rs13177918	0.798	rs13182116	ENSG00000224114.1	RP11-343H5.4	-10.2	5.31e-14	3.35e-06	-1.4	-0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:206695837~206696269:-
UVM	trans	rs6732160	0.65	rs7560224	ENSG00000236165.1	PRADC1P1	10.13	6.62e-14	4.13e-06	1	0.81	Intelligence (multi-trait analysis);	chr2:73179054	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.656	rs2043093	ENSG00000236165.1	PRADC1P1	10.13	6.62e-14	4.13e-06	1	0.81	Intelligence (multi-trait analysis);	chr2:73180214	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.684	rs2043095	ENSG00000236165.1	PRADC1P1	10.13	6.62e-14	4.13e-06	1	0.81	Intelligence (multi-trait analysis);	chr2:73180314	chr3:36976316~36976840:+
UVM	trans	rs12291225	0.679	rs1043237	ENSG00000236360.2	RP11-334A14.2	10.13	6.66e-14	4.14e-06	0.97	0.81	Sense of smell;	chr11:14267507	chr1:52993201~52993702:-
UVM	trans	rs928391	1	rs2644615	ENSG00000227183.3	HDGFP1	10.12	6.93e-14	4.27e-06	1.31	0.81	Platelet count;	chr1:156791826	chrX:131646639~131646890:+
UVM	trans	rs928391	1	rs2777929	ENSG00000227183.3	HDGFP1	10.12	6.93e-14	4.27e-06	1.31	0.81	Platelet count;	chr1:156797879	chrX:131646639~131646890:+
UVM	trans	rs928391	1	rs2768767	ENSG00000227183.3	HDGFP1	10.12	6.93e-14	4.27e-06	1.31	0.81	Platelet count;	chr1:156797933	chrX:131646639~131646890:+
UVM	trans	rs928391	1	rs928392	ENSG00000227183.3	HDGFP1	10.12	6.93e-14	4.27e-06	1.31	0.81	Platelet count;	chr1:156801024	chrX:131646639~131646890:+
UVM	trans	rs928391	1	rs10157555	ENSG00000227183.3	HDGFP1	-10.12	6.93e-14	4.27e-06	-1.31	-0.81	Platelet count;	chr1:156802060	chrX:131646639~131646890:+
UVM	trans	rs12291225	0.585	rs10832242	ENSG00000236360.2	RP11-334A14.2	-10.09	7.51e-14	4.52e-06	-0.89	-0.81	Sense of smell;	chr11:14318958	chr1:52993201~52993702:-
UVM	trans	rs12291225	0.546	rs12291662	ENSG00000236360.2	RP11-334A14.2	10.09	7.51e-14	4.52e-06	0.89	0.81	Sense of smell;	chr11:14321403	chr1:52993201~52993702:-
UVM	trans	rs12291225	0.545	rs11023187	ENSG00000236360.2	RP11-334A14.2	10.09	7.51e-14	4.52e-06	0.89	0.81	Sense of smell;	chr11:14324013	chr1:52993201~52993702:-
UVM	trans	rs12291225	0.585	rs11023194	ENSG00000236360.2	RP11-334A14.2	10.09	7.51e-14	4.52e-06	0.89	0.81	Sense of smell;	chr11:14348223	chr1:52993201~52993702:-
UVM	trans	rs13177918	0.626	rs2748240	ENSG00000224114.1	RP11-343H5.4	10.09	7.68e-14	4.6e-06	1.23	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:206695837~206696269:-
UVM	trans	rs7121616	0.576	rs11218967	ENSG00000234176.1	HSPA8P1	10.09	7.72e-14	4.6e-06	1.21	0.81	Breast cancer;	chr11:123087551	chrX:121203182~121205014:-
UVM	trans	rs12291225	0.585	rs34171876	ENSG00000236360.2	RP11-334A14.2	10.07	8.25e-14	4.89e-06	0.89	0.81	Sense of smell;	chr11:14332411	chr1:52993201~52993702:-
UVM	trans	rs13177918	0.581	rs2748244	ENSG00000239528.1	RPS14P8	10.06	8.36e-14	4.94e-06	1.25	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150436487	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.559	rs3901731	ENSG00000239528.1	RPS14P8	10.06	8.36e-14	4.94e-06	1.25	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437405	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.626	rs13175436	ENSG00000213058.3	RP4-765C7.2	10.05	8.63e-14	5.08e-06	1.25	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.603	rs13175992	ENSG00000213058.3	RP4-765C7.2	10.05	8.63e-14	5.08e-06	1.25	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.626	rs67026795	ENSG00000213058.3	RP4-765C7.2	10.05	8.63e-14	5.08e-06	1.25	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:178411616~178411972:+
UVM	trans	rs6732160	0.596	rs7605923	ENSG00000236165.1	PRADC1P1	10.05	8.67e-14	5.09e-06	1	0.81	Intelligence (multi-trait analysis);	chr2:73175205	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.691	rs10197935	ENSG00000236165.1	PRADC1P1	10.05	8.67e-14	5.09e-06	1	0.81	Intelligence (multi-trait analysis);	chr2:73185234	chr3:36976316~36976840:+
UVM	trans	rs13177918	0.581	rs2245384	ENSG00000224114.1	RP11-343H5.4	10.04	9.17e-14	5.37e-06	1.31	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437705	chr1:206695837~206696269:-
UVM	trans	rs7121616	0.595	rs7941144	ENSG00000234176.1	HSPA8P1	9.97	1.15e-13	6.6e-06	1.21	0.81	Breast cancer;	chr11:123079805	chrX:121203182~121205014:-
UVM	trans	rs13177918	0.578	rs35919198	ENSG00000224114.1	RP11-343H5.4	9.96	1.19e-13	6.78e-06	1.23	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.603	rs10447222	ENSG00000224114.1	RP11-343H5.4	9.96	1.19e-13	6.78e-06	1.23	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:206695837~206696269:-
UVM	trans	rs928391	1	rs12129173	ENSG00000227183.3	HDGFP1	9.94	1.29e-13	7.27e-06	1.3	0.81	Platelet count;	chr1:156803833	chrX:131646639~131646890:+
UVM	trans	rs928391	1	rs2768766	ENSG00000227183.3	HDGFP1	9.94	1.29e-13	7.27e-06	1.3	0.81	Platelet count;	chr1:156805842	chrX:131646639~131646890:+
UVM	trans	rs928391	1	rs928391	ENSG00000227183.3	HDGFP1	9.94	1.29e-13	7.27e-06	1.3	0.81	Platelet count;	chr1:156806925	chrX:131646639~131646890:+
UVM	trans	rs928391	1	rs2644606	ENSG00000227183.3	HDGFP1	9.94	1.29e-13	7.27e-06	1.3	0.81	Platelet count;	chr1:156808053	chrX:131646639~131646890:+
UVM	trans	rs6732160	0.593	rs2288630	ENSG00000236165.1	PRADC1P1	9.82	1.92e-13	1.06e-05	1.07	0.81	Intelligence (multi-trait analysis);	chr2:73230424	chr3:36976316~36976840:+
UVM	trans	rs13177918	0.603	rs2748241	ENSG00000239528.1	RPS14P8	9.82	1.95e-13	1.07e-05	1.19	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr5:116562562~116562930:+
UVM	trans	rs6732160	0.845	rs6718690	ENSG00000236165.1	PRADC1P1	-9.81	2.03e-13	1.1e-05	-0.93	-0.81	Intelligence (multi-trait analysis);	chr2:73160034	chr3:36976316~36976840:+
UVM	trans	rs116095464	0.558	rs55838121	ENSG00000185986.11	SDHAP3	9.78	2.25e-13	1.17e-05	0.99	0.8	Breast cancer;	chr5:266775	chr5:1572222~1594620:-
UVM	trans	rs13177918	0.603	rs2748241	ENSG00000224114.1	RP11-343H5.4	9.77	2.29e-13	1.17e-05	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:206695837~206696269:-
UVM	trans	rs6732160	0.574	rs12465780	ENSG00000236165.1	PRADC1P1	-9.73	2.61e-13	1.32e-05	-1.05	-0.8	Intelligence (multi-trait analysis);	chr2:73244884	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.631	rs7557285	ENSG00000236165.1	PRADC1P1	9.73	2.61e-13	1.32e-05	1.05	0.8	Intelligence (multi-trait analysis);	chr2:73215684	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.574	rs7557055	ENSG00000236165.1	PRADC1P1	9.73	2.61e-13	1.32e-05	1.05	0.8	Intelligence (multi-trait analysis);	chr2:73245542	chr3:36976316~36976840:+
UVM	trans	rs1045902	0.967	rs10207625	ENSG00000236165.1	PRADC1P1	9.73	2.63e-13	1.33e-05	1.07	0.8	Intelligence (multi-trait analysis);	chr2:73237680	chr3:36976316~36976840:+
UVM	trans	rs1045902	0.967	rs1469530	ENSG00000236165.1	PRADC1P1	9.73	2.63e-13	1.33e-05	1.07	0.8	Intelligence (multi-trait analysis);	chr2:73237820	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.774	rs1367291	ENSG00000236165.1	PRADC1P1	9.7	2.99e-13	1.49e-05	0.95	0.8	Intelligence (multi-trait analysis);	chr2:73147737	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.838	rs13411380	ENSG00000236165.1	PRADC1P1	9.7	2.99e-13	1.49e-05	0.95	0.8	Intelligence (multi-trait analysis);	chr2:73155718	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.809	rs6728959	ENSG00000236165.1	PRADC1P1	9.7	2.99e-13	1.49e-05	0.95	0.8	Intelligence (multi-trait analysis);	chr2:73156199	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.809	rs13406142	ENSG00000236165.1	PRADC1P1	9.7	2.99e-13	1.49e-05	0.95	0.8	Intelligence (multi-trait analysis);	chr2:73156970	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.845	rs6752507	ENSG00000236165.1	PRADC1P1	9.7	2.99e-13	1.49e-05	0.95	0.8	Intelligence (multi-trait analysis);	chr2:73158030	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.845	rs6546809	ENSG00000236165.1	PRADC1P1	9.69	3.04e-13	1.51e-05	0.95	0.8	Intelligence (multi-trait analysis);	chr2:73162553	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.845	rs13413175	ENSG00000236165.1	PRADC1P1	9.69	3.04e-13	1.51e-05	0.95	0.8	Intelligence (multi-trait analysis);	chr2:73162788	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.845	rs72807999	ENSG00000236165.1	PRADC1P1	9.69	3.05e-13	1.51e-05	0.95	0.8	Intelligence (multi-trait analysis);	chr2:73164567	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.845	rs10203125	ENSG00000236165.1	PRADC1P1	9.67	3.21e-13	1.57e-05	0.95	0.8	Intelligence (multi-trait analysis);	chr2:73134023	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.741	rs10203600	ENSG00000236165.1	PRADC1P1	9.67	3.21e-13	1.57e-05	0.95	0.8	Intelligence (multi-trait analysis);	chr2:73134270	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.845	rs10203718	ENSG00000236165.1	PRADC1P1	9.67	3.21e-13	1.57e-05	0.95	0.8	Intelligence (multi-trait analysis);	chr2:73134387	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.845	rs9989755	ENSG00000236165.1	PRADC1P1	9.67	3.21e-13	1.57e-05	0.95	0.8	Intelligence (multi-trait analysis);	chr2:73134820	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.809	rs13416592	ENSG00000236165.1	PRADC1P1	9.67	3.21e-13	1.57e-05	0.95	0.8	Intelligence (multi-trait analysis);	chr2:73137928	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.809	rs13387480	ENSG00000236165.1	PRADC1P1	9.67	3.21e-13	1.57e-05	0.95	0.8	Intelligence (multi-trait analysis);	chr2:73143879	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.774	rs11890053	ENSG00000236165.1	PRADC1P1	9.67	3.21e-13	1.57e-05	0.95	0.8	Intelligence (multi-trait analysis);	chr2:73146320	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.525	rs2303907	ENSG00000236165.1	PRADC1P1	9.65	3.47e-13	1.69e-05	1.05	0.8	Intelligence (multi-trait analysis);	chr2:73243369	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.574	rs1991612	ENSG00000236165.1	PRADC1P1	9.65	3.47e-13	1.69e-05	1.05	0.8	Intelligence (multi-trait analysis);	chr2:73253373	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.549	rs6744529	ENSG00000236165.1	PRADC1P1	9.65	3.47e-13	1.69e-05	1.05	0.8	Intelligence (multi-trait analysis);	chr2:73253741	chr3:36976316~36976840:+
UVM	trans	rs13177918	0.798	rs12514700	ENSG00000239528.1	RPS14P8	9.65	3.51e-13	1.71e-05	1.37	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.578	rs35919198	ENSG00000239528.1	RPS14P8	9.63	3.75e-13	1.81e-05	1.19	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.603	rs10447222	ENSG00000239528.1	RPS14P8	9.63	3.75e-13	1.81e-05	1.19	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr5:116562562~116562930:+
UVM	trans	rs6732160	0.809	rs4299358	ENSG00000236165.1	PRADC1P1	9.61	4.02e-13	1.93e-05	0.96	0.8	Intelligence (multi-trait analysis);	chr2:73132213	chr3:36976316~36976840:+
UVM	trans	rs116095464	0.558	rs6962	ENSG00000185986.11	SDHAP3	9.61	4.07e-13	1.94e-05	1.02	0.8	Breast cancer;	chr5:256394	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.51	rs73016876	ENSG00000185986.11	SDHAP3	9.59	4.39e-13	2.06e-05	1.01	0.8	Breast cancer;	chr5:244360	chr5:1572222~1594620:-
UVM	trans	rs7943191	0.805	rs12226821	ENSG00000186676.3	EEF1GP1	9.58	4.42e-13	2.07e-05	1.22	0.8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62601546	chr7:125033453~125035301:+
UVM	trans	rs13253073	0.723	rs12548344	ENSG00000260318.1	COX6CP1	9.58	4.44e-13	2.08e-05	1.43	0.8	Glucose homeostasis traits;	chr8:99868676	chr16:11903923~11904137:-
UVM	trans	rs13177918	0.906	rs12652032	ENSG00000239528.1	RPS14P8	9.56	4.81e-13	2.23e-05	1.35	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr5:116562562~116562930:+
UVM	trans	rs13177918	1	rs13161334	ENSG00000239528.1	RPS14P8	9.56	4.81e-13	2.23e-05	1.35	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr5:116562562~116562930:+
UVM	trans	rs13177918	1	rs35007082	ENSG00000239528.1	RPS14P8	9.56	4.81e-13	2.23e-05	1.35	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr5:116562562~116562930:+
UVM	trans	rs13177918	1	rs13177918	ENSG00000239528.1	RPS14P8	9.56	4.81e-13	2.23e-05	1.35	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr5:116562562~116562930:+
UVM	trans	rs928391	1	rs3765787	ENSG00000227183.3	HDGFP1	-9.53	5.34e-13	2.44e-05	-1.23	-0.8	Platelet count;	chr1:156784673	chrX:131646639~131646890:+
UVM	trans	rs928391	0.895	rs12042999	ENSG00000227183.3	HDGFP1	9.53	5.34e-13	2.44e-05	1.23	0.8	Platelet count;	chr1:156768636	chrX:131646639~131646890:+
UVM	trans	rs928391	0.895	rs11264547	ENSG00000227183.3	HDGFP1	9.53	5.34e-13	2.44e-05	1.23	0.8	Platelet count;	chr1:156776326	chrX:131646639~131646890:+
UVM	trans	rs928391	1	rs61816272	ENSG00000227183.3	HDGFP1	9.53	5.34e-13	2.44e-05	1.23	0.8	Platelet count;	chr1:156778073	chrX:131646639~131646890:+
UVM	trans	rs928391	0.947	rs11264549	ENSG00000227183.3	HDGFP1	9.53	5.34e-13	2.44e-05	1.23	0.8	Platelet count;	chr1:156781017	chrX:131646639~131646890:+
UVM	trans	rs928391	1	rs12134991	ENSG00000227183.3	HDGFP1	9.53	5.34e-13	2.44e-05	1.23	0.8	Platelet count;	chr1:156781285	chrX:131646639~131646890:+
UVM	trans	rs928391	1	rs2274501	ENSG00000227183.3	HDGFP1	9.53	5.34e-13	2.44e-05	1.23	0.8	Platelet count;	chr1:156782460	chrX:131646639~131646890:+
UVM	trans	rs928391	1	rs12043405	ENSG00000227183.3	HDGFP1	9.53	5.34e-13	2.44e-05	1.23	0.8	Platelet count;	chr1:156784508	chrX:131646639~131646890:+
UVM	trans	rs6477998	0.535	rs10817475	ENSG00000238072.1	RP11-305M3.2	9.52	5.53e-13	2.52e-05	1.09	0.8	Hematology traits;	chr9:113296774	chr7:129410113~129410370:-
UVM	trans	rs1816752	0.905	rs9511264	ENSG00000237917.1	PARP4P1	-9.48	6.29e-13	2.85e-05	-0.79	-0.8	Obesity-related traits;	chr13:24438079	chrY:26594851~26634652:-
UVM	trans	rs7121616	0.576	rs4936767	ENSG00000234176.1	HSPA8P1	9.46	6.94e-13	3.01e-05	1.1	0.8	Breast cancer;	chr11:123047451	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.563	rs1461494	ENSG00000234176.1	HSPA8P1	9.46	6.94e-13	3.01e-05	1.1	0.8	Breast cancer;	chr11:123055777	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.576	rs4802	ENSG00000234176.1	HSPA8P1	9.46	6.94e-13	3.01e-05	1.1	0.8	Breast cancer;	chr11:123057914	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.563	rs4936770	ENSG00000234176.1	HSPA8P1	9.46	6.94e-13	3.01e-05	1.1	0.8	Breast cancer;	chr11:123058167	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.562	rs2061602	ENSG00000234176.1	HSPA8P1	9.46	6.94e-13	3.01e-05	1.1	0.8	Breast cancer;	chr11:123065079	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.562	rs7131452	ENSG00000234176.1	HSPA8P1	9.46	6.94e-13	3.01e-05	1.1	0.8	Breast cancer;	chr11:123065314	chrX:121203182~121205014:-
UVM	trans	rs7949030	0.504	rs2516633	ENSG00000186676.3	EEF1GP1	-9.45	7.08e-13	3.01e-05	-1.2	-0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62604301	chr7:125033453~125035301:+
UVM	trans	rs7943191	0.81	rs7942154	ENSG00000186676.3	EEF1GP1	9.45	7.08e-13	3.01e-05	1.2	0.79	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569691	chr7:125033453~125035301:+
UVM	trans	rs7949030	0.523	rs12223627	ENSG00000186676.3	EEF1GP1	9.45	7.08e-13	3.01e-05	1.2	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601085	chr7:125033453~125035301:+
UVM	trans	rs7943191	0.768	rs34065644	ENSG00000186676.3	EEF1GP1	9.45	7.08e-13	3.01e-05	1.2	0.79	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62604466	chr7:125033453~125035301:+
UVM	trans	rs13177918	0.559	rs10447224	ENSG00000224114.1	RP11-343H5.4	9.45	7.15e-13	3.03e-05	1.15	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.559	rs10447225	ENSG00000224114.1	RP11-343H5.4	9.45	7.15e-13	3.03e-05	1.15	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.559	rs12109637	ENSG00000224114.1	RP11-343H5.4	9.45	7.15e-13	3.03e-05	1.15	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:206695837~206696269:-
UVM	trans	rs13253073	0.723	rs35429753	ENSG00000260318.1	COX6CP1	9.41	8.17e-13	3.44e-05	1.06	0.79	Glucose homeostasis traits;	chr8:99891015	chr16:11903923~11904137:-
UVM	trans	rs13253073	0.723	rs1130474	ENSG00000260318.1	COX6CP1	9.41	8.17e-13	3.44e-05	1.06	0.79	Glucose homeostasis traits;	chr8:99892049	chr16:11903923~11904137:-
UVM	trans	rs13253073	0.723	rs1130569	ENSG00000260318.1	COX6CP1	9.39	8.7e-13	3.66e-05	1.12	0.79	Glucose homeostasis traits;	chr8:99887565	chr16:11903923~11904137:-
UVM	trans	rs1816752	0.905	rs9511249	ENSG00000237917.1	PARP4P1	9.38	9.17e-13	3.7e-05	0.83	0.79	Obesity-related traits;	chr13:24425457	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.638	rs9578730	ENSG00000237917.1	PARP4P1	9.38	9.17e-13	3.7e-05	0.83	0.79	Obesity-related traits;	chr13:24425545	chrY:26594851~26634652:-
UVM	trans	rs6732160	0.845	rs6546805	ENSG00000236165.1	PRADC1P1	9.37	9.43e-13	3.7e-05	0.94	0.79	Intelligence (multi-trait analysis);	chr2:73158987	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.741	rs6546806	ENSG00000236165.1	PRADC1P1	9.37	9.43e-13	3.7e-05	0.94	0.79	Intelligence (multi-trait analysis);	chr2:73159032	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.845	rs11894833	ENSG00000236165.1	PRADC1P1	-9.37	9.43e-13	3.7e-05	-0.94	-0.79	Intelligence (multi-trait analysis);	chr2:73161290	chr3:36976316~36976840:+
UVM	trans	rs928391	0.948	rs2735657	ENSG00000227183.3	HDGFP1	9.32	1.12e-12	4.18e-05	1.27	0.79	Platelet count;	chr1:156810514	chrX:131646639~131646890:+
UVM	trans	rs116095464	0.558	rs1968374	ENSG00000185986.11	SDHAP3	9.31	1.16e-12	4.31e-05	1.15	0.79	Breast cancer;	chr5:248910	chr5:1572222~1594620:-
UVM	trans	rs6732160	0.691	rs13432787	ENSG00000236165.1	PRADC1P1	9.3	1.18e-12	4.38e-05	1.02	0.79	Intelligence (multi-trait analysis);	chr2:73203106	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.657	rs10171459	ENSG00000236165.1	PRADC1P1	9.3	1.18e-12	4.38e-05	1.02	0.79	Intelligence (multi-trait analysis);	chr2:73207600	chr3:36976316~36976840:+
UVM	trans	rs116095464	0.619	rs28731093	ENSG00000185986.11	SDHAP3	9.3	1.18e-12	4.38e-05	0.99	0.79	Breast cancer;	chr5:240913	chr5:1572222~1594620:-
UVM	trans	rs116095464	0.764	rs28710899	ENSG00000185986.11	SDHAP3	9.3	1.18e-12	4.38e-05	0.99	0.79	Breast cancer;	chr5:240914	chr5:1572222~1594620:-
UVM	trans	rs13177918	0.906	rs12652032	ENSG00000224114.1	RP11-343H5.4	9.29	1.23e-12	4.51e-05	1.36	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:206695837~206696269:-
UVM	trans	rs13177918	1	rs13161334	ENSG00000224114.1	RP11-343H5.4	9.29	1.23e-12	4.51e-05	1.36	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:206695837~206696269:-
UVM	trans	rs13177918	1	rs35007082	ENSG00000224114.1	RP11-343H5.4	9.29	1.23e-12	4.51e-05	1.36	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:206695837~206696269:-
UVM	trans	rs13177918	1	rs13177918	ENSG00000224114.1	RP11-343H5.4	9.29	1.23e-12	4.51e-05	1.36	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:206695837~206696269:-
UVM	trans	rs6732160	0.845	rs2901420	ENSG00000236165.1	PRADC1P1	9.29	1.25e-12	4.57e-05	0.95	0.79	Intelligence (multi-trait analysis);	chr2:73138873	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.706	rs1430348	ENSG00000236165.1	PRADC1P1	9.29	1.25e-12	4.57e-05	0.95	0.79	Intelligence (multi-trait analysis);	chr2:73139930	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.706	rs1430347	ENSG00000236165.1	PRADC1P1	9.29	1.25e-12	4.57e-05	0.95	0.79	Intelligence (multi-trait analysis);	chr2:73139931	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.774	rs7606271	ENSG00000236165.1	PRADC1P1	9.29	1.25e-12	4.57e-05	0.95	0.79	Intelligence (multi-trait analysis);	chr2:73140570	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.845	rs10209587	ENSG00000236165.1	PRADC1P1	9.27	1.32e-12	4.81e-05	0.95	0.79	Intelligence (multi-trait analysis);	chr2:73132680	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.845	rs10197227	ENSG00000236165.1	PRADC1P1	9.27	1.32e-12	4.81e-05	0.95	0.79	Intelligence (multi-trait analysis);	chr2:73132681	chr3:36976316~36976840:+
UVM	trans	rs2657294	0.603	rs11543	ENSG00000172974.11	AC007318.5	9.24	1.46e-12	5.28e-05	1.17	0.79	Pneumonia;	chr10:75210855	chr2:65205108~65205988:+
UVM	trans	rs12291225	0.585	rs12270374	ENSG00000236360.2	RP11-334A14.2	9.19	1.74e-12	6.19e-05	0.86	0.79	Sense of smell;	chr11:14353533	chr1:52993201~52993702:-
UVM	trans	rs12291225	0.585	rs10832246	ENSG00000236360.2	RP11-334A14.2	9.19	1.74e-12	6.19e-05	0.86	0.79	Sense of smell;	chr11:14359282	chr1:52993201~52993702:-
UVM	trans	rs12291225	0.585	rs4517475	ENSG00000236360.2	RP11-334A14.2	9.19	1.74e-12	6.19e-05	0.86	0.79	Sense of smell;	chr11:14364599	chr1:52993201~52993702:-
UVM	trans	rs12291225	0.546	rs11023199	ENSG00000236360.2	RP11-334A14.2	9.19	1.74e-12	6.19e-05	0.86	0.79	Sense of smell;	chr11:14372712	chr1:52993201~52993702:-
UVM	trans	rs1816752	1	rs1816752	ENSG00000237917.1	PARP4P1	9.18	1.84e-12	6.39e-05	0.78	0.79	Obesity-related traits;	chr13:24406811	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.935	rs4770676	ENSG00000237917.1	PARP4P1	9.18	1.84e-12	6.39e-05	0.78	0.79	Obesity-related traits;	chr13:24429745	chrY:26594851~26634652:-
UVM	trans	rs1816752	1	rs7326932	ENSG00000237917.1	PARP4P1	9.18	1.84e-12	6.39e-05	0.78	0.79	Obesity-related traits;	chr13:24430355	chrY:26594851~26634652:-
UVM	trans	rs1816752	1	rs7999554	ENSG00000237917.1	PARP4P1	9.18	1.84e-12	6.39e-05	0.78	0.79	Obesity-related traits;	chr13:24435631	chrY:26594851~26634652:-
UVM	trans	rs1816752	1	rs9511265	ENSG00000237917.1	PARP4P1	9.18	1.84e-12	6.39e-05	0.78	0.79	Obesity-related traits;	chr13:24438221	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs1348110	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24406537	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.748	rs6490912	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24408941	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.819	rs1981276	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24409361	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.755	rs1981277	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24409375	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.837	rs57052031	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24409730	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.712	rs9507335	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24409766	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.774	rs2862895	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24410328	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.811	rs9507337	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24410807	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.783	rs7317439	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24410939	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.819	rs7316961	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24411039	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.819	rs7317504	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24411287	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.783	rs7317712	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24411365	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.783	rs7139527	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24411374	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.837	rs7139748	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24411531	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.819	rs9511240	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24411768	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.819	rs7988388	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24412675	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.875	rs7993132	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24412903	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.792	rs7330956	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24413174	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.777	rs6490915	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24413724	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.819	rs4770664	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24414695	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.819	rs4770665	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24414810	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs4770666	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24414891	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.721	rs7399656	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24415708	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs7400631	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24415927	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.749	rs77832754	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24416016	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs8002215	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24416229	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.633	rs8002387	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24416306	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.819	rs7985478	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24417135	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs9511242	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24419261	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs7317850	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24419899	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.819	rs6490917	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24423119	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.719	rs11841989	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24423560	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.87	rs9581025	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24423687	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs9581026	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24423788	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.87	rs9581027	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24423790	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.87	rs9318529	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24424190	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs7991450	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24425898	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.774	rs7986162	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24425941	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs4769352	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24426237	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.805	rs4769353	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24426318	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs7571	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24426479	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.837	rs7324645	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24426717	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs1050112	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24435159	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs13428	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24435303	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.87	rs8000215	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24435648	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs11839006	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24435893	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.87	rs2033955	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24436406	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.87	rs2033954	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24436429	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs9511260	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24437038	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.87	rs7320102	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24437435	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs7339140	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24437764	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.87	rs9511261	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24437880	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs9511262	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24437885	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs9511266	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24438366	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.817	rs7985394	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24438714	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.789	rs7986037	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24438715	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs7995492	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24438885	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs7995909	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24439159	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs6490927	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24439802	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs6490928	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24439921	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs6490929	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24440114	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.87	rs3825449	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24440303	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.87	rs7998797	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24440850	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.87	rs7981337	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24440915	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.87	rs7981480	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24440966	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.837	rs4769355	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24441059	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs4770680	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24441110	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.805	rs61614647	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24441829	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.774	rs55888616	ENSG00000237917.1	PARP4P1	9.13	2.19e-12	6.91e-05	0.81	0.78	Obesity-related traits;	chr13:24441954	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.819	rs4769349	ENSG00000237917.1	PARP4P1	-9.13	2.19e-12	6.91e-05	-0.81	-0.78	Obesity-related traits;	chr13:24408694	chrY:26594851~26634652:-
UVM	trans	rs7943191	0.81	rs7942991	ENSG00000186676.3	EEF1GP1	-9.06	2.79e-12	8.63e-05	-1.18	-0.78	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569731	chr7:125033453~125035301:+
UVM	trans	rs13177918	0.581	rs2245384	ENSG00000213058.3	RP4-765C7.2	9.05	2.91e-12	8.99e-05	1.21	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437705	chr1:178411616~178411972:+
UVM	trans	rs941207	0.855	rs2256341	ENSG00000121089.4	NACA3P	-9.05	2.91e-12	8.99e-05	-1.25	-0.78	Platelet count;	chr12:56599930	chr4:164943290~164943937:+
UVM	trans	rs941207	0.805	rs2958139	ENSG00000121089.4	NACA3P	-9.05	2.91e-12	8.99e-05	-1.25	-0.78	Platelet count;	chr12:56610884	chr4:164943290~164943937:+
UVM	trans	rs7949030	0.523	rs67308910	ENSG00000186676.3	EEF1GP1	9.05	2.95e-12	9.07e-05	1.19	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62609887	chr7:125033453~125035301:+
UVM	trans	rs13177918	0.798	rs13182116	ENSG00000239528.1	RPS14P8	-9.01	3.34e-12	0.000101	-1.32	-0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr5:116562562~116562930:+
UVM	trans	rs9611565	0.694	rs5758347	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41425015	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs202613	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41425989	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs202614	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41426146	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs202616	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41426217	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.569	rs188057	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41426301	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs202617	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41426789	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs202618	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41426852	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs202622	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41429338	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs202625	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41431078	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.729	rs169362	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41431585	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.592	rs5751101	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41432107	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs7285041	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41433145	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs9611591	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41434208	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs202641	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41437112	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs79005	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41439540	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.608	rs202652	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41442788	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs202653	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41444154	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.729	rs202654	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41445030	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs202655	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41445560	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs202656	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41446199	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs202657	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41448782	chr19:56672574~56673901:-
UVM	trans	rs727563	0.58	rs202626	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Crohn's disease;Inflammatory bowel disease;	chr22:41451186	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.532	rs202627	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41451363	chr19:56672574~56673901:-
UVM	trans	rs202629	1	rs202629	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Cannabis dependence symptom count;	chr22:41453971	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.685	rs169363	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41457113	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.605	rs202638	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41459454	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs202639	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41460133	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs5751107	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41461808	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs5751108	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41462031	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs5758365	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41462653	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs79009	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41464860	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs202631	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41467419	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.729	rs505533	ENSG00000268568.1	AC007228.9	8.99	3.55e-12	0.000103	1.47	0.78	Vitiligo;	chr22:41468212	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs106860	ENSG00000268568.1	AC007228.9	-8.99	3.55e-12	0.000103	-1.47	-0.78	Vitiligo;	chr22:41444403	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs202628	ENSG00000268568.1	AC007228.9	-8.99	3.55e-12	0.000103	-1.47	-0.78	Vitiligo;	chr22:41453509	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs79008	ENSG00000268568.1	AC007228.9	-8.99	3.55e-12	0.000103	-1.47	-0.78	Vitiligo;	chr22:41454496	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs5758368	ENSG00000268568.1	AC007228.9	-8.99	3.55e-12	0.000103	-1.47	-0.78	Vitiligo;	chr22:41466284	chr19:56672574~56673901:-
UVM	trans	rs1816752	0.935	rs3816219	ENSG00000237917.1	PARP4P1	8.99	3.62e-12	0.000104	0.79	0.78	Obesity-related traits;	chr13:24442995	chrY:26594851~26634652:-
UVM	trans	rs1816752	1	rs7988810	ENSG00000237917.1	PARP4P1	8.99	3.62e-12	0.000104	0.79	0.78	Obesity-related traits;	chr13:24444958	chrY:26594851~26634652:-
UVM	trans	rs5758343	1	rs5758343	ENSG00000268568.1	AC007228.9	8.99	3.63e-12	0.000104	1.47	0.78	Allergic disease (asthma, hay fever or eczema);	chr22:41420648	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs5758344	ENSG00000268568.1	AC007228.9	8.99	3.63e-12	0.000104	1.47	0.78	Vitiligo;	chr22:41421681	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.729	rs12165508	ENSG00000268568.1	AC007228.9	8.99	3.63e-12	0.000104	1.47	0.78	Vitiligo;	chr22:41423956	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs2142505	ENSG00000268568.1	AC007228.9	8.99	3.63e-12	0.000104	1.47	0.78	Vitiligo;	chr22:41424537	chr19:56672574~56673901:-
UVM	trans	rs12291225	0.585	rs11023197	ENSG00000236360.2	RP11-334A14.2	8.99	3.64e-12	0.000104	0.85	0.78	Sense of smell;	chr11:14359452	chr1:52993201~52993702:-
UVM	trans	rs1816752	0.633	rs9578729	ENSG00000237917.1	PARP4P1	8.99	3.64e-12	0.000104	0.81	0.78	Obesity-related traits;	chr13:24425106	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.87	rs9581029	ENSG00000237917.1	PARP4P1	8.99	3.64e-12	0.000104	0.81	0.78	Obesity-related traits;	chr13:24425147	chrY:26594851~26634652:-
UVM	trans	rs13177918	0.581	rs2748244	ENSG00000224114.1	RP11-343H5.4	8.98	3.79e-12	0.000108	1.22	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150436487	chr1:206695837~206696269:-
UVM	trans	rs13177918	0.559	rs3901731	ENSG00000224114.1	RP11-343H5.4	8.98	3.79e-12	0.000108	1.22	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437405	chr1:206695837~206696269:-
UVM	trans	rs12291225	0.585	rs4757250	ENSG00000236360.2	RP11-334A14.2	8.95	4.11e-12	0.000116	0.85	0.78	Sense of smell;	chr11:14354137	chr1:52993201~52993702:-
UVM	trans	rs6732160	0.619	rs12105975	ENSG00000236165.1	PRADC1P1	8.92	4.69e-12	0.000132	0.97	0.78	Intelligence (multi-trait analysis);	chr2:73178921	chr3:36976316~36976840:+
UVM	trans	rs1816752	1	rs9507341	ENSG00000237917.1	PARP4P1	-8.9	4.95e-12	0.000137	-0.77	-0.78	Obesity-related traits;	chr13:24432440	chrY:26594851~26634652:-
UVM	trans	rs13177918	0.603	rs2343806	ENSG00000224114.1	RP11-343H5.4	8.9	5.01e-12	0.000138	1.13	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr1:206695837~206696269:-
UVM	trans	rs1816752	0.87	rs73469543	ENSG00000237917.1	PARP4P1	8.87	5.43e-12	0.000149	0.82	0.78	Obesity-related traits;	chr13:24424832	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.806	rs3816218	ENSG00000237917.1	PARP4P1	8.86	5.78e-12	0.000157	0.81	0.78	Obesity-related traits;	chr13:24443033	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.666	rs7994022	ENSG00000237917.1	PARP4P1	8.86	5.78e-12	0.000157	0.81	0.78	Obesity-related traits;	chr13:24443092	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.712	rs6490932	ENSG00000237917.1	PARP4P1	8.86	5.78e-12	0.000157	0.81	0.78	Obesity-related traits;	chr13:24443313	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.713	rs7336357	ENSG00000237917.1	PARP4P1	8.86	5.78e-12	0.000157	0.81	0.78	Obesity-related traits;	chr13:24443452	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.683	rs7330532	ENSG00000237917.1	PARP4P1	8.86	5.78e-12	0.000157	0.81	0.78	Obesity-related traits;	chr13:24443453	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.59	rs61947036	ENSG00000237917.1	PARP4P1	8.86	5.78e-12	0.000157	0.81	0.78	Obesity-related traits;	chr13:24443544	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.746	rs9511270	ENSG00000237917.1	PARP4P1	8.86	5.78e-12	0.000157	0.81	0.78	Obesity-related traits;	chr13:24444542	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.719	rs11843470	ENSG00000237917.1	PARP4P1	8.85	5.91e-12	0.00016	0.8	0.78	Obesity-related traits;	chr13:24423561	chrY:26594851~26634652:-
UVM	trans	rs13253073	0.723	rs7009713	ENSG00000260318.1	COX6CP1	8.81	6.88e-12	0.000183	1.4	0.77	Glucose homeostasis traits;	chr8:99869626	chr16:11903923~11904137:-
UVM	trans	rs13253073	0.723	rs12546882	ENSG00000260318.1	COX6CP1	8.81	6.88e-12	0.000183	1.4	0.77	Glucose homeostasis traits;	chr8:99869919	chr16:11903923~11904137:-
UVM	trans	rs2657294	0.62	rs7903537	ENSG00000172974.11	AC007318.5	8.8	7.11e-12	0.000189	1.2	0.77	Pneumonia;	chr10:75087732	chr2:65205108~65205988:+
UVM	trans	rs2657294	0.62	rs2395136	ENSG00000172974.11	AC007318.5	8.8	7.11e-12	0.000189	1.2	0.77	Pneumonia;	chr10:75088213	chr2:65205108~65205988:+
UVM	trans	rs3749237	0.595	rs1464567	ENSG00000197582.5	GPX1P1	-8.77	7.95e-12	0.000209	-0.96	-0.77	Resting heart rate;	chr3:49421819	chrX:13378735~13379340:-
UVM	trans	rs13253073	0.723	rs6468695	ENSG00000260318.1	COX6CP1	8.76	8.15e-12	0.000214	1.41	0.77	Glucose homeostasis traits;	chr8:99857123	chr16:11903923~11904137:-
UVM	trans	rs13253073	0.723	rs6468696	ENSG00000260318.1	COX6CP1	8.76	8.15e-12	0.000214	1.41	0.77	Glucose homeostasis traits;	chr8:99857130	chr16:11903923~11904137:-
UVM	trans	rs3749237	0.595	rs4955412	ENSG00000197582.5	GPX1P1	8.74	8.68e-12	0.000226	0.91	0.77	Resting heart rate;	chr3:49380735	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.595	rs6797765	ENSG00000197582.5	GPX1P1	8.74	8.68e-12	0.000226	0.91	0.77	Resting heart rate;	chr3:49386543	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.557	rs7631908	ENSG00000197582.5	GPX1P1	8.74	8.68e-12	0.000226	0.91	0.77	Resting heart rate;	chr3:49388274	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.615	rs6792911	ENSG00000197582.5	GPX1P1	8.74	8.68e-12	0.000226	0.91	0.77	Resting heart rate;	chr3:49392423	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.615	rs55957735	ENSG00000197582.5	GPX1P1	8.74	8.68e-12	0.000226	0.91	0.77	Resting heart rate;	chr3:49400725	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.595	rs4855877	ENSG00000197582.5	GPX1P1	8.74	8.68e-12	0.000226	0.91	0.77	Resting heart rate;	chr3:49411094	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.595	rs6784820	ENSG00000197582.5	GPX1P1	-8.74	8.68e-12	0.000226	-0.91	-0.77	Resting heart rate;	chr3:49413431	chrX:13378735~13379340:-
UVM	trans	rs9611565	0.694	rs19573	ENSG00000268568.1	AC007228.9	8.73	9.16e-12	0.000238	1.44	0.77	Vitiligo;	chr22:41469805	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs79011	ENSG00000268568.1	AC007228.9	8.73	9.16e-12	0.000238	1.44	0.77	Vitiligo;	chr22:41470934	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.765	rs727563	ENSG00000268568.1	AC007228.9	8.73	9.16e-12	0.000238	1.44	0.77	Vitiligo;	chr22:41471373	chr19:56672574~56673901:-
UVM	trans	rs2657294	0.62	rs4746261	ENSG00000172974.11	AC007318.5	-8.71	9.91e-12	0.000256	-1.13	-0.77	Pneumonia;	chr10:75085874	chr2:65205108~65205988:+
UVM	trans	rs9611565	0.879	rs5758307	ENSG00000268568.1	AC007228.9	-8.7	1.02e-11	0.000262	-1.45	-0.77	Vitiligo;	chr22:41354215	chr19:56672574~56673901:-
UVM	trans	rs1816752	0.875	rs1050110	ENSG00000237917.1	PARP4P1	8.67	1.11e-11	0.000281	0.8	0.77	Obesity-related traits;	chr13:24435347	chrY:26594851~26634652:-
UVM	trans	rs7121616	0.595	rs7949414	ENSG00000234176.1	HSPA8P1	8.67	1.12e-11	0.000284	1.05	0.77	Breast cancer;	chr11:123072787	chrX:121203182~121205014:-
UVM	trans	rs13253073	0.723	rs13274441	ENSG00000260318.1	COX6CP1	8.67	1.13e-11	0.000286	1.39	0.77	Glucose homeostasis traits;	chr8:99861038	chr16:11903923~11904137:-
UVM	trans	rs13253073	0.723	rs62534626	ENSG00000260318.1	COX6CP1	8.67	1.13e-11	0.000286	1.39	0.77	Glucose homeostasis traits;	chr8:99866119	chr16:11903923~11904137:-
UVM	trans	rs13253073	0.723	rs7840626	ENSG00000260318.1	COX6CP1	8.67	1.13e-11	0.000286	1.39	0.77	Glucose homeostasis traits;	chr8:99867598	chr16:11903923~11904137:-
UVM	trans	rs13253073	0.723	rs7812991	ENSG00000260318.1	COX6CP1	8.65	1.2e-11	0.000301	1.1	0.77	Glucose homeostasis traits;	chr8:99884095	chr16:11903923~11904137:-
UVM	trans	rs13253073	0.76	rs62534633	ENSG00000260318.1	COX6CP1	8.65	1.2e-11	0.000301	1.1	0.77	Glucose homeostasis traits;	chr8:99884533	chr16:11903923~11904137:-
UVM	trans	rs13253073	0.723	rs12548840	ENSG00000260318.1	COX6CP1	8.65	1.2e-11	0.000301	1.1	0.77	Glucose homeostasis traits;	chr8:99885580	chr16:11903923~11904137:-
UVM	trans	rs1816752	0.905	rs4769348	ENSG00000237917.1	PARP4P1	8.65	1.23e-11	0.000307	0.8	0.77	Obesity-related traits;	chr13:24400975	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.819	rs7400583	ENSG00000237917.1	PARP4P1	8.64	1.26e-11	0.000314	0.78	0.77	Obesity-related traits;	chr13:24415916	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.712	rs2862898	ENSG00000237917.1	PARP4P1	8.64	1.27e-11	0.000316	0.79	0.77	Obesity-related traits;	chr13:24414323	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.652	rs2902356	ENSG00000237917.1	PARP4P1	8.64	1.27e-11	0.000316	0.79	0.77	Obesity-related traits;	chr13:24414333	chrY:26594851~26634652:-
UVM	trans	rs877636	0.562	rs1131017	ENSG00000225071.1	GS1-184P14.2	-8.64	1.28e-11	0.000319	-0.9	-0.77	Cognitive function;	chr12:56042145	chrX:24429573~24429920:-
UVM	trans	rs13177918	0.911	rs12186451	ENSG00000239528.1	RPS14P8	8.59	1.52e-11	0.000372	1.31	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150432625	chr5:116562562~116562930:+
UVM	trans	rs3749237	0.595	rs2878298	ENSG00000197582.5	GPX1P1	8.58	1.53e-11	0.000374	0.9	0.77	Resting heart rate;	chr3:49368647	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.595	rs17595772	ENSG00000197582.5	GPX1P1	8.58	1.53e-11	0.000374	0.9	0.77	Resting heart rate;	chr3:49372271	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.595	rs7621003	ENSG00000197582.5	GPX1P1	8.58	1.53e-11	0.000374	0.9	0.77	Resting heart rate;	chr3:49373971	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.555	rs2117939	ENSG00000197582.5	GPX1P1	8.58	1.53e-11	0.000374	0.9	0.77	Resting heart rate;	chr3:49377746	chrX:13378735~13379340:-
UVM	trans	rs9611565	0.729	rs73176686	ENSG00000268568.1	AC007228.9	-8.56	1.68e-11	0.000406	-1.41	-0.76	Vitiligo;	chr22:41386115	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.729	rs73176689	ENSG00000268568.1	AC007228.9	-8.56	1.68e-11	0.000406	-1.41	-0.76	Vitiligo;	chr22:41386629	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.729	rs4822027	ENSG00000268568.1	AC007228.9	-8.56	1.68e-11	0.000406	-1.41	-0.76	Vitiligo;	chr22:41390223	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.729	rs132902	ENSG00000268568.1	AC007228.9	-8.56	1.68e-11	0.000406	-1.41	-0.76	Vitiligo;	chr22:41401754	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs202645	ENSG00000268568.1	AC007228.9	8.56	1.68e-11	0.000406	1.41	0.76	Vitiligo;	chr22:41402516	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs202664	ENSG00000268568.1	AC007228.9	8.56	1.68e-11	0.000406	1.41	0.76	Vitiligo;	chr22:41417882	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs202665	ENSG00000268568.1	AC007228.9	8.56	1.68e-11	0.000406	1.41	0.76	Vitiligo;	chr22:41418397	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs202666	ENSG00000268568.1	AC007228.9	8.56	1.68e-11	0.000406	1.41	0.76	Vitiligo;	chr22:41418715	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.879	rs5758311	ENSG00000268568.1	AC007228.9	-8.53	1.85e-11	0.000445	-1.43	-0.76	Vitiligo;	chr22:41363371	chr19:56672574~56673901:-
UVM	trans	rs1816752	0.905	rs8002309	ENSG00000237917.1	PARP4P1	8.53	1.87e-11	0.000448	0.8	0.76	Obesity-related traits;	chr13:24402217	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.875	rs8001187	ENSG00000237917.1	PARP4P1	8.53	1.87e-11	0.000448	0.8	0.76	Obesity-related traits;	chr13:24402276	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.783	rs9507333	ENSG00000237917.1	PARP4P1	8.53	1.87e-11	0.000448	0.8	0.76	Obesity-related traits;	chr13:24404172	chrY:26594851~26634652:-
UVM	trans	rs1816752	0.905	rs2000153	ENSG00000237917.1	PARP4P1	8.53	1.87e-11	0.000448	0.8	0.76	Obesity-related traits;	chr13:24405752	chrY:26594851~26634652:-
UVM	trans	rs13177918	0.626	rs2748240	ENSG00000213058.3	RP4-765C7.2	8.52	1.93e-11	0.000462	1.11	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:178411616~178411972:+
UVM	trans	rs9611565	0.877	rs3817999	ENSG00000268568.1	AC007228.9	8.51	2.03e-11	0.000475	1.45	0.76	Vitiligo;	chr22:41351713	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.918	rs9611566	ENSG00000268568.1	AC007228.9	8.51	2.03e-11	0.000475	1.45	0.76	Vitiligo;	chr22:41372621	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.838	rs4239894	ENSG00000268568.1	AC007228.9	-8.51	2.03e-11	0.000475	-1.45	-0.76	Vitiligo;	chr22:41349544	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.918	rs2281333	ENSG00000268568.1	AC007228.9	-8.51	2.03e-11	0.000475	-1.45	-0.76	Vitiligo;	chr22:41353626	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.918	rs7290404	ENSG00000268568.1	AC007228.9	-8.51	2.03e-11	0.000475	-1.45	-0.76	Vitiligo;	chr22:41353792	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.918	rs6002351	ENSG00000268568.1	AC007228.9	-8.51	2.03e-11	0.000475	-1.45	-0.76	Vitiligo;	chr22:41361219	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.918	rs9611561	ENSG00000268568.1	AC007228.9	-8.51	2.03e-11	0.000475	-1.45	-0.76	Vitiligo;	chr22:41361230	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.918	rs4822024	ENSG00000268568.1	AC007228.9	-8.51	2.03e-11	0.000475	-1.45	-0.76	Vitiligo;	chr22:41361643	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.879	rs4820437	ENSG00000268568.1	AC007228.9	-8.51	2.03e-11	0.000475	-1.45	-0.76	Vitiligo;	chr22:41365286	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.918	rs4820438	ENSG00000268568.1	AC007228.9	-8.51	2.03e-11	0.000475	-1.45	-0.76	Vitiligo;	chr22:41371131	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.84	rs4822025	ENSG00000268568.1	AC007228.9	-8.51	2.03e-11	0.000475	-1.45	-0.76	Vitiligo;	chr22:41380642	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.84	rs2234052	ENSG00000268568.1	AC007228.9	-8.51	2.03e-11	0.000475	-1.45	-0.76	Vitiligo;	chr22:41381237	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.527	rs2234053	ENSG00000268568.1	AC007228.9	-8.51	2.03e-11	0.000475	-1.45	-0.76	Vitiligo;	chr22:41381311	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.84	rs9607799	ENSG00000268568.1	AC007228.9	-8.51	2.03e-11	0.000475	-1.45	-0.76	Vitiligo;	chr22:41381554	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.802	rs2234058	ENSG00000268568.1	AC007228.9	-8.51	2.03e-11	0.000475	-1.45	-0.76	Vitiligo;	chr22:41381879	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.84	rs2234059	ENSG00000268568.1	AC007228.9	-8.51	2.03e-11	0.000475	-1.45	-0.76	Vitiligo;	chr22:41381909	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.84	rs3788584	ENSG00000268568.1	AC007228.9	-8.51	2.03e-11	0.000475	-1.45	-0.76	Vitiligo;	chr22:41383069	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.765	rs767593	ENSG00000268568.1	AC007228.9	-8.51	2.03e-11	0.000475	-1.45	-0.76	Vitiligo;	chr22:41383967	chr19:56672574~56673901:-
UVM	trans	rs2950393	0.895	rs2958154	ENSG00000121089.4	NACA3P	-8.48	2.27e-11	0.00053	-1.04	-0.76	Platelet distribution width;	chr12:56671929	chr4:164943290~164943937:+
UVM	trans	rs13177918	0.603	rs2343806	ENSG00000239528.1	RPS14P8	8.43	2.7e-11	0.000618	1.08	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr5:116562562~116562930:+
UVM	trans	rs9611565	1	rs1109151	ENSG00000268568.1	AC007228.9	-8.43	2.71e-11	0.000619	-1.47	-0.76	Vitiligo;	chr22:41356940	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.918	rs28638318	ENSG00000268568.1	AC007228.9	-8.43	2.71e-11	0.000619	-1.47	-0.76	Vitiligo;	chr22:41357055	chr19:56672574~56673901:-
UVM	trans	rs13253073	0.723	rs12548542	ENSG00000260318.1	COX6CP1	8.41	2.84e-11	0.000645	1.09	0.76	Glucose homeostasis traits;	chr8:99890167	chr16:11903923~11904137:-
UVM	trans	rs6477998	0.934	rs4979223	ENSG00000238072.1	RP11-305M3.2	8.39	3.07e-11	0.000694	0.96	0.76	Hematology traits;	chr9:113219836	chr7:129410113~129410370:-
UVM	trans	rs6477998	0.9	rs7850357	ENSG00000238072.1	RP11-305M3.2	8.39	3.07e-11	0.000694	0.96	0.76	Hematology traits;	chr9:113222319	chr7:129410113~129410370:-
UVM	trans	rs6477998	0.874	rs10739390	ENSG00000238072.1	RP11-305M3.2	8.39	3.07e-11	0.000694	0.96	0.76	Hematology traits;	chr9:113226209	chr7:129410113~129410370:-
UVM	trans	rs6477998	0.903	rs4979226	ENSG00000238072.1	RP11-305M3.2	8.39	3.07e-11	0.000694	0.96	0.76	Hematology traits;	chr9:113239516	chr7:129410113~129410370:-
UVM	trans	rs6477998	0.903	rs7041615	ENSG00000238072.1	RP11-305M3.2	8.39	3.07e-11	0.000694	0.96	0.76	Hematology traits;	chr9:113244747	chr7:129410113~129410370:-
UVM	trans	rs7121616	0.576	rs11600486	ENSG00000234176.1	HSPA8P1	8.39	3.14e-11	0.000698	1.2	0.76	Breast cancer;	chr11:123047060	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.545	rs11600517	ENSG00000234176.1	HSPA8P1	8.39	3.14e-11	0.000698	1.2	0.76	Breast cancer;	chr11:123047247	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.576	rs73610509	ENSG00000234176.1	HSPA8P1	8.39	3.14e-11	0.000698	1.2	0.76	Breast cancer;	chr11:123048564	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.576	rs73610510	ENSG00000234176.1	HSPA8P1	8.39	3.14e-11	0.000698	1.2	0.76	Breast cancer;	chr11:123049365	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.576	rs7942164	ENSG00000234176.1	HSPA8P1	8.39	3.14e-11	0.000698	1.2	0.76	Breast cancer;	chr11:123050459	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.576	rs7102045	ENSG00000234176.1	HSPA8P1	8.39	3.14e-11	0.000698	1.2	0.76	Breast cancer;	chr11:123052713	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.576	rs56131320	ENSG00000234176.1	HSPA8P1	8.39	3.14e-11	0.000698	1.2	0.76	Breast cancer;	chr11:123053058	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.576	rs7929869	ENSG00000234176.1	HSPA8P1	8.39	3.14e-11	0.000698	1.2	0.76	Breast cancer;	chr11:123054435	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.576	rs7111590	ENSG00000234176.1	HSPA8P1	8.39	3.14e-11	0.000698	1.2	0.76	Breast cancer;	chr11:123055419	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.576	rs1841580	ENSG00000234176.1	HSPA8P1	8.39	3.14e-11	0.000698	1.2	0.76	Breast cancer;	chr11:123055956	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.576	rs7123232	ENSG00000234176.1	HSPA8P1	8.39	3.14e-11	0.000698	1.2	0.76	Breast cancer;	chr11:123056237	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.545	rs7109336	ENSG00000234176.1	HSPA8P1	8.39	3.14e-11	0.000698	1.2	0.76	Breast cancer;	chr11:123056530	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.545	rs7109348	ENSG00000234176.1	HSPA8P1	8.39	3.14e-11	0.000698	1.2	0.76	Breast cancer;	chr11:123056555	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.576	rs7949127	ENSG00000234176.1	HSPA8P1	8.39	3.14e-11	0.000698	1.2	0.76	Breast cancer;	chr11:123057408	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.576	rs7949220	ENSG00000234176.1	HSPA8P1	8.39	3.14e-11	0.000698	1.2	0.76	Breast cancer;	chr11:123057418	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.576	rs7948948	ENSG00000234176.1	HSPA8P1	8.39	3.14e-11	0.000698	1.2	0.76	Breast cancer;	chr11:123057467	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.576	rs1064585	ENSG00000234176.1	HSPA8P1	8.39	3.14e-11	0.000698	1.2	0.76	Breast cancer;	chr11:123058699	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.531	rs1461497	ENSG00000234176.1	HSPA8P1	8.39	3.14e-11	0.000698	1.2	0.76	Breast cancer;	chr11:123060505	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.531	rs41361350	ENSG00000234176.1	HSPA8P1	8.39	3.14e-11	0.000698	1.2	0.76	Breast cancer;	chr11:123060917	chrX:121203182~121205014:-
UVM	trans	rs13177918	0.559	rs10447224	ENSG00000239528.1	RPS14P8	8.38	3.21e-11	0.000713	1.08	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.559	rs10447225	ENSG00000239528.1	RPS14P8	8.38	3.21e-11	0.000713	1.08	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr5:116562562~116562930:+
UVM	trans	rs13177918	0.559	rs12109637	ENSG00000239528.1	RPS14P8	8.38	3.21e-11	0.000713	1.08	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr5:116562562~116562930:+
UVM	trans	rs9611565	0.918	rs9611562	ENSG00000268568.1	AC007228.9	-8.37	3.38e-11	0.00074	-1.46	-0.76	Vitiligo;	chr22:41364168	chr19:56672574~56673901:-
UVM	trans	rs13177918	0.798	rs2343805	ENSG00000224114.1	RP11-343H5.4	8.36	3.48e-11	0.000761	1.22	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150460501	chr1:206695837~206696269:-
UVM	trans	rs3749237	0.595	rs3870338	ENSG00000197582.5	GPX1P1	8.36	3.51e-11	0.000768	0.9	0.76	Resting heart rate;	chr3:49519618	chrX:13378735~13379340:-
UVM	trans	rs12711490	0.651	rs13330932	ENSG00000278595.1	RP5-1068H6.6	8.31	4.18e-11	0.000905	0.96	0.76	Systemic lupus erythematosus and Systemic sclerosis;Monocyte count;	chr16:85940901	chr20:4761300~4761696:+
UVM	trans	rs7121616	0.576	rs1461495	ENSG00000234176.1	HSPA8P1	-8.28	4.6e-11	0.000994	-1.14	-0.75	Breast cancer;	chr11:123056136	chrX:121203182~121205014:-
UVM	trans	rs1816752	0.837	rs9318530	ENSG00000237917.1	PARP4P1	-8.26	4.99e-11	0.00107	-0.78	-0.75	Obesity-related traits;	chr13:24424419	chrY:26594851~26634652:-
UVM	trans	rs7121616	0.531	rs10892958	ENSG00000234176.1	HSPA8P1	8.25	5.22e-11	0.00112	1.16	0.75	Breast cancer;	chr11:123061415	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.531	rs11218941	ENSG00000234176.1	HSPA8P1	8.25	5.22e-11	0.00112	1.16	0.75	Breast cancer;	chr11:123061701	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.515	rs11218966	ENSG00000234176.1	HSPA8P1	8.21	5.89e-11	0.00125	1.39	0.75	Breast cancer;	chr11:123086510	chrX:121203182~121205014:-
UVM	trans	rs9611565	0.625	rs2076199	ENSG00000268568.1	AC007228.9	-8.2	6.09e-11	0.00128	-1.38	-0.75	Vitiligo;	chr22:41507739	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.729	rs137831	ENSG00000268568.1	AC007228.9	-8.2	6.09e-11	0.00128	-1.38	-0.75	Vitiligo;	chr22:41507809	chr19:56672574~56673901:-
UVM	trans	rs941207	1	rs941207	ENSG00000121089.4	NACA3P	-8.2	6.1e-11	0.00128	-1.2	-0.75	Platelet count;	chr12:56629500	chr4:164943290~164943937:+
UVM	trans	rs3749237	0.595	rs4855873	ENSG00000197582.5	GPX1P1	8.17	6.75e-11	0.00142	0.91	0.75	Resting heart rate;	chr3:49421681	chrX:13378735~13379340:-
UVM	trans	rs6477998	1	rs4560868	ENSG00000238072.1	RP11-305M3.2	-8.15	7.51e-11	0.00155	-1.02	-0.75	Hematology traits;	chr9:113223219	chr7:129410113~129410370:-
UVM	trans	rs6477998	1	rs6477998	ENSG00000238072.1	RP11-305M3.2	-8.15	7.51e-11	0.00155	-1.02	-0.75	Hematology traits;	chr9:113234969	chr7:129410113~129410370:-
UVM	trans	rs6477998	0.932	rs4129395	ENSG00000238072.1	RP11-305M3.2	8.15	7.51e-11	0.00155	1.02	0.75	Hematology traits;	chr9:113213109	chr7:129410113~129410370:-
UVM	trans	rs6477998	0.966	rs7859354	ENSG00000238072.1	RP11-305M3.2	8.15	7.51e-11	0.00155	1.02	0.75	Hematology traits;	chr9:113214165	chr7:129410113~129410370:-
UVM	trans	rs6477998	1	rs10739388	ENSG00000238072.1	RP11-305M3.2	8.15	7.51e-11	0.00155	1.02	0.75	Hematology traits;	chr9:113214895	chr7:129410113~129410370:-
UVM	trans	rs6477998	0.966	rs7851395	ENSG00000238072.1	RP11-305M3.2	8.15	7.51e-11	0.00155	1.02	0.75	Hematology traits;	chr9:113240184	chr7:129410113~129410370:-
UVM	trans	rs6477998	1	rs7038769	ENSG00000238072.1	RP11-305M3.2	8.15	7.51e-11	0.00155	1.02	0.75	Hematology traits;	chr9:113245303	chr7:129410113~129410370:-
UVM	trans	rs6477998	1	rs7022397	ENSG00000238072.1	RP11-305M3.2	8.15	7.51e-11	0.00155	1.02	0.75	Hematology traits;	chr9:113245397	chr7:129410113~129410370:-
UVM	trans	rs6477998	1	rs10759636	ENSG00000238072.1	RP11-305M3.2	8.15	7.51e-11	0.00155	1.02	0.75	Hematology traits;	chr9:113256497	chr7:129410113~129410370:-
UVM	trans	rs6477998	0.966	rs10759637	ENSG00000238072.1	RP11-305M3.2	8.15	7.51e-11	0.00155	1.02	0.75	Hematology traits;	chr9:113262744	chr7:129410113~129410370:-
UVM	trans	rs13177918	0.581	rs2748244	ENSG00000213058.3	RP4-765C7.2	8.14	7.54e-11	0.00155	1.13	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150436487	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.559	rs3901731	ENSG00000213058.3	RP4-765C7.2	8.14	7.54e-11	0.00155	1.13	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150437405	chr1:178411616~178411972:+
UVM	trans	rs3749237	0.595	rs1464566	ENSG00000197582.5	GPX1P1	8.13	7.92e-11	0.00163	0.91	0.75	Resting heart rate;	chr3:49421943	chrX:13378735~13379340:-
UVM	trans	rs13177918	0.798	rs12514700	ENSG00000213058.3	RP4-765C7.2	8.13	7.98e-11	0.00164	1.25	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:178411616~178411972:+
UVM	trans	rs941207	0.526	rs2950390	ENSG00000121089.4	NACA3P	8.11	8.56e-11	0.00173	1.05	0.75	Platelet count;	chr12:56661507	chr4:164943290~164943937:+
UVM	trans	rs2950393	0.895	rs2926740	ENSG00000121089.4	NACA3P	8.11	8.56e-11	0.00173	1.05	0.75	Platelet distribution width;	chr12:56666751	chr4:164943290~164943937:+
UVM	trans	rs941207	0.547	rs56183434	ENSG00000121089.4	NACA3P	8.11	8.56e-11	0.00173	1.05	0.75	Platelet count;	chr12:56676145	chr4:164943290~164943937:+
UVM	trans	rs941207	0.526	rs7303216	ENSG00000121089.4	NACA3P	8.11	8.56e-11	0.00173	1.05	0.75	Platelet count;	chr12:56680909	chr4:164943290~164943937:+
UVM	trans	rs941207	0.507	rs7297289	ENSG00000121089.4	NACA3P	8.11	8.56e-11	0.00173	1.05	0.75	Platelet count;	chr12:56682703	chr4:164943290~164943937:+
UVM	trans	rs941207	0.526	rs4759028	ENSG00000121089.4	NACA3P	8.11	8.56e-11	0.00173	1.05	0.75	Platelet count;	chr12:56686399	chr4:164943290~164943937:+
UVM	trans	rs2950393	0.857	rs1563896	ENSG00000121089.4	NACA3P	8.11	8.56e-11	0.00173	1.05	0.75	Platelet distribution width;	chr12:56699312	chr4:164943290~164943937:+
UVM	trans	rs9611565	0.729	rs203320	ENSG00000268568.1	AC007228.9	-8.09	9.02e-11	0.00182	-1.37	-0.75	Vitiligo;	chr22:41517473	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.729	rs203319	ENSG00000268568.1	AC007228.9	-8.09	9.02e-11	0.00182	-1.37	-0.75	Vitiligo;	chr22:41518589	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs4822032	ENSG00000268568.1	AC007228.9	-8.09	9.02e-11	0.00182	-1.37	-0.75	Vitiligo;	chr22:41529531	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.625	rs12483991	ENSG00000268568.1	AC007228.9	-8.09	9.02e-11	0.00182	-1.37	-0.75	Vitiligo;	chr22:41539281	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs5758389	ENSG00000268568.1	AC007228.9	-8.09	9.02e-11	0.00182	-1.37	-0.75	Vitiligo;	chr22:41545745	chr19:56672574~56673901:-
UVM	trans	rs1045902	0.583	rs2303904	ENSG00000236165.1	PRADC1P1	-8.09	9.1e-11	0.00184	-1.01	-0.75	Intelligence (multi-trait analysis);	chr2:73220647	chr3:36976316~36976840:+
UVM	trans	rs1045902	0.583	rs36106493	ENSG00000236165.1	PRADC1P1	8.09	9.1e-11	0.00184	1.01	0.75	Intelligence (multi-trait analysis);	chr2:73215211	chr3:36976316~36976840:+
UVM	trans	rs9611565	0.572	rs139569	ENSG00000268568.1	AC007228.9	-8.09	9.31e-11	0.00188	-1.26	-0.75	Vitiligo;	chr22:41815137	chr19:56672574~56673901:-
UVM	trans	rs3749237	0.595	rs11130196	ENSG00000197582.5	GPX1P1	8.05	1.07e-10	0.00215	0.89	0.74	Resting heart rate;	chr3:49452716	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.595	rs4855839	ENSG00000197582.5	GPX1P1	8.05	1.07e-10	0.00215	0.89	0.74	Resting heart rate;	chr3:49470414	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.595	rs1568661	ENSG00000197582.5	GPX1P1	8.05	1.07e-10	0.00215	0.89	0.74	Resting heart rate;	chr3:49483525	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.595	rs4855864	ENSG00000197582.5	GPX1P1	8.05	1.07e-10	0.00215	0.89	0.74	Resting heart rate;	chr3:49484541	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.595	rs11130199	ENSG00000197582.5	GPX1P1	8.05	1.07e-10	0.00215	0.89	0.74	Resting heart rate;	chr3:49501366	chrX:13378735~13379340:-
UVM	trans	rs6477998	0.868	rs10513189	ENSG00000238072.1	RP11-305M3.2	8.03	1.16e-10	0.00232	0.95	0.74	Hematology traits;	chr9:113227941	chr7:129410113~129410370:-
UVM	trans	rs13253073	0.723	rs7157	ENSG00000260318.1	COX6CP1	8.02	1.16e-10	0.00232	1.15	0.74	Glucose homeostasis traits;	chr8:99877449	chr16:11903923~11904137:-
UVM	trans	rs13253073	0.723	rs4626565	ENSG00000260318.1	COX6CP1	8.02	1.16e-10	0.00232	1.15	0.74	Glucose homeostasis traits;	chr8:99878314	chr16:11903923~11904137:-
UVM	trans	rs13253073	0.723	rs7844439	ENSG00000260318.1	COX6CP1	8.02	1.16e-10	0.00232	1.15	0.74	Glucose homeostasis traits;	chr8:99878567	chr16:11903923~11904137:-
UVM	trans	rs13253073	0.723	rs7813557	ENSG00000260318.1	COX6CP1	8.02	1.16e-10	0.00232	1.15	0.74	Glucose homeostasis traits;	chr8:99878665	chr16:11903923~11904137:-
UVM	trans	rs13253073	0.723	rs4510829	ENSG00000260318.1	COX6CP1	8.02	1.16e-10	0.00232	1.15	0.74	Glucose homeostasis traits;	chr8:99878982	chr16:11903923~11904137:-
UVM	trans	rs13253073	0.723	rs1135382	ENSG00000260318.1	COX6CP1	8.02	1.16e-10	0.00232	1.15	0.74	Glucose homeostasis traits;	chr8:99879402	chr16:11903923~11904137:-
UVM	trans	rs13253073	0.723	rs7828241	ENSG00000260318.1	COX6CP1	8.02	1.16e-10	0.00232	1.15	0.74	Glucose homeostasis traits;	chr8:99880417	chr16:11903923~11904137:-
UVM	trans	rs3749237	0.595	rs1464568	ENSG00000197582.5	GPX1P1	8.01	1.21e-10	0.00241	0.92	0.74	Resting heart rate;	chr3:49420833	chrX:13378735~13379340:-
UVM	trans	rs6732160	0.624	rs10865397	ENSG00000236165.1	PRADC1P1	7.99	1.31e-10	0.00259	0.84	0.74	Intelligence (multi-trait analysis);	chr2:73131164	chr3:36976316~36976840:+
UVM	trans	rs3749237	0.595	rs11130192	ENSG00000197582.5	GPX1P1	7.97	1.4e-10	0.00275	0.89	0.74	Resting heart rate;	chr3:49429773	chrX:13378735~13379340:-
UVM	trans	rs13096760	1	rs13096760	ENSG00000197582.5	GPX1P1	7.97	1.4e-10	0.00275	0.89	0.74	Intelligence (multi-trait analysis);	chr3:49439373	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.595	rs885592	ENSG00000197582.5	GPX1P1	7.97	1.4e-10	0.00275	0.89	0.74	Resting heart rate;	chr3:49460450	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.595	rs10865955	ENSG00000197582.5	GPX1P1	7.97	1.4e-10	0.00275	0.89	0.74	Resting heart rate;	chr3:49462396	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.636	rs1568662	ENSG00000197582.5	GPX1P1	7.97	1.4e-10	0.00275	0.89	0.74	Resting heart rate;	chr3:49483830	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.595	rs3924462	ENSG00000197582.5	GPX1P1	7.97	1.4e-10	0.00275	0.89	0.74	Resting heart rate;	chr3:49486803	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.595	rs4855861	ENSG00000197582.5	GPX1P1	7.97	1.4e-10	0.00275	0.89	0.74	Resting heart rate;	chr3:49488529	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.595	rs4855859	ENSG00000197582.5	GPX1P1	7.97	1.4e-10	0.00275	0.89	0.74	Resting heart rate;	chr3:49488867	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.595	rs7643845	ENSG00000197582.5	GPX1P1	7.97	1.4e-10	0.00275	0.89	0.74	Resting heart rate;	chr3:49493278	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.595	rs7637999	ENSG00000197582.5	GPX1P1	7.97	1.4e-10	0.00275	0.89	0.74	Resting heart rate;	chr3:49497682	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.576	rs3877784	ENSG00000197582.5	GPX1P1	7.97	1.4e-10	0.00275	0.89	0.74	Resting heart rate;	chr3:49501984	chrX:13378735~13379340:-
UVM	trans	rs13177918	0.906	rs12652032	ENSG00000213058.3	RP4-765C7.2	7.97	1.43e-10	0.0028	1.23	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:178411616~178411972:+
UVM	trans	rs13177918	1	rs13161334	ENSG00000213058.3	RP4-765C7.2	7.97	1.43e-10	0.0028	1.23	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:178411616~178411972:+
UVM	trans	rs13177918	1	rs35007082	ENSG00000213058.3	RP4-765C7.2	7.97	1.43e-10	0.0028	1.23	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:178411616~178411972:+
UVM	trans	rs13177918	1	rs13177918	ENSG00000213058.3	RP4-765C7.2	7.97	1.43e-10	0.0028	1.23	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:178411616~178411972:+
UVM	trans	rs13253073	0.723	rs7831963	ENSG00000260318.1	COX6CP1	7.95	1.51e-10	0.00295	1.32	0.74	Glucose homeostasis traits;	chr8:99853014	chr16:11903923~11904137:-
UVM	trans	rs7121616	0.576	rs60405069	ENSG00000234176.1	HSPA8P1	7.95	1.52e-10	0.00297	1.17	0.74	Breast cancer;	chr11:123043616	chrX:121203182~121205014:-
UVM	trans	rs7121616	0.576	rs73608699	ENSG00000234176.1	HSPA8P1	7.95	1.52e-10	0.00297	1.17	0.74	Breast cancer;	chr11:123044718	chrX:121203182~121205014:-
UVM	trans	rs10865397	0.506	rs13414160	ENSG00000236165.1	PRADC1P1	7.91	1.8e-10	0.00348	0.88	0.74	Intelligence (multi-trait analysis);	chr2:73156133	chr3:36976316~36976840:+
UVM	trans	rs10865397	0.539	rs13414338	ENSG00000236165.1	PRADC1P1	7.91	1.8e-10	0.00348	0.88	0.74	Intelligence (multi-trait analysis);	chr2:73156247	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.51	rs57825971	ENSG00000236165.1	PRADC1P1	7.91	1.8e-10	0.00348	0.88	0.74	Intelligence (multi-trait analysis);	chr2:73157668	chr3:36976316~36976840:+
UVM	trans	rs10865397	0.506	rs60764301	ENSG00000236165.1	PRADC1P1	7.91	1.8e-10	0.00348	0.88	0.74	Intelligence (multi-trait analysis);	chr2:73157722	chr3:36976316~36976840:+
UVM	trans	rs9611565	0.918	rs9538	ENSG00000268568.1	AC007228.9	-7.9	1.83e-10	0.00355	-1.43	-0.74	Vitiligo;	chr22:41359853	chr19:56672574~56673901:-
UVM	trans	rs3749237	0.595	rs35701831	ENSG00000197582.5	GPX1P1	7.9	1.86e-10	0.00359	0.9	0.74	Resting heart rate;	chr3:49477567	chrX:13378735~13379340:-
UVM	trans	rs13253073	0.723	rs7832488	ENSG00000260318.1	COX6CP1	7.88	1.99e-10	0.00383	1.31	0.74	Glucose homeostasis traits;	chr8:99853185	chr16:11903923~11904137:-
UVM	trans	rs13253073	0.657	rs35135010	ENSG00000260318.1	COX6CP1	7.87	2.04e-10	0.00391	1.14	0.74	Glucose homeostasis traits;	chr8:99864209	chr16:11903923~11904137:-
UVM	trans	rs13253073	0.723	rs34830464	ENSG00000260318.1	COX6CP1	7.87	2.04e-10	0.00391	1.14	0.74	Glucose homeostasis traits;	chr8:99866638	chr16:11903923~11904137:-
UVM	trans	rs877636	0.692	rs2271194	ENSG00000225071.1	GS1-184P14.2	-7.87	2.08e-10	0.00398	-0.85	-0.74	Cognitive function;	chr12:56083910	chrX:24429573~24429920:-
UVM	trans	rs877636	0.692	rs10876870	ENSG00000225071.1	GS1-184P14.2	-7.87	2.08e-10	0.00398	-0.85	-0.74	Cognitive function;	chr12:56084218	chrX:24429573~24429920:-
UVM	trans	rs877636	0.692	rs7971751	ENSG00000225071.1	GS1-184P14.2	-7.87	2.08e-10	0.00398	-0.85	-0.74	Cognitive function;	chr12:56084874	chrX:24429573~24429920:-
UVM	trans	rs13177918	0.603	rs2748241	ENSG00000213058.3	RP4-765C7.2	7.86	2.1e-10	0.00401	1.07	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:178411616~178411972:+
UVM	trans	rs877636	0.692	rs11171739	ENSG00000225071.1	GS1-184P14.2	7.85	2.17e-10	0.00413	0.85	0.74	Cognitive function;	chr12:56076841	chrX:24429573~24429920:-
UVM	trans	rs877636	0.669	rs7297175	ENSG00000225071.1	GS1-184P14.2	-7.85	2.17e-10	0.00413	-0.85	-0.74	Cognitive function;	chr12:56080024	chrX:24429573~24429920:-
UVM	trans	rs3749237	0.537	rs4459909	ENSG00000197582.5	GPX1P1	7.85	2.19e-10	0.00416	0.88	0.74	Resting heart rate;	chr3:49431784	chrX:13378735~13379340:-
UVM	trans	rs12711490	0.651	rs12600127	ENSG00000278595.1	RP5-1068H6.6	7.85	2.21e-10	0.00419	0.91	0.74	Systemic lupus erythematosus and Systemic sclerosis;Monocyte count;	chr16:85939173	chr20:4761300~4761696:+
UVM	trans	rs7121616	0.515	rs76088419	ENSG00000234176.1	HSPA8P1	7.84	2.24e-10	0.00425	1.24	0.74	Breast cancer;	chr11:123066813	chrX:121203182~121205014:-
UVM	trans	rs6732160	0.518	rs6731057	ENSG00000236165.1	PRADC1P1	7.83	2.37e-10	0.00449	0.88	0.74	Intelligence (multi-trait analysis);	chr2:73172295	chr3:36976316~36976840:+
UVM	trans	rs1816752	0.905	rs3818938	ENSG00000237917.1	PARP4P1	7.79	2.72e-10	0.00505	0.7	0.73	Obesity-related traits;	chr13:24454945	chrY:26594851~26634652:-
UVM	trans	rs12711490	0.651	rs12598434	ENSG00000278595.1	RP5-1068H6.6	7.76	3.09e-10	0.00569	0.9	0.73	Systemic lupus erythematosus and Systemic sclerosis;Monocyte count;	chr16:85939453	chr20:4761300~4761696:+
UVM	trans	rs10865397	0.506	rs6546807	ENSG00000236165.1	PRADC1P1	7.73	3.46e-10	0.00634	0.86	0.73	Intelligence (multi-trait analysis);	chr2:73159084	chr3:36976316~36976840:+
UVM	trans	rs877636	0.562	rs1131017	ENSG00000235459.5	RPS26P31	-7.71	3.61e-10	0.00657	-0.94	-0.73	Cognitive function;	chr12:56042145	chr7:122681315~122681662:+
UVM	trans	rs10865397	0.506	rs6546810	ENSG00000236165.1	PRADC1P1	7.68	4.15e-10	0.00753	0.84	0.73	Intelligence (multi-trait analysis);	chr2:73162588	chr3:36976316~36976840:+
UVM	trans	rs728616	0.558	rs55803802	ENSG00000172186.7	HMGN1P35	7.65	4.52e-10	0.00792	1.62	0.73	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79992908	chrX:69174124~69174717:+
UVM	trans	rs9611565	0.592	rs5751129	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41619761	chr19:56672574~56673901:-
UVM	trans	rs727563	0.565	rs132774	ENSG00000268568.1	AC007228.9	-7.65	4.53e-10	0.00792	-1.27	-0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41635949	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.607	rs132792	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41666818	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.592	rs5758405	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41680377	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.592	rs5758406	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41680637	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.592	rs6519270	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41682662	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs5758411	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41683730	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.5	rs10775759	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41692154	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.546	rs739134	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41693619	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.608	rs2003816	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41699136	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs11090056	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41699900	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.644	rs2413652	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41701234	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.546	rs5758426	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41702759	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.592	rs5758427	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41703684	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.546	rs5758430	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41713840	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.546	rs5758431	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41713913	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.573	rs9306355	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41715892	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs5758434	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41720159	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.57	rs12159188	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41725121	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.5	rs2011053	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41725274	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs738422	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41727395	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.546	rs2092274	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41727733	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs2064189	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41731995	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs5751144	ENSG00000268568.1	AC007228.9	-7.65	4.53e-10	0.00792	-1.27	-0.73	Vitiligo;	chr22:41732093	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.568	rs2413656	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41733353	chr19:56672574~56673901:-
UVM	trans	rs4822044	0.617	rs13054514	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Cannabis dependence symptom count;	chr22:41734379	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.568	rs5758441	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41736884	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs5758442	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41737056	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.58	rs5758449	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41744156	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.504	rs5758452	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41748923	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.532	rs4401299	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41760513	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs2413659	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41768858	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs9623450	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41779227	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.568	rs5751159	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41779361	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs5758466	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41780055	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs6002480	ENSG00000268568.1	AC007228.9	-7.65	4.53e-10	0.00792	-1.27	-0.73	Vitiligo;	chr22:41780913	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs4822050	ENSG00000268568.1	AC007228.9	-7.65	4.53e-10	0.00792	-1.27	-0.73	Vitiligo;	chr22:41781449	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs139540	ENSG00000268568.1	AC007228.9	-7.65	4.53e-10	0.00792	-1.27	-0.73	Vitiligo;	chr22:41782036	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs139553	ENSG00000268568.1	AC007228.9	7.65	4.53e-10	0.00792	1.27	0.73	Vitiligo;	chr22:41791195	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.649	rs139559	ENSG00000268568.1	AC007228.9	-7.65	4.53e-10	0.00792	-1.27	-0.73	Vitiligo;	chr22:41795632	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.918	rs12484074	ENSG00000268568.1	AC007228.9	-7.65	4.64e-10	0.00811	-1.38	-0.73	Vitiligo;	chr22:41356743	chr19:56672574~56673901:-
UVM	trans	rs7312770	0.612	rs773114	ENSG00000235459.5	RPS26P31	7.62	5.03e-10	0.00872	0.97	0.73	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr7:122681315~122681662:+
UVM	trans	rs2657294	0.62	rs9783273	ENSG00000172974.11	AC007318.5	7.6	5.47e-10	0.00944	1.14	0.73	Pneumonia;	chr10:75081982	chr2:65205108~65205988:+
UVM	trans	rs2657294	0.62	rs4746259	ENSG00000172974.11	AC007318.5	7.6	5.47e-10	0.00944	1.14	0.73	Pneumonia;	chr10:75082310	chr2:65205108~65205988:+
UVM	trans	rs2657294	0.62	rs7475340	ENSG00000172974.11	AC007318.5	7.6	5.48e-10	0.00945	1.14	0.73	Pneumonia;	chr10:75079597	chr2:65205108~65205988:+
UVM	trans	rs2657294	0.62	rs2395132	ENSG00000172974.11	AC007318.5	7.6	5.48e-10	0.00945	1.14	0.73	Pneumonia;	chr10:75080840	chr2:65205108~65205988:+
UVM	trans	rs13177918	0.911	rs12186451	ENSG00000224114.1	RP11-343H5.4	7.6	5.49e-10	0.00947	1.27	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150432625	chr1:206695837~206696269:-
UVM	trans	rs3749237	0.595	rs11720264	ENSG00000197582.5	GPX1P1	7.59	5.67e-10	0.00964	0.91	0.73	Resting heart rate;	chr3:49542914	chrX:13378735~13379340:-
UVM	trans	rs9611565	0.694	rs202637	ENSG00000268568.1	AC007228.9	7.59	5.79e-10	0.00983	1.37	0.72	Vitiligo;	chr22:41457924	chr19:56672574~56673901:-
UVM	trans	rs7312770	0.637	rs705700	ENSG00000235459.5	RPS26P31	7.56	6.4e-10	0.0108	0.97	0.72	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr7:122681315~122681662:+
UVM	trans	rs3749237	0.595	rs12489092	ENSG00000197582.5	GPX1P1	7.54	6.91e-10	0.0114	0.89	0.72	Resting heart rate;	chr3:49513481	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.595	rs3870337	ENSG00000197582.5	GPX1P1	7.54	6.91e-10	0.0114	0.89	0.72	Resting heart rate;	chr3:49519662	chrX:13378735~13379340:-
UVM	trans	rs13253073	0.662	rs34513504	ENSG00000260318.1	COX6CP1	7.5	7.77e-10	0.0122	1.24	0.72	Glucose homeostasis traits;	chr8:99848918	chr16:11903923~11904137:-
UVM	trans	rs9611565	0.729	rs2413646	ENSG00000268568.1	AC007228.9	-7.49	8.12e-10	0.0127	-1.39	-0.72	Vitiligo;	chr22:41510321	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.729	rs2413647	ENSG00000268568.1	AC007228.9	-7.49	8.12e-10	0.0127	-1.39	-0.72	Vitiligo;	chr22:41511144	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs9611602	ENSG00000268568.1	AC007228.9	-7.49	8.12e-10	0.0127	-1.39	-0.72	Vitiligo;	chr22:41512401	chr19:56672574~56673901:-
UVM	trans	rs7312770	0.612	rs1873914	ENSG00000235459.5	RPS26P31	7.48	8.42e-10	0.0131	0.96	0.72	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:122681315~122681662:+
UVM	trans	rs877636	0.562	rs1131017	ENSG00000242970.2	AC068522.4	-7.48	8.58e-10	0.0134	-1.02	-0.72	Cognitive function;	chr12:56042145	chr8:58588420~58588764:-
UVM	trans	rs3749237	0.555	rs7637665	ENSG00000197582.5	GPX1P1	7.44	9.71e-10	0.015	0.91	0.72	Resting heart rate;	chr3:49514862	chrX:13378735~13379340:-
UVM	trans	rs3749237	0.615	rs11130202	ENSG00000197582.5	GPX1P1	7.44	9.71e-10	0.015	0.91	0.72	Resting heart rate;	chr3:49529282	chrX:13378735~13379340:-
UVM	trans	rs9611565	0.765	rs9607800	ENSG00000268568.1	AC007228.9	-7.43	1.03e-09	0.0157	-1.36	-0.72	Vitiligo;	chr22:41388558	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.802	rs9611571	ENSG00000268568.1	AC007228.9	-7.43	1.03e-09	0.0157	-1.36	-0.72	Vitiligo;	chr22:41388863	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.802	rs73176692	ENSG00000268568.1	AC007228.9	-7.43	1.03e-09	0.0157	-1.36	-0.72	Vitiligo;	chr22:41389731	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.765	rs28604950	ENSG00000268568.1	AC007228.9	-7.43	1.03e-09	0.0157	-1.36	-0.72	Vitiligo;	chr22:41389808	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.802	rs73176694	ENSG00000268568.1	AC007228.9	-7.43	1.03e-09	0.0157	-1.36	-0.72	Vitiligo;	chr22:41390784	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.802	rs4822028	ENSG00000268568.1	AC007228.9	-7.43	1.03e-09	0.0157	-1.36	-0.72	Vitiligo;	chr22:41393404	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.802	rs9611577	ENSG00000268568.1	AC007228.9	-7.43	1.03e-09	0.0157	-1.36	-0.72	Vitiligo;	chr22:41397086	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.765	rs132905	ENSG00000268568.1	AC007228.9	7.43	1.03e-09	0.0157	1.36	0.72	Vitiligo;	chr22:41403102	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.765	rs132906	ENSG00000268568.1	AC007228.9	7.43	1.03e-09	0.0157	1.36	0.72	Vitiligo;	chr22:41403763	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.765	rs132907	ENSG00000268568.1	AC007228.9	7.43	1.03e-09	0.0157	1.36	0.72	Vitiligo;	chr22:41405264	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.681	rs6002372	ENSG00000268568.1	AC007228.9	7.43	1.03e-09	0.0157	1.36	0.72	Vitiligo;	chr22:41405295	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.765	rs132908	ENSG00000268568.1	AC007228.9	7.43	1.03e-09	0.0157	1.36	0.72	Vitiligo;	chr22:41405791	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.765	rs132909	ENSG00000268568.1	AC007228.9	7.43	1.03e-09	0.0157	1.36	0.72	Vitiligo;	chr22:41406027	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.681	rs5751094	ENSG00000268568.1	AC007228.9	7.43	1.03e-09	0.0157	1.36	0.72	Vitiligo;	chr22:41407275	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.765	rs132914	ENSG00000268568.1	AC007228.9	7.43	1.03e-09	0.0157	1.36	0.72	Vitiligo;	chr22:41409745	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.765	rs132915	ENSG00000268568.1	AC007228.9	7.43	1.03e-09	0.0157	1.36	0.72	Vitiligo;	chr22:41409778	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.802	rs132916	ENSG00000268568.1	AC007228.9	7.43	1.03e-09	0.0157	1.36	0.72	Vitiligo;	chr22:41410764	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.681	rs132918	ENSG00000268568.1	AC007228.9	7.43	1.03e-09	0.0157	1.36	0.72	Vitiligo;	chr22:41412346	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.643	rs202634	ENSG00000268568.1	AC007228.9	7.43	1.03e-09	0.0157	1.36	0.72	Vitiligo;	chr22:41413619	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.722	rs202635	ENSG00000268568.1	AC007228.9	7.43	1.03e-09	0.0157	1.36	0.72	Vitiligo;	chr22:41413633	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.765	rs132920	ENSG00000268568.1	AC007228.9	7.43	1.03e-09	0.0157	1.36	0.72	Vitiligo;	chr22:41414166	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.765	rs202659	ENSG00000268568.1	AC007228.9	7.43	1.03e-09	0.0157	1.36	0.72	Vitiligo;	chr22:41415616	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.765	rs132921	ENSG00000268568.1	AC007228.9	7.43	1.03e-09	0.0157	1.36	0.72	Vitiligo;	chr22:41416040	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.765	rs202663	ENSG00000268568.1	AC007228.9	7.43	1.03e-09	0.0157	1.36	0.72	Vitiligo;	chr22:41416815	chr19:56672574~56673901:-
UVM	trans	rs13253073	0.55	rs6468697	ENSG00000260318.1	COX6CP1	7.4	1.12e-09	0.017	0.86	0.72	Glucose homeostasis traits;	chr8:99858154	chr16:11903923~11904137:-
UVM	trans	rs9611565	0.659	rs4822035	ENSG00000268568.1	AC007228.9	7.38	1.21e-09	0.0179	1.38	0.72	Vitiligo;	chr22:41539908	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs1569516	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41514240	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs9611603	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41516746	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs17367716	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41517840	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs11090049	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41519325	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs9611604	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41519997	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs12484694	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41523326	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.579	rs73178621	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41525661	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs17367849	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41527640	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs1810460	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41531696	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs1810461	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41531816	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.625	rs73178625	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41532316	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs73178626	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41532367	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs4822034	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41535006	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.625	rs9611606	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41535070	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs116959331	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41536770	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs56319767	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41537833	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs73178632	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41538569	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs28530678	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41538957	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs12483998	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41539358	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs4822036	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41540015	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs12483786	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41542532	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs12484228	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41543735	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs28623192	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41544520	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs9607812	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41545239	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs9607813	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41545475	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.527	rs73178638	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41546900	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs4822037	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41549109	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs9611609	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41549353	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs9611610	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41553255	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs9607815	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41554667	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.694	rs9607816	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41554893	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs56364401	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41555239	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs12484175	ENSG00000268568.1	AC007228.9	-7.38	1.21e-09	0.0179	-1.38	-0.72	Vitiligo;	chr22:41557735	chr19:56672574~56673901:-
UVM	trans	rs7312770	0.612	rs773114	ENSG00000225071.1	GS1-184P14.2	7.38	1.23e-09	0.0181	0.87	0.72	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:24429573~24429920:-
UVM	trans	rs13177918	0.798	rs2343805	ENSG00000239528.1	RPS14P8	7.37	1.26e-09	0.0185	1.13	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150460501	chr5:116562562~116562930:+
UVM	trans	rs2622590	0.877	rs952675	ENSG00000093100.13	XXbac-B461K10.4	-7.37	1.28e-09	0.0188	-0.93	-0.71	Serum thyroid-stimulating hormone levels;	chr8:55468134	chr22:17787652~17811497:-
UVM	trans	rs9611565	0.918	rs73176685	ENSG00000268568.1	AC007228.9	-7.34	1.41e-09	0.0205	-1.39	-0.71	Vitiligo;	chr22:41385090	chr19:56672574~56673901:-
UVM	trans	rs12711490	0.651	rs11117419	ENSG00000278595.1	RP5-1068H6.6	7.34	1.44e-09	0.0208	0.84	0.71	Systemic lupus erythematosus and Systemic sclerosis;Monocyte count;	chr16:85938276	chr20:4761300~4761696:+
UVM	trans	rs12711490	0.651	rs11117421	ENSG00000278595.1	RP5-1068H6.6	7.34	1.44e-09	0.0208	0.84	0.71	Systemic lupus erythematosus and Systemic sclerosis;Monocyte count;	chr16:85938354	chr20:4761300~4761696:+
UVM	trans	rs12711490	0.651	rs11117423	ENSG00000278595.1	RP5-1068H6.6	7.34	1.44e-09	0.0208	0.84	0.71	Systemic lupus erythematosus and Systemic sclerosis;Monocyte count;	chr16:85938575	chr20:4761300~4761696:+
UVM	trans	rs12711490	0.651	rs11117424	ENSG00000278595.1	RP5-1068H6.6	7.34	1.44e-09	0.0208	0.84	0.71	Systemic lupus erythematosus and Systemic sclerosis;Monocyte count;	chr16:85938631	chr20:4761300~4761696:+
UVM	trans	rs12711490	0.651	rs11117425	ENSG00000278595.1	RP5-1068H6.6	7.34	1.44e-09	0.0208	0.84	0.71	Systemic lupus erythematosus and Systemic sclerosis;Monocyte count;	chr16:85938665	chr20:4761300~4761696:+
UVM	trans	rs12711490	0.6	rs11648012	ENSG00000278595.1	RP5-1068H6.6	7.34	1.44e-09	0.0208	0.84	0.71	Systemic lupus erythematosus and Systemic sclerosis;Monocyte count;	chr16:85938801	chr20:4761300~4761696:+
UVM	trans	rs12711490	0.651	rs11643999	ENSG00000278595.1	RP5-1068H6.6	7.34	1.44e-09	0.0208	0.84	0.71	Systemic lupus erythematosus and Systemic sclerosis;Monocyte count;	chr16:85938963	chr20:4761300~4761696:+
UVM	trans	rs12711490	0.651	rs11648084	ENSG00000278595.1	RP5-1068H6.6	7.34	1.44e-09	0.0208	0.84	0.71	Systemic lupus erythematosus and Systemic sclerosis;Monocyte count;	chr16:85938992	chr20:4761300~4761696:+
UVM	trans	rs9611565	0.614	rs4822053	ENSG00000268568.1	AC007228.9	-7.31	1.58e-09	0.0227	-1.17	-0.71	Vitiligo;	chr22:41816932	chr19:56672574~56673901:-
UVM	trans	rs2622590	0.816	rs2929029	ENSG00000093100.13	XXbac-B461K10.4	-7.29	1.7e-09	0.0243	-0.92	-0.71	Serum thyroid-stimulating hormone levels;	chr8:55474545	chr22:17787652~17811497:-
UVM	trans	rs877636	0.692	rs11171739	ENSG00000242970.2	AC068522.4	7.27	1.83e-09	0.026	0.99	0.71	Cognitive function;	chr12:56076841	chr8:58588420~58588764:-
UVM	trans	rs877636	0.669	rs7297175	ENSG00000242970.2	AC068522.4	-7.27	1.83e-09	0.026	-0.99	-0.71	Cognitive function;	chr12:56080024	chr8:58588420~58588764:-
UVM	trans	rs13177918	0.798	rs13182116	ENSG00000213058.3	RP4-765C7.2	-7.26	1.9e-09	0.0269	-1.17	-0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:178411616~178411972:+
UVM	trans	rs941207	0.507	rs73337030	ENSG00000121089.4	NACA3P	-7.26	1.9e-09	0.0269	-0.96	-0.71	Platelet count;	chr12:56652410	chr4:164943290~164943937:+
UVM	trans	rs877636	0.692	rs2271194	ENSG00000242970.2	AC068522.4	-7.26	1.91e-09	0.0271	-0.99	-0.71	Cognitive function;	chr12:56083910	chr8:58588420~58588764:-
UVM	trans	rs877636	0.692	rs10876870	ENSG00000242970.2	AC068522.4	-7.26	1.91e-09	0.0271	-0.99	-0.71	Cognitive function;	chr12:56084218	chr8:58588420~58588764:-
UVM	trans	rs877636	0.692	rs7971751	ENSG00000242970.2	AC068522.4	-7.26	1.91e-09	0.0271	-0.99	-0.71	Cognitive function;	chr12:56084874	chr8:58588420~58588764:-
UVM	trans	rs2950393	0.804	rs1466382	ENSG00000121089.4	NACA3P	-7.25	1.99e-09	0.028	-0.94	-0.71	Platelet distribution width;	chr12:56723050	chr4:164943290~164943937:+
UVM	trans	rs728616	0.51	rs12416084	ENSG00000172186.7	HMGN1P35	7.24	2.02e-09	0.028	1.59	0.71	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79989459	chrX:69174124~69174717:+
UVM	trans	rs728616	0.51	rs34817075	ENSG00000172186.7	HMGN1P35	7.24	2.02e-09	0.028	1.59	0.71	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79989984	chrX:69174124~69174717:+
UVM	trans	rs728616	0.558	rs116434658	ENSG00000172186.7	HMGN1P35	7.24	2.02e-09	0.028	1.59	0.71	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79994870	chrX:69174124~69174717:+
UVM	trans	rs728616	0.51	rs61860860	ENSG00000172186.7	HMGN1P35	7.24	2.02e-09	0.028	1.59	0.71	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79998816	chrX:69174124~69174717:+
UVM	trans	rs9411103	0.582	rs12352684	ENSG00000248240.1	RP11-159F24.5	7.24	2.02e-09	0.028	0.6	0.71	Reticulocyte fraction of red cells;	chr9:74553183	chr5:43515274~43525310:+
UVM	trans	rs9411103	0.582	rs7869849	ENSG00000248240.1	RP11-159F24.5	7.24	2.02e-09	0.028	0.6	0.71	Reticulocyte fraction of red cells;	chr9:74573742	chr5:43515274~43525310:+
UVM	trans	rs2950393	0.927	rs11171914	ENSG00000121089.4	NACA3P	-7.24	2.05e-09	0.0283	-1.02	-0.71	Platelet distribution width;	chr12:56649462	chr4:164943290~164943937:+
UVM	trans	rs941207	0.526	rs11171916	ENSG00000121089.4	NACA3P	-7.24	2.05e-09	0.0283	-1.02	-0.71	Platelet count;	chr12:56653236	chr4:164943290~164943937:+
UVM	trans	rs7312770	0.637	rs705700	ENSG00000225071.1	GS1-184P14.2	7.24	2.06e-09	0.0285	0.86	0.71	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chrX:24429573~24429920:-
UVM	trans	rs3749237	0.595	rs1050088	ENSG00000197582.5	GPX1P1	-7.23	2.09e-09	0.0289	-0.92	-0.71	Resting heart rate;	chr3:49533449	chrX:13378735~13379340:-
UVM	trans	rs7312770	0.612	rs1873914	ENSG00000225071.1	GS1-184P14.2	7.2	2.35e-09	0.0321	0.86	0.71	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:24429573~24429920:-
UVM	trans	rs4867568	0.524	rs11948132	ENSG00000228554.1	AC004837.5	7.19	2.43e-09	0.0333	0.59	0.71	Knee osteoarthritis;	chr5:28534066	chr7:39700341~39703296:-
UVM	trans	rs4867568	0.524	rs7710959	ENSG00000228554.1	AC004837.5	7.19	2.43e-09	0.0333	0.59	0.71	Knee osteoarthritis;	chr5:28540127	chr7:39700341~39703296:-
UVM	trans	rs9611565	0.659	rs169361	ENSG00000268568.1	AC007228.9	7.17	2.67e-09	0.0364	1.4	0.7	Vitiligo;	chr22:41481985	chr19:56672574~56673901:-
UVM	trans	rs9411103	0.502	rs1323357	ENSG00000248240.1	RP11-159F24.5	-7.17	2.68e-09	0.0365	-0.63	-0.7	Reticulocyte fraction of red cells;	chr9:74577677	chr5:43515274~43525310:+
UVM	trans	rs7312770	0.612	rs773114	ENSG00000243403.1	RP11-330L19.1	7.16	2.72e-09	0.0369	0.89	0.7	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr15:64592979~64593326:+
UVM	trans	rs727563	0.593	rs132770	ENSG00000268568.1	AC007228.9	7.16	2.75e-09	0.0373	1.26	0.7	Crohn's disease;Inflammatory bowel disease;	chr22:41621260	chr19:56672574~56673901:-
UVM	trans	rs13177918	0.578	rs35919198	ENSG00000213058.3	RP4-765C7.2	7.14	2.97e-09	0.04	1.03	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:178411616~178411972:+
UVM	trans	rs13177918	0.603	rs10447222	ENSG00000213058.3	RP4-765C7.2	7.14	2.97e-09	0.04	1.03	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:178411616~178411972:+
UVM	trans	rs877636	0.562	rs1131017	ENSG00000243403.1	RP11-330L19.1	-7.12	3.21e-09	0.0429	-0.85	-0.7	Cognitive function;	chr12:56042145	chr15:64592979~64593326:+
UVM	trans	rs9611565	0.592	rs9611612	ENSG00000268568.1	AC007228.9	-7.09	3.5e-09	0.0446	-1.32	-0.7	Vitiligo;	chr22:41565185	chr19:56672574~56673901:-
UVM	trans	rs9611565	0.659	rs73178641	ENSG00000268568.1	AC007228.9	-7.09	3.53e-09	0.045	-1.34	-0.7	Vitiligo;	chr22:41556071	chr19:56672574~56673901:-
UVM	trans	rs13177918	0.911	rs12186451	ENSG00000213058.3	RP4-765C7.2	7.09	3.54e-09	0.045	1.18	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150432625	chr1:178411616~178411972:+
UVM	trans	rs6732160	0.932	rs768851	ENSG00000236165.1	PRADC1P1	7.09	3.57e-09	0.0453	0.85	0.7	Intelligence (multi-trait analysis);	chr2:73151113	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.934	rs2421390	ENSG00000236165.1	PRADC1P1	7.09	3.57e-09	0.0453	0.85	0.7	Intelligence (multi-trait analysis);	chr2:73151975	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.932	rs6546802	ENSG00000236165.1	PRADC1P1	7.09	3.57e-09	0.0453	0.85	0.7	Intelligence (multi-trait analysis);	chr2:73152436	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.932	rs13417029	ENSG00000236165.1	PRADC1P1	7.09	3.57e-09	0.0453	0.85	0.7	Intelligence (multi-trait analysis);	chr2:73153295	chr3:36976316~36976840:+
UVM	trans	rs6732160	0.932	rs6546803	ENSG00000236165.1	PRADC1P1	7.09	3.57e-09	0.0453	0.85	0.7	Intelligence (multi-trait analysis);	chr2:73154187	chr3:36976316~36976840:+
UVM	trans	rs7942486	0.893	rs11823901	ENSG00000259658.3	RP11-89K11.1	-7.08	3.64e-09	0.046	-0.71	-0.7	Neuroticism;	chr11:13258402	chr15:101737099~101745710:-
UVM	trans	rs7312770	0.637	rs705700	ENSG00000243403.1	RP11-330L19.1	7.06	3.93e-09	0.0493	0.88	0.7	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr15:64592979~64593326:+